AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS

The present invention relates to novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, and their use as CCR6 receptor modulators in the treatment or prevention of various diseases, conditions or disorders ameliorated by modulating said receptor. Furthermore, the present invention concerns related aspects such as pharmaceutical compositions containing one or more compounds of Formula (I) and processes for the preparation of said compounds.

Chemokine receptors comprise a family G-protein coupled receptors (GPCRs) that recognize and bind to peptide chemokine ligands. The predominant functions of chemokine receptors and their ligands are to induce leukocyte trafficking to-and-from lymphoid organs and tissues in the steady state, as well as in the context of an infection or inflammation. Additionally, chemokine signaling events can induce the activation of integrin molecules on the surface of immune cells, allowing firm adhesion to activated endothelium, facilitating migration from blood into inflamed tissue (Montresor A, Frontiers in Imm., 2012; Meissner A, Blood, 2003). Chemokine receptor 6 (CCR6, aliases BN-1, C-C CKR-6, CD196, CKRL3, CMKBR6, DCR2, DRY6, GPR29, GPRCY4, STRL22) is a GPCR mainly expressed on effector CD4+ T helper cells, but is also present on B cells, CD8+ cytotoxic T cells, regulatory T cells (Treg), immature dendritic cells (DC) and type 3 innate lymphoid cells (ILC3) (Cua DJ, Nat Rev Immunol. 2010 Jul; 10(7):479-89. doi: 10.1038/nri2800). CCR6 binds to the chemokine CCL20 (chemokine (C-C motif) ligand 20) (Greaves DR, J Exp Med. 1997 Sep 15; 186(6):837-44. doi: 10.1084/jem.186.6.837.). CCL20 is also called macrophage inflammatory protein 3a (MIP-3a), liver and activation-regulated chemokine (LARC), or Exodus-1 (Schutyser E, Cytokine Growth Factor Rev. 2003 Oct; 14(5):409-26. doi: 10.1016/s1359-6101 (03)00049-2) . CCR6/CCL20 interactions dictate the humoral response in the intestinal mucosa and are required for lymphocyte homeostasis in the mucosa of the small intestine (Cook DN, Immunity. 2000 May; 12(5):495-503. doi: 10.1016/s1074-7613(00)80201-0). Under steady state conditions, CCR6 and CCL20 regulate production of IgA in the intestine, where CCL20 expressed in Peyer's patches guides CCR6+lgA+ B cells to the mucosa and secretory IgA can be released into the gut lumen (Lin YL, Front Immunol. 2017; 8:805. doi: 10.3389/fimmu.2017.00805; Reboldi A, Science. 2016 May 13; 352 (6287) :aaf4822. doi: 10.1126/science. aaf4822). Under inflammatory conditions, expression of CCL20 is highly upregulated by proinflammatory cytokines including IL-17A, TNFa and IL-1 b in both endothelial and epithelial cells (Harper EG, J Invest Dermatol. 2009 Sep; 129(9):2175-83. doi: 10.1038/jid.2009.65; PLoS One. 2015; 10(11):e0141710. doi: 10.1371/journal. pone.0141710) and tissue fibroblasts (Hattori T, Mediators Inflamm. 2015; 2015:436067. doi: 10.1155/2015/436067). Interleukin (IL)-17A expression is restricted to cells expressing the transcription factor RORgt (Cell. 2006 Sep 22; 126(6): 1121-33. doi: 10.1016/j.cell.2006.07.035). I L-17A expression has been shown to segregate with CCR6 expression on human T cells (Singh SP, J Immunol. 2008 Jan 1; 180(1):214-21. doi: 10.4049/jimmunol.180.1 .214; Nat Immunol. 2007 Jun; 8(6):639-46. doi: 10.1038/ni1467). CCR6 was also described as a target gene of RORgt (PLoS One. 2017; 12(8):e0181868. doi: 10.1371 /journal. pone.0181868; Skepner J, J Immunol. 2014 Mar 15; 192(6):2564-75. doi: 10.4049/jimmunol.1302190), thus clarifying the co-expression of IL-17A and CCR6 in RORgt+ cell types.

Certain disclosures in the prior art may be regarded as relating to modulation of CCR6. For instance, Tawaraishia et al. (Bioorganic & Medicinal Chemistry Letters, Volume 28, Issue 18, 2018, Pages 3067-3072, ISSN 0960-894X, https://doi.Org/10.1016/j.bmcl.2018.07.042) disclose a series of benzenesulfonyl-aminocyclohexane derivatives as selective CCR6 inhibitors. CN103588697 teaches sulfonamide derivatives as CCR6 antagonists and their use in treating CCR6-mediated diseases such as autoimmune diseases, inflammation, psoriasis, multiple sclerosis or cancer. WO2014/075580 describes the use of aurintricarboxylic acid for targeting chemokine receptors. WO2015/084842 teaches certain sulfonamides which may be used in treating CCR6 related diseases. WO2017/087607, WO2010/131145, WO2013/061004, WO2013/061005, WO2019/036374 and W02020/058869 provide certain cyclobutenediones for use in the treatment of chemokine/CCR6 related diseases. WO2019/136370 teaches a method of treating a certain type of psoriasis. WO2019/147862 proposes azetidine derivatives which may be used as chemokine modulators.

Further, W01999/43664 discloses certain pyrrolidinones with anti-inflammatory and analgesic properties. In W02019/105915 certain heterocyclic compounds are provided which may be used as MAGL inhibitors. WO2015/057626, US2015/0105366, WO2014/062658, W02015/057205 and Tanis VM et al. (Bioorg Med Chem Lett. 2019 Jun 15; 29(12): 1463-1470. doi: 10.1016/j.bmcl.2019.04.021) relate to modulators of the RORyt receptor which may be used in treating rheumatoid arthritis or psoriasis. W003/022808 proposes certain azetidine derivatives for use as pesticides. W02008/103426 and W02007/022351 disclose certain quaternary ammonium compounds useful as muscarinic receptor antagonists. W02006/136830 teaches certain heteroaryl-alkylamines as protein kinase inhibitors. W091/13359 proposes heterocyclic cholinergic enhancers. US28141 teaches certain pyrrolidines which may be used for treating depression. GB 1304650 discloses spasmolytic pyrrolidines. US3479370, US3489769, US3499002, US 3542807 and US3651085 relate to certain pyrrolidines with analgesic/tranquilizing activity.

The present CCR6 modulators may be useful, alone, or in combination in the treatment or prevention of the following diseases or disorders: Rheumatoid arthritis (RA) causes chronic inflammation of the joints and chemokines regulate infiltration of the inflamed synovium by inflammatory cells. RA is characterized by the increased release of CCL20 and the subsequent recruitment of CCR6+ T cells to the inflamed joints. CCL20 is highly expressed in the synovial fluid of RA (Hirota, J Exp Med. 2007 Nov 26; 204(12):2803-12. doi: 10.1084/jem.20071397; Matsui T, Clin Exp Immunol. 2001 Jul; 125(1): 155-61. doi: 10.1046/j.1365-2249.2001.01542.x). In patients with RA, CCR6+ Th cells have been found in the inflamed synovium and increased proportions of peripheral blood CCR6+ Th cells have been found in patients with early RA (van Flamburg JP, Arthritis Rheum. 2011 Jan; 63(1):73-83. doi: 10.1002/art.30093; Leipe J Arthritis Rheum. 2010 Oct; 62(10):2876-85. doi: 10.1002/art.27622; Nistala K, Arthritis Rheum. 2008 Mar; 58(3):875-87. doi: 10.1002/art.23291 ). The production of CCL20 is known to be up-regulated in synovium explants or fibroblast-like synoviocytes from RA patients after stimulation of TNF-a, IL-1 b and IL-17 (Matsui T, Clin Exp Immunol. 2001 Jul; 125(1): 155-61. doi: 10.1046/j.1365-2249.2001 .01542.x; J Immunol. 2001 Nov 15; 167(10):6015-20. doi: 10.4049/jimmunol.167.10.6015; Chevrel G, Ann Rheum Dis. 2002 Aug; 61 (8):730-3. doi: 10.1136/ard.61.8.730). CCR6+ B cells in RA synovium have been reported, contributing to pathogenesis by antigen presentation, autoantibody production and/or inflammatory cytokine production. Furthermore, Rituximab is an efficacious therapy for RA (Cohen SB, Arthritis Rheum. 2006 Sep; 54(9):2793-806. doi: 10.1002/art.22025), supporting a role for CCR6+ B cells in RA pathogenesis. Additionally, CCR6-deficient mice have impaired lgG1 -dependent memory B cell responses (J Immunol. 2015 Jan 15; 194(2):505-13. doi: 10.4049/jimmunol.1401553). Preclinical rodent models showed that CCR6-deficient mice developed a less severe joint inflammation in the collagen-induced arthritis (CIA) model. Reduced production of collagen-specific antibodies in CCR6-deficient mice were observed compared to WT mice, and arthritic inflammation was also reduced (J Cell Mol Med. 2018 Nov; 22(11):5278-5285. doi: 10.1111/jcmm.13783). Furthermore, depletion of CCR6+ cells reduced the severity of SKG arthritis (Hirota K, J Exp Med. 2007 Nov 26; 204(12):2803-12. doi: 10.1084/jem.20071397).

CCR6+ Th17 are increased in peripheral blood in ankylosing spondylitis patients (Shen FI, Arthritis Rheum. 2009 Jun; 60(6): 1647-56. doi: 10.1002/art.24568). Circulating interleukin-17-secreting interleukin-23 receptor-positive g/d T cells were also reported in patients with active ankylosing spondylitis (Kenna TJ, Arthritis Rheum. 2012 May; 64(5): 1420-9. doi: 10.1002/art.33507). Secukinumab, an IL-17A inhibitor, in was shown to be efficacious in ankylosing spondylitis (AS) (Baeten D, N Engl J Med. 2015 Dec 24; 373(26):2534-48. doi: 10.1056/NEJMoal 505066). CD32B expression on memory B cells in AS was increased and was associated with disease activity. Furthermore, CCR6- cytotoxic T-cells and CD32B- memory B-cells were highly enriched within the synovial compartment of AS patients (Sueur A, Clin Exp Rheumatol. 2019 Nov 20; PMID: 31820725).

Psoriasis is a commonly occurring autoimmune skin disease. The role of Th17-associated cytokines has been clinically validated and their role in psoriatic inflammation confirmed (Paul C, J Eur Acad Dermatol Venereol. 2015 Jun; 29(6): 1082-90. doi: 10.1111/jdv.12751). An IL-17R-blocking antibody (brodalumab, AMG 827) were shown to reduce clinical manifestations of psoriasis and also to reduce CCL20 expression in skin biopsies from psoriasis patients (Papp KA, N Engl J Med. 2012 Mar 29; 366(13):1181-9. doi: 10.1056/NEJMoa1109017). Also, an IL-23 neutralizing antibody (guselkumab) was shown to be efficacious in reducing psoriatic inflammation (Reich K, Lancet. 2019 Sep 7; 394(10201):831 -839. doi: 10.1016/S0140-6736(19)31773-8). CCR6-deficient mice failed to develop psoriasiform skin lesions following intradermal IL-23 injections (Hedrick MN, J Clin Invest. 2009 Aug; 119(8):2317-29. doi: 10.1172/jci37378). Small molecule CCR6 antagonists have also been shown to be efficacious in the Aldara and IL-36a- injection mouse psoriasis models (Campbell JJ, J Immunol. 2019 Mar 15; 202 (6): 1687- 1692. doi: 10.4049/jimmunol.1801519; Campbell JJ, J Immunol. 2017 Nov 1; 199(9):3129-3136. doi: 10.4049/jimmunol.1700826). Furthermore, CCR6-deficient mice have been shown to be protected from imiquimod-induced ear swelling (Yu S, J Invest Dermatol. 2019 Feb; 139(2): 485-488. doi: 10.1016/j.jid.2018.07.036).

Anti-CCR6 neutralizing antibodies have also shown efficacy in Aldara induced ear swelling in mice (Robert R, JCI Insight. 2017 Aug 3; 2(15): e94821. Published online 2017 Aug 3. doi: 10.1172/jci.insight.94821). An engineered disulfide-linked CCL20 dimer, which binds CCR6 but inhibits T cell migration, was shown to reduce skin swelling in an IL-23-dependent mouse model of psoriasis (Getschman AE, Proc Natl Acad Sci U S A. 2017 Nov 21 ; 114(47): 12460- 12465. doi: 10.1073/pnas.1704958114). Collectively, these data show that a positive feedback consisting of epidermal and dermal production of CCL20, potent recruitment of CCR6+ T cells or into inflamed psoriatic skin, their activation by IL-23 and their expression of IL-17A and IL-22, drives a pathogenic Th17 response in psoriatic skin lesions. Inhibition of CCR6 has therefore been recognized as a potential therapeutic pathway to treat psoriasis (Hedrick MN, Expert Opin Ther Targets. 2010 Sep; 14(9):911-22. doi: 10.1517/14728222.2010.504716; Mabuchi T, J Dermatol Sci. 2012 Jan;65(1):4-11. doi: 10.1016/j . jdermsci .2011.11.007). CCR6 expression was shown to be upregulated in synovial membranes of psoriatic arthritis (PsA) patients (Dolcino M, PLoS One. 2015 Jun 18;10(6):e0128262. doi: 10.1371/journal. pone.0128262). IL-17A- and GM-CSF-expressing CD4+ T cells isolated from synovial fluid of PsA patients also expressed CCR6 (Al-Mossawi et al., Nat Commun. 2017 Nov 15;8(1):1510. doi: 10.1038/s41467-017- 01771-2). CCL20 was shown to be highly upregulated in synovial fluid retrieved from PsA patients (Melis L, Ann Rheum Dis. 2010 Mar;69(3):618-23. doi: 10.1136/ard.2009.107649).

Additional inflammatory skin disorders including rosacea have been shown to have highly elevated levels of CCL20 in inflamed skin (Buhl T, JID, 2015).

CCR6 and CCL20 are highly elevated in active Crohn's disease (CD) and ulcerative colitis (UC) (Skovdahl et al., PLoS One. 2015 Nov 4;10(11):e0141710. doi: 10.1371/journal. pone.0141710). Increased enterocyte CCL20 production has been proposed to play an important role in lymphocyte recruitment to the colonic epithelium in irritable bowel disease (IBD) (Kwon JH, Gut. 2002 Dec; 51 (6):818-26. doi: 10.1136/gut.51 .6.818). CCL20 and CCR6 expression are also correlated with histological severity in rectum resected from UC patients. CCL20 expression in chronic UC is higher than that in acute UC after pathological examination (Uchida K, Gastroenterol Res Pract. 2015; 2015:856532. doi: 10.1155/2015/856532). Expression of CCL20 was significantly up-regulated in the PBMCs of patients with UC compared with those of normal healthy controls. UC groups treated with sulfasalazine and GC showed decreases of CCL20 expression in PBMCs, accompanied by ameliorated disease. TNFa or IL-1 b-induced CCL20 secretion was strongly reduced by sulfasalazine and/or GC treatment of human intestinal epithelial cell lines (Lee FI J, 2 Inflamm Bowel Dis. 2005 Dec; 11 (12): 1070-9. doi: 10.1097/01. mib.0000187576.26043.ac). CCR6 deficiency resulted in reduced intestinal pathology in mice treated with dextran sodium sulfate (DSS) to induce colonic inflammation (Varona R, Eur J Immunol. 2003 Oct; 33(10): 2937-46. doi: 10.1002/ej i .200324347) . Th17 cells expressing CCR6 were shown to be important effectors mediating dry eye disease (DED), an inflammatory state at the ocular surface, potentially resulting in corneal perforation. Antibody-mediated neutralization of CCL20 in a DED mouse model reduced Th17 recruitment into the ocular surface, resulting in improved clinical readouts (Dohlman TH, Invest Ophthalmol Vis Sci. 2013 Jun 12; 54(6):4081-91 . doi: 10.1167/iovs.12-11216). Inhibition of the CCR6/CCL20 axis was therefore proposed as a therapeutic mechanism to treat DED.

CCR6 expression has been described on T cells isolated from the cerebrospinal fluid of multiple sclerosis (MS) patients (van Langelaar J, Brain, 2018 May 1; 141 (5): 1334-1349. doi: 10.1093/brai n/awy069) . CCR6 expression was also shown on T cells infiltrating the inflamed CNS in experimental autoimmune encephalomyelitis (EAE) (Mony JT, Front Cell Neurosci. 2014; 8:187. doi: 10.3389/f ncel .2014.00187). Furthermore, CCL20 gene polymorphisms have been shown to be associated with MS patient cohorts (El Sharkav et al., Gene. 2019 Feb 15; 685:164-169. doi: 10.1016/j. gene.2018.11.006). Preclinical data has shown that CCR6 is important for development of EAE (Reboldi A, Nat Immunol. 2009 May; 10(5):514-23. doi: 10.1038/ni.1716). This finding was confirmed in later study, showing that CCR6-deficient mice were resistant to disease induction with reduced peak severity. In the same study, vaccination with hCCL20 produced an anti-mouse CCL20 response in the host mice, which was sufficient to reduce clinical scores (Abraham M, Clin Immunol. 2017 Oct; 183:316-324. doi: 10.1016/j. dim.2017.09.018). However, conflicting data exists concerning the role for CCR6 in EAE development (J Neuroimmunol. 2009 Aug 18; 213(1-2):91-9. doi: 10.1016/j.jneuroim.2009.05.011). EAE severity and histopathology were significantly reduced after injection of anti- CCL20 upon first clinical manifestations (Kohler RE, J Immunol. 2003 Jun 15; 170(12):6298-306. doi: 10.4049/jimmunol.170.12.6298). Anti-CCR6 neutralizing antibodies were shown to reduce the severity of EAE in mice (Robert R, JCI Insight. 2017 Aug 3; 2(15): e94821. Published online 2017 Aug 3. doi: 10.1172/jci.insight.94821). IL-6 and IL-17 increase the expression of CCL20 from murine astrocytes (Meares GP, Glia. 2012 May; 60(5):771-81. doi: 10.1002/glia.22307).

CCR6 and CCL20 are proposed to influence kinetics of germinal center (GC) formation and B cell responses and CCR6 is considered a marker memory B cell precursors in both mouse and human germinal centers (Suan D, Immunity. 2017 Dec 19; 47(6): 1142-1153.e4. doi: 10.1016/j.immuni.2017.11.022). Expression of CCR6 on naive, pre-GC, GC/plasma cell and memory B cells in peripheral B cells of systemic lupus erythematosus (SLE) patients was increased (Lee AYS, Clin Rheumatol. 2017 Jun; 36 (6): 1453- 1456. doi: 10.1007/s10067-017-3652-3). CD4^JCR6+ cells may also contribute to disease severity in SLE patients and were shown to be increased in anti-DNA+ SLE patients, which correlated with disease severity and erythrocyte sedimentation rate (Zhong W, PeerJ. 2018; 6:e4294. doi: 10.7717/peerj .4294). Increased CCR6 expression in the salivary glands of patients with primary Sjogren's syndrome (pSS) was demonstrated [Scand J Immunol. 2020 Mar;91(3):e12852. doi: 10.1111/sji.12852], A trend towards increased CCL20 mRNA expression was also observed. Significant reductions in CCR6+ Th cells (both CCR9- and CCR9+) in the circulation of patients with pSS as compared with healthy controls (HCs) were demonstrated [Scand J Immunol. 2020 Mar; 91 (3) :e 12852. doi: 10.1111/sji.12852],

In an animal model of autoimmune hepatitis (AIH), administering anti-TNF-a suppressed hepatic CCL20 expression. Mice receiving anti-CCL20 showed reduced AIH. Furthermore, TNFa stimulation enhanced CCL20 expression in hepatocytes. These findings suggest that TNFa is essential in the induction of AIH through upregulation of hepatic CCL20 expression, which recruits CCR6+ T cells which drive pathology (Clin Immunol. 2013 Jan; 146(1): 15-25. doi: 10.1016/j.clim.2012.10.008).

The present CCR6 modulators may be useful, alone, or in combination in the treatment or prevention of autoimmune diseases or disorders including Posterior uveitis, allergic conjunctivitis, allergic disease in the gastrointestinal tract, type I diabetes and endometriosis (Medicina (Kaunas). 2018 Nov 16; 54(5). doi: 10.3390/medicina54050088). CCR6 modulators may also be useful, alone or in combination, to treat diseases of the ocular surface in which elevated levels of IL-17A have been recorded, including meibomian gland dysfunction; GVHD, graft-versus host disease; autoimmune keratitis, filamentary keratitis, dry eye syndrome with rheumatic arthritis; dry eye syndrome without systemic disease; Stevens-Johnson syndrome. (J Korean Med Sci. 2011 J u I ; 26 (7) : 938-44. doi: 10.3346/jkms.2011 .26.7.938).

The present CCR6 modulators may be useful, alone, or in combination in the treatment or prevention of malignant diseases. Modulation of the CCR6/CCL20 axis using siRNA, shRNA, CCR6 knock-out animals, CCL20 ligand treatment or antibodies has been shown to alter tumor growth and metastatic processes in experimental disease models as single agents, or in combination with immunotherapy (such as especially PD1 and/or PDL1 blockade) for the prevention / prophylaxis or treatment of cancers.

The therapeutic potential of modulating this axis for the treatment of malignancies has been described in tumor mouse models using small interfering RNA (siRNA) or small hairpin RNA (shRNA)-mediated silencing of CCR6 or CCL20. Specifically, in a mouse model of cutaneous T cell lymphoma (My-La cells), Abe et al. reported that the administration of a CCR6-targeted siRNA prolonged survival of animals when compared with control animals (Oncotarget. 2017 Jan 31; 8(5)7572-7585. doi: 10.18632/oncotarget.13810.). Using another approach, Ito and colleagues demonstrated that mice, injected with T lymphoma cells (My-La) harboring a CCR6 silencing siRNA construct, survived significantly longer than mice injected with control cells (Blood. 2014 Mar 6; 123(10): 1499-511 . doi: 10.1182/blood-2013-09-527739.). Zhu and co-workers demonstrated that, the average volume and weight of tumor nodules in mice injected subcutaneously with a set of colorectal cancer cell lines was decreased when CCR6 was silenced in the cancer cells by means of shRNA (PMID Biochim Biophys Acta Mol Basis Dis. 2018 Feb; 1864(2): 387-397. doi: 10.1016/j.bbadis.2017.10.033.). In glioblastoma xenograft models using patient-derived glioblastoma cell lines, mice injected with cells harboring a shRNA construct silencing CCR6 expression survived longer than those injected with control cells. In addition, histology and immunohistochemistry revealed that tumors formed by glioma cells with CCR6-targeting shRNA were much smaller, and tumor vessel formation was significantly lower versus control tumors. Collectively, these data further support the notion that CCR6 signaling enhances the oncogenic potential of malignancies including lymphoma, colorectal tumors and glioblastoma (Oncogene. 2018 Jun; 37(23): 3070-3087. doi: 10.1038/s41388-018-0182-7. ) . Specifically, the implication of the CCR6/CCL20 axis in tumorigenesis using CCR6 knock-out animals was reported in the literature. In the CMT93 mouse model of colorectal cancer (CRC), the infiltration of T regulatory cells was completely prevented in tumors of mice deficient in CCR6 in comparison to wildtype animals. The reported data further suggest that the homing and trafficking of tumor-infiltrating T regulatory cells to the tumor mass is dependent on the chemokine receptor CCR6 in vivo (PLoS One. 2011 Apr 29; 6(4):e19495. doi: 10.1371/journal. pone.0019495.). According to Nandi and colleagues, in a mouse model of spontaneous intestinal tumorigenesis [APCMIN/+ mice, heterozygous for a mutation in the adenomatous polyposis coli (APC) gene], mice deficient in CCR6 had a lower occurrence of spontaneous intestinal tumorigenesis (PLoS One. 2014; 9(5):e97566. doi: 10.1371 /journal .pone.0097566.).

The potential role of the CCR6/CCL20 axis in tumorigenesis was also demonstrated by administrating the recombinant CCL20 chemokine. Specifically, in a mouse model of colorectal cancer (CMT93 cells), Liu and colleagues showed that tumor size was significantly increased in mice treated with recombinant mouse CCL20 compared with PBS controls, suggesting a critical role for CCL20 in colorectal cancer growth and development (PLoS One. 2011 Apr 29; 6(4):e19495. doi: 10.1371/journal. pone.0019495.).

Specifically, using neutralizing CCL20 antibodies, the potential role of the CCR6/CCL20 axis in tumor promotion was demonstrated in the literature using mouse models. Ikeda and co-workers used a specific cutaneous T cell lymphoma (CTCL) mouse model in which animals succumb to metastasis of CTCL cells into multiple organs. However, administration of a neutralizing CCL20 antibody significantly prolonged the survival of the xenografted mice (Oncotarget. 2016 Mar 22; 7(12):13563-74. doi: 10.18632/oncotarget.6916.). Lee and co-workers described in a mouse model of metastatic breast cancer (MDA-MB-231 cells were injected into the left cardiac ventricles of nude mice) that the administration of an anti-CCL20 antibody prevented the development of bone metastasis, one of the major site of breast cancer metastasis in human disease (Sci Rep. 2017 Aug 29; 7(1):9610. doi: 10.1038/s41598-017-09040-4.). In a humanized mouse model of nasopharyngeal carcinoma, Mrizak et al. observed a significant decrease of T regulatory cell recruitment into the tumor when mice were injected with anti-CCL20 monoclinal antibody in comparison to sham treated animals (J Natl Cancer Inst. 2015 Jan; 107(1):363. doi: 10.1093/jnci/dju363.). In addition, in a mouse model of hepatocarcinoma (Hepa1-6 cells), blockade of CCL20 activity in immunocompetent mice using an anti-CCL20 antibody, attenuated tumor incidence, restrained tumor growth and distal metastasis. Moreover, the authors reported that in this mouse model, tumor angiogenesis was significantly inhibited upon CCL20 neutralization. (He at al., PMID 28560063 - Am J Cancer Res. 2017; 7 (5) : 1151-1163.). Using the same mouse model, the administration of the anti-CCL20 neutralizing antibody remarkably reduced the infiltration of T regulatory cells into the tumor, especially CCR6 positive T regulatory cells, and significantly decreased tumor growth. Antitumor efficacy was further enhanced when the mice were co-treated with an anti-PDL-1 antibody. Collectively these data sets suggest that CCL20 blockade could abrogate anti-PD-L1 resistance in a mouse model of hepatocarcinoma by inhibiting T regulatory recruitment to the tumor (Hepatology. 2019 Jul; 70(1): 198-214. doi: 10.1002/hep.30593.).

Specifically, the potential role of the CCR6/CCL20 axis in tumor metastasis was described in the literature. Dellacasagrande and colleagues reported that, in a mouse model of plasmacytoma, tumor cells that disseminated to the liver overexpressed functional CCR6 in comparison with tumor cells of the primary tumor (from s.c. injection of mouse plasmacytoma (MOPC315)). The same authors found that CCR6 was overexpressed in small liver metastases of colon, thyroid and ovarian carcinomas compared with normal liver (Scand J Immunol. 2003 Jun; 57(6):534-44. doi : 10.1046/j .1365-3083.2003.01263.x.).

Furthermore, the present CCR6 modulators may be useful, alone, or in combination in the treatment or prevention of cancers where the expression of CCR6 and/or CCL20 correlates with disease progression and resistance to standard treatment care. Specifically, the correlation of CCR6 expression with disease progression was described in the literature for numerous cancer indications. For example, in renal cell carcinoma CCR6 expression is associated with a lower overall survival (Cancers (Basel). 2019 Dec 30; 12(1). doi: 10.3390/cancersl 2010089.). In colorectal cancer, tumor expression of CCR6 positively correlates with metastasis and upregulated CCR6 predicts poor survival, shorter disease- free survival (PLoS One. 2014; 9(6):e101137. doi: 10.1371/journal. pone.0101137.), and poorer 5-year overall survival (Biochim Biophys Acta Mol Basis Dis. 2018 Feb; 1864(2):387-397. doi: 10.1016/j.bbadis.2017.10.033.). In ovarian cancer high CCR6 mRNA expression was also associated with a worse prognosis (Cancer Lett. 2020 Mar 1; 472:59- 69. doi: 10.1016/j. can let.2019.12.024.). CCR6 expression was associated with rectal cancer aggressiveness, indeed, high-level expression of CCR6 protein was more common in non-responders to radiotherapy than in responders (Cancer Res Treat. 2018 Oct; 50(4) : 1203- 1213. doi: 10.4143/crt.2017.538.). The expression level of CCR6 in prostate cancer was associated with clinical and pathologic features of more advanced and aggressive disease (J Cancer Res Clin Oncol. 2008 Nov; 134(11):1181-9. doi: 10.1007/s00432-008-0403-5. ) . In non-small cell lung cancer (NSCLC) high CCR6 expression was associated with shorter disease-free survival and conferred a disease stage-independent 5-fold increased risk for disease recurrence (PLoS One. 2011; 6(9):e24856. doi: 10.1371/journal. pone.0024856.). Hepatocarcinoma patients with increased infiltrated CCR6 positive immune cells in tumor tissues showed a poorer prognosis (Am J Cancer Res. 2017; 7(5): 1151-1163.).

Analogous to CCR6, expression of its ligand CCL20 has been reported to correlate with poorer disease outcome for several indications. Specifically, in breast cancer, elevated CCL20 expression significantly correlated with lower overall free survival, lower percent metastasis free survival (Sci Rep. 2017 Aug 29; 7(1):9610. doi: 10.1038/s41598-017- 09040-4.), with higher histological grade, higher Ki67 index, and axillary lymph node metastases. Moreover, breast tumor CCL20 expression positively correlated with expression of FOXP3, a marker of T regulatory cells. Patients with axillary lymph node metastases, and concomitant elevation in CCL20 expression and FOXP3-positive T regulatory cells, had the worst overall survival. (Medicine (Baltimore). 2019 Dec; 98(50):e18403. doi: 10.1097/M D.0000000000018403.). In NSCLC higher expression of CCL20 was associated with a lower overall survival (Biomed Pharmacother. 2015 Feb; 69:242-8. doi: 10.1016/j.biopha.2014.12.008.)(Cancer Lett. 2015 Jul 10; 363(1):60-70. doi: 10.1016/j.canlet.2015.04.005.). Analogous to NSCLC, hepatocellular carcinoma patients with high CCL20 expression had poorer overall survival and poorer recurrence-free survival. The same authors described that CCL20 expression was significantly associated with tumor size, tumor number, vascular invasion, tumor differentiation and tumor recurrence (J Gastrointest Surg. 2012 Apr; 16(4):828-36. doi: 10.1007/s11605-011-1775-4.). In addition to CCR6 or CCL20 alone, correlation of CCR6/CCL20 co-expression with disease progression is stated in literature. Indeed, overexpression of both, CCL20 and CCR6, was detected in high-grade glioma tissues as compared to low-grade tissues and increased with ascending tumor World Health Organization (WHO) grades. Particularly glioma patients with CCL20/CCR6 co-expression had the shortest overall survival (Med Oncol. 2012 Dec; 29(5):3491-7. doi: 10.1007/s 12032-012-0314-9.).

Besides, CCR6 and/or CCL20 expression correlates with enhance chemotherapeutic resistance and is associated with metastasis. Indeed, CCL20 expression can increase the chemotherapeutic resistance of breast cancer cells (PLoS Biol. 2018 Jul; 16(7):e2005869. doi: 10.1371/journal. pbio.2005869.). Rubie and colleagues describe that in colorectal liver metastases (CRLM) and in human samples of hepatocellular carcinoma (HCC), significant up-regulation of CCL20/CCR6 was detected (RT-PCR). Moreover, CCL20 was significantly overexpression in colorectal liver metastases as compared to the primary HCC, indicating an involvement of the CCL20/CCR6 ligand-receptor pair in the carcinogenesis and progression of hepatic malignancies (World J Gastroenterol. 2006 Nov 7; 12(41):6627-33. doi: 10.3748/wjg.v12.Ϊ41 .6627.).

The present CCR6 modulators may be useful, alone, or in combination in the treatment or prevention of diseases or disorders where CCR6 and/or CCL20 are expressed or overexpressed in patient samples or cancer cell lines. Specifically, the chemokine receptor CCR6 is described to be expressed in several cancer types or cancer cell lines in the literature. Lu and coworkers describe that CCR6 expression was higher in laryngeal cancer tissues compared with their normal controls. The authors reported that CCR6 was also expressed in commonly used laryngeal cancer cells such as TU212, M4E, M2E and Hep-2 (Biomed Pharmacother. 2017 Jan; 85:486-492. doi: 10.1016/j.biopha.2016.11.055.). Based on gene expression data from malignant melanoma, among the biological networks reported CCR6 gene was described and characterized as a valuable factor involved in immune responses and tumor progression (PLoS One. 2018; 13(1 ):e0190447. doi: 10.1371/journal. pone.0190447.) Whole exome sequencing in 21 MALT lymphomas of the salivary gland and thyroid revealed that CCR6 was expressed (Haematologica. 2018 Aug; 103(8): 1329-1336. doi: 10.3324/haematol.2018.191601.). In samples of adult human T-cell leukemia / lymphoma (ATLL) transcripts of CCR6 were detected, and CCR6 was further found at the protein level using flow cytometric analysis (Leuk Lymphoma. 2006 Oct; 47(10):2163-73. doi: 10.1080/10428190600775599.). In patient- derived prostate cancer samples the gene expression of CCR6 (mRNA) was significantly higher in tumor tissue as compared to adjacent normal tissue (Cancer Res Treat. 2015 Apr; 47(2):306-12. doi: 10.4143/crt.2014.015.). CCR6 expression was detected in commonly used cancer cell lines, indeed, according to Mays and co-workers, in salivary adenoid cystic carcinoma cells SACC-83, among other CC chemokine receptors, CCR6 was expressed using RT-PCR gene analysis (Anticancer Res. 2016 Aug; 36 (8): 4013-8.). According to Moller and colleagues, in multiple myeloma (MM) cell lines including U266 1970, U-266 1984, U-1958, Karpas 707, LP-1,28 L-363, HL407E and HL407L.3, CCR6 was also expressed (Leukemia. 2003 Jan; 17(1):203-10. doi: 10.1038/sj. leu.2402717.).

Analogous to CCR6, the ligand CCL20 was reported to be expressed in multiple tumor samples and tumor cell lines in the literature. For example, Zhang and co-workers demonstrated that in samples from NSCLC patients, using RT-PCR, CCL20 showed higher expression in tumor samples than in samples of adjacent tissue, this was also verified at the protein level using immunohistochemistry (Biomed Pharmacother. 2015 Feb; 69:242-8. doi: 10.1016/j.biopha.2014.12.008.). Gene expression analysis of cholangiocarcinoma samples and corresponding normal tissue revealed CCL20 to be one of the genes most significantly over-expressed in malignant vs healthy tissue (EXCLI J. 2020; 19:154-166. doi: 10.17179/excli2019-1893.). CCL20 expression was also reported in multiple myeloma (MM) human samples (Cancer Res. 2008 Aug 15; 68(16):6840-50. doi: 10.1158/0008-5472. CAN-08-0402.). Besides, according to Rubies et al., CCL20 mRNA and protein was significantly up-regulated in pancreatic carcinoma (8-fold) as compared to matched normal pancreas in which CCL20 was weakly expressed (J Transl Med. 2010 May 10; 8:45. doi: 10.1186/1479-5876-8-45.). .). CCL20 is also expressed in oral squamous cell carcinoma (IHC staining) and Lee et al. reported that expression is enriched in human CCR6+ regulatory T cells with superior suppressive activity (J Immunol. 2017 Jul 15; 199 (2): 467-476. doi: 10.4049/jimmunol.1601815.).

In addition to CCR6 or CCL20 alone, the co-expression of both CCR6 and CCL20 is reported for samples of cancer patients and cancer cells lines in literature. Both genes have been described to be expressed in adult T-cell leukemia/lymphoma patient samples (Microarray and IHC protein staining) (Int J Oncol. 2014 Sep; 45(3):1200-8. doi: 10.3892/ijo.2014.2524.) and in CTCL. In the latter, CCL20 and CCR6 were detected at the mRNA and protein levels (Clin Cancer Res. 2011 Dec 15; 17(24)7529-38. doi: 10.1158/1078-0432. CCR-11-1192.). Transcriptomic analysis (nanostring) of samples of hepatocellular carcinoma revealed CCR6 and CCL20 expression. Moreover, a chemotactic gradient between non-tumor and tumor tissues was reported and a recruitment process of T regulatory cells, tumor associated macrophages and natural killer cells involving the CCR6/CCL20 axis suggested (Proc Natl Acad Sci U S A. 2017 Jul 18; 114(29): E5900-E5909. doi: 10.1073/pnas.1706559114.). Similarly, Guo and co-workers reported CCR6 and CCL20 upregulation in hepatocarcinoma lesions compared to healthy tissue as well as CCR6 and CCL20 expression in hepatocarcinoma cell lines (L02, Li-/, Huh-7, SNU-387, Hep3B) (Oncol Rep. 2019 Sep; 42(3): 1075-1089. doi: 10.3892/or.2019.7221 .). In human colorectal cancer, both CCL20 and CCR6 are expressed according to Nandi et al. (IHC protein staining). Both, CCR6 and CCL20, were found to be highly expressed in samples of NSCLC (protein and mRNA) (Oncol Lett. 2017 Dec; 14(6):8183-8189. doi: 10.3892/ol .2017.7253) . Using in situ hybridization, both CCL20 and CCR6 mRNA moieties were strongly expressed in all pancreatic cancer samples analysed. In contrast, in healthy pancreas CCL20 and CCR6 expression was low (Int J Cancer. 1999 May 17; 81 (4):650-7. doi: 10.1002/(sici)1097-0215(19990517)81 :4<650::aid-ijc23>3.0.co;2-#.). Jin and co-workers examined CCR6 and CCL20 expression in glioblastoma using publicly available datasets. The authors used the GEO dataset GSE2223 to compare the mRNA levels of CCL20 and CCR6, between normal brain and glioblastoma tissues. Again, CCR6 and CCL20 expression levels were significantly higher in glioblastoma tissues than in normal brain tissues (Oncogene. 2018 Jun; 37(23) :3070-3087. doi : 10.1038/s41388-018-0182-7. ). In addition, Wallace and colleagues observed that in endometrial adenocarcinoma explants and cell lines, expression of CCL20 and its receptor CCR6 were higher compared to non-malignant endometrium (mRNA, RT-PCR) (Mol Cell Endocrinol. 2011 Jan 1; 331 (1): 129-35. doi: 10.1016/j.mce.2010.08.018.). CCL20/CCR6 axis may play a role in breast cancer, cholangiocarcinoma, and thyroid cancer since expression of CCR6/CCL20 genes and/or proteins was reported in patient derived breast cancer cells (Mol Carcinog. 2016 Jul; 55(7): 1175-86. doi: 10.1002/mc.22360.), in HuCCTI and TFK-1 cholangiocarcinoma cell lines () (Win et al., PMID 32194362 ) (EXCLI J. 2020; 19:154-166. doi: 10.17179/excli2019-1893.) and thyroid cancer cell lines such as TPC-1, BCPAP, FTC-133, and SW1736 (Tumour Biol. 2016 Apr; 37 (4): 5569-75. doi: 10.1007/s 13277- 015-4418-7.). Furthermore, the present CCR6 modulators may be useful, alone, or in combination in the treatment or prevention of cancers where the expression and/or evidence of CCR6/CCL20 axis activity has been reported, or where CCR6+ regulatory T cells have been identified inside the tumor microenvironment.

1) One aspect of the present invention relates to compounds of Formula (I), wherein

Formula (I)

A represents a 6-membered heteroaryl containing from one to three ring nitrogen atom(s) (notably one or two ring nitrogen atoms; especially one or two ring nitrogen atoms in n?efa-position(s) and/or para- position of A with respect to the point of attachment of A to the rest of the molecule), wherein said 6-membered heteroaryl is independently unsubstituted, mono-, di- or tri-substituted (notably mono- or di-substituted in meta- and/or para- position of A with respect to the point of attachment of A to the rest of the molecule), wherein the substituent(s), if any, is(are) independently selected from

• halogen (especially fluorine);

• cyano;

• hydroxy-Ci-6-alkyl which is optionally further substituted with one to three fluorine atoms (wherein notably the hydroxy group is separated from any one fluorine atom by at least two carbon atoms; especially such hydroxy- Ci- ₆ -alkyl represents 3-hydroxy-propyl, 4-hydroxy-butyl, 3-hydroxy-butyl, 3-hydroxy-3-methyl-butyl, 3-hydroxy- 4-methyl-pentyl, 3-hydroxy-3-trifluoromethyl-butyl, or 2,2-difluoro-3-hydroxy-prop-1-yl);

• Ci_5-alkyl (notably methyl, ethyl, propyl, isopropyl, butyl, or isobutyl) which is unsubstituted or mono-substituted with

> Ci-3-alkoxy (especially methoxy);

> C3-6-cycloalkyl which is optionally fused with a pyridine ring (notably at positions 2 and 3 adjacent to the nitrogen atom of said pyridine ring), wherein said C3-6-cycloalkyl is unsubstituted or mono- substituted with hydroxy (notably at the point of attachment of the C3-6-cycloal kyl to the C -alkyl);

> -O-R ⁰¹ , wherein R ⁰¹ represents C3-6-cycloalkyl (especially cyclopentyl) or pyrrolidinyl (especially pyrrolidin-2-yl) which is independently unsubstituted or mono-substituted with Ci_3-alkyl (especially methyl) or Ci-4-al kyl-carbonyl (especially acetyl);

> phenyl— L ¹ —, wherein said phenyl is unsubstituted or mono-substituted with fluorine, Ci_ ₄ -alkoxy- carbonyl (especially methoxy-carbonyl), or hydroxy-Ci_ ₄ -alkyl (especially hydroxy-methyl); wherein - L ¹ - represents a bond (i.e. the phenyl is attached directly to said alkyl), oxygen (i.e. the phenyl is attached via oxygen to said alkyl), or the group -CH2-O- (wherein the phenyl is attached to the methylene group);

> C4-6-heterocyclyl containing one or two ring heteroatoms independently selected from nitrogen and oxygen (notably azetidinyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, piperidinyl, or tetrahydropyranyl; especially azetidin-3-yl, tetrahydropyran-4-yl, imidazolidin-1-yl, pyrrolidin-1-yl, oxazolidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl), wherein said C4-6-heterocyclyl is unsubstituted, mono-, or di-substituted with oxo, hydroxy, Ci_ ₃ -alkyl (especially methyl), Ci_ ₄ -alkyl-carbonyl (especially acetyl), or Ci. ₄ -alkoxy-carbonyl (especially tert-butoxy-carbonyl);

[in particular such C4-6-heterocyclyl represents 1-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl, tetrahydropyran-4-yl, 4-hydroxy-tetrahydropyran-4-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-3-methyl- imidazolidin-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo-oxazolidin-3-yl, 2-oxo-oxazolidin-3-yl, N-acetyl-2- methyl-pyrrolidin-2-yl, N-(tert-butoxy-carbonyl)-3-hydroxy-pyrrolidin-3-yl, N-acetyl-piperidin-4-yl, or N-(tert-butoxy-carbonyl)-piperidin-4-yl]

> 5-membered heteroaryl containing one or two ring nitrogen atoms (notably pyrazolyl; especially pyrazol-4-yl), wherein said 5-membered heteroaryl is unsubstituted or mono-substituted with Ci_ ₃ - alkyl (especially methyl);

> -NR ^N1 R ^N1 wherein R ^N1 represents hydrogen and R ^N2 represents C 1 _ ₃ -al kyl-carbonyl (especially acetyl) or hydroxy-Ci-3-alkyl-carbonyl (especially hydroxymethyl-carbonyl) [in particular such -NR ^N1 R ^N2 represent acetyl-amino or hydroxymethyl-carbonyl-amino]; > indolyl (especially indol-2-yl);

> pyrrolopyridinyl (especially 1H-pyrrolo[2,3-b]pyridin-2-yl));

> N-(Ci-3-alkyl)-amino-carbonyl-oxy; or

> 1 -hydroxy-1- C _3-5 -cycloalkyl-1-(pyridinyl)-methyl (especially 1 -hydroxy-1 -cyclopropyl-1 -(pyridin-2-yl)- methyl);

[in particular such C -alkyl represents methyl, ethyl, isopropyl, cyclopentyl-oxy-methyl, 2-(1-hydroxy- cyclopropyl)-ethyl, 2-(1-hydroxy-cyclobutyl)-ethyl, 2-(1-hydroxy-cyclopentyl)-ethyl, 3-methoxy-propyl, 4-fluoro- phenoxy-methyl, 2-(2-(methoxy-carbonyl)-phenyl)-ethyl, benzyl-oxy-methyl, N-(isopropyl)-amino-carbonyl- oxy-methyl, 2-(1-(tert-butoxy-carbonyl)-3-hydroxyazetidin-3-yl)-ethyl, 3-methyl-3-(2-oxo-imidazolidin-1-yl)- butyl, 3-methyl-3-(2-oxo-3-methyl-imidazolidin-1-yl)-butyl, 3-methyl-3-(2-oxo-pyrrolidin-1-yl)-butyl, 2-(N-(tert- butoxy-carbonyl)-3-hydroxy-pyrrolidin-3-yl)-ethyl, 3-methyl-3-(2-oxo-oxazolidin-3-yl)-butyl, 2-(1 -methyl-1 H- pyrazol-4-yl)-ethyl, 2-(2-hydroxymethyl-phenyl)-ethyl, 2-(tetrahydropyran-4-yl)-ethyl, 2-(4-hydroxy- tetrahydropyran-4-yl)-ethyl, 2-(indol-2-yl)-ethyl, 2-(8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl)-ethyl, 2-(7- hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethyl, 2-(N-acetyl-piperidin-4-yl)-ethyl, 2-(N-(tert-butoxy- carbonyl)-piperidin-4-yl)-ethyl, N-acetyl-2-methyl-pyrrolidin-2-yl-oxy-methyl, acetyl-amino-isopropyl, N- (hydroxymethyl-carbonyl)-amino-methyl, 3-hydroxy-3-cyclopropyl-3-(pyridin-2-yl)-propyl, 2-(indol-2-yl)-ethyl, or 2-(1 H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl]

• C3-5-alkyl (especially n-propyl, n-butyl, or n-pentyl) which is substituted with hydroxy and R ^A1 , wherein said substituents are both at position 3 with respect to the point of attachment of said C3-s-alkyl to the rest of the molecule; wherein

> R ^A1 represents

^■ tetrahydropyranyl (especially tetrahydropyran-4-yl);

^■ phenyl which is unsubstituted or mono-substituted with fluorine (especially 3-fluoro-phenyl) or Ci-3-alkoxy (especially 2-methoxy-phenyl or 4-methoxy-phenyl);

^■ 5- or 6-membered heteroaryl containing one or two ring heteroatom(s) being independently selected from nitrogen or sulfur (notably thiazolyl, pyrazolyl, pyridinyl, pyrazinyl, or pyrimidinyl; especially thiazol-4-yl, thiazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, pyrazin-2-yl, or pyrimidin-4-yl), wherein said 5- or 6-membered heteroaryl is independently unsubstituted, mono- or di- substituted, and wherein the substituent(s), if any, is(are) independently selected from Ci_ ₃ -alkyl (especially methyl), Cs s-cycloalkyl (especially cyclopropyl), or Ci. ₃ -alkoxy (especially methoxy); or

^■ indazolyl (especially indazol-3-yl); [in particular such C3-5-alkyl which represents 3-hydroxy-3-(tetrahydropyran-4-yl)-propyl, 3-hydroxy-3-phenyl- propyl, 3-hydroxy-3-phenyl-butyl, 3-hydroxy-3-(3-fluoro-phenyl)-butyl, 3-hydroxy-3-(2-methoxy-phenyl)-butyl,

3-hydroxy-3-(4-methoxy-phenyl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1-methyl- pyrazol-3-yl)-butyl, 3-hydroxy-3-(1 -cyclopropyl- 1 H-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3- yl)-propyl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-butyl, 3-hydroxy-3-(2-methyl-thiazol-5-yl)-butyl, 3-hydroxy-3-(6- methoxy-pyridin-2-yl)-butyl, 3-hydroxy-3-(5-methyl-pyridin-3-yl)-butyl, 3-hydroxy-3-(pyridin-2-yl)-butyl, 3- hydroxy-3-(6-methyl-pyridin-2-yl)-butyl, 3-hydroxy-3-(pyrimidin-2-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyrimidin-

4-yl)-butyl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-pentyl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-butyl, 3- hydroxy-3-(5-methyl-pyrazin-2-yl)-butyl, 3-hydroxy-3-(1 H-indazol-3-yl)-butyl, 3-hydroxy-3-(1 ,3-dimethyl- pyrazol-4-yl)-propyl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-propyl, 3-hydroxy-3-(pyridin-2-yl)-pentyl, or 3- hydroxy-3-(6-methoxy-pyridin-2-yl)-pentyl]

• C ₃ -5-alkenyl which is unsubstituted (especially isopropenyl) or mono-substituted with hydroxy (especially 4- hydroxy-but-1 -en-2-yl);

• C4-6-cycloalkenyl (notably cyclopentenyl; especially cyclopent- 1 -en- 1 -y I) which is unsubstituted, mono-, or di- substituted with Ci-3-alkyl, oxo, or hydroxy; wherein optionally one ring carbon atom of said C4-6-cycloalkenyl is replaced by an oxygen atom;

[in particular such C4-6-cy cl o al ke ny I represents cyclopent-1-en-1-yl, 3-oxo-cyclopent-1-en-1-yl, 3-hydroxy- cyclopent-1 -en-1 -yl, 3-hydroxy-3-methyl-cyclopent-1 -en-1 -yl, or 2,3-dihydro-furan-3-yl]

> C3-6-cycloalkyl which is unsubstituted, mono-, or di-substituted with Ci-3-alkyl (especially methyl, ethyl, isopropyl), hydroxy or hy droxy-Ci -3-al ky I (especially 1 -hydroxy-1 -methyl-ethyl), wherein optionally one ring carbon atom of said C3-6-cycloalkyl is replaced by an oxygen atom;

[in particular such C _3-6 -cycloalkyl represents cyclopropyl, cyclopentyl, 3-hydroxy-cyclopentyl, 3-hydroxy-3- methyl-cyclopentyl, 3-hydroxy-3-ethyl-cyclopentyl, 3-hydroxy-3-isopropyl-cyclopentyl, 2-(2-hydroxy- isopropyl)-cyclopropyl, 4-hydroxy-cyclohexyl, 4-hydroxy-4-methyl-cyclohexyl, oxetan-3-yl, tetrahydrofuran-3- yl, tetrahydrofuran-2-yl, tetrahydropyran-4-yl, 5-methyl-tetrahydrofuran-2-yl, or 5,5-dimethyl-tetrahydrofuran- 2-yl]

> -O-R ⁰² , wherein

> R ⁰² represents

^■ Ci-4-alkyl (especially methyl, ethyl, isopropyl, sec-butyl, or isobutyl);

^■ C2-5-alkyl which is mono-substituted with hydroxy or Ci_3-alkoxy (especially methoxy);

[in particular such C ₂ -5-alkyl represents 2-hydroxy-ethyl, 3-hydroxy-propyl, 2-hydroxy-2- methyl-propyl, 3-hydroxy-3-methyl-butyl, or 2-methoxy-ethyl] ^■ -L ² -CY ² , wherein

❖ -L ² - independently represents a bond (i.e. the CY ² is directly attached to the rest of the molecule), -CH ₂ -, or -CH ₂ -CH ₂ -; and

❖ CY ² independently represents o phenyl which is unsubstituted or mono-substituted with hydroxy-Ci- ₃ -alkyl (especially 2-hydroxy-ethyl); o benzyl-oxy; o 5- to 6-membered heteroaryl containing one to three ring heteroatom(s) being independently selected from nitrogen, oxygen, or sulfur (notably pyridinyl, oxadiazolyl, or triazolyl); especially pyridin-2-yl, 1,2,4-oxadiazol- 5-yl, or 1,2,4-triazol-1-yl), wherein said 5- or 6-membered heteroaryl is independently unsubstituted, mono- or di- substituted; wherein the substituent(s), if any, is(are) independently selected from Ci_3-alkyl (especially methyl) or Ci-3-cycloalkyl (especially cyclopropyl); o C3-6-cycloalkyl, wherein optionally one carbon ring atom is replaced by one heteroatom selected from oxygen and nitrogen (especially oxetanyl, cyclopentyl or cyclohexyl); wherein said C3-6-cycloalkyl is unsubstituted, mono-, or di-substituted, wherein the substituents are selected from C1-3- alkyl (especially methyl), hydroxy, fluoro, oxo, Ci-3-alkyl-carbonyl (especially acetyl), and Ci. ₃ -alkoxy (especially methoxy); o benzooxazolonyl (especially 3H-benzooxazol-2-on-6-yl); o chromanyl (especially chroman-6-yl);

[in particular such -L ² -CY ² represents phenyl, 4-(2-hydroxy-ethyl)-phenyl, 2-(2-hydroxy- ethyl)-phenyl, benzyl, 2-(benzyl-oxy)-ethyl, 2-(pyridin-2-yl)-ethyl, 3-cyclopropyl-1 ,2,4- oxadiazol-5-yl-methyl, 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethyl, oxetan-3-yl-methyl, 2,2- dimethyl-cyclopentyl, 3,3-difluoro-cyclopentyl, 3-methoxy-cyclopentyl, cyclohexyl, 4- hydroxy-cyclohexyl, 4-methyl-4-hydroxy-cyclohexyl, 4-oxo-cyclohexyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-4-yl-methyl, N-acetyl-piperidin-4-yl-methyl, 3H- benzooxazol-2-on-6-yl, or chroman-6-yl]

[in particular such -O-R ⁰² represents methoxy, ethoxy, isopropoxy, isobutoxy, sec-butoxy, phenoxy, 4-(2- hydroxy-ethyl)-phenoxy, 2-(2-hydroxy-ethyl)-phenoxy, benzyl-oxy, 2-(benzyl-oxy)-ethoxy, 2-methoxy-ethoxy, 3-hydroxy-propoxy, 2-hydroxy-2-methyl-propoxy, 2-hydroxy-ethoxy, 3-hydroxy-3-methyl-butoxy, 2,2-dimethyl- cyclopentyl-oxy, 3,3-difluoro-cyclopentyl-oxy, cyclohexyl-oxy, 4-hydroxy-cyclohexyl-oxy, 4-methyl-4-hydroxy- cyclohexyl-oxy,4-oxo-cyclohexyl-oxy, tetrahydrofuran-3-yl-oxy, tetrahydropyran-4-yl-oxy, tetrahydropyran-4- yl-methoxy, 3-methoxy-cyclopentyl-oxy, oxetan-3-yl-methoxy, 2-(pyridin-2-yl)-ethyl-oxy, (3-cyclopropyl-1 ,2,4- oxadiazol-5-yl)-methoxy, 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethoxy, N-acetyl-piperidin-4-yl-methyl-oxy, 3H- benzooxazol-2-on-6-yl, or chroman-6-yl-oxy]

• -CºC-R ^T1 , wherein

> R ^T1 represents

^■ Ci-4-alkyl (notably methyl, ethyl, isopropyl, or isobutyl), wherein said C -alkyl independently is mono-substituted with

❖ hydroxy;

[in particular said Ci-4-alkyl represents hydroxy-methyl, 1 -hydroxy-ethyl, 2-hydroxy-ethyl, 1- hydroxy-2-methyl-propyl, 1 -hydroxy-1 -methyl-ethyl, or 1 -hydroxy-1 -trifluoromethyl-ethyl];

❖ Ci-3-alkoxy (especially methoxy);

❖ -S(=0) ₂ -R ^sot , wherein R ^S0T represents Ci_ ₃ -alkyl, Ci_ ₃ -alkyl-amino, or C _3.5 - cycloalkyl (especially such -S(=0) ₂ -R ^S0T represents methyl-sulfonyl, methyl- amino-sulfonyl or cyclopropyl-sulfonyl);

❖ -NR ^NT1 R ^NT2 wherein R ^NT1 represents hydrogen and R ^NT2 represents Ci. ₃ -alkyl- carbonyl, Ci- ₃ -alkoxy-Ci. ₃ -alkyl-carbonyl, or C ₃ -5-cycloal kyl-carbonyl (especially such -NR ^NT1 R ^NT2 represent acetyl-amino, isopropyl-carbonyl-amino, methoxy- methyl-carbonyl-amino, or cyclopropyl-carbonyl-amino);

❖ C4-6-heterocyclyl containing one or two ring heteroatom(s) independently selected from nitrogen and oxygen (notably oxazolidinyl, imidazolidinyl, or pyrrolidinyl; especially oxazolidin-3-yl, imidazolidin-3-yl, or pyrrolidin-1-yl); wherein said C _4-6 - heterocyclyl is mono-substituted with oxo; or di-substituted with oxo and Ci. ₃ -alkyl (especially methyl); (especially such C4-6-heterocyclyl represents oxazolidin-2-on- 3-yl, imidazolidin-2-on-3-yl, 1-methyl-imidazolidin-2-on-3-yl, or pyrrolidin-2-on-1- yl); or

❖ N-(Ci- ₃ -alkyl-carbonyl)-piperidinyl-Ci- ₃ -al kyl (especially N-acetyl-piperidin-4-yl- methyl);

^■ C _3-6 -cycloalkyl (especially cyclopropyl) which is mono-substituted (especially at the point of attachment of the C _3-6 -cycloalkyl to the rest of the molecule) with

❖ hydroxy;

❖ amino-sulfonyl which is optionally di-substituted with methyl;

❖ phenyl which is mono-substituted with halogen (especially 4-fluoro-phenyl); ❖ pyridinyl (especially pyridine-2-yl);

❖ pyrimidinyl which is mono-substituted with Ci_ ₃ -alkyl (especially 6-methyl-pyrimidin- 4-yi);

❖ oxazolidinonyl (especially oxazolidin-2-on-3-yl);

[in particular such C3-6-cycloalkyl represents 1 -hydroxy-cyclopropyl, 1 -hydroxy-cyclobutyl, 1- hydroxy-cyclopenty, 1 -(amino-sulfonyl)-cyclopropyl, 1 -(dimethyl-amino-sulfonyl)- cyclopropyl, 1-(6-methyl-pyrimidin-4-yl)-cyclopropyl, 1-(pyridine-2-yl)-cyclopropyl, 1-(4- fluoro-phenyl)-cyclopropyl, 1-(pyridine-2-yl)-cyclopropyl, or 1-(oxazolidin-2-on-3-yl)- cyclopropyl];

^■ C _3-6 -cycloalkyl (notably cyclopentyl or cyclohexyl) fused with a pyridine ring (notably at positions 2 and 3 of the pyridine ring), wherein said C _3-6 -cycloalkyl is mono-substituted with hydroxy (notably at position 1 of the C _3-6 -cycloalkyl ring); wherein optionally one ring carbon atom in said C _3.6 -cycloalkyl is replaced with one oxygen atom;

[in particular such C _3.6 -cycloalkyl represents 8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl, 7- hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl, or 4-hydroxy-3,4-dihydro-2H-pyrano[3,2- b]pyridin-4-yl);

^■ C4-6-heterocyclyl containing one ring heteroatom independently selected from nitrogen and oxygen (notably azetidinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl; especially azetidin-3- yl, piperidin-4-yl, pyrrolidin-3-yl, pyrrolidin-2-yl, pyrrolidine-1-yl, or tetrahydropyran-4-yl); wherein said C _4-6 -heterocyclyl is mono-, di-, or tri-substituted (especially mono- or di- substituted), wherein the substituent(s) is(are) independently selected from Ci_ ₃ -alkyl (especially methyl), hydroxy, oxo, Ci. ₃ -alkyl-carbonyl (especially acetyl), Ci_ ₃ -alkoxy- carbonyl (especially tert-butoxy-carbonyl), Ci. ₃ -alkyl-sulfonyl (especially methyl-sulfonyl), and Ci- ₃ -alkyl-amino-sulfonyl (especially methyl-amino-sulfonyl);

[in particular such C4-6-heterocyclyl represents N-(isopropyl-carbonyl)-3-hydroxy-azetidin-3- yl, N-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl, N-methyl-3-hydroxy-pyrrolidin-2-one-3- yl, N-acetyl-2-methyl-pyrrolidin-2-yl, 3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl, 2- oxo-pyrrolidine-1-yl, N-acetyl-piperidin-4-yl, N-acetyl-4-methyl-piperidin-4-yl, N-(methyl- amino-sulfonyl)-4-methyl-piperidin-4-yl, N-acety l-4-hydroxy-pi peri di n-4-yl , N-(methyl- sulfonyl)-piperidin-4-yl, N-(tert-butoxy-carbonyl)-piperidin-4-yl, 3-hydroxy-2-oxo-1-methyl- pyrrolidin-2-yl, or 4-hydroxy-tetrahydropyran-4-yl);

^■ pyrazolyl (notably 1 H-pyrazol-4-yl) which is N-substituted with methyl; ^■ indolyl (especially indol-2-yl);

^■ 3-hydroxy-1 -methyl-1, 3-d i hy d ro-i ndol-2-on-3-y I ; or

^■ 4-hydroxy-3,4-dihydro-2H-pyrano[3,2-b] pyridin-4-yl;

[in particular such -CºC-R ^T1 represents 3-hydroxy-3-trifluoromethyl-but-1-yn-1-yl, 3-hydroxy-prop- 1 -y n-1 -yl , 4- hydroxy-but-1 -yn-1 -yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methyl-but-1-yn-1-yl, 3-methyl-3-(pyrrolidin-2-on- 1-yl)-but-1-yn-1-yl, 3-methyl-3-(cyclopropyl-sulfonyl)-but-1 -yn-1 -yl, 3-methyl-3-(acetyl-amino)-but-1 -yn-1 -yl, 3- methyl-3-(oxazolidin-2-on-3-yl)-but-1 -yn-1 -yl, 3-methyl-3-(imidazolidin-2-on-3-yl)-but-1 -yn-1 -yl, 3-methyl-3-(1- methyl-imidazolidin-2-on-3-yl)-but-1-yn-1-yl, 3-methyl-3-(2-oxo-pyrrolidine-1 -yl)-but-1 -yn-1 -yl, 3-methyl-3- (methyl-sulfonyl)-but-l -yn-1 -yl, 3-methyl-3-(cyclopropyl-carbonyl-amino)-but-1 -yn-1 -yl, 3-methyl-3-( isopropyl- carbonyl-amino)-but-1 -yn-1 -yl, 3-methyl-3-(methoxy-methyl-carbonyl-amino)-but-1-yn-1-yl, 3-hydroxy-4- methyl-pent-1 -yn-1 -yl, 3-methoxy-prop-1 -yn-1 -yl, 3-(N-acetyl-piperidin-4-yl)-prop-1-yn-1-yl, (1-hydroxy- cyclopropyl)-ethynyl, (l-hydroxy-cyclobutyl)-ethynyl, (l-hydroxy-cyclopentyl)-ethynyl, (8-hy d roxy-5, 6,7,8- tetrahydroquinolin-8-yl)-ethynyl, (7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethynyl , (1-methyl- pyrazol-4-yl)-ethynyl, (tetrahydropyran-4-yl)-ethynyl, (4-hydroxy-tetrahydropyran-4-yl)-ethynyl, indol-2-yl- ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl, (1-(tert-butoxy-carbonyl)-3-hydroxy-azetidin- 3-yl)-ethynyl, (1-(6-methyl-pyrimidin-4-yl)-cyclopropyl)-ethynyl, (N-acetyl-4-methyl-piperidin-4-yl)-ethynyl, (N- acetyl-4-hydroxy-piperidin-4-yl)-ethynyl, (1-(4-fluoro-phenyl)-cyclopropyl)-ethynyl, (N-acetyl-piperidin-4-yl)- ethynyl, (N-(methyl-sulfonyl)-piperidin-4-yl)-ethynyl, (1-(dimethyl-amino-sulfonyl)-cyclopropyl)-ethynyl, (1- (amino-sulfonyl)-cyclopropyl)-ethynyl, (N-(methyl-amino-sulfonyl)-4-methyl-piperidin-4-yl)-ethynyl, (1- (pyridine-2-yl)-cyclopropyl)-ethynyl, (3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl)-ethynyl , (1- (oxazolidin-2-on-3-yl)-cyclopropyl)-ethynyl, (3-hydroxy-1 -methyl-1, 3-dihydro-indol-2-on-3-yl)-ethynyl, (4- hydroxy-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-ethynyl, (N-(tert-butoxy-carbonyl)-piperidin-4-yl)-ethynyl, (N-acetyl-2-methyl-pyrrolidin-2-yl)-ethynyl, or (3-hydroxy-2-oxo-1-methyl-pyrrolidin-3-yl)-ethynyl]

• -CºC-C(OH)(R ^T2 )(R ^T3 ), wherein

> R ^T2 represents hydrogen or Ci_3-alkyl (notably methyl or ethyl; especially methyl);

> R ^T3 represents

^■ phenyl which is unsubstituted or mono-substituted, wherein the substituent, if any, is selected from Ci_3-alkoxy (notably methoxy) or halogen (notably fluorine);

[in particular such phenyl which is unsubstituted or mono-substituted is 2-fluoro-phenyl, 4- methoxy-phenyl, or 2-methoxy-phenyl]

^■ 5- to 6-membered heteroaryl containing one or two ring heteroatom(s) being independently selected from nitrogen, oxygen, or sulfur (notably thiophenyl, thiazolyl, pyrrolyl, pyrazolyl, isoxazolyl, pyridinyl, pyrazinyl, or pyrimidinyl; especially thiophen-2-yl, thiazol-4-yl, thiazol- 5-yl, pyrrol-2-yl, pyrazol-3-yl, pyrazol-4-yl, isoxazol-5-yl, pyridin-2-yl, pyrimidin-2-yl, pyrazin- 2-yl, or pyrimidin-4-yl), wherein said 5- or 6-membered heteroaryl is independently unsubstituted, mono- or di- substituted, and wherein the substituent(s), if any, is(are) independently selected from Ci-3-alkyl (especially methyl), Ci-3-cycloalkyl (especially cyclopropyl), Ci-3-fluoroalkyl (notably Crfluoroalkyl; especially difluoromethyl or trifluoromethyl), and Ci-3-alkoxy (especially methoxy);

[in particular such 5- to 6-membered heteroaryl is 5-methyl-thiophen-2-yl, 2-methyl-thiazol- 5-yl, 1 -methyl-1 H-pyrrol-2-yl, 1 -cyclopropyl- 1 H-pyrazol-3-yl, 1 -methyl-1 H-pyrazol-3-yl, 1,3- dimethyl-pyrazol-4-yl, 1,5-dimethyl-1 H-pyrazol-3-yl, 2-methyl-thiazol-4-yl, 3-methyl- isoxazol-5-yl, 1 -methyl-1 H-imidazol-2-yl, pyridin-2-yl, 6-methoxy-pyridin-2-yl, 6-methyl- pyridin-2-yl, pyrimidin-2-yl, 2-methoxy-pyrimidin-4-yl, 6-methoxy-py rimi di n-4-yl , pyrimidin-4- yl, 2-methyl-pyrimidin-4-yl, 6-methyl-pyrimidin-4-yl, 2,6-dimethyl-pyrimidin-4-yl, 2,6- dimethoxy-pyrimidin-4-yl, 2-methyl-6-methoxy-pyrimidin-4-yl, 2-methoxy-6-methyl- pyrimidin-4-yl, 5-methyl-pyrazin-2-yl, 1 -cyclopropyl- 1 H-pyrazol-3-yl, 6-cyclopropyl- pyrimidin-4-yl, 6-difluoromethyl-pyrimidin-4-yl, 2-trifluoromethyl-pyrimidin-4-yl, 6- trifluoromethyl-pyrimidin-4-yl, or 1 ,5-dimethyl-1 H-pyrazol-3-yl]

^■ C4-7-heterocyclyl containing one ring heteroatom selected from nitrogen and oxygen; wherein said C ₄ -7-heterocyclyl is unsubstituted, mono-, or di-substituted, wherein the substituent(s), if any, is(are) independently selected from Ci_ ₃ -alkyl (especially methyl) or Ci_3-alkyl-carbonyl (especially acetyl); or

[in particular such C4-7-heterocyclyl represents N-acetyl-piperidin-4-yl, N-acetyl-4-methyl- piperidin-4-yl, or tetrahydropyran-4-yl]

^■ indazolyl (especially indazol-3-yl);

[in particular such -CºC-C(OH)(R ^T2 )(R ^T3 ) represents 3-hydroxy-3-(5-methyl-thiophen-2-yl)-but-1 -yn-1 -yl, 3- hydroxy-3-(2-methyl-thiazol-5-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1 -methyl-1 H-pyrrol-2-yl)-but-1 -yn-1 -yl, 3-hydroxy-3- (3-methyl-isoxazol-5-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(1-methyl-1H-pyrrol-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl- 1H-imidazol-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(5-methyl-pyrazin-2-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(tetrahydropyran- 4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(N-acetyl-piperidin-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(N-acetyl-4-methyl- piperidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-phenyl-prop-1 -yn-1 -yl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-prop-1 -yn-1 - yl, 3-hydroxy-3-(1,3-dimethyl-pyrazol-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-but-1 -yn-1 -yl, 3-hydroxy-3-(1- methyl-1 H-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-cyclopropyl-1H-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3- (1,5-dimethyl-1H-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1 -methyl-pyrazol-3-yl)-but-1 -yn-1 -yl, 3-hydroxy-3- (pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1 -methyl-pyrazol-3-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(3-fluoro-phenyl)-but- 1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-pyrimidin-4-yl)-but-1-yn-1- yl, 3-hydroxy-3-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-1-yn-1-y l, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-but-1- yn-1-yl, 3-hydroxy-3-(2,6-dimethoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-but-1-yn- 1-yl, 3-hy d roxy-3-(6-methoxy-2-methy l-py ri midi n-4-y l)-but- 1 -y n- 1 -y 1 , 3-hydroxy-3-(pyridin-2-yl)-pent-1-yn-1-yl, 3- hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3- (6-methyl-pyridin-2-yl)-pent-1 -yn-1 -yl, 3-hydroxy-3-(2,6-dimethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6- methoxy-pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(1H-indazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-cyclopropyl- pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(6-difluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2- trifluoromethyl-pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(6-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl , 3- hydroxy-3-(indazol-3-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl, or 3-hydroxy-3-(2-methoxy- phenyl)-but-1 -yn-1 -yl]

• -NR ^N3 R ^N4 wherein

> R ^N3 represents Ci_3-alkyl (especially methyl); and

R ^N4 represents hydroxy-Ci-3-alkyl (especially 2-hydroxy-ethyl) or 2-(benzyl-oxy)-Ci- ₃ -alkyl (especially 2-(benzyl-oxy)-ethyl); or

> R ^N3 and R ^N4 form, together with the nitrogen to which they are attached, a heterocyclic ring of 4 to 6 members (notably 5 to 6 members), wherein the members needed to complete said heterocyclic ring are each independently selected from -CH2-, -0-, -(C=0)-, -CHR ^X - and -C(R ^Y )2-; wherein said heterocyclic ring does not contain more than one member independently selected from the group consisting of -O- and -(C=0)-; wherein said heterocyclic ring does not contain more than two members selected from the group consisting of -CHR ^X -; and wherein said heterocyclic ring does not contain more than two members selected from the group consisting of -C(R ^Y )2-; wherein R ^x independently represents fluorine, methyl, isopropyl, isobutyl, tert-butyl, hydroxy, trifluoromethyl, hydroxy-methyl, 1 -hydroxy-ethyl, 1 -hydroxy- 1 -methyl -ethyl , cyclopropyl, 2-methoxy-ethyl, 2-methyl- thiazol-5-yl, 4-methyl-thiazol-2-yl, phenyl, benzyl, tetrahydropyran-4-yl, N-acetyl-piperidin-4-yl, 1,2,4- oxadiazolyl, 3-methyl-1,2,4-oxadiazol-5-yl, 2-methyl-2H-[1,2,3]triazol-4-yl, 1 -methyl-1 H-pyrazol-4-yl, 1 -difluoromethyl-1 H-pyrazol-4-yl, 1 ,3-dimethyl-1 H-pyrazol-4-yl, pyridin-2-yl, 6-methyl-pyridin-3-yl, 6- isopropyl-pyridin-2-yl, 6-trifluoromethyl-pyridin-3-yl, 2-isopropyl-pyrimidin-4-yl, or 1-methoxy-methyl; and wherein R ^Y independently represents fluorine, hydroxy, cyclopropyl, methyl, hydroxy-methyl, or trifluoromethyl [notably such -NR ^N3 R ^N4 is pyrrolidinyl; 2-pyrrolidonyl; oxazolidinonyl (especially 1,3- oxazolidin-2-on-3-yl); piperidinyl; or morpholinyl, optionally independently substituted with one or two substituents independently selected from a group consisting of R ^x and R ¹¹ ];

[in particular such -NR ^N3 R ^N4 represents pyrrolidin-1-yl, 3-fluoro-pyrrolidin-l-yl, 3,3-difluoro-pyrrolidin-1-yl, 3,4- difluoro-pyrrolidin-1-yl, 3-isopropyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2- methyl-pyrrolidin-1-yl, 3-hydroxy-3-methyl-pyrrolidin-1-yl, 3-(hydroxy-methyl)-pyrrolidin-1-yl, 2-(hydroxy- methyl)-pyrrolidin-1-yl, 3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-hydroxy-3-cyclopropyl-pyrrolidin-1-yl, 3-hydroxy- 3-trifluoromethyl-pyrrolidin-1-yl, 3-trifluoromethyl-pyrrolidin-1-yl, 3-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl,

3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-(hydroxy-methyl)-3-methyl-pyrrolidin-1-yl, 1,3-oxazolidin-2-on-3-yl, 5- (tert-butyl)-1,3-oxazolidin-2-on-3-yl, 5-phenyl-1,3-oxazolidin-2-on-3-yl, 5-benzyl-1,3-oxazolidin-2-on-3-yl, 5- isopropyl-1 ,3-oxazolidin-2-on-3-yl, 5-(tetrahydropyran-4-yl)-1,3-oxazolidin-2-on-3-yl, 5,5-dimethyl-1,3- oxazolid i n-2-on-3-yl , morpholin-4-yl, piperidin-1-yl, 4-hydroxy-piperidin-1-yl, 3-hydroxy-piperidin-1-yl, 3- (tetrahydropyran-4-yl)-pyrrolid-2-on-1-yl, N-methyl-N-(2-(benzyl-oxy)-ethyl)-amino, N-methyl-N-(2-hydroxy- ethyl)-amino, pyrrolidin-2-on-1-yl, 4-phenyl-pyrrolidin-2-on-1-yl, 4-(N-acetyl-piperidin-4-yl)-pyrrolidin-2-on-1-yl,

4-(pyridin-2-yl)-pyrrolidin-2-on-1-yl, 4-(6-methyl-pyridin-3-yl)-pyrrolidin-2-on-1-yl, 4-(2-isopropyl-pyrimidin-4- yl)-pyrrolidin-2-on-1-yl, 4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-on-1-yl, 4-(6-trifluoromethyl-pyridin-3-yl)- pyrrolidin-2-on-1-yl, 4-methyl-pyrrolidin-2-on-1-yl, 4-isopropyl-pyrrolidin-2-on-1-yl, 3-isopropyl-pyrrolidin-2-on- 1-yl, 3,3-dimethyl-pyrrolidin-2-on-1-yl, 4,4-dimethyl-pyrrolidin-2-on-1-yl, 3-(piperidin-4-yl)-pyrrolidin-2-on-1-yl, 4-(1 -methyl-1 H-pyrazol-4-yl)-pyrrolidin-2-on-1-yl, 4-(1-difluoromethyl-1H-pyrazol-4-yl)-pyrrolidin-2-on-1-yl, 4- (1,3-dimethyl-1H-pyrazol-4-yl)-pyrrolidin-2-on-1-yl, 4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-on-1-yl, 4-isobutyl- pyrrolidin-2-on-1-yl, 4-cyclopropyl-pyrrolidin-2-on-1-yl, 4-trifluoromethyl-pyrrolidin-2-on-1-yl, 3-(2-methoxy- ethyl)-pyrrolidin-2-on-1-yl, 4-(2-methoxy-ethyl)-pyrrolidin-2-on-1-yl, 2,2,6,6-tetrafluoro-morpholin-4-yl, 2,6- dimethyl-morpholin-4-yl, 2-(methoxy-methyl)-morpholin-4-yl, 3-(3-methy I- 1 , 2, 4-oxad i azol-5-y I )-pyrrol idin- 1 -y I, 4-(2-methyl-thiazol-5-yl)-pyrrolidin-2-on-1-yl, 4-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrrolidin-2-on-1-yl, 3-(4- methyl-thiazol-2-yl)-pyrrolidin-1-yl, or 3-(phenyl)-pyrrolidin-1-yl]

• -(C=0)-N(R ^N5 )(R ^N6 ), wherein

> R ^N5 represents hydrogen; and

R ^N6 represents C3-6-cycloalkyl (especially cyclopentyl) or tetrahydropyranyl (especially tetrahydropyran-4-yl); or

> R ^N5 and R ^N6 form, together with the nitrogen to which they are attached, pyrrolidinyl;

[in particular such -(C=0)-N(R ^N5 )(R ^N6 ) represents N-cyclopentyl-amino-carbonyl, N-(tetrahydropyran- 4-yl)-amino-carbonyl, or pyrrolidinyl-carbonyl] > piperidin-4-yl or pyrrolidin-3-yl which are mono-substituted at the nitrogen ring atom, wherein the substituent is independently selected from C -alkoxy-carbonyl (especially tert-butoxy-carbonyl), pyridinyl (especially pyridin-2-yl), phenyl and (4-methylphenyl)-sulfonyl;

[in particular such piperidin-4-yl or pyrrolidin-3-yl are N-(tert-butoxy-carbonyl)-piperidin-4-yl, N-(tert-butoxy- carbonyl)-pyrrolidin-3-yl, N-(pyridin-2-yl)-piperidin-4-yl, N-(phenyl)-piperidin-4-yl, or N-((4-methylphenyl)- sulfonyl)-piperidin-4-yl]

> 5- or 6-membered heteroaryl containing from one to three (notably two or three; especially three) ring heteroatom(s) independently selected from nitrogen, oxygen and sulfur (notably pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrimidinyl, or pyridinyl; especially pyrazol-1-yl, 1 H-1 ,2,3-triazol-1-yl, oxazol-2-yl, thiazol- 2-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, pyrimidin-2-yl, or pyridin-2-yl); wherein said 5- or 6-membered heteroaryl is independently unsubstituted, mono-, di-, or tri-substituted (notably mono-substituted; especially mono-substituted in position 3 with respect to the point of attachment of said 5- or 6-membered heteroaryl to A), wherein the substituent(s), if any, is(are) independently selected from

> Ci-4-alkyl (notably methyl, ethyl, propyl, isopropyl, or tert-butyl) which is

^■ unsubstituted; or

^■ mono-substituted with

❖ hydroxy;

❖ Ci-4-alkoxy (especially methoxy and tert-butoxy); or

❖ -N(R ^N7 )(R ^N8 ), wherein R ^N7 represents hydrogen or Ci_ ₃ -alkyl (especially methyl); and R ^N8 independently represent C ₃ -5-cycloalkyl-carbonyl (especially cyclopropyl- carbonyl), Ci-3-alkyl (especially methyl), Ci_3-alkyl-carbonyl including deuterated Ci-3-alkyl-carbonyl (especially acetyl, ethyl-carbonyl, isopropyl-carbonyl, or acetyl- 2,2,2-d ₃ ), Ci-3-alkoxy-Ci-3-alkyl-carbonyl (especially methoxy-methyl-carbonyl), tetrahydropyranyl-carbonyl (especially tetrahydropyran-4-yl-carbonyl), or hydroxy- Ci-3-alkyl-carbonyl (especially hydroxy-methyl-carbonyl);

^■ di-substituted, wherein one substituent is hydroxy, and the other substituent is trifluoromethyl; or both substituents are hydroxy; or

^■ di- or tri-substituted, wherein two substituents are fluorine and, if present, a further substituent is hydroxy (wherein especially the hydroxy group is separated by at least two carbon atoms from any of said fluorine substituents);

[in particular such C -alkyl represents methyl, isopropyl, hydroxy-methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1 , 1 -dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1- methoxy-1 -methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1, 1-dimethyl-ethyl, tert-butoxy- methyl; 1,2-dihydroxy-ethyl, N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl, 2- (methylcarboxamido)-2-methyl-propyl, 2-(ethylcarboxamido)-2-methyl-propyl, 2-(cyclopropyl- carboxamido)-2-methyl-propyl, 2-(tetrahydropyran-4-yl-carboxamido)-2-methyl-propyl, 2-(methoxy- methyl-carboxamido)-2-methyl-propyl, 2-(ethyl-carboxamido)-2-methyl-propyl, 2-(isopropyl- carboxamido)-2-methyl-propyl, 2-(methyl-d3-carboxamido)-2-methyl-propyl, N-methyl-N-(hydroxy- methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl, 2, 2, 2-trifluoro-1 -hydroxy-1 - methyl-ethyl, 1 , 1 -difluoro-2-hydroxy-ethyl, 1,1-difluoro-ethyl, or N-methyl-N-(acetyl-2,2,2-d ₃ )-2- amino-ethyl; in particular such C -alkyl group is 1 -hydroxy-1 -methyl-ethyl, 2-hydroxy-2-methyl- propyl, or 2-hydroxy-1 , 1 -dimethyl-ethyl]

> -L ³ -CY ³ , wherein

^■ -L ³ - independently represents a bond (i.e. the CY ³ is directly attached to the rest of the molecule), -CH ₂ -, -CH ₂ -CH ₂ -, -C(CH ₃ ) ₂ -, -CH(OH)-, or -0-CH ₂ -, wherein when -L ³ - is -0- CH ₂ -, said CY ³ is attached to the oxygen atom of said -0-CH ₂ -; and

^■ CY ³ independently represents C3-6-cycloalkyl or C4-6-heterocyclyl, said C4-6-heterocyclyl containing one or two ring heteroatoms independently selected from nitrogen and oxygen (especially CY ³ represents cyclopropyl, cyclobutyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, morpholinyl, imidazolidinyl, piperidinyl, or piperazinyl); wherein said CY ³ independently is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents is selected from

> halogen (especially fluorine);

> oxo;

> hydroxy;

> Ci-3-alkyl which is optionally mono-substituted with Ci-3-alkoxy (especially such Ci_ 3-alkyl represents methyl, ethyl, isopropyl, or methoxy-methyl);

> Ci-3-alkoxy (especially methoxy);

> -(C=0)-R ^co , wherein R ^co represents o Ci-3-alkyl which is optionally mono-substituted with hydroxy or Ci-3-alkoxy (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy-methyl, methoxy-methyl, benzyl-oxy, or 2-methoxy-ethyl); o Ci-3-fluoroalkyl (especially 2,2,2-trifluoro-ethyl); o Ci-3-alkoxy, wherein said Ci-3-alkoxy is optionally mono-substituted with Ci-3-alkoxy (especially methoxy, ethoxy, or 2-methoxy-ethoxy); o C3-6-cycloalkyl-(CH2) _n -, wherein optionally one or two carbon ring atom(s) is/are replaced by one or two oxygen ring atom(s); wherein n represents the integer 0, 1, or 2 (especially such C3-5-cycloalkyl-(CH ₂ ) _n - represents cyclopropyl, cyclopentyl, oxetan-3-yl, oxetan-3-yl-methyl, 1,4-dioxan-2-yl, or tetrahydropyran-4-yl); or o phenyl;

[especially such -(C=0)-R ^co represents acetyl, ethyl-carbonyl, n-propyl-carbonyl, isopropyl-carbonyl, tert-butyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro- ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy- carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetan-3-yl-carbonyl, oxetan-3-yl-methyl-carbonyl, phenyl- carbonyl, or tetrahydropyran-4-yl-carbonyl, methoxy-methyl-carbonyl, or 1,4- dioxan-2-yl-carbonyl]

> -N(R ^N9 )(R ^N10 ), wherein R ^N9 represents hydrogen or Ci_3-alkyl (especially methyl); and R ^N1 ° represents Ci_3-alkyl (especially methyl), C i -3-al kyl-carbony I (especially acetyl), Ci-3-alkyl-sulfonyl (especially methyl-sulfonyl), Ci-3-alkoxy-carbonyl (especially ethoxy-carbonyl), C i -3-al koxy-C 1-3-alky l-carbony I (especially methoxy- methyl-carbonyl), or tetrahydropyranyl-carbonyl (especially tetrahydropyran-4-yl- carbonyl);

> -S(=0) ₂ -R ^so , wherein R ^so represents o Ci_ ₃ -alkyl which is optionally mono-substituted with hydroxy, Ci_ ₃ -alkoxy, or amino (especially such Ci_3-alkyl is methyl, n-propyl, isopropyl, 2- hydroxy-ethyl, 2-methoxy-ethyl, or methyl-amino); or o C3-5-cycloalkyl, wherein optionally one carbon ring atom is replaced by one oxygen ring atom (especially represents cyclopropyl, cyclopentyl, or tetrahydropyranyl);

[especially such -S(=0) ₂ -R ^so represents methyl-sulfonyl, n-propyl-sulfonyl, isopropyl-sulfonyl, 2-hydroxyethyl-sulfonyl, cyclopropyl-sulfonyl, cyclopentyl- sulfonyl, 2-methoxy-ethyl-sulfonyl, methyl-amino-sulfonyl, or tetrahydropyran-4-yl- sulfonyl]

> 5-membered heteroaryl containing one ring heteroatom selected from nitrogen, oxygen, and sulfur (notably oxygen); wherein said 5-membered heteroaryl is unsubstituted (notably furanyl; especially furan-2-yl); and > phenyl-(CH2) _P -, wherein p represents the integer 0, 1 , or 2 (especially such phenyl- (CH ₂ ) _p - represents phenyl or benzyl);

[in particular such -L ³ -CY ³ representsl -hydroxy-cyclopropyl, 1-(methyl-amino)-cyclopropyl, 1- (acetyl-amino)-cycloprop-l-yl-methyl, 1-(N-acetyl-N-methyl-amino)-cycloprop-1-yl-methyl, 1-(N- (methoxy-methyl-carbonyl)-amino)-cycloprop-1-yl-methyl, 1-(N-(ethoxy-carbonyl)-N-methyl-amino)- cycloprop-1-yl, 1-(N-methylacetamido)-cycloprop-1-yl (including 1-(N-methylacet-d3-amido)- cycloprop-1-yl), 1-(1-(methoxy-methyl)-cyclopropyl)-methyl, 1-(tetrahydropyran-4-yl-carbonyl- amino)-cyclopropyl-methyl, cyclobutyl-oxy-methyl, 1 -hydroxy-cyclobutyl, 3-hydroxy-cyclobutyl, 1- methoxy-cyclobutyl, 1-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 1 -hydroxy-cyclohexyl, 4-hydroxy-cyclohexyl, (1 -hydroxy-cyclohexyl)-methyl, (1 -hydroxy-cyclobutyl)-methyl, 1 -hydroxy-1 - cyclohexyl-methyl, 1-methoxy-cyclopentyl, oxetan-3-yl, tetrahydrofuran-2-yl-methyl, tetrahydrofuran-

2-yl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, 4-hydroxy-tetrahydropyran-4-yl, 4-hydroxy-tetrahydropyran-4-yl-methyl, 4-methyl-tetrahydropyran-4-yl-methyl, 4-methyl- tetrahydropyran-4-yl, 2,6-dimethyl-tetrahydropyran-4-yl, 4-methoxy-tetrahydropyran-4-yl, 4-fluoro- tetrahydropyran-4-yl, tetrahydropyran-4-yl-methyl, 2-(tetrahydropyran-4-yl)-ethyl, 1 -(tetrahydropyran- 4-yl)-1 -methyl-ethyl, tetrahydropyran-4-yl-oxy-methyl, (4-methyl-tetrahydropyran-4-yl)-oxy-methyl, N- acetyl-3-fluoro-azetidin-3-yl (including N-acetyl-d3-3-fluoro-azetidin-3-yl), N-acetyl-3-methyl-azetidin-

3-yl (including N-acetyl-d3-3-methyl-azetidin-3-yl), 2-oxo-azetidin-3-yl, 2-oxo-azetidin-4-yl, N-acetyl- azetidin-3-yl, 5-oxo-py rrol i d i n-2-yl , N-phenyl-5-oxo-pyrrolidin-2-yl, N-phenyl-5-oxo-pyrrolidin-3-yl, N- benzyl-5-oxo-pyrrolidin-3-yl, N-benzyl-2-oxo-pyrrolidin-3-yl, 5-oxo-py rrolid i n-3-y I , N-(furan-2-yl- methyl)-5-oxo-pyrrolidin-3-yl, 3-methyl-5-oxo-pyrrolidin-3-yl, 1-methyl-5-oxo-pyrrolidin-3-yl, 1- isopropyl-5-oxo-pyrrolidin-3-yl, 1,3-dimethyl-2-oxo-pyrrolidin-3-yl, 2-oxo-pyrrolidin-1 -yl-methyl, 2- oxo-pyrrolidin-1-yl-methyl, 1-ethyl-5-oxo-pyrrolidin-3-yl, 1-isobutyl-5-oxo-pyrrolidin-3-yl, N-acetyl- pyrrolidin-3-yl, N-acetyl-pyrrolidin-3-yl-methyl, 2, 5-dioxo-3,3-dimethyl-pyrrolidin-1 -yl-methyl, 2-oxo- imidazolidin-1-yl-methyl, 2-oxo-oxazolidin-3-yl-methyl, piperidin-4-yl, 1 -methyl-2, 6-dioxo-piperidin-4- yl, 4-methyl-piperidin-4-yl, 4-fluoro-piperidin-4-yl, 2-oxo-piperidin-4-yl, 6-oxo-piperidin-2-yl, 6-oxo- piperidin-3-yl, 1-methyl-6-oxo-piperidin-3-yl, 3-methyl-6-oxo-piperidin-3-yl, N-acetyl-piperidin-4-yl, N- acetyl-piperidin-4-yl-methyl, N-acetyl-2-methy I -pi perid i n-4-y I , N-acetyl-4-fluoro-piperidin-4-yl, N- acetyl-3-methyl-piperidin-4-yl, N-acetyl-4-methyl-piperidin-4-yl, N-acetyl-4-hydroxy-piperidin-4-yl, N- acetyl-4-methoxy-piperidin-4-yl, N-acetyl-piperidin-3-yl, N-acetyl-piperidin-3-yl-methyl, N-acetyl-3- methyl-piperidin-3-yl, N-acety l-3-hy d roxy-pi perid i n-3-y I , N-(isopropyl-carbonyl)-4-hydroxy-piperidin-

4-yl, N-(tert-butyl-carbonyl)-piperidin-4-yl, N-(2-methoxy-ethoxy-carbonyl)-piperidin-4-yl, N- (hydroxymethyl-carbonyl)-piperidin-4-yl, N-(cyclopropyl-sulfonyl)-piperidin-4-yl, N-(methyl-sulfonyl)- piperidin-4-yl, N-(n-propyl-sulfonyl)-piperidin-4-yl, N-(isopropyl-sulfonyl)-piperidin-4-yl, N-(2-hydroxy- ethyl-sulfonyl)-piperidin-4-yl, N-(cyclopentyl-sulfonyl)-piperidin-4-yl, N-(methoxy-carbonyl)-piperidin- 4-yl, N-(cyclopropyl-carbonyl)-piperidin-4-yl, N-(cyclopentyl-carbonyl)-piperidin-4-yl, N-(methyl- amino-sulfonyl)-piperidin-4-yl, N-(2-methoxy-ethyl-sulfonyl)-piperidin-4-yl, N-(ethyl-carbonyl)-4- hydroxy-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-piperidin-4-yl, N-(ethoxy-carbonyl)-piperidin-4- yl, N-acetyl-4-ethyl-piperidin-4-yl, N-(n-propyl-carbonyl)-piperidin-4-yl, N-(2-methoxy-ethyl-carbonyl)- piperidin-4-yl, N-(oxetan-3-yl-carbonyl)-piperidin-4-yl, N-(oxetan-3-yl-methyl-carbonyl)-piperidin-4-yl, N-(2,2,2-trifluoro-ethyl-carbonyl)-piperidin-4-yl, N-(tetrahydropyran-4-yl-carbonyl)-piperidin-4-yl, N- (phenyl-carbonyl)-piperidin-4-yl, N-(tetrahydropyran-4-yl-sulfonyl)-piperidin-4-yl, N-(benzyl-oxy- carbonyl)-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-4-isopropyl-piperidin-4-yl, N-(1,4-dioxan-2-yl- carbonyl)-piperidin-4-yl, morpholin-4-yl, morpholin-4-yl-methyl, 1-methyl-1-(morpholin-4-yl)-ethyl, (2,6-dimethyl-morpholin-4-yl)-methyl, 2,4-dioxo-imidazolidin-1-yl-methyl, 2,5-dioxo-imidazolidin-1-yl- methyl, 2,5-dioxo-3-methyl-imidazolidin-1-yl-methyl, 2,4-dioxo-3-methyl-imidazolidin-1-yl-methyl, 2- oxo-3-methyl-imidazolidin-1-yl-methyl, 2-oxo-3-cyclopropyl-imidazolidin-1-yl-methyl, 2,5-dioxo- pyrrolidin-1-yl-methyl, N-acetyl-pyrrolidin-3-yl, or 4-acetyl-piperazin-1-yl];

> phenyl or 6-membered heteroaryl containing one or two ring nitrogen atom(s) (notably pyridinyl or pyrimidinyl; especially pyridin-3-yl or pyrimidin-4-yl); wherein said phenyl or 6-membered heteroaryl is independently unsubstituted or mono-substituted with Ci_3-alkyl (especially methyl) or Ci_3-alkoxy (especially methoxy);

[in particular such phenyl or 6-membered heteroaryl is 3-methoxy-phenyl, pyridin-3-yl, or 6-methyl- pirimidin-4-yl]

> py razoly I -C i_ ₃ -al ky I (especially 2-(pyrazol-1-yl)-ethyl);

> Ci-3-alkyl-sulfonyl-Ci-3-alkyl (especially methyl-sulfonyl-methyl);

> 3-hydroxymethyl-bicyclo[1.1.1]pent-1 -yl;

> 7-oxa-bicyclo[2.2.1]hept-2-yl; and

> 6-oxa-sp i ro [2.5] oct- 1 -y I ;

• 5-oxo-4-oxa-6-azaspiro[2.4]hept-6-yl, 5-aza-spiro[2.4]heptan-6-on-5yl, 2,2-dimethyl-6-oxo-5-oxa-7- azaspiro[3.4]oct-7-yl, 2-cyclopropyl-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-oxo-1-oxa-3-azaspiro[4.4]non-3-yl, 8,8-difluoro-2-oxo-1-oxa-3-azaspiro[4.5]dec-3-yl, or 8-oxo-7-oxa-9-azadispiro[3.1.4.1]undec-9-yl;

• 7-aza-bicyclo[2.2.1]hept-7-yl, 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl, or 8- oxa-3-azabicyclo[3.2.1]oct-3-yl;

• 5-oxo-6-azaspiro[3.4]oct-6-yl, 3-oxo-2-azaspiro[4.4]non-2-yl, 1-oxa-3-aza-spiro[4.5]decan-2-on-3-yl, 1-oxo-2- azaspiro[4.5]dec-2-yl, 1-oxo-8-oxa-2-azaspiro[4.5]dec-2-yl, 3-oxo-8-oxa-2-azaspiro[4.5]dec-2-yl, or 4-oxo- hexahydro-5H-furo[2,3-c]pyrrol-5-yl; • 3-(7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)propyl or 3-(8-hydroxy-5,6,7,8-tetrahydroquinolin-8- yl)propyl);

• 6-acetyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-yl;

• 6-acetyl-5,6,7,8-tetrahydro-1 ,6-naphthyridine-2-yl;

• 2-(6,7-dihydro-5H-[1]pyrindin-7-ol)-ethyl;

• 2-(8-hydroxy-5,6,7,8-tetrahydro-quinolin-8-yl)-ethyl;

• 7,8-dihydro-5H-[1 ,6]naphthyridin-6-yl;

• 2,3-dihydro-isoindol-1 -on-2-yl;

• 7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl; and

• 6-acetyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-yl;

B represents phenyl, which is unsubstituted, mono-, di- or tri-substituted, wherein a first substituent (especially in para- position with respect to the point of attachment of B to the rest of molecule), if present, is selected from

> halogen (especially bromine);

> Ci-5-alkyl (notably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, 1 -ethyl-propyl, 2,2-dimethyl- propyl, 1,1 -dimethyl-propyl; especially methyl, ethyl, or isopropyl; in particular isopropyl);

> C2-4-alkenyl (especially prop-1 -en-2-yl);

> Ci-3-alkoxy (especially methoxy, ethoxy, or isopropoxy);

> Ci-3-alkoxy-Ci-4-alkyl (especially 3-methoxy-propyl);

> Ci-4-fluoroalkyl (especially trifluoromethyl, 1 -methyl- 1 -fl uoro-ethy 1 , 1,1-difluoro-ethyl, 2,2,2-trifluoro-ethyl, 1,1- dimethyl-1-trifluoromethyl-methyl, 1 , 1 ,2,2,2-pentafluoro-ethyl, or 1 ,2,2,2-tetrafluoro-1 -trifluoromethyl-ethyl);

> C ₃ -5-cycloalkyl (especially cyclopropyl or cyclobutyl) which independently is unsubstituted or mono-substituted (notably at the point of attachment of said C ₃ -5-cycloalkyl to the rest of the molecule) with Ci_ ₃ -alkyl (especially methyl) or Ci-3-fluoroalkyl (especially trifluoromethyl);

> -SFs;

> bicyclo[1.1.1]pent-1-yl;

> C3-5-cycloalkoxy (especially cyclopropoxy or cyclobutoxy); and

> C ₁ - ₃ -f I uo ro al koxy (especially trifluoromethoxy); and the remaining substituent/s of B, if present, independently is/are selected from halogen (notably fluorine or chlorine; especially said remaining substituent(s) are in eia-position with respect to the point of attachment of B to the rest of molecule) and Ci_ ₃ -alkyl (especially methyl); or B represents benzothiophenyl (notably 1 -benzothiopheny I; especially 1 -benzothiophen-5-yl) or naphthalenyl (especially naphthalen-2-yl); [in particular such B is phenyl, 4-bromo-phenyl, 4-methyl-phenyl, 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-butyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 4-(1-ethyl-propyl)-phenyl, 4-(1,1-dimethyl-propyl)-phenyl, 4-(2,2- dimethyl-propyl)-phenyl, 3-chloro-4-isopropyl-phenyl, 3-fl uoro-4-isopropy l-pheny 1 , 3,5-difluoro-4-isopropyl-phenyl, 3- methyl-4-isopropyl-phenyl, 4-(prop-1-en-2-yl)-phenyl, 4-cyclopropyl-phenyl, 4-methoxy-phenyl, 4-ethoxy-phenyl, 4- isopropoxy-phenyl, 4-trifluoromethyl-phenyl, 4-(1 -methyl-1 -fluoro-ethyl)-phenyl, 4-(1,1-difluoro-ethyl)-phenyl, 4-(2,2,2- trifluoro-ethyl)-phenyl, 4-(1,1 -dimethyl-1 -trifluoromethyl-methyl)-phenyl, 4-(1,1,2,2,2-pentafluoro-ethyl)-phenyl, 4- (1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl, 4-trifluoromethoxy-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4- cyclobutyl-phenyl, 4-(pentafluoro-l6-sulfaneyl)-phenyl, 4-(bicyclo[1.1.1]pent-1-yl)-phenyl, 4-cyclopropoxy-phenyl, 4- cyclobutoxy-phenyl, 4-(trifluoromethoxy)-phenyl, 4-(3-methoxy-propyl)-phenyl, 4-(1 -trifluoromethyl-cyclopropyl)-phenyl, naphthalen-2-yl, or 1 -benzothiophen-5-yl]

R ¹ represents Ci_ ₃ -alkyl (especially methyl or ethyl), cyano, or halogen (especially fluorine);

R ² represents Ci_ ₄ -alkyl (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl or isobutyl), C _3.5 -cycloalkyl (especially cyclopropyl or cyclobutyl), C3-5-cycloalkyl-Ci-3-alkyl (especially cyclopropyl-methyl), hydroxy-Ci-3-alkyl (especially 2- hydroxy-ethyl), Ci-3-alkoxy-Ci-3-alkyl (especially 2-methoxy-ethyl), or Ci-3-fluoroalkyl (especially 2,2-difluoro-ethyl, 3,3,3-trifluoro-propyl, or 2-fluoroethyl).

Definitions provided herein are intended to apply uniformly to the compounds of Formula (I) as defined in any one of embodiments 1) to 53), and, mutatis mutandis, throughout the description and the claims unless an otherwise expressly set out definition provides a broader or narrower definition. It is well understood that a definition or preferred definition of a term defines and may replace the respective term independently of (and in combination with) any definition or preferred definition of any or all other terms as defined herein. If not explicitly defined otherwise in the respective embodiment or claim, groups defined herein are unsubstituted.

The term "halogen”, used alone or in combination, means fluorine, chlorine, bromine, or iodine; notably fluorine or chlorine; especially fluorine.

The term "cyano", used alone or in combination, refers to a group -CN.

The term "oxy", used alone or in combination, refers to a group -0-.

The term "oxo”, used alone or in combination, refers to the group =0.

The term "amino”, used alone or in combination, refers to the group -NFI ₂ .

The term "amino-carbonyl”, used alone or in combination, refers to the group -C(=0)-NH ₂ .

The term "amino-carbonyl-oxy”, used alone or in combination, refers to the group -0-C(=0)-NH ₂ , wherein substitutions to the amino group may be further defined. For example, l\l-(Ci-3-alkyl)-amino-carbonyl-oxy- means that the amino group of said amino-carbonyl-oxy group is substituted with a Cu-alkyl group, said Cu-alkyl group being defined hereinbelow. An example of N-(Ci-3-alkyl)-amino-carbonyl-oxy- is N-(isopropyl)-amino-carbonyl-oxy.

The term "alkyl”, used alone or in combination, refers to a saturated straight or branched hydrocarbon chain group containing one to six carbon atoms. The term “C _x-y -al kyl” (x and y each being an integer), refers to an alkyl group as defined before, containing x to y carbon atoms. In case a C _x-y -alkyl group is used in combination with another substituent, the term means that said substituent is linked through a C _x-y -alkyl group to the rest of the molecule. For example, a Ci_ 6-alkyl group contains from one to six carbon atoms. Examples of Ci-6-alkyl groups are the Cu-alkyl groups methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, and isobutyl, as well as n-pentyl, and isopentyl. A preferred example of a Cu-alkyl as used for the substituent R ¹ is methyl. A preferred example of a Cu-alkyl as used for the substituent R ² is ethyl or methyl; most preferably methyl. A particularly preferred example of a Cu-alkyl as used for the substituent of B is isopropyl.

The term "amino-alkyl”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by an amino group. The term "amino-C _x-y -alkyl” (x and y each being an integer), used alone or in combination, refers to an amino-alkyl group as defined before wherein the alkyl group contains x to y carbon atoms. For example, amino-Cu-alkyl is an amino-alkyl group containing from one to four carbon atoms. Examples of such amino-Cu-alkyl groups are amino-methyl, 1 -amino-ethyl, 2-amino-ethyl and 2-amino-2, 2-dimethyl-ethyl.

The term “hydroxyalkyl”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by a hydroxy group. The term "hydroxy-C _x.y -alkyl” (x and y each being an integer), used alone or in combination, refers to a hydroxyalkyl group as defined before wherein the alkyl group contains x to y carbon atoms. For example, a hydroxy-Cu-alkyl group is a hydroxyalkyl group as defined before which contains from one to six carbon atoms.

The term "hydroxy-alkyl” refers to an alkyl group as defined herein, wherein one hydrogen atom is replaced by one hydroxy group.

The term “oxetanyl-alkyl”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by an oxetanyl group; especially such oxetanyl group is oxetan-3-yl. The term “oxetanyl-C _x-y -alkyl” (x and y each being an integer), used alone or in combination, refers to an oxetanyl-alkyl group as defined before, wherein the alkyl group contains x to y carbon atoms. For example, an oxetanyl-Ci-3-alkyl group is an oxetanyl-alkyl group as defined before which contains from one to three carbon atoms.

The term “pyridinyl-al kyl”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by a pyridinyl group; especially such pyridinyl group is pyridin-2-yl. The term “pyridinyl-C _x-y -alkyl” (x and y each being an integer), used alone or in combination, refers to a pyridinyl-alkyl group as defined before, wherein the alkyl group contains x to y carbon atoms. For example, a pyridinyl-Ci-3-alkyl group is a pyridinyl-alkyl group as defined before which contains from one to three carbon atoms.

The term “pyrazolyl-alkyl”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by a pyrazolyl group; especially such pyrazolyl group is pyrazol-1-yl. The term "pyrazolyl-C _x-y -alkyl” (x and y each being an integer), used alone or in combination, refers to a pyrazolyl-alkyl group as defined before, wherein the alkyl group contains x to y carbon atoms. For example, a py razoly l-C 1-3-al ky I group is a pyrazolyl-alkyl group as defined before which contains from one to three carbon atoms.

The term “benzyl-oxy-alkyl”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by the group C ₆ H ₅ -CH ₂ -O-. The term "benzyl-oxy-C _x-y -alkyl” (x and y each being an integer), used alone or in combination, refers to a benzyl-oxy-alkyl group as defined before, wherein the alkyl group contains x to y carbon atoms. For example, a benzyl-oxy-Ci_ ₃ -alkyl group is benzyl-oxy-alkyl group as defined before which contains from one to three carbon atoms.

The term "alkyl-carbonyl”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by the group -C(=0)-. The term “C _x-y -alkyl-carbonyl” (x and y each being an integer), used alone or in combination, refers to an alkyl-carbonyl group as defined before, wherein the alkyl group contains x to y carbon atoms. For example, a Ci-3-alkyl-carbonyl group is an alkyl-carbonyl group as defined before which contains from one to three carbon atoms.

The term "amino-carbonyl-oxy”, used alone or in combination, refers to the group F N-C(=0)-0-, wherein substitutions to the amino group may be further defined.

The term “(hydroxy-alkyl)-carbonyl”, used alone or in combination, refers to a hydroxy-alkyl group as defined before, wherein one hydrogen atom of the alkyl has been replaced by the group -C(=0)-. The term "(hydroxy-C _x.y -alkyl)- carbonyl” (x and y each being an integer), used alone or in combination, refers to (hydroxy-alkyl)-carbonyl group as defined before, wherein the alkyl group contains x to y carbon atoms. For example, a (hydroxy-Ci-3-alkyl)-carbonyl group is an (hydroxy-alkyl)-carbonyl group as defined before which contains from one to three carbon atoms.

The term “alkyl-sulfonyl-alkyl”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by an alkyl-sulfonyl group, wherein the alkyl part of the said alkyl-sulfonyl is as defined before. The term “C _xi-yi -alkyl-sulfonyl-C _X 2- _y 2-alkyl” (x1, x2, y1 and y2 each being an integer), used alone or in combination, refers to an alkyl-sulfonyl-alkyl group as defined before, wherein the alkyl groups contain independently from one another x1 to y1 and x2 to y2 carbon atoms. For example, a Ci_ ₃ -al kyl-sulfonyl-Ci_3-alkyl is an alkyl-sulfonyl- alkyl group as defined before which contains in both alkyl pats independently from one to three carbon atoms.

The term "fluoroalkyl”, used alone or in combination, refers to an alkyl group as defined before in which one or more (and possibly all) hydrogen atoms have been replaced by fluorine. The term “C _x-y -fluoroalkyl” (x and y each being an integer) refers to a fluoroalkyl group as defined before containing x to y carbon atoms. For example, a Ci-3-fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. Examples of Ci_ ₃ -fluoroalkyl groups are trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl.

The term "alkenyl”, used alone or in combination, refers to a straight or branched hydrocarbon chain an alkyl group as defined before, wherein said chain comprises one double bond. The term “C _x-y -alkenyl” (x and y each being an integer), used alone or in combination, refers to an alkenyl group as defined before, containing from x to y carbon atoms. For example, the term C3-5-alkenyl, used alone or in combination, refers to an alkenyl group as defined before containing from 3 to 5 carbon atoms. Examples of C3-5-alkenyl groups are -CH=CH2, -CH=CH2-CH3, -CH2-CH=CH2, and - C(CH ₃ )=CH ₂ .

The term "alkylene”, used alone or in combination, refers to a saturated, branched or straight, bivalent aliphatic hydrocarbon group, regarded as derived from an alkane by removal of two hydrogen atoms. The term "C _x.y -alkylene” (x and y each being an integer), used alone or in combination, refers to an alkylene group as defined before containing x to y carbon atoms. For example, a Ci-2-alkylene is an alkylene group as defined above containing one or two carbon atoms. Examples of Ci-2-alkylene groups are -CH2-, -(CFh^- and -CH(CH3)-.

The term "hydroxy-alkylene”, used alone or in combination, refers to an alkylene group as defined before, wherein one hydrogen atom has been replaced with a hydroxy group. The term "hydroxy-C _x-y -alkylene” (x and y each being an integer), used alone or in combination, refers to a hydroxy-alkylene group as defined before containing x to y carbon atoms. For example, a hydroxy-Ci-2-alkylene is a hydroxy-alkylene group as defined above containing one or two carbon atoms. Examples of hydroxy-Ci_ ₂ -alkylene groups are -CH(OH)-, -CH(OH)-CH ₂ -, and -C(OH)(CH ₃ )-; preferably - CH(OH)-.

The term oxy-Ci_ ₂ -alkylene, used alone or in combination, refers to the group -0-Ci_ ₂ -alkyiene, wherein Ci_ ₂ -alkylene is defined above. Preferably, oxy-Ci-2-alkylene is the group -O-CH2-.

The term "alkoxy”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by -O-.The term "C _x.y -alkoxy” (x and y each being an integer), used alone or in combination, refers to an alkoxy group as defined before, wherein the alkoxy group contains x to y carbon atoms. For example, a C1-3- alkoxy group is an alkoxy group as defined before which contains from one to three carbon atoms. Examples of C1-3- alkoxy groups are methoxy, ethoxy, n-propoxy, or isopropoxy; notably methoxy.

The term “alkoxy-alkyl”, used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by an alkoxy group as defined before. The term “C _xi _ _yi -al koxy-C^-^-al ky I” (x1, x2, y1 and y2 each being an integer), used alone or in combination, refers to an alkoxy-alkyl group as defined before, wherein the two hydrocarbon parts of the group contain independently from one another x1 to y1 and x2 to y2 carbon atoms. For example, a Ci-3-alkoxy-Ci-3-alkyl is an alkoxy-alkyl group as defined before which contains in the two hydrocarbon parts of the group independently from one to three carbon atoms. Examples of C i -3-al koxy-C i -3-al ky I groups are methoxy- methyl or ethoxy-ethyl.

The term "fluoroalkoxy”, used alone or in combination, refers to an alkoxy group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term "C _x-y -fluoroalkoxy” (x and y each being an integer) refers to a fluoroalkoxy group as defined before containing x to y carbon atoms. For example, a C i -3-f I u o r o al k oxy group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced by fluorine. Examples of C i -3-f I u oro al koxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy and 2,2,2-trifluoroethoxy.

The term “C -alkoxy-carbonyl" refers to an alkoxy group as defined before attached to a carbonyl group (i.e. Ci- ₄ - alkoxy-C(=0)-).

The term "cycloalkyl", used alone or in combination, refers to a saturated monocyclic hydrocarbon ring containing three to seven carbon atoms (preferably three to six carbon atoms). The term "C _x.y -cycloalkyl" (x and y each being an integer), refers to a saturated monocyclic hydrocarbon ring containing x to y carbon atoms. For example, a C3-6-cycloalkyl group contains from three to six carbon atoms. Examples of C3-6-cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

Likewise, the term "C _x-y -heterocyclyl” refers to a cycloalkyl group as define above containing x to y ring atoms, wherein in said group one or more ring carbon atoms are replaced by heteroatoms as explicitly defined.

The term "cycloalkenyl”, used alone or in combination, refers to an unsaturated monocyclic hydrocarbon ring containing one double carbon-carbon ring bond, said ring containing four to six carbon (preferably five) atoms. The term "C _x.y - cycloalkenyl " (x and y each being an integer), refers to a cycloalkenyl ring as defined before containing x to y carbon atoms. For example, a C _4-6 -cycloalkenyl group contains from four to six carbon atoms. Examples of C _4-6 -cycloalkenyl groups are cyclobutenyl, cyclopentenyl and cyclohexenyl; notably cyclopentenyl; especially cyclopent- 1 -en- 1 -y I .

The term "cycloalkoxy”, used alone or in combination, refers to an cycloalkyl group as defined before, wherein one hydrogen atom has been replaced by -O-.The term "C _x-y -cycloalkoxy” (x and y each being an integer), used alone or in combination, refers to a cycloalkoxy group as defined before, wherein the cycloalkoxy group contains x to y carbon atoms. For example, a C3-5-cycloalkoxy group is a cycloalkoxy group as defined before which contains from three to five carbon atoms. Examples of C3-5-cycloalkoxy groups are cyclopropoxy, cyclobutoxy, or cyclopentoxy.

The term "cycloalkyl-sulfonyl", used alone or in combination, refers to a cycloalkyl group as defined before, wherein one hydrogen atom is replaced by a sulfonyl group (i.e. -S(=0) ₂ -). The term "C _x.y -cycloalkyl-sulfonyl" (x and y each being an integer), refers to a cycloalkyl group containing x to y carbon atoms. For example, a C3- ₅ -cycloalkyl-sulfonyl group contains from three to six carbon atoms. Examples of C3-5-cycloalkyl-sulfonyl groups are cyclopropyl-sulfonyl, cyclobutyl-sulfonyl and cyclopentyl-sulfonyl. The term "cycloalkyl-alkyl", used alone or in combination, refers to an alkyl group as defined before, wherein one hydrogen atom has been replaced by a cycloalkyl group as defined before. The term " C _xi-yi -cycloalkyl-C _X 2- _y 2-alkyl" (x1, x2, y1 and y2 each being an integer), used alone or in combination, refers to an cycloalkyl-alkyl group as defined before, wherein the two hydrocarbon parts of the group contain independently from one another x1 to y1 and x2 to y2 carbon atoms. For example, C3-5-cycloalkyl-Ci-3-alkyl is a cycloalkyl-alkyl group as defined before which contains in the cycloalkyl part from three to five carbon atoms, and an alkyl part which contains from one to three carbon atoms. Examples of C3-5-cycloalkyl-Ci-3-alkyl groups are cyclopropyl-methyl or cyclopropyl-ethyl.

The term “C3-6-cycloal kyl fused with a pyridine ring”, used alone or in combination, refers to a C3-6-cycloalkyl group as defined before which is fused with a pyridine ring. Examples of C3-6-cycloalkyl fused with a pyridine ring are the following groups: preferably the last two groups from left to right. It is understood that when a substituent is referred to as "C _3-6 -cycloalkyl fused with a pyridine ring” the point of attachment of said substituent to the rest of the molecule is in the C3-6-cycloalkyl part of the substituent and not in the fused pyridine ring.

The term “ hy d roxy-azeti d i ny I” , used alone or in combination, refers to an azetidinyl group substituted with a hydroxy group. Preferably, the term hydroxy-azetidinyl refers to 3-hydroxy-azetidin-3-yl.

The term "heteroaryl", used alone or in combination, means a 5- to 10-membered monocyclic or bicyclic aromatic ring containing one to a maximum of four heteroatoms (notably containing one to a maximum of three heteroatoms), each independently selected from oxygen, nitrogen and sulfur. Examples of such heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrrolopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, pyrrolopyrazinyl, imidazopyridinyl, imidazopyridazinyl, and imidazothiazolyl. The above-mentioned heteroaryl / heteroarylene groups are unsubstituted or substituted as explicitly defined.

The term "5- to 6-membered heteroaryl", used alone or in combination, refers to a 5- to 6-membered monocyclic aromatic ring and containing one to a maximum of four ring heteroatoms (preferably one to a maximum of three ring heteroatoms), each independently selected from oxygen, nitrogen and sulfur. Examples of 5-membered groups are 5- membered heteroaryl groups such as furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl; notably pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl; most preferably 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl. Examples of 6-membered heteroaryl groups are groups such as pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl. The above-mentioned heteroaryl groups are unsubstituted or substituted as explicitly defined.

In the context of mono-substituted 5-membered heteroaryl groups, it is understood that a substitution in position 3 with respect to the point of attachment of a 5-membered heteroaryl to A means that the substituent in position 3 and the point of attachment to A are in a relative 1,3-arrangement. Preferred examples of such 5-membered heteroaryl groups which are mono-substituted in position 3 with respect to the point of attachment of said 5-membered heteroaryl to A are selected from a group consisting of wherein one asterisk (*) denotes the attachment point to the substituent and two asterisks (**) denote the attachment point to A. Especially preferred are the last two (from left to right) 5-membered heteroaryl groups.

Further embodiments of the invention are presented hereinafter:

2) One embodiment relates to compounds according to embodiment 1), wherein A represents pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl (notably pyridazinyl or pyridinyl; especially pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, or pyridazin-4-yl), wherein A is independently unsubstituted, mono-, di- or tri-substituted (notably mono- or di-substituted in meta- and/or para- position of A with respect to the point of attachment of A to the rest of the molecule; especially mono-substituted in eia-position of A with respect to the point of attachment of A to the rest of the molecule), wherein the substituent(s), if any, is(are) as defined in embodiment 1).

3) Another embodiment relates to compounds according to embodiment 1), wherein A represents pyridin-3-yl, pyridin- 4-yl, or pyridazin-4-yl (in particular pyridin-3-yl or pyridazin-4-yl), wherein A is independently unsubstituted, mono-, di- or tri-substituted (notably mono- or di-substituted in meta- and/or para- position of A with respect to the point of attachment of A to the rest of the molecule; especially mono-substituted in meia-position of A with respect to the point of attachment of A to the rest of the molecule), wherein the substituent(s), if any, is(are) as defined in embodiment 1).

In a sub-embodiment, A is independently > unsubstituted; > mono-substituted (notably in eia-position of A with respect to the point of attachment of A to the rest of the molecule), wherein the substituent is as defined in embodiment 1); or

> di-substituted, wherein a first substituent is (notably in meia-position of A with respect to the point of attachment of A to the rest of the molecule) selected from the substituents defined in embodiment 1) (especially excluding halogen (especially fluorine) or cyano); and a second substituent is (notably in para- position of A with respect to the point of attachment of A to the rest of the molecule) selected from halogen (especially fluorine) and cyano.

4) Another embodiment relates to compounds according to embodiment 1), wherein A represents pyridin-3-yl, pyridin- 4-yl, or pyridazin-4-yl (especially pyridin-3-yl or pyridazin-4-yl; in particular pyridin-3-yl), wherein A is mono-substituted (notably in meia-position of A with respect to the point of attachment of A to the rest of the molecule), wherein the substituent is as defined in embodiment 1).

5) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein said substituent of A / at least one of said substituents of A is

• -O-R ⁰² as defined in embodiment 1).

6) Another embodiment relates to compounds according to embodiment 5), wherein said substituent of A / at least one of said substituents of A is

> -O-R ⁰² , wherein

> R ⁰² represents

^■ Ci-4-alkyl (especially isopropyl, sec-butyl, or isobutyl);

^■ C2-5-alkyl which is mono-substituted with hydroxy or Ci-3-alkoxy (especially methoxy);

[in particular such C ₂ -5-alkyl represents 2-hydroxy-ethyl, 3-hydroxy-propyl, 2-hydroxy-2- methyl-propyl, 3-hydroxy-3-methyl-butyl, or 2-methoxy-ethyl]

^■ -L ² -CY ² , wherein

❖ -L ² - independently represents a bond (i.e. the CY ² is directly attached to the rest of the molecule); and

❖ CY ² independently represents o C3-6-cycloalkyl (especially oxetanyl, cyclopentyl or cyclohexyl), wherein optionally one carbon ring atom is replaced by one oxygen atom; wherein said C _3-6 -cycloalkyl is unsubstituted, mono-, or di-substituted, wherein the substituents are selected from Ci_ ₃ -alkyl (especially methyl), hydroxy, fluoro, oxo, Ci-3-alkyl-carbonyl (especially acetyl), and Ci. ₃ -alkoxy (especially methoxy); o chromanyl (especially chroman-6-yl);

[in particular such -L^CY ² represents 2-(benzyl-oxy)-ethyl, 2,2-dimethyl-cyclopentyl, 3,3- difluoro-cyclopentyl, 3-methoxy-cyclopentyl, cyclohexyl, 4-hydroxy-cyclohexyl, 4-methyl-4- hydroxy-cyclohexyl, 4-oxo-cyclohexyl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-4-yl-methyl, or chroman-6-yl]

[in particular such -O-R ⁰² represents isopropoxy, isobutoxy, sec-butoxy, 2-(benzyl-oxy)-ethoxy, 2-methoxy- ethoxy, 3-hydroxy-propoxy, 2-hydroxy-2-methyl-propoxy, 2-hydroxy-ethoxy, 3-hydroxy-3-methyl-butoxy, 2,2- dimethyl-cyclopentyl-oxy, 3,3-difluoro-cyclopentyl-oxy, cyclohexyl-oxy, 4-hydroxy-cyclohexyl-oxy, 4-methyl-4- hydroxy-cyclohexyl-oxy,4-oxo-cyclohexyl-oxy, tetrahydrofuran-3-yl-oxy, tetrahydropyran-4-yl-oxy, tetrahydropyran-4-yl-methoxy, 3-methoxy-cyclopentyl-oxy, or chroman-6-yl-oxy]

7) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein said substituent of A / at least one of said substituents of A is

• C3-5-alkyl as defined in embodiment 1).

8) Another embodiment relates to compounds according to embodiment 7), wherein said substituent of A / at least one of said substituents of A is

• C3-5-alkyl (especially n-propyl, n-butyl, or n-pentyl) which is substituted with hydroxy and R ^A1 , wherein said substituents are both at position 3 with respect to the point of attachment of said C3-5-alkyl to the rest of the molecule; wherein

> R ^A1 represents

^■ phenyl which is unsubstituted or mono-substituted with fluorine (especially 3-fluoro-phenyl) or Ci-3-alkoxy (especially 2-methoxy-phenyl or 4-methoxy-phenyl);

^■ 6-membered heteroaryl containing one or two ring nitrogen heteroatom(s) (notably pyridin- 2-yl, pyridin-3-yl, pyrimidin-2-yl, pyrazin-2-yl, or pyrimidin-4-yl), wherein said 5- or 6- membered heteroaryl is independently unsubstituted, mono- or di- substituted, and wherein the substituent(s), if any, is(are) independently selected from Ci-3-alkyl (especially methyl), C3-5-cycloalkyl (especially cyclopropyl), or Ci_3-alkoxy (especially methoxy); or

[in particular such C3-5-alkyl which represents 3-hydroxy-3-phenyl-propyl, 3-hydroxy-3-phenyl-butyl, 3-hydroxy- 3-(3-fluoro-phenyl)-butyl, 3-hydroxy-3-(2-methoxy-phenyl)-butyl, 3-hydroxy-3-(4-methoxy-phenyl)-butyl, 3- hydroxy-3-(6-methoxy-pyridin-2-yl)-butyl, 3-hydroxy-3-(5-methyl-pyridin-3-yl)-butyl, 3-hydroxy-3-(pyridin-2-yl)- butyl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-butyl, 3-hydroxy-3-(pyrimidin-2-yl)-butyl, 3-hydroxy-3-(6-methoxy- pyrimidin-4-yl)-butyl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-pentyl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)- butyl, 3-hydroxy-3-(5-methyl-pyrazin-2-yl)-butyl, 3-hydroxy-3-(pyridin-2-yl)-pentyl, or 3-hydroxy-3-(6-methoxy- pyridin-2-yl)-pentyl]

9) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein said substituent of A / at least one of said substituents of A is

• -NR ^N3 R ^N4 , wherein R ^N3 and R ^N4 form, together with the nitrogen to which they are attached, a heterocyclic ring as defined in embodiment 1).

10) Another embodiment relates to compounds according to embodiment 9), wherein said substituent of A / at least one of said substituents of A is

• -NR ^N3 R ^N4 wherein

> R ^N3 and R ^N4 form, together with the nitrogen to which they are attached, a heterocyclic ring of 4 to 6 members (notably 5 to 6 members), wherein the members needed to complete said heterocyclic ring are each independently selected from -CH2-, -0-, -(C=0)-, -CHR ^X - and -C(R ^Y )2-; wherein said heterocyclic ring does not contain more than one member independently selected from the group consisting of -O- and -(C=0)-; wherein said heterocyclic ring does not contain more than two members selected from the group consisting of -CHR ^X -; and wherein said heterocyclic ring does not contain more than two members selected from the group consisting of -C(R ^Y )2-; wherein R ^x independently represents fluorine, methyl, isopropyl, hydroxy, trifluoromethyl, cyclopropyl, phenyl, 3- methyl-1 ,2,4-oxadiazol-5-yl; and wherein R ^Y independently represents fluorine, hydroxy, cyclopropyl, methyl, or trifluoromethyl [notably such -NR ^N3 R ^N4 is pyrrolidinyl; 2-pyrrolidonyl; oxazolidinonyl (especially 1,3-oxazolidin-2-on-3-yl); piperidinyl; or morpholinyl, optionally independently substituted with one or two substituents independently selected from a group consisting of R ^x and R ¹¹ ].

[in particular such -NR ^N3 R ^N4 represents pyrrolidin-1-yl, 3-fluoro-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, 3,4- difluoro-pyrrolidin-1-yl, 3-isopropyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2- methyl-pyrrolidin-1-yl, 3-hydroxy-3-methyl-pyrrolidin-1-yl, 3-hydroxy-3-trifluoromethyl-pyrrolidin-1-yl, 3- trifluoromethyl-pyrrolidin-1-yl, morpholin-4-yl, 3-(tetrahydropyran-4-yl)-pyrrolid-2-on-1-yl, pyrrolidin-2-on-1-yl, 4-phenyl-pyrrolidin-2-on-1-yl, 4-(pyridin-2-yl)-pyrrolidin-2-on-1-yl, 4-(6-methyl-pyridin-3-yl)-pyrrolidin-2-on-1-yl, 4-(2-isopropyl-pyrimidin-4-yl)-pyrrolidin-2-on-1-yl, 4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-on-1-yl, 4-(6- trifluoromethyl-pyridin-3-yl)-pyrrolidin-2-on-1-yl, 4-methyl-pyrrolidin-2-on-1-yl, 4-isopropyl-pyrrolidin-2-on-1-yl, 3-isopropyl-pyrrolidin-2-on-1-yl, 3,3-dimethyl-pyrrolidin-2-on-1-yl, 4,4-dimethyl-pyrrolidin-2-on-1-yl, 3- (piperidin-4-yl)-pyrrolidin-2-on-1-yl, 4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-on-1-yl, 4-isobutyl-pyrrolidin-2-on- 1-yl, 4-cyclopropyl-pyrrolidin-2-on-1-yl, 4-trifluoromethyl-pyrrolidin-2-on-1-yl, 2,2,6,6-tetrafluoro-morpholin-4- yl, 2,6-dimethyl-morpholin-4-yl, 3-(3-methyl-1,2,4-oxadiazol-5-yl)-pyrrolidin-1-yl, or 3-(phenyl)-pyrrolidin-1-yl] 11) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein said substituent of A / at least one of said substituents of A is

> 5- or 6-membered heteroaryl as defined in embodiment 1 ), wherein the substituent(s) of said 5- or 6-membered heteroaryl, if any, is(are) independently selected from

> Ci-4-alkyl as defined in embodiment 1).

12) Another embodiment relates to compounds according to embodiment 11), wherein said substituent of A / at least one of said substituents of A is

> 5- or 6-membered heteroaryl containing from one to three (notably two or three; especially three) ring heteroatom(s) independently selected from nitrogen, oxygen and sulfur (notably pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrimidinyl, or pyridinyl; especially pyrazol-1-yl, 1 H-1 ,2,3-triazol-1 -yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, pyrimidin-2-yl, or pyridin-2-yl; notably 1,2,4-oxadiazol-5-yl or 1,2,4- oxadiazol-3-yl; especially 1,2,4-oxadiazol-3-yl); wherein said 5- or 6-membered heteroaryl is independently unsubstituted, mono-, di-, or tri-substituted (notably mono-substituted; especially mono-substituted in position 3 with respect to the point of attachment of said 5- or 6-membered heteroaryl to A), wherein the substituent(s), if any, is(are) independently selected from

> Ci-4-alkyl (especially methyl, ethyl, propyl, isopropyl, or tert-butyl) which is

^■ unsubstituted;

^■ mono-substituted with

❖ hydroxy; or

❖ Ci_ ₄ -alkoxy (especially methoxy and tert-butoxy); or

[in particular such Ci-4-alkyl represents methyl, isopropyl, hydroxy-methyl, 1-hydroxy-1- methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1 , 1 -dimethyl-ethyl, methoxy- methyl, 2-methoxy-ethyl, 1 -methoxy-1 -methyl-ethyl, 2-methoxy-2-methyl-propyl, 2- methoxy-1 , 1 -dimethyl-ethyl, or tert-butoxy-methyl; in particular such C -alkyl represents 1 -hydroxy-1 -methyl-ethyl, 2-hydroxy-2-methyl-propyl, or 2-hydroxy-1,1- dimethyl-ethyl]

^■ di-substituted, wherein one substituent is hydroxy, and another substituent is trifluoromethyl; or two substituents are hydroxy;

^■ di- or tri-substituted, wherein two substituents are fluorine and, if present, one substituent is hydroxy (wherein the hydroxy group is separated by at least two carbon atoms from any of said fluorine substituents);

[in particular such C -alkyl represents methyl, isopropyl, hydroxy-methyl, 1-hydroxy-1-methyl-ethyl,

2-hydroxy-2-methyl-propyl, 2-hydroxy-1 , 1 -dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1- methoxy-1 -methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1, 1-dimethyl-ethyl, tert-butoxy- methyl; 1,2-dihydroxy-ethyl, N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl, 2- (methylcarboxamido)-2-methyl-propyl, 2-(ethylcarboxamido)-2-methyl-propyl, 2-(cyclopropyl- carboxamido)-2-methyl-propyl, 2-(tetrahydropyran-4-yl-carboxamido)-2-methyl-propyl, 2-(methoxy- methyl-carboxamido)-2-methyl-propyl, 2-(ethyl-carboxamido)-2-methyl-propyl, 2-(isopropyl- carboxamido)-2-methyl-propyl, 2-(methyl-d3-carboxamido)-2-methyl-propyl, N-methyl-N-(hydroxy- methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl, 2, 2, 2-trifluoro-1 -hydroxy-1 - methyl-ethyl, 1 , 1 -difluoro-2-hydroxy-ethyl, 1,1-difluoro-ethyl, or N-methyl-N-(acetyl-2,2,2-d ₃ )-2- amino-ethyl; in particular such C -alkyl group is 1 -hydroxy-1 -methyl-ethyl, 2-hydroxy-2-methyl- propyl, or 2-hydroxy-1 , 1 -dimethyl-ethyl]

13) Another embodiment relates to compounds according to embodiment 11), wherein said substituent of A / at least one of said substituents of A is

> 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl (especially 1,2,4-oxadiazol-3-yl), wherein said oxadiazolyl groups are mono-substituted, wherein the substituent is independently selected from

> Ci-4-alkyl (especially methyl, ethyl, propyl, isopropyl, ot tetrt-butyl) which is

^■ mono-substituted with

❖ hydroxy; or

❖ Ci-4-alkoxy (especially methoxy and tert-butoxy).

[in particular such Ci_ ₄ -alkyl represents hydroxy-methyl, 1 -hydroxy-1 -methyl-ethyl, 2- hydroxy-2-methyl-propyl, 2-hydroxy-1 , 1 -dimethyl-ethyl, methoxy-methyl, 2-methoxy- ethyl, 1 -methoxy-1 -methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1 , 1 -dimethyl- ethyl, or tert-butoxy-methyl; in particular such C -alkyl represents 1 -hydroxy-1 -methyl- ethyl, 2-hydroxy-2-methyl-propyl, or 2-hydroxy-1 , 1 -dimethyl-ethyl]

14) Another embodiment relates to compounds according to embodiment 11), wherein said substituent of A / at least one of said substituents of A is

> 1 , 2 , 4-oxad i azo I -3-y I , which is mono-substituted (especially in position 3 with respect to the point of attachment of said oxadiazolyl to A), wherein the substituent is

> Ci-4-alkyl (especially methyl, ethyl, propyl, isopropyl, or tert-butyl) which is

^■ mono-substituted with

❖ hydroxy;

[in particular such C -alkyl represents hydroxy-methyl, 1 -hydroxy-1 -methyl-ethyl, 2- hydroxy-2-methyl-propyl, 2-hydroxy-1 , 1 -dimethyl-ethyl, in particular such C -alkyl represents 1 -hydroxy-1 -methyl-ethyl, 2-hydroxy-2-methyl-propyl, or 2-hydroxy-1 ,1- dimethyl-ethyl]

15) Another embodiment relates to compounds according to embodiment 11), wherein A represents pyridin-3-yl, wherein said pyridin-3-yl is mono-substituted in eia-position with respect to the point of attachment of said pyridin-3- yl to the rest of the molecule, wherein the substituent is

> 1 , 2 , 4-oxad i azo I -3-y I , which is mono-substituted (especially in position 3 with respect to the point of attachment of said oxadiazolyl to A), wherein the substituent is hydroxy-methyl, 1 -hydroxy- 1 -methyl-ethyl, 2-hydroxy-2- methyl-propyl, or 2-hydroxy-1 , 1 -dimethyl-ethyl.

[in particular such 1,2,4-oxadiazol-3-yl represents 5-(hydroxy-methyl)-1,2,4-oxadiazol-3-yl, 5-(1 -hydroxy-1 - methyl-ethyl)-1,2,4-oxadiazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-oxadiazol-3-yl, or 5-(2-hydroxy-1,1- dimethyl-ethyl)-1,2,4-oxadiazol-3-yl]

16) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein said substituent of A / at least one of said substituents of A is

> 5- or 6-membered heteroaryl as defined in embodiment 1 ), wherein the substituent(s) of said 5- or 6-membered heteroaryl, if any, is(are) independently selected from

> -L ³ -CY ³ as defined in embodiment 1).

17) Another embodiment relates to compounds according to embodiment 16), wherein said substituent of A / at least one of said substituents of A is

• 5- or 6-membered heteroaryl containing from one to three (notably two or three; especially three) ring heteroatom(s) independently selected from nitrogen, oxygen and sulfur (notably pyrazolyl, oxazolyl, thiazolyl, oxadiazolyl, pyrimidinyl, or pyridinyl; especially pyrazol-1-yl, 1/7-1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-oxadiazol-3-yl, pyrimidin-2-yl, or pyridin-2-yl; notably 1,2,4-oxadiazol-5-yl or 1,2,4- oxadiazol-3-yl; especially 1,2,4-oxadiazol-3-yl); wherein said 5- or 6-membered heteroaryl is independently unsubstituted, mono-, di-, or tri-substituted (notably mono-substituted; especially mono-substituted in position 3 with respect to the point of attachment of said 5- or 6-membered heteroaryl to A), wherein the substituent(s), if any, is(are) independently selected from

> -L ³ -CY ³ , wherein

^■ -L ³ - independently represents a bond (i.e. the CY ³ is directly attached to the rest of the molecule), -CH ₂ -, -CH ₂ -CH ₂ -, -C(CH ₃ ) ₂ -, -CH(OH)-, or -0-CH ₂ -, wherein when -L ³ - is -O- CH ₂ -, said CY ³ is attached to the oxygen atom of said -0-CH ₂ -; and

^■ CY ³ independently represents piperidinyl; wherein said piperidinyl independently is unsubstituted, mono-, di-, or tri-substituted as defined in embodiment 1). 18) Another embodiment relates to compounds according to embodiment 16), wherein said substituent of A / at least one of said substituents of A is

> 1,2,4-oxadiazol-5-yl or 1,2, 4-oxad i azol -3-y I (especially 1,2,4-oxadiazol-3-yl), wherein said oxadiazolyl groups are mono-substituted, wherein the substituent is independently selected from • -L ³ -CY ³ , wherein

^■ -L ³ - independently represents a bond (i.e. the CY ³ is directly attached to the rest of the molecule), -CH2-, -CH2-CH2-, -C(CH3)2-, -CH(OH)-, or -O-CH2-, wherein when -L ³ - is -0- CH2-, said CY ³ is attached to the oxygen atom of said -O-CH2-; and

^■ CY ³ independently represents piperidinyl (notably piperidin-2-yl, piperidin-3-yl, or piperidin- 4-yl; especially piperidin-4-yl) wherein said piperidinyl independently is unsubstituted, mono- , di-, or tri-substituted (especially unsubstituted, mono-, or di-substituted) with

> halogen (especially fluorine);

> oxo;

> hydroxy;

> Ci-3-alkyl which is optionally mono-substituted with Ci-3-alkoxy (especially such Ci_ 3-alkyl represents methyl, ethyl, propyl, isopropyl, or methoxy-methyl);

> Ci-3-alkoxy (especially methoxy);

> -(C=0)-R ^co , wherein R ^co represents o Ci-3-alkyl which is optionally mono-substituted with hydroxy or Ci-3-alkoxy (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy-methyl, methoxy-methyl, benzyl-oxy, or 2-methoxy-ethyl; in particular said - (C=0)-R¥ is acetyl); o Ci-3-fluoroalkyl (especially 2, 2 , 2-trif I u 0 ro-ethy I ) ; o Ci-3-alkoxy (especially methoxy); o C3-6-cycloalkyl-(CH2)n-, wherein optionally one or two carbon ring atom(s) is/are replaced by one or two oxygen ring atom(s); wherein n represents the integer 0, or 1 (especially such C3-5-cycloalkyl-(CH2) _n - represents cyclopropyl, cyclopentyl, oxetan-3-yl, oxetan-3-yl-methyl, 1,4-dioxan-2-yl, or tetrahydropyran-4-yl); or o phenyl;

[especially such -(C=0)-R ^co represents acetyl, ethyl-carbonyl, n-propyl -carbonyl , isopropyl-carbonyl, tert-butyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro- ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy- carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetan-3-yl-carbonyl, oxetan-3-yl-methyl-carbonyl, phenyl- carbonyl, or tetrahyd ropy ran -4-y I -car bo ny I , methoxy-methyl-carbonyl, or 1,4- dioxan-2-yl-carbonyl]

> -S(=0) ₂ -R ^so , wherein R ^so represents o Ci-3-alkyl which is optionally mono-substituted with hydroxy, Ci-3-alkoxy, or amino (especially methyl, n-propyl, isopropyl, 2-hydroxy-ethyl, 2- methoxy-ethyl, or methyl-amino); or o C3-5-cycloalkyl, wherein optionally one carbon ring atom is replaced by one oxygen ring atom (especially represents cyclopropyl, cyclopentyl, or tetrahydropyran-4-yl);

[especially such -S(=0) ₂ -R ^so represents methyl-sulfonyl, n-propyl-sulfonyl, isopropyl-sulfonyl, 2-hydroxyethyl-sulfonyl, cyclopropyl-sulfonyl, cyclopentyl- sulfonyl, 2-methoxy-ethyl-sulfonyl, methyl-amino-sulfonyl, or tetrahydropyran-4-yl- sulfonyl]

[in particular such — L ³ — CY ³ piperidin-4-yl, 1-methyl-2,6-dioxo-piperidin-4-yl, 4-methyl-piperidin-4-yl, 4-fl uoro-pi perid i n-4-y 1 , 2-oxo-piperidin-4-yl, 6-oxo-piperidin-2-yl, 6-oxo-pi peridi n-3-yl , 1-methyl-6-oxo- piperidin-3-yl, 3-methyl-6-oxo-piperidin-3-yl, N-acetyl-piperidin-4-yl, N-acetyl-piperidin-4-yl-methyl, N-acetyl-2-methyl-piperidin-4-yl, N-acetyl-4-fluoro-piperidin-4-yl, N-acetyl-3-methyl-piperidin-4-yl, N- acetyl-4-methyl-piperidin-4-yl, N-acetyl-4-hydroxy-piperidin-4-yl, N-acetyl-4-methoxy-piperidin-4-yl, N-acetyl-piperidin-3-yl, N-acetyl-piperidin-3-yl-methyl, N-acetyl-3-methyl-piperidin-3-yl, N-acetyl-3- hydroxy-piperidin-3-yl, N-(isopropyl-carbonyl)-4-hydroxy-piperidin-4-yl, N-(tert-butyl-carbonyl)- piperidin-4-yl, N-(2-methoxy-ethoxy-carbonyl)-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin- 4-yl, N-(cyclopropyl-sulfonyl)-piperidin-4-yl, N-(methyl-sulfonyl)-piperidin-4-yl, N-(n-propyl-sulfonyl)- piperidin-4-yl, N-(isopropyl-sulfonyl)-piperidin-4-yl, N-(2-hydroxy-ethyl-sulfonyl)-piperidin-4-yl, N- (cyclopentyl-sulfonyl)-piperidin-4-yl, N-(methoxy-carbonyl)-piperidin-4-yl, N-(cyclopropyl-carbonyl)- piperidin-4-yl, N-(cyclopentyl-carbonyl)-piperidin-4-yl, N-(methyl-amino-sulfonyl)-piperidin-4-yl, N-(2- methoxy-ethyl-sulfonyl)-piperidin-4-yl, N-(ethyl-carbonyl)-4-hydroxy-piperidin-4-yl, N-(methoxy- methyl-carbonyl)-piperidin-4-yl, N-(ethoxy-carbonyl)-piperidin-4-yl, N-acetyl-4-ethyl-piperidin-4-yl, N- (n-propyl-carbonyl)-piperidin-4-yl, N-(2-methoxy-ethyl-carbonyl)-piperidin-4-yl, N-(oxetan-3-yl- carbonyl)-piperidin-4-yl, N-(oxetan-3-yl-methyl-carbonyl)-piperidin-4-yl, N-(2,2,2-trifluoro-ethyl- carbonyl)-piperidin-4-yl, N-(tetrahydropyran-4-yl-carbonyl)-piperidin-4-yl, N-(phenyl-carbonyl)- piperidin-4-yl, N-(tetrahydropyran-4-yl-sulfonyl)-piperidin-4-yl, N-(benzyl-oxy-carbonyl)-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-4-isopropyl-piperidin-4-yl, N-(1,4-dioxan-2-yl-carbonyl)-piperidin-4-yl],

19) Another embodiment relates to compounds according to embodiment 16), wherein said substituent of A / at least one of said substituents of A is

> 1,2,4-oxadiazol-3-yl, wherein said oxadiazolyl group is mono-substituted, wherein the substituent is independently selected from • -L ³ -CY ³ , wherein

^■ -L ³ -represents a bond (i.e. the CY ³ is directly attached to the rest of the molecule); and

^■ CY ³ independently represents piperidin-4-yl which is unsubstituted, or mono- or di- substituted, wherein

> one substituent is attached to the nitrogen atom of said piperidine ring, wherein the substituent is -(C=0)-R ^co , wherein R ^co represents o Ci-3-alkyl optionally mono-substituted, wherein the substituent represents Ci-3-alkoxy or hydroxy (especially such Ci-3-alkyl is methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy-methyl, methoxy-methyl, or 2-methoxy-ethyl; in particular said -(C=0)-R ^co is acetyl); o Ci-3-fluoroalkyl (especially 2,2,2-trifluoro-ethyl); o Ci-3-alkoxy (especially methoxy); o C3-6-cycloalkyl-(CH2) _n -, wherein optionally one or two carbon ring atom(s) is/are replaced by one or two oxygen ring atom(s); wherein n represents the integer 0, or 1 (especially such C3_ ₅ -cycloal kyl-(CH ₂ ) _n - represents cyclopropyl, cyclopentyl, oxetan-3-yl, oxetan-3-yl-methyl, 1,4-dioxan-2-yl, or tetrahydropyran-4-yl); or

[especially such -(C=0)-R ^co represents acetyl, ethyl-carbonyl, n-propyl-carbonyl, isopropyl-carbonyl, tert-butyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro- ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy- carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetan-3-yl-carbonyl, oxetan-3-yl-methyl-carbonyl, tetrahydropyran-4-yl-carbonyl, methoxy-methyl-carbonyl, or 1,4-dioxan-2-yl- carbonyl]

> and/or one substitutent is attached to a carbon atom of the piperidine ring, wherein said substituent is Ci-3-alkyl (especially methyl), halogen (especially fluorine), hydroxy, or C1-3- alkoxy (especially methoxy). 20) Another embodiment relates to compounds according to any one of embodiments 1) to 4), wherein said substituent of A / at least one of said substituents of A independently is

• -CºC-R ^T1 ; or

• -CºC-C(OH)(R ^T2 )(R ^T3 ); wherein said groups are as defined in embodiment 1).

21) Another embodiment relates to compounds according to embodiment 20), wherein said substituent of A / at least one of said substituents of A is

• -CºC-R ^T1 , wherein

> R ^T1 represents

^■ Ci-4-alkyl (notably methyl, ethyl, isopropyl, or isobutyl), wherein said C -alkyl independently is mono-substituted with

❖ hydroxy;

[especially such C -alkyl represents hydroxy-methyl, 1 -hydroxy-ethyl, 2-hydroxy-ethyl, 1- hyd roxy-2-methy I - pro py I , or 1 -hydroxy-1 -methyl-ethyl];

❖ Ci_3-alkoxy (especially methoxy);

❖ -S(=0) ₂ -R ^sot , wherein R ^S0T represents Cu-alkyl, Ci-3-alkyl-amino, or C3-5- cycloalkyl (especially such -S(=0) ₂ -R ^S0T represents methyl-sulfonyl, methyl- amino-sulfonyl or cyclopropyl-sulfonyl);

❖ C4-6-heterocyclyl containing one or two ring heteroatom(s) independently selected from nitrogen and oxygen (notably oxazolidinyl, imidazolidinyl, or pyrrolidinyl; especially oxazolidin-3-yl, imidazolidin-3-yl, or pyrrolidin-1-yl); wherein said C4-6- heterocyclyl is mono-substituted with oxo; or di-substituted with oxo and one C1-3- alkyl (especially methyl); (especially such C _4-6 -heterocyclyl represents oxazolidin- 2-on-3-yl, imidazolidin-2-on-3-yl, 1-methyl-imidazolidin-2-on-3-yl, or pyrrolidin-2- on-1-yl);

^■ Ci-4-alkyl (notably methyl, ethyl, isopropyl, or isobutyl) which is independently di-substituted, wherein one substituent is hydroxy, and a second substituent is trifluoromethyl (especially 1 -hydroxy-1 -trifluoromethyl-ethyl);

^■ C3-6-cycloalkyl (especially cyclopropyl) which is mono-substituted (especially at the point of attachment of the C3-6-cycloalkyl to the rest of the molecule) with

❖ hydroxy;

❖ amino-sulfonyl which is optionally di-substituted with methyl;

❖ phenyl which is mono-substituted with halogen (especially 4-fluoro-phenyl); ❖ pyridinyl (especially pyridine-2-yl);

❖ pyrimidinyl which is mono-substituted with Ci_ ₃ -alkyl (especially 6-methyl-pyrimidin- 4-yl);

❖ oxazolidinonyl (especially oxazolidin-2-on-3-yl);

[in particular such C3-6-cycloalkyl represents 1 -hydroxy-cyclopropyl, 1 -hydroxy-cyclobutyl, 1- hydroxy-cyclopenty, 1 -(amino-sulfonyl)-cyclopropyl, 1 -(dimethyl-amino-sulfonyl)- cyclopropyl, 1-(6-methyl-pyrimidin-4-yl)-cyclopropyl, 1-(pyridine-2-yl)-cyclopropyl, 1-(4- fluoro-phenyl)-cyclopropyl, 1-(pyridine-2-yl)-cyclopropyl, or 1-(oxazolidin-2-on-3-yl)- cyclopropyl];

^■ C _4-6 -heterocyclyl containing one ring heteroatom independently selected from nitrogen and oxygen (notably azetidinyl, pyrrolidinyl, piperidinyl, tetrahydropyranyl; especially azetidin-3- yl, piperidin-4-yl, pyrrolidin-3-yl, pyrrolidin-2-yl, pyrrolidine-1-yl, or tetrahydropyran-4-yl); wherein said C4-6-heterocyclyl is mono-, di-, or tri-substituted (especially mono- or di- substituted), wherein the substituent(s) is(are) independently selected from Ci-3-alkyl (especially methyl), hydroxy, oxo, Ci-3-alkyl-carbonyl (especially acetyl), Ci_3-alkoxy- carbonyl (especially tert-butoxy-carbonyl), Ci-3-alkyl-sulfonyl (especially methyl-sulfonyl), and Ci-3-alkyl-amino-sulfonyl (especially methyl-amino-sulfonyl);

[in particular such C4-6-heterocyclyl represents N-(isopropyl-carbonyl)-3-hydroxy-azetidin-3- yl, N-(tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl, N-methyl-3-hydroxy-pyrrolidin-2-one-3- yl, N-acetyl-2-methyl-pyrrolidin-2-yl, 3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl, 2- oxo-pyrrolidine-1-yl, N-acetyl-piperidin-4-yl, N-acetyl-4-methyl-piperidin-4-yl, N-(methyl- amino-sulfonyl)-4-methyl-piperidin-4-yl, N-acety l-4-hydroxy-pi peri di n-4-yl , N-(methyl- sulfonyl)-piperidin-4-yl, N-(tert-butoxy-carbonyl)-piperidin-4-yl, 3-hydroxy-2-oxo-1-methyl- pyrrolidin-2-yl, or 4-hydroxy-tetrahydropyran-4-yl);

^■ indolyl (especially indol-2-yl);;

^■ 3-hydroxy-1 -methyl-1, 3-dihydro-indol-2-on-3-yl; or

[in particular such -CºC-R ^T1 represents 3-hydroxy-3-trifluoromethyl-but-1-yn-1-yl, 3-hydroxy-prop-1 -yn-1 -yl, 4- hydroxy-but-1 -yn-1 -yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methy l-but- 1 -y n- 1 -y 1 , 3-hydroxy-4-methyl-pent-1- yn-1-yl, (l-hydroxy-cyclopropyl)-ethynyl, (l-hydroxy-cyclobutyl)-ethynyl, (l-hydroxy-cyclopentyl)-ethynyl, (8- hydroxy-5,6,7,8-tetrahydroquinolin-8-yl)-ethynyl, (7-hydroxy-6,7-dihydro-5H-cyclopenta[b] pyridin-7-yl)- ethynyl, (4-hydroxy-tetrahydropyran-4-yl)-ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl, (1- (tert-butoxy-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl, (N-acetyl-4-hydroxy-piperidin- (3-hydroxy-N-(tert- butoxy-carbonyl)-pyrrolidin-3-yl)-ethynyl, (3-hydroxy- 1 -methyl-1, 3-dihydro-indol-2-on-3-yl)-ethynyl, or (3- hydroxy-2-oxo-1-methyl-pyrrolidin-3-yl)-ethynyl]

• -CºC-C(OH)(R ^T2 )(R ^T3 ) is as defined in embodiment 1).

22) Another embodiment relates to compounds according to embodiment 20), wherein said substituent of A / at least one of said substituents of A is

• -CºC-C(OH)(R ^T2 )(R ^T3 ), wherein

> R ^T2 represents hydrogen or Ci-3-alkyl (notably methyl or ethyl; especially methyl);

> R ^T3 represents

^■ 6-membered heteroaryl containing one or two ring nitrogen atoms (especially pyridinyl, pyrazinyl, or pyrimidinyl; especially pyridin-2-yl, pyrimidin-2-yl, pyrazin-2-yl, or pyrimidin-4- yl; in particular pyrimidin-4-yl), wherein said 6-membered heteroaryl is independently unsubstituted, mono- or di- substituted; wherein the substituent(s), if any, is(are) independently selected from Ci_ ₃ -alkyl (especially methyl), Ci_3-cycloalkyl (especially cyclopropyl), Ci_ ₃ -fluoroalkyl (notably Crfluoroalkyl; especially difluoromethyl or trifluoromethyl), and Ci-3-alkoxy (especially methoxy);

[in particular such 6-membered heteroaryl is pyridin-2-yl, 6-methoxy-pyridin-2-yl, 6-methyl- pyridin-2-yl, pyrimidin-2-yl, 2-methoxy-pyrimidin-4-yl, 6-methoxy-py rimi di n-4-yl , pyrimidin-4- yl, 2-methyl-pyrimidin-4-yl, 6-methyl-pyrimidin-4-yl, 2,6-dimethyl-pyrimidin-4-yl, 2,6- dimethoxy-pyrimidin-4-yl, 2-methyl-6-methoxy-pyrimidin-4-yl, 2-methoxy-6-methyl- pyrimidin-4-yl, 5-methyl-pyrazin-2-yl, 6-cyclopropyl-pyrimidin-4-yl, 6-difluoromethyl- pyrimidin-4-yl, 2-trifluoromethyl-pyrimidin-4-yl, or 6-trifluoromethyl-pyrimidin-4-yl]

[in particular such -CºC-C(OH)(R ^T2 )(R ^T3 ) represents 3-hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6- methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2- methoxy-6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy- 3-(2,6-dimethoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3- (6-methoxy-2-methyl-pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(6- methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(6-methyl- pyridin-2-yl)-pent-1 -yn-1 -yl, 3-hydroxy-3-(2,6-dimethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy- pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(6-cyclopropyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6- difluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-trifluoromethyl-pyrimidin-4-yl)-but-1 -yn-1 -yl, or 3- hydroxy-3-(6-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl] 23) Another embodiment relates to compounds according to any one of embodiments 1) to 22), wherein B represents phenyl, which is mono-, di- or tri-substituted, wherein a first substituent is attached in para- position with respect to the point of attachment of B to the rest of molecule, wherein said substituent is selected from

> Ci-5-alkyl (notably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, 1 -ethyl-propyl, 2,2-dimethyl- propyl, 1,1 -dimethyl-propyl; especially methyl, ethyl, or isopropyl; in particular isopropyl);

> Ci-3-alkoxy-Ci-4-alkyl (especially 3-methoxy-propyl);

> Ci-2-fluoroalkyl (especially trifluoromethyl or 2,2,2-trifluoro-ethyl);

> C3-5-cycloalkyl (especially cyclopropyl or cyclobutyl) which independently is unsubstituted or mono-substituted (notably at the point of attachment of said C3-5-cycloalkyl to the rest of the molecule) with Ci-3-alkyl (especially methyl) or Ci_ ₃ -fluoroal kyl (especially trifluoromethyl); and

> Crfluoroalkoxy (especially trifluoromethoxy); and the remaining substituent(s) of B (wherein especially said remaining substituent(s) is/are attached in eia-position with respect to the point of attachment of B to the rest of molecule), if present, independently is/are selected from halogen (notably fluorine or chlorine; especially fluorine).

[in particular such group B represents 4-methyl-phenyl, 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-butyl- phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 4-(1-ethyl-propyl)-phenyl, 4-(1,1-dimethyl-propyl)-phenyl, 4-(2,2- dimethyl-propyl)-phenyl, 3-chloro-4-isopropyl-phenyl, 3-fl uoro-4-isopropy l-pheny 1 , 3,5-difluoro-4-isopropyl-phenyl, 4- cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-trifluoromethoxy-phenyl, 4-(1-methyl- cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, 4-(3-methoxy-propyl)-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl]

24) Another embodiment relates to compounds according to any one of embodiments 1) to 22), wherein B represents phenyl, which is mono-, di- or tri-substituted, wherein a first substituent is attached in para- position with respect to the point of attachment of B to the rest of molecule, wherein said substituent is selected from

> C2-4-alkyl (notably n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl; in particular isopropyl);

> trifluoromethyl or 2,2,2-trifluoro-ethyl;

> C3-5-cycloalkyl (especially cyclopropyl or cyclobutyl) which independently is unsubstituted or mono-substituted (notably at the point of attachment of said C3-5-cycloalkyl to the rest of the molecule) with Ci_3-alkyl (especially methyl) or Ci-3-fluoroalkyl (especially trifluoromethyl); and

> Crfluoroalkoxy (especially trifluoromethoxy); and the remaining substituent(s) of B (wherein especially said remaining substituent(s) is/are attached in meia-position with respect to the point of attachment of B to the rest of molecule), if present, independently is/are selected from halogen (notably fluorine or chlorine; especially fluorine). [in particular such group B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-butyl-phenyl, 4-isobutyl-phenyl, 4-tert- butyl-phenyl, 3-chloro-4-isopropyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl- phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-(1 -methyl-cyclopropyl)- phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl]

25) Another embodiment relates to compounds according to any one of embodiments 1) to 22), wherein B represents phenyl, which is mono-substituted, wherein the substituent is attached in para- position with respect to the point of attachment of B to the rest of molecule, wherein said substituent is selected from isopropyl (preferred), trifluoromethyl, trifluoromethoxy, trifluoromethyl, cyclopropyl, cyclobutyl, 1 -methyl-cyclopropyl, and 1-trifluoromethyl-cyclopropyl.

[in particular such group B represents 4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4- trifluoromethoxy-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)- phenyl]

26) Another embodiment relates to compounds according to any one of embodiments 1) to 25), wherein R ¹ represents Ci-3-alkyl (notably methyl or ethyl; especially methyl);

27) Another embodiment relates to compounds according to any one of embodiments 1) to 26), wherein R ² represents Ci-4-alkyl (especially methyl (preferred), ethyl, n-propyl, isopropyl, tert-butyl or isobutyl), C3-s-cycloalkyl (especially cyclopropyl or cyclobutyl), C3-5-cycloalkyl-Ci-3-alkyl (especially cyclopropyl-methyl), or Ci-3-fluoroalkyl (especially 2,2- difluoro-ethyl, or 2-fluoroethyl).

28) Another embodiment relates to compounds according to any one of embodiments 1) to 26), wherein R ² represents methyl (preferred), ethyl, n-propyl, isopropyl, cyclopropyl, or cyclobutyl.

29) Another embodiment relates to compounds according to embodiment 1), wherein A represents pyridin-3-yl, wherein said pyridin-3-yl is mono-substituted in eia-position with respect to the point of attachment of said pyridin-3-yl to the rest of the molecule, wherein the substituent is 5-(hydroxy-methyl)-1,2,4-oxadiazol-3-yl, 5-(1-hydroxy-1-methyl-ethyl)- 1,2,4-oxadiazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-oxadiazol-3-yl, or 5-(2-hydroxy-1 , 1 -dimethyl-ethyl)-1 ,2,4- oxadiazol-3-yl;

B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2- trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl;

R ¹ represents methyl; and R ² represents methyl.

30) Another embodiment relates to compounds according to embodiment 1), wherein A represents pyridin-3-yl, wherein said pyridin-3-yl is mono-substituted in eia-position with respect to the point of attachment of said pyridin-3-yl to the rest of the molecule, wherein the substituent is > 1 , 2 , 4-oxad i azol -3-y I , wherein said oxadiazolyl group is mono-substituted, wherein the substituent is piperidin- 4-yl which is unsubstituted, or mono- or di-substituted, wherein one substituent is attached to the nitrogen atom of said piperidine ring, wherein the substituent is

• acetyl, ethyl-carbonyl, n-propy I -carbonyl , isopropyl-carbonyl, tert-butyl-carbonyl, hydroxymethyl- carbonyl, 2,2,2-trifluoro-ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy-carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl- carbonyl, oxetan-3-yl-carbonyl, oxetan-3-yl-methyl-carbonyl, tetrahydropyran-4-yl-carbonyl, methoxy-methyl-carbonyl, or 1,4-dioxan-2-yl-carbonyl; and/or one substituent is attached to a carbon atom of the piperidine ring, wherein said substituent is Ci_3-alkyl (especially methyl), halogen (especially fluorine), hydroxy, or Ci-3-alkoxy (especially methoxy).

B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2- trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl;

R ¹ represents methyl; and R ² represents methyl.

31) Another embodiment relates to compounds according to embodiment 1), wherein A represents pyridin-3-yl, wherein said pyridin-3-yl is mono-substituted in eia-position with respect to the point of attachment of said pyridin-3-yl to the rest of the molecule, wherein the substituent is 3-hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl- pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-6-methyl- pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethoxy- pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-2-methyl- pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethyl-pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(6-cyclopropyl- pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(6-difluoromethyl-pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(2- trifluoromethyl-pyrimidin-4-yl)-but-1 -yn-1 -yl, or 3-hydroxy-3-(6-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl ]

B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2- trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl;

R ¹ represents methyl; and R ² represents methyl.

32) Another embodiment relates to compounds according to any one of embodiments 1) to 31), which are also compounds of Formula (II) (i.e. the asymmetric carbon atom to which A and B are attached has the absolute configuration depicted in Formula (II)) 33) Another embodiment relates to a compound according to embodiment 1) selected from a group consisting of

(3-Fluoro-1-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyri din-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

3-[Hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluorom ethoxy-phenyl)-methyl]-1-methyl-azetidine-3-carbonitrile;

(R)-(1-Ethyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-p yridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

(R)-(3-Methyl-1-propyl-azetidin-3-yl)-(5-pyrrolidin-1-yl- pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

(R)-(1-lsopropyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1- yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

(R)-(1-Cyclopropylmethyl-3-methyl-azetidin-3-yl)-(5-pyrro lidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methano l;

(R)-(1-Cyclobutyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1 -yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

(R)-(1-lsobutyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-y l-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin- 1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

(R)-[1-(2-Fluoro-ethyl)-3-methyl-azetidin-3-yl]-(5-pyrrol idin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol ;

(R)-[1-(2,2-Difluoro-ethyl)-3-methyl-azetidin-3-yl]-(5-py rrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-meth anol;

(R)-(1-tert-Butyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1 -yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-m ethoxy-prop-1-ynyl)-pyridin-3-yl]-methanol

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-prop-1-yn-1-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; 1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopentanol; 1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanol;

3-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-ylethynyl}-3-hydroxy-azetidine-1- carboxylic acid tert-butyl ester;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclobutanol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-1-ol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(1-methyl -1 H-pyrazol-4-ylethynyl)-pyridin-3-yl]-methanol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-prop-2-yn-1-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-but-3-yn-2-ol; 1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-4-methyl-pent-1-yn-3-ol; 4-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-ylethynyl}-tetrahydro-pyran-4-ol; 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-pyran-4-yl)-prop -

2-yn-1-ol;

3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 -(1 ,3-dimethyl-1 H-pyrazol-4- yl)-prop-2-yn-1-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (tetrahydro-pyran-4-ylethynyl)-pyridin-3-yl]-methanol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazol-4-yl)-p rop-

2-yn-1-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-but-3-y n-2- ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-but-3- yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-but-3- yn-2-ol;

4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1-methyl-1 H-pyrazol-3-yl)- but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-4-yl)-b ut-3- yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)- but-

3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl-but-3-yn-2 -ol; 4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1 ,5-dimethyl-1 H-pyrazol-3- yl)-but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl) - but-3-yn-2-ol;

3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 -(1 ,5-dimethyl-1 H-pyrazol-3- yl)-prop-2-yn-1-ol;

8-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-5,6,7 _J 8-tetrahydro- quinolin-8-ol;

7-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-6,7-dihydro-5H-

[1]pyrindin-7-ol;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pent-1-yn-3- ol;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)- pent-1-yn-3-ol; 1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-azetidin- 1 -y l)-2-methy l-propan- 1 -one;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(1 H-indol-2-ylethynyl)-pyridin-3-yl]-(4-isopropyl-phenyl)-meth anol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-methox y-propyl)-pyridin-3-yl]-methanol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-propan-1-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-butan-2-ol;

(S)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-butan-2-ol; (R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-yl}-butan-2-ol; 1-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopentanol; 1-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopropanol;

3-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-3-hydroxy-azetidi ne- 1 -carboxylic acid tert-butyl ester;

1-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclobutanol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-butan-1-ol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[2-(1-met hyl-1 H-pyrazol-4-yl)-ethyl]-pyridin-3-yl}-methanol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-propan-1-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-butan-2-ol; 1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-4-methyl-pentan-3-ol; 4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-tetrahydro-pyran-4- ol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-pyran-4-yl)- propan-1 -ol;

3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 -(1 ,3-dimethyl-1 H-pyrazol-4- yl)-propan-1-ol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[2-(tetra hydro-pyran-4-yl)-ethyl]-pyridin-3-yl}-methanol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazol-4-yl)- propan-1 -ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-butan-2 -ol; 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-butan-2- ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-butan- 2- ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1 H-pyrazol-3-yl)- butan-2-ol; 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-4-yl)- butan-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)- butan-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl-butan-2-ol ; 4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1 ,5-dimethyl-1 H-pyrazol-3- yl)-butan-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl) - butan-2-ol;

3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 -(1 ,5-dimethyl-1 H-pyrazol-3- yl)-propan-1-ol;

8-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-5,6,7,8-tetrahydr o- quinolin-8-ol;

7-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-6,7-dihydro-5H-

[1]pyrindin-7-ol;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pentan-3-ol;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)- pentan-3-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[2-(1H-indol-2-yl)-et hyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(4-Cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[ 3-(tetrahydro-pyran-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyridin-3-yl}- methanol;

(R)-(4-Cyclopropyl-phenyl)-(1 ,3-dimethyl-azetidin-3-yl)-{5-[3-(2-methoxy-1 , 1 -dimethyl-ethyl)-[1 ,2,4]oxadiazol-5-yl]- pyridin-3-yl}-methanol;

(R)-[5-(3-Cyclobutoxymethyl-[1,2,4]oxadiazol-5-yl)-pyridi n-3-yl]-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-{5-[3- (tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol-5-yl]-pyri din-

3-yl}-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-{5-[3-(tetrahyd ro-pyran-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyridin-3-yl}- methanol;

(R)-[5-(3-Cyclobutoxymethyl-[1,2,4]oxadiazol-5-yl)-pyridi n-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-propyl-phenyl)- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [3-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3- yl}- methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3- morpholin-4-ylmethyl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[3-(2,6-dimethyl-morp holin-4-ylmethyl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-(4- isopropyl-phenyl)-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-met hyl-tetrahydro-pyran-4-yl)-[1 ,2,4]oxadiazol-5-yl]- pyridin-3-yl}-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [(1S,2S,4R)-3-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]oxadiaz ol-

5-yl]-pyridin-3-yl}-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(tetra hydro-pyran-4-yloxymethyl)-[1 ,2,4]oxadiazol-5-yl]- pyridin-3-yl}-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (3-morpholin-4-yl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-metha nol; (R)-(4-Cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[ 3-(4-methoxy-tetrahydro-pyran-4-yl)-[1 ,2,4]oxadiazol-5-yl]- pyridin-3-yl}-methanol;

(R)-(4-Cyclopropyl-phenyl)-(1 ,3-dimethyl-azetidin-3-yl)-{5-[3-(3-hydroxymethyl-bicyclo[1. 1.1]pent-1 -yl)- [1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[3-(3-hydroxymethyl-b icyclo[1.1.1]pent-1-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl} -(4- isopropyl-phenyl)-methanol;

2-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-2 - methyl-propan-1-ol;

2-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)- propan-2-ol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1 -methoxy-1 -methyl-ethyl)-[1 ,2,4]oxadiazol-5-yl]-pyridin-3- yl}-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-met hoxy-cyclobutyl)-[1 ,2,4]oxadiazol-5-yl]-pyridin-3-yl}- methanol;

1-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)-2 - methyl-propan-2-ol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-methan esulfonylmethyl-[1 ,2,4]oxadiazol-3-yl)-pyridin-3-yl]- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(2-methoxy-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (5-methoxymethyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]- methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5- (tetrahydro-furan-3-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl} - methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetra hydro-pyran-4-yl)-[1 ,2,4]oxadiazol-3-yl]-pyridin-3-yl}- methanol;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- cyclohexanol;

(R)-[5-(5-tert-Butoxymethyl-[1,2,4]oxadiazol-3-yl)-pyridi n-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(tetrahydro-pyran-4-ylmethyl)-[1,2,4]oxadiazol-3-yl]-pyri din-

3-yl}-methanol;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- cyclohexanol;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-cyclohexanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(1-methoxy-cyclobutyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-y l}- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(6-oxa-spiro[2.5]oct-1-yl)-[1,2,4]oxadiazol-3-yl]-pyridin -3-yl}- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(tetrahydro-pyran-3-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3- yl}- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5- {5-[1-(tetrahydro-furan-2-yl)methyl]-[1,2,4]oxadiazol-3-yl}- pyridin-3-yl)-methanol;

(R)-2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- 1,1,1 -trifluoro-propan-2-ol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1 -methoxy-1 -methyl-ethyl)-[1 ,2,4]oxadiazol-3-yl]-pyridin-3- yl}-methanol;

(R)-{5-[5-((R)-Cyclohexyl-hydroxy-methyl)-[1,2,4]oxadiazo l-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopro pyl- phenyl)-methanol;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- cyclopropanol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propan-2-ol;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- cyclopentanol; 3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-[1 ,2,4]oxadiazol-5-yl)- cyclobutanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[5-(4-fluoro-tetrahyd ro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopr opyl- phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[5-((2R,4R,6S)-2,6-di methyl-tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin -3- yl}-(4-isopropyl-phenyl)-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetra hydro-pyran-4-yloxymethyl)-[1 ,2,4]oxadiazol-3-yl]- pyridin-3-yl}-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-met hyl-1-(tetrahydro-pyran-4-yl)-ethyl]-[1 ,2,4]oxadiazol- 3-yl}-pyndin-3-yl)-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[2-(te trahydro-pyran-4-yl)-ethyl]-[1 ,2,4]oxadiazol-3-yl}- pyridin-3-yl)-methanol;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- cyclobutanol;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2 - methyl-propan-2-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]oxadiazol-3-yl]-py ridin-

3-yl}-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-met hyl-tetrahydro-pyran-4-yloxymethyl)-[1,2,4]oxadiazol- 3-yl]-pyridin-3-yl}-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (5-oxetan-3-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol ; (R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-met hoxy-1 , 1 -dimethyl-ethyl)-[1 ,2,4]oxadiazol-3-yl]- pyridin-3-yl}-methanol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2 - methyl-propan-1-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(2-methoxy-2-methyl-propyl)-[1,2,4]oxadiazol-3-yl]-pyridi n-

3-yl}-methanol;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-cyclobutanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-met hoxymethyl-cyclopropylmethyl)-[1 ,2,4]oxadiazol-3-yl]- pyridin-3-yl}-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-pyr azol-1-yl-ethyl)-[1 ,2,4]oxadiazol-3-yl]-pyridin-3-yl}- methanol; (R)-N-(2-(3-(5-((1 ,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl) pyridin-3-yl)-1,2,4-oxadiazol-5- yl)ethyl)acetamide-2,2,2-d ₃ ;

(R)-N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-is opropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-2- methylpropan-2-yl)acetamide-2,2,2- / _¾

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- piperidin-1-yl]-2-hydroxy-ethanone;

(R)-1-(4-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-is opropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5- yl)piperidin-1-yl)ethan-1-one-2,2,2-d3;

N-[2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- ethyl]-2-hydroxy-N-methyl-acetamide;

(R)-N-(2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-is opropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)ethy l)- N-methylacetamide-d ₃ ;

(1 ,3-Dimethyl-azetidin-3-yl)-(6-methoxy-pyridin-3-yl)-(4-trifl uoromethoxy-phenyl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(6-phenoxy-pyridin-3-yl)-(4-trifl uoromethoxy-phenyl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(6-ethoxy-pyridin-3-yl)-(4-triflu oromethoxy-phenyl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(5-methyl-pyridin-3-yl)-(4-triflu oromethoxy-phenyl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-(5-pyrrolidin-1 -yl-pyridin-3-yl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-methoxy-phenyl)-(5-pyrrolidin- 1-yl-pyridin-3-yl)-methanol; (1,3-Dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-(5-pyrrolidin- 1-yl-pyridin-3-yl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-phenyl-(5-pyrrolidin-1-yl-pyridin -3-yl)-methanol;

(4-Cyclobutyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyr rolidin-1-yl-pyridin-3-yl)-methanol;

(4-Cyclobutoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-py rrolidin-1-yl-pyridin-3-yl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-ethoxy-phenyl)-(5-pyrrolidin-1 -yl-pyridin-3-yl)-methanol;

(4-tert-Butyl-phenyl)-(1 ,3-dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)- methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropoxy-phenyl)-(5-pyrrolid in-1-yl-pyridin-3-yl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)- [4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-[4-(1-methyl-cyclopropyl)-phenyl] -(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclopropoxy-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrr olidin-1-yl-pyridin-3-yl)-methanol;

(S)-[2-(3,3-Difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3- dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-[2-((3R,4S)-3,4-Difluoro-pyrrolidin-1-yl)-pyridin-4-yl]- (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-(1,3-Dimethyl-azetidin-3-yl)-(2-isobutoxy-pyridin-4-yl)- (4-isopropyl-phenyl)-methanol; 4-{4-[(S)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-2-yl}-2-methyl-butan-2-ol; (R)-[6-(3,3-Difluoro-pyrrolidin-1-yl)-pyridazin-4-yl]-(1,3-d imethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-5-tert-Butyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydr oxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-oxazolidin-2- one;

(R)-1-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-pyrrolidin-3-ol;

(S)-1-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-pyrrolidin-3-ol; (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-((S)-3-hydroxymethyl-pyr rolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5- pyrrolidin-1-yl-pyridin-3-yl)-methanol;

(S)-1-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-3-methyl-pyrrolidin-3-ol; 3-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy -(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; 2-((S)-1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)-propan - 2-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5- morpholin-4-yl-pyridin-3-yl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3, 4,5,6-tetrahydro-2H-[1,3']bipyridinyl-5'-yl)-methanol;

(R)-[5-(7-Aza-bicyclo[2.2.1]hept-7-yl)-pyridin-3-yl]-(1,3 -dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- ((S)-2-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-3-trifluoromethyl-pyrrolidi n-3- ol;

(R)-[5-(3,3-Difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3- dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol;

5'-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl -phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-4-o l;

5'-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl -phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-3-o l:

(R)-{5-[(2-Benzyloxy-ethyl)-methyl-amino]-pyridin-3-yl}-( 1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[4-(1-methyl-cyclopropyl )-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol;

(R)-[5-((3R,4S)-3,4-Difluoro-pyrrolidin-1-yl)-pyridin-3-y l]-(1,3-dimethyl-azetidin-3-yl)-[4-(1-trifluoromethyl-cyclop ropyl)- phenylj-methanol;

2-[(S)-1-(5-{(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyc lopropyl)-phenyl]-methyl}-pyridin-3-yl)- pyrrolidin-3-yl]-propan-2-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyrid in-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol ;

(R)-(4-tert-Butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(3 ,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-5'-yl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyrid in-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

(R)-{5-[5-(1-Cyclopropanesulfonyl-piperidin-4-yl)-[1,2,4] oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-( 4- isopropyl-phenyl)-methanol;

2-({5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-yl}-methyl-amino)-ethanol; (R)-1-((S)-1-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-pyrrolidin-3-yl)- ethanol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-oxazolidin-2-one; 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-5-phenyl-oxazolidin-2-one;

5-Benzyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-( 4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-oxazolidin-2-one; 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-5-isopropyl-oxazolidin-2-one;

6-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-oxa-6-aza-spiro[2.4]hepta n- 5-one;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-1-oxa-3-aza-spiro[4.4]nonan -

2-one;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-5-(tetrahydro-pyran-4-yl)- oxazolidin-2-one;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-5,5-dimethyl-oxazolidin-2-o ne;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-8,8-difluoro-1-oxa-3-aza- spiro[4.5]decan-2-one;

9-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-7-oxa-9-aza- dispiro[3.1.4.1]undecan-8-one;

2-Cyclopropyl-7-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydr oxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-oxa-7-aza- spiro[3.4]octan-6-one;

7-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2,2-dimethyl-5-oxa-7-aza- spiro[3.4]octan-6-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-phenyl-pyrrolidin-2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-isopropyl-pyrrolidin-2-on e;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-3-isopropyl-pyrrolidin-2-on e;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4,4-dimethyl-pyrrolidin-2-o ne;

5-(5-((R)-(1,3-Dimethyl-azetidin-3-yl)(hydroxy)(4-isoprop yl-phenyl)methyl)pyridin-3-yl)hexahydro-4H-furo[2,3-c]pyrrol -

4-one;

2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4.4]nonan-3-one ;

6-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-6-aza-spiro[3.4]octan-5-one ;

2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]decan -

3-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-3-(tetrahydro-pyran-4-yl)- pyrrolidin-2-one;

2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4.5]decan-1-one ; 2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]decan- 1-one; (S)-1-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-4-isobutyl-pyrrolidin-2-one; 4-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy -(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-2-one ; 1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-4-trifluoromethyl-pyrrolidin-2 - one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-3-(2-methoxy-ethyl)-pyrroli din-

2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methoxy-ethyl)-pyrroli din-

2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-pyrrolidin-2-one;

(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((R) -3-isopropyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-((2R,6S)-2,6-dimethyl -morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol ;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl)-pyridin-3-yl]-methanol ;

(R)-[5-((3R,4S)-3,4-Difluoro-pyrrolidin-1-yl)-pyridin-3-y l]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methano l;

(R)-[5-((3S,4S)-3,4-Difluoro-pyrrolidin-1-yl)-pyridin-3-y l]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methano l;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-((2S,6S)-2,6-dimethyl -morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol ;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-((2R,6R)-2,6-dimethyl -morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol ;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(3-met hyl-[1,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-pyridin-3-yl}- methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-met hyl-thiazol-2-yl)-pyrrolidin-1-yl]-pyridin-3-yl}- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (3-phenyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(3,3-dimethyl-pyrroli din-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[(1 S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (2,2,6,6-tetrafluoro-morpholin-4-yl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- ((R)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- ((S)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (3-trifluoromethyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[(1 R,4R)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[(1 S,5R)-5-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-yl]- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[(1S,4S)-5-(2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-[4-(1-trifluoromethyl - cyclopropyl)-phenyl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-(5-pyrroli din-1-yl-pyridin-3-yl)-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-[5-(6-oxa- 3-aza-bicyclo[3.1.1]hept-3-yl)-pyridin-3-yl]-methanol; (R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-[(1 S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]- methanol;

(R)-(5-Benzyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-y l)-(4-isopropyl-phenyl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(2-pyridi n-2-yl-ethoxy)-pyridin-3-yl]-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(2-methox y-ethoxy)-pyridin-3-yl]-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(oxetan-3 -ylmethoxy)-pyridin-3-yl]-methanol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yloxy}-propan-1-ol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(5-isopropoxy-pyridin-3-yl) -(4-isopropyl-phenyl)-methanol; (R)-(5-Cyclohexyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3- yl)-(4-isopropyl-phenyl)-methanol;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yloxy}-2-methyl-propan-2-ol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3- methoxy-cyclopentyloxy)-pyridin-3-yl]-methanol; (R)-[5-(3-Cyclopropyl-[1,2,4]oxadiazol-5-ylmethoxy)-pyridin- 3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[2-(3,5-dimethyl-[1,2 ,4]triazol-1-yl)-ethoxy]-pyridin-3-yl}-(4-isopropyl-phenyl)- methanol;

4-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-yloxy}-2-methyl-butan-2-ol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-met hoxy-pyridin-3-yl)-methanol; (R)-[5-(2-Benzyloxy-ethoxy)-pyridin-3-yl]-(1,3-dimethyl-azet idin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(te trahydro-pyran-4-yloxy)-pyridin-3-yl]-methanol;

2-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-yloxy}-ethanol; 4-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-yloxy}-cyclohexanol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yloxy}-1-methyl-cyclohexanol; (1,3-Dimethyl-azetidin-3-yl)-(2-phenoxy-pyrimidin-5-yl)-(4-t rifluoromethoxy-phenyl)-methanol; (6-Benzyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-t rifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azetidin-3-yl)-(5-pyrazol-1-yl-pyridin-3-yl)-( 4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azetidin-3-yl)-(6-fluoro-5-pyrrolidin-1-yl-pyr idin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;

5-[(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-trifluorometho xy-phenyl)-methyl]-3-pyrrolidin-1-yl-pyridine-2-carbonitrile ; (1,3-Dimethyl-azetidin-3-yl)-[6-(tetrahydro-pyran-4-yloxy)-p yridin-3-yl]-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azetidin-3-yl)-[6-(oxetan-3-ylmethoxy)-pyridin -3-yl]-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(4-meth yl-thiazol-2-yl)-pyridin-3-yl]-methanol; (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-meth yl-thiazol-2-yl)-pyridin-3-yl]-methanol; (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-methoxy -pyrimidin-5-yl)-methanol; (S)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyr rolidin-1-yl-pyridin-4-yl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-[2-((R)-2-hydroxymethyl-pyrrolidi n-1-yl)-pyridin-4-yl]-(4-isopropyl-phenyl)-methanol; (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3,4,5,6-t etrahydro-2H-[1,2']bipyridinyl-4'-yl)-methanol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-morpholin -4-yl-pyridin-4-yl)-methanol; (S)-(1,3-Dimethyl-azetidin-3-yl)-(2-ethyl-pyridin-4-yl)-(4-i sopropyl-phenyl)-methanol;

(S)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[2-(tetrahyd ro-pyran-4-ylmethoxy)-pyridin-4-yl]-methanol;

(S)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[2-(2-methox y-ethoxy)-pyridin-4-yl]-methanol;

(S)-(2-Cyclopentyl-pyridin-4-yl)-(1,3-dimethyl-azetidin-3 -yl)-(4-isopropyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyrid in-3-yl)-(4-trifluoromethyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-((R)-3-hydroxymethyl- 3-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl) - methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-((S)-3-fluoro-pyrroli din-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[4-(tetra hydro-pyran-4-yl)-[1,2,3]triazol-1-yl]-pyridin-3-yl}- methanol;

(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-meth yl-pyridin-3-yl)-methanol;

(1,3-Dimethyl-azetidin-3-yl)-(5-isopropenyl-pyridin-3-yl) -(4-isopropyl-phenyl)-methanol;

(5-Cyclopropyl-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl) -(4-isopropyl-phenyl)-methanol;

(5-Cyclopent-1-enyl-pyridin-3-yl)-(1,3-dimethyl-azetidin- 3-yl)-(4-isopropyl-phenyl)-methanol;

3-{5-[(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-p henyl)-methyl]-pyridin-3-yl}-cyclopent-2-enol;

(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-isop ropyl-pyridin-3-yl)-methanol;

(5-Cyclopentyl-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl) -(4-isopropyl-phenyl)-methanol;

3-{5-[(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-p henyl)-methyl]-pyridin-3-yl}-cyclopentanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-pyr idin-3-yl-methanol;

3-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-yl}-cyclopent-2-enone;

3-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-yl}-1-methyl-cyclopent-2-enol;

(3S)-3-(5-((R)-(1, 3-dimethyl azetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-y l)-1-methylcyclopentan-1-ol;

(3R)-3-(5-((R)-(1,3-dimethylazetidin-3-yl)(hydroxy)(4-iso propylphenyl)methyl)pyridin-3-yl)-1-methylcyclopentan-1-ol;

3-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-yl}-1-ethyl-cyclopentanol;

3-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-yl}-1-isopropyl-cyclopentanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (4-methyl-oxazol-2-yl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(5-ethyl-pyridin-3-yl)-( 4-isopropyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5- methyl-pyridin-3-yl)-methanol;

(R)-[5-(4,5-Dihydro-furan-3-yl)-pyridin-3-yl]-(1,3-dimeth yl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (tetrahydro-furan-3-yl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-but-3-en-1-ol; N-Cyclopentyl-5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-nicotinamide;

{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-pyrrolidin-1-yl-methanone; 5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]-N-(tetrahydro-pyran-4-yl)-nicotinamide;

(1 ,3-Dimethyl-azetidin-3-yl)-[4-(3-methoxy-propyl)-phenyl]-(5- pyrrolidin-1-yl-pyridin-3-yl)-methanol;

(R)-(4-Cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-( 5-pyrrolidin-1-yl-pyridin-3-yl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyrid in-3-yl)-p-tolyl-methanol;

5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl -1'- carboxylic acid tert-butyl ester;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidine-1-carboxylic acid tert-butyl ester;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (tetrahydro-pyran-4-yl)-pyridin-3-yl]-methanol;

(R)-(1 _l 3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3' _l 4' _l 5' _l 6'-tetrahydro-2'H-[2 _l 1';4' _l 3"]terpyridin-5"-yl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(1' -phenyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-5-yl)- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[1' -(toluene-4-sulfonyl)-1',2',3',4',5',6'-hexahydro-[3,4']bipy ridinyl-

5-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (tetrahydro-furan-2-yl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (5-methyl-tetrahydro-furan-2-yl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(5,5-dimethyl-tetrahy dro-furan-2-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2,2-difluoro-propan-1-ol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5- methyl-oxazol-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5- (tetrahydro-pyran-4-yl)-oxazol-2-yl]-pyridin-3-yl}-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(4-fluoro-phenoxymethyl) -pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; Isopropyl-carbamic acid 5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]-pyridin-3-ylmethyl ester;

(R)-[5-(2-Benzyloxy-ethyl)-pyridin-3-yl]-(1,3-dimethyl-az etidin-3-yl)-(4-isopropyl-phenyl)-methanol;

4-{5-[(R)-(1 _J 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-yl}-1-methyl-cyclohexanol; 2-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-cyclopropyl)-propan-2-ol;

(S)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{2- [5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-4- yl}- methanol;

(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyrr olidin-1-yl-pyrimidin-5-yl)-methanol; and (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(6-pyrroli din-1-yl-pyrazin-2-yl)-methanol.

34) Another embodiment relates to a compound according to embodiment 1) selected from a group consisting of (R)-N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopr opylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5- yl)cyclopropyl)acetamide-2,2,2-d3;

(R)-N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-is opropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5- yl)cyclopropyl)-N-methylacetamide-d3;

(R)-N-((3-(5-((1, 3-dimethyl azetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-y l)-1, 2, 4-oxadiazol-5-yl)methyl)- N-methylacetamide-d3;

N-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-2-hydroxy-acetamide;

(R)-N-((3-(5-((1, 3-dimethyl azetidin-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-y l)-1, 2, 4-oxadiazol-5- yl)methyl)acetamide-2,2,2-d3;

1-(3-{5-[(R)-Hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl) -(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol -5- yl)-2-methyl-propan-2-ol;

1-(3-{5-[(R)-(1-Ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-2- methyl-propan-2-ol;

2-(3-{5-[(R)-Hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl) -(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol -5- yl)-propan-2-ol;

2-(3-{5-[(R)-(1-Ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- propan-2-ol;

4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)- piperidine-1 -carboxylic acid benzyl ester;

1-[4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl )- piperidin-1 -yl]-ethanone;

(R)-1-(3-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-is opropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5- yl)azetidin-1-yl)ethan-1-one-2,2,2-d3;

(R)-1-(3-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-is opropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3- methylazetidin-1-yl)ethan-1-one-2,2,2-d3;

(R)-1-(3-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-is opropylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)-3- fluoroazetidin-1 -yl)ethan-1 -one-2,2,2-d3;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(1 -methyl-1 -morpholin-4-yl-ethyl)-[1, 2, 4]oxadiazol-3-yl]- pyridin-3-yl}-methanol;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1 - methyl-piperidin-2-one;

1-[(S)-3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5- yl)-pyrrolidin-1-yl]-ethanone; 1-[(R)-3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- yl)-pyrrolidin-1-yl]-ethanone;

N-[1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-1- methyl-ethyl]-acetamide;

1-Benzyl-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydrox y-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazo l-5- yl)-pyrrolidin-2-one;

3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1 ,3- dimethyl-pyrrolidin-2-one;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1 - isobutyl-pyrrolidin-2-one;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1 - furan-2-ylmethyl-pyrrolidin-2-one;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1 - phenyl-pyrrolidin-2-one;

1-Benzyl-4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydrox y-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazo l-5- yl)-pyrrolidin-2-one;

5-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1 - phenyl-pyrrolidin-2-one;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- pyrrolidin-2-one;

(S)-5-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- pyrrolidin-2-one;

(R)-5-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- pyrrolidin-2-one;

(S)-6-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- piperidin-2-one;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-2-one;

(S)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- azetidin-2-one;

(S)-3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- azetidin-2-one;

(S)-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-is opropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl) -1,4- dimethyl-pyrrolidin-2-one; (R)-4-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-[1 ,2,4]oxadiazol-5-yl)- 1 ,4-dimethyl-pyrrolidin-2-one;

(R) or (S)-4-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-[1 ,2,4]oxadiazol- 5-yl)-1,4-dimethyl-pyrrolidin-2-one;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (5-piperidin-4-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-metha nol; (R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-met hyl-piperidin-4-yl)-[1 ,2,4]oxadiazol-3-yl]-pyridin-3-yl}- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[5-(4-fluoro-piperidi n-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl-ph enyl)- methanol;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- piperidin-1 -yl]-butan-1 -one;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- piperidin-1 -yl]-2,2-dimethyl-propan-1 -one;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- piperidin-1-yl]-2-methoxy-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- piperidin-1-yl]-3-methoxy-propan-1-one;

Cyclopropyl-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hy droxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone;

Cyclopentyl-[4-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hy droxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone;

[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-[1 ,2,4]oxadiazol-5-yl)- piperidin-1-yl]-(tetrahydro-pyran-4-yl)-methanone;

[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-1-yl]-phenyl-methanone;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidine-1 -carboxylic acid methyl ester;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidine-1 -carboxylic acid ethyl ester;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidine-1 -carboxylic acid 2-methoxy-ethyl ester;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(1-methanesulfonyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl] - pyridin-3-yl}-methanol; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5- [1-(propane-2-sulfonyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-y l}- pyridin-3-yl)-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(pr opane-1-sulfonyl)-piperidin-4-yl]-[1 ,2,4]oxadiazol-3-yl}- pyridin-3-yl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5- {5-[1-(2-methoxy-ethanesulfonyl)-piperidin-4-yl]-

[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol;

2-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- piperidine-1 -sulfonyl]-ethanol;

(R)-{5-[5-(1-Cyclopentanesulfonyl-piperidin-4-yl)-[1,2,4] oxadiazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-( 4- isopropyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5- {5-[1-(tetrahydro-pyran-4-sulfonyl)-piperidin-4-yl]-

[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methanol;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidine-1 -sulfonic acid methylamide;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(1-methylamino-cyclopropyl)-[1,2,4]oxadiazol-3-yl]-pyridi n-

3-yl}-methanol;

[1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- cyclopropyl]-methyl-carbamic acid ethyl ester;

N-[1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- cyclopropyl]-N-methyl-methanesulfonamide;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[6-(2,2-dimethyl-cyclope ntyloxy)-pyridazin-4-yl]-(4-isopropyl-phenyl)-methanol;

(R)-[6-(3,3-Difluoro-cyclopentyloxy)-pyridazin-4-yl]-(1,3 -dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol;

2-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridazin-3-yloxy}-phenyl)-ethanol;

2-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridazin-3-yloxy}-phenyl)-ethanol;

(R)-[6-(Chroman-6-yloxy)-pyridazin-4-yl]-(1,3-dimethyl-az etidin-3-yl)-(4-isopropyl-phenyl)-methanol; 6-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridazin-3-yloxy}-3H-benzooxazol-2-one; 1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)- pent-1-yn-3-ol;

(S)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4 - yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4 - yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H- pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H- pyrazol-3-yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1 ,5-dimethyl-1 H- pyrazol-3-yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H- pyrazol-3-yl)-but-3-yn-2-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[1-(4-fluoro-phenyl)- cyclopropylethynyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-metha nol;

(S)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1-methyl-1 H-pyrazol-3- yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1-methyl-1 H-pyrazol-3- yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1-methyl-1 H-pyrazol-3- yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1-methyl-1 H-pyrazol-3- yl)-but-3-yn-2-ol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-pyrrolidin e-

1 -carboxylic acid tert-butyl ester;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidine-1-carboxy lic acid tert-butyl ester;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl) - pentan-3-ol;

2-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-benzoic acid methyl ester;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[2-(2-hydroxymethyl-p henyl)-ethyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl )- butan-2-ol;

3-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-3-hydroxy- pyrrolidine-1 -carboxylic acid tert-butyl ester;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [2-(1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl]-pyridin-3-yl}-meth anol;

4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-piperidine-1- carboxylic acid tert-butyl ester;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-pyridin-2-yl-butan-2-ol; 1-Cyclopropyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy -(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-pyridin-2-yl- propan-1 -ol; 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyridin-3-yl)- butan-2-ol;

8-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridazin-3-yl}-ethyl)-5,6,7,8-tetrahy dro- quinolin-8-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-2-(6-methoxy-pyridin-2-yl )- butan-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-2-(6-methyl-pyridin-2-yl) - butan-2-ol;

(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(6-pyrrolidi n-1-yl-pyridin-2-yl)-methanol;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-4- fluoro-piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-4- methyl-piperidin-1-yl]-ethanone;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanone; 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-cyclohexanol; (R)-(5-Cyclopentyloxymethyl-pyridin-3-yl)-(1 ,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol; 1-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylmethoxy}-piperidin-1-yl)- ethanone;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[6- (tetrahydro-pyran-4-yl)-pyridazin-4-yl]-methanol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-2-phenyl-butan-2-ol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{6-[(S)-(tet rahydro-furan-3-yl)oxy]-pyridazin-4-yl}-methanol;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{6-[(R)-(tet rahydro-furan-3-yl)oxy]-pyridazin-4-yl}-methanol;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-4-methyl-pyrrolidin-2-one ;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-3-isopropyl-pyrrolidin-2- one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-3,3-dimethyl-pyrrolidin-2 - one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-4,4-dimethyl-pyrrolidin-2 - one;

5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-5-aza-spiro[2.4]heptan-6- one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-4-trifluoromethyl-pyrroli din-

2-one;

4-Cyclopropyl-1-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridazin-3-yl}-pyrrolidin-2- one; 2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridazin-3-yl}-8-oxa-2-aza- spiro[4.5]decan-3-one;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-1-oxa-3-aza- spiro[4.5]decan-2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-4-pyridin-2-yl-pyrrolidin -2- one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-3-(2-methoxy-ethyl)- pyrrolidin-2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-4-phenyl-pyrrolidin-2-one ;

2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-2,3-dihydro-isoindol-1-on e; 2-(3-{5-[(S)-(3-Fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4-is opropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl) - propan-2-ol;

2-(3-{5-[(S)-(1-Cyclopropyl-3-fluoro-azetidin-3-yl)-hydro xy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiaz ol-

5-yl)-propan-2-ol;

1-[4-(3-{5-[(S)-(3-Fluoro-1-methyl-azetidin-3-yl)-hydroxy -(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol -5- yl)-piperidin-1 -yl]-ethanone;

1-[4-(3-{5-[(S)-(1-Cyclopropyl-3-fluoro-azetidin-3-yl)-hy droxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone;

2-(3-{5-[(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-hydro xy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiaz ol- 5-yl)-propan-2-ol;

1-[4-(3-{5-[(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-hy droxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone;

(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-p henyl)-{5-[5-(tetrahydro-pyran-4-yl)-[1 ,2,4]oxadiazol-3-yl]- pyridin-3-yl}-methanol; trans-4-(3-{5-[(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-hy droxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadi azol-5-y l)-cyclohexanol ;

(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-p henyl)-[5-(5-oxetan-3-yl-[1 ,2,4]oxadiazol-3-yl)-pyridin-3-yl]- methanol;

1-[(R)-3-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-[1 ,2,4]oxadiazol-5- ylmethyl)-pyrrolidin-1-yl]-ethanone;

1-[3-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-1 -yl]-ethanone;

1-[3-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-3- hydroxy-piperidin-1-yl]-ethanone; 1-[3-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-3- methyl-piperidin-1-yl]-ethanone;

1-[3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-4-hydroxy-piperidin-1-yl]-ethanone;

N-[1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-cyclopropyl]-acetamide;

Tetrahydro-pyran-4-carboxylic acid [1-(3-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]- pyridin-3-yl}-[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-amid e;

N-[1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-cyclopropyl]-2-methoxy-acetamide;

N-[1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-cyclopropyl]-N-methyl-acetamide;

N-[2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-

1 , 1 -dimethyl-ethyl]-propionamide;

N-[2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-

1 , 1 -dimethyl-ethyl]-2-methoxy-acetamide;

Tetrahydro-pyran-4-carboxylic acid [2-(3-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]- pyridin-3-yl}-[1 ,2,4]oxadiazol-5-yl)-1 , 1 -dimethyl-ethyl]-amide;

N-[2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-

1 , 1 -dimethyl-ethyl]-isobutyramide;

Cyclopropanecarboxylic acid [2-(3-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3- yl}-[1,2,4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-amide;

1-[cis-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5-yl)

-2-methyl-piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-4- hydroxy-piperidin-1-yl]-2-methyl-propan-1-one;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-4- hydroxy-piperidin-1 -yl]-propan-1 -one;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-4- methoxy-piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- piperidin-1-yl]-3,3,3-trifluoro-propan-1-one; 1-[4-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-1-yl]-2-oxetan-3-yl-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-4- ethyl-piperidin-1 -yl]-ethanone;

[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-[1 ,2,4]oxadiazol-5-yl)- piperidin-1-yl]-oxetan-3-yl-methanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-4- isopropyl-piperidin-1-yl]-2-methoxy-ethanone;

1-[cis-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5-yl)-

3-methyl-piperidin-1-yl]-ethanone;

5-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1 - methyl-piperidin-2-one;

5-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-5 - methyl-piperidin-2-one;

5-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-2-one;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-4 - methyl-pyrrolidin-2-one;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-3,3-dimethyl-pyrrolidine-2,5-dione;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-imidazolidine-2,4-dione;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-pyrrolidin-2-one;

3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-imidazolidine-2,4-dione;

3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-1-methyl-imidazolidine-2,4-dione;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-3-methyl-imidazolidine-2,4-dione;

3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-oxazolidin-2-one;

1-Cyclopropyl-3-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-h ydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-ylmethyl)-imidazolidin-2-one; 1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-pyrrolidine-2,5-dione;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-3-methyl-imidazolidin-2-one;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-imidazolidin-2-one;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propane-1 ,2-diol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (5-pyridin-3-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methano l;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-piperidin-1-yl]-ethanone;

(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- acetonitrile;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-4- hydroxy-piperidin-1-yl]-ethanone;

3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propionitrile;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )-3- methoxy-piperidin-1-yl]-ethanone;

1-[(R)-3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5- yl)-piperidin-1 -yl]-ethanone;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- tetrahydro-pyran-4-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[5-(3-hydroxymethyl-b icyclo[1.1.1]pent-1-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl} -(4- isopropyl-phenyl)-methanol;

4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-1 - methyl-piperidine-2, 6-dione;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2 ,2- difluoro-ethanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(3-methoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(5-isopropyl-[1,2,4]o xadiazol-3-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [5-(6-methyl-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin- 3-yl}- methanol; (R)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- 1- methyl-pyrrolidin-2-one;

(S)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-1- methyl-pyrrolidin-2-one;

(S)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-1- ethyl-pyrrolidin-2-one;

(R)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-1- ethyl-pyrrolidin-2-one;

(R)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-1- ethyl-pyrrolidin-2-one;

(S)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-1- ethyl-pyrrolidin-2-one;

(S)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-1- isopropyl-pyrrolidin-2-one;

(R)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-1- isopropyl-pyrrolidin-2-one;

(R)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-1- isopropyl-pyrrolidin-2-one;

(S)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)-1- isopropyl-pyrrolidin-2-one;

1-[(S)-3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5- ylmethyl)-pyrrolidin-1-yl]-ethanone;

(S)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- piperidin-2-one;

(R)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- piperidin-2-one;

(R)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- piperidin-2-one;

(S)-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- piperidin-2-one;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (5-methyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol;

(R)-{5-[5-(1,1-Difluoro-ethyl)-[1,2,4]oxadiazol-3-yl]-pyr idin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl) - methanol; 4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-[1 ,2,4]oxadiazol-3-yl)- tetrahydro-pyran-4-ol;

(R)-[5-(3-tert-Butoxymethyl-[1,2,4]oxadiazol-5-yl)-pyridi n-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)- methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(3-hydroxymethyl-[1,2 ,4]oxadiazol-5-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methan ol; 1-[4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)- piperazin-1 -yl]-ethanone;

1-[3-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3- ylmethyl)-azetidin-1-yl]-ethanone;

4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3- ylmethyl)-tetrahydro-pyran-4-ol;

[4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-[1 ,2,4]oxadiazol-3-yl)- piperidin-1-yl]-[1,4]dioxan-2-yl-methanone;

1-[4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl )- piperidin-1-yl]-2-methoxy-ethanone;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-met hanesulfonyl-piperidin-4-yl)-[1 ,2,4]oxadiazol-5-yl]- pyridin-3-yl}-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5- {3-[1-(2-methoxy-ethanesulfonyl)-piperidin-4-yl]-

[1.2.4]oxadiazol-5-yl}-pyridin-3-yl)-methanol;

1-[4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl )- piperidin-1-yl]-2-hydroxy-ethanone;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5- [1,2,4]oxadiazol-3-yl-pyridin-3-yl)-methanol;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- piperidin-1 -yl]-ethanone;

2-(3-{5-[(R)-(4-Bromo-phenyl)-(1,3-dimethyl-azetidin-3-yl )-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propa n- 2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-naphtha len-2-yl-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan -2- ol;

2-[3-(5-{(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyc lopropyl)-phenyl]-methyl}-pyridin-3-yl)-

[1.2.4]oxadiazol-5-yl]-propan-2-ol;

2-[3-(5-{(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2 ,2-trifluoro-1,1-dimethyl-ethyl)-phenyl]-methyl}-pyridin-3-y l)-

[1,2,4]oxadiazol-5-yl]-propan-2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propan-2-ol; 2-[3-(5-{(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(1,2,2, 2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-methyl}-pyrid in-

3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2-ol;

(R)-2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-(pent afluoro- 6-sulfaneyl)phenyl) methyl)pyridin-3-yl)-1 ,2,4- oxadiazol-5-yl)propan-2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-(3-fluoro-4-iso propyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazo l-5- yl)-propan-2-ol;

2-(3-{5-[(R)-(4-tert-Butyl-phenyl)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1 ,2,4]oxadiazol-5-yl)- propan-2-ol;

2-(3-{5-[(R)-Benzo[b]thiophen-5-yl-(1,3-dimethyl-azetidin -3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propan-2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-pent afluoroethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5- yl)-propan-2-ol;

2-[3-(5-{(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(1-m ethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-

[1,2,4]oxadiazol-5-yl]-propan-2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-3-methyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazo l-

5-yl)-propan-2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-trif luoromethoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5- yl)-propan-2-ol;

1-[4-(3-{5-[(R)-(4-Bromo-phenyl)-(1,3-dimethyl-azetidin-3 -yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-1 -yl]-ethanone;

2-[3-(5-{(R)-(1,3-Dimethyl-azetidin-3-yl)-[4-(1-fluoro-1- methyl-ethyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-

[1.2.4]oxadiazol-5-yl]-propan-2-ol;

2-(3-{5-[(R)-[4-(1,1-Difluoro-ethyl)-phenyl]-(1,3-dimethy l-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadia zol-5- yl)-propan-2-ol;

2-(3-{5-[(R)-(4-Bicyclo[1.1.1]pent-1-yl-phenyl)-(1,3-dime thyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-propan-2-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-{5-[5-(tetrahydro-pyran- 4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-[4-(2,2,2-trifluo ro- ethyl)-phenyl]-methanol;

2-[3-(5-{(R)-(1 ,3-Dimethyl-azetidin-3-yl)-[4-(1 , 1 -dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-

[1.2.4]oxadiazol-5-yl]-propan-2-ol;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-(3-fluoro-4- isopropyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadi azol-

5-yl)-piperidin-1-yl]-ethanone;

1-{4-[3-(5-{(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-( 1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl) -

[1.2.4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone; 1-[4-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy-pheny l)-methyl]-pyridin-3-yl}-[1 ,2,4]oxadiazol- 5-yl)-piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- piperidin-1 -yl]-ethanone;

2-(3-{5-[(R)-(3-Chloro-4-isopropyl-phenyl)-(1,3-dimethyl- azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazo l-5- yl)-propan-2-ol;

2-(3-{5-[(R)-(4-Cyclobutyl-phenyl)-(1,3-dimethyl-azetidin -3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propan-2-ol;

1-[4-(3-{5-[(R)-(4-Cyclobutyl-phenyl)-(1,3-dimethyl-azeti din-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- piperidin-1 -yl]-ethanone;

1-[4-(3-{5-[(R)-(3,5-Difluoro-4-isopropyl-phenyl)-(1,3-di methyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone;

2-(3-{5-[(R)-(3,5-Difluoro-4-isopropyl-phenyl)-(1,3-dimet hyl-azetidin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-propan-2-ol;

1-[4-(3-{5-[(R)-(4-Cyclobutoxy-phenyl)-(1,3-dimethyl-azet idin-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- yl)- piperidin-1 -yl]-ethanone;

2-[3-(5-{(1,3-Dimethyl-azetidin-3-yl)-[4-(1-ethyl-propyl) -phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl ]- propan-2-ol;

1-{4-[3-(5-{(1,3-Dimethyl-azetidin-3-yl)-[4-(1-ethyl-prop yl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5 -yl]- piperidin-1 -yl}-ethanone;

2-[3-(5-{(1,3-Dimethyl-azetidin-3-yl)-[4-(2,2-dimethyl-pr opyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol -5- yl]-propan-2-ol;

1-{4-[3-(5-{(1,3-Dimethyl-azetidin-3-yl)-[4-(2,2-dimethyl -propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]oxadia zol-

5-yl]-piperidin-1-yl}-ethanone;

1-{4-[3-(5-{(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl) -phenyl]-methyl}-pyridin-3-yl)-

[1.2.4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-prop yl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-prop an- 2-ol;

2-(3-{5-[(R)-(4-Cyclopropyl-phenyl)-(1,3-dimethyl-azetidi n-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl) - propan-2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-ethyl-phenyl )-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propa n-2- ol;

2-(3-{5-[(R)-(4-Butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl )-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propa n-2- ol; 2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-trifluo romethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl )- propan-2-ol;

2-[3-(5-{(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2 ,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxa diazol-

5-yl]-propan-2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isob utyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propan-2-ol;

2-(3-{5-[(R)-(4-Cyclobutoxy-phenyl)-(1,3-dimethyl-azetidi n-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl) - propan-2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropenyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl) - propan-2-ol;

1-{4-[3-(5-{(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-( 2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-

[1.2.4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-p ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-1 -yl]-ethanone;

1-[4-(3-{5-[(R)-Hydroxy-(1-isopropyl-3-methyl-azetidin-3- yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadia zol-

5-yl)-piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-[1-(2,2-Difluoro-ethyl)-3-methyl-azetidin -3-yl]-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-Hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-aze tidin-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-(1-Cyclopropylmethyl-3-methyl-azetidin-3- yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone;

1-{4-[3-(5-{(R)-Hydroxy-(4-isopropyl-phenyl)-[1-(2-methox y-ethyl)-3-methyl-azetidin-3-yl]-methyl}-pyridin-3-yl)-

[1.2.4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone;

1-{4-[3-(5-{(R)-Hydroxy-(4-isopropyl-phenyl)-[3-methyl-1- (3,3,3-trifluoro-propyl)-azetidin-3-yl]-methyl}-pyridin-3-yl )-

[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone;

1-[4-(3-{5-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-1- propyl-azetidin-3-yl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol -5- yl)-piperidin-1 -yl]-ethanone;

1-[4-(3-{5-[(R)-(1-Ethyl-3-methyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5- yl)-piperidin-1 -yl]-ethanone;

1-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidin-1-yl)- ethanone;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-1,1,1-trifluoro-2-methyl-bu t-3- yn-2-ol; Cyclopropanecarboxylic acid (3-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}- 1 , 1 -dimethyl-prop-2-ynyl)-amide;

N-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 , 1 -dimethyl-prop-2-ynyl)- isobutyramide;

N-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 , 1 -dimethyl-prop-2-ynyl)-

2-methoxy-acetamide;

3-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 , 1 -dimethyl-prop-2-ynyl)- oxazolidin-2-one;

1 -(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 , 1 -dimethyl-prop-2-ynyl)- pyrrolidin-2-one;

1 -(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 , 1 -dimethyl-prop-2-ynyl)-3- methyl-imidazolidin-2-one;

1 -(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 , 1 -dimethyl-prop-2-ynyl)- imidazolidin-2-one;

3-(1-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-ylethynyl}-cyclopropyl)- oxazolidin-2-one;

1-((R)-2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-2-methyl- pyrrolidin-1-yl)-ethanone;

1-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-hydroxy-piperid in-

1-yl)-ethanone;

1-[4-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1-hydroxy-1-methyl- prop-2-ynyl)-piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop-2-ynyl )- piperidin-1-yl]-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-2-ynyl)-piperidi n-1- yl]-ethanone;

1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop-2-ynyl )-

4-methyl-piperidin-1-yl]-ethanone;

1-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidi n-1- yl)-ethanone;

(R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(1-methan esulfonyl-piperidin-4-ylethynyl)-pyridin-3-yl]- methanol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidine- 1- sulfonic acid methylamide; (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3- methanesulfonyl-3-methyl-but-1-ynyl)-pyridin-3-yl]- methanol;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanesulfonic acid dimethylamide;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanesulfonic acid amide;

(R)-[5-(3-Cyclopropanesulfonyl-3-methyl-but-1-ynyl)-pyrid in-3-yl]-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)- methanol;

(R)-3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1- methyl-pyrrolidin-2-one;

(S)-3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1- methyl-pyrrolidin-2-one;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-3,4-dihydro-2H- pyrano[3,2-b] pyridin-4-ol;

3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl- 1,3-dihydro-indol-2-one;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-but-3-y n-2- ol;

4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1-methyl-1 H-indazol-3-yl)- but-3-yn-2-ol;

2-(1-Cyclopropyl-1H-pyrazol-3-yl)-4-{5-[(R)-(1,3-dimethyl -azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin -3- yl}-but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl) - but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyrazin-2-yl)-b ut-

3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-5-yl)-b ut-3- yn-2-ol;

2-(6-Cyclopropyl-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl- azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin- 3- yl}-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin- 4- yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin- 4- yl)-but-3-yn-2-ol; N-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 , 1 -dimethyl-prop-2-ynyl)- acetamide;

(S)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin- 4- yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin- 4- yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin- 4- yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(2-methoxy-pynmidin-4- yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(2-methoxy-pynmidin-4- yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin- 4- yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimid in- 4-yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimid in-

4-yl)-but-3-yn-2-ol;

(R)-(S)-2-(2,6-Dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]- pyridi n-3-y l}-but-3-yn-2-ol ;

(S)-2-(2,6-Dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]- pyridin-3-yl}-but-3-yn-2-ol;

(R)-2-(2,6-Dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]- pyridi n-3-y l}-but-3-yn-2-ol ;

(S)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(2-methoxy-6-methyl- pyrimidin-4-yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(2-methoxy-6-methyl- pyrimidin-4-yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(6-methoxy-2-methyl- pyrimidin-4-yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(6-methoxy-2-methyl- pyrimidin-4-yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(6-methoxy-2-methyl- pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl- pyrimidin-4-yl)-but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(6-trifluoromethyl-pyrimi din-

4-yl)-but-3-yn-2-ol;

2-(6-Difluoromethyl-pyrimidin-4-yl)-4-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-

3-yl}-but-3-yn-2-ol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5- (1-pyridin-2-yl-cyclopropylethynyl)-pyridin-3-yl]-methanol;

(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5- [1-(6-methyl-pyrimidin-4-yl)-cyclopropylethynyl]-pyridin-3-y l}- methanol;

1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-piperidin-1-yl ]- ethanone;

4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-1 , 1 , 1 -trifluoro-2-methyl-butan-

2-ol;

3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-1,1 -dimethyl-propyl)- oxazolidin-2-one;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-1,1 -dimethyl-propyl)- pyrrolidin-2-one;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-3- methyl-imidazolidin-2-one;

1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-1,1 -dimethyl-propyl)- imidazolidin-2-one;

1-[(S)-2-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-2-methyl- pyrrolidin-1-yl]-ethanone;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-butan-2 -ol;

2-(1-Cyclopropyl-1H-pyrazol-3-yl)-4-{5-[(R)-(1,3-dimethyl -azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin -3- yl}-butan-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl) - butan-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyrazin-2-yl)- butan-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazol-5-yl)- butan-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(3-methyl-isoxazol-5-yl)- but-

3-yn-2-ol; 4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1-methyl-1 H-imidazol-2-yl)- but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-thiophen-2-yl)- but-

3-yn-2-ol;

4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(1-methyl-1 H-pyrrol-2-yl)- but-3-yn-2-ol;

(R)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(2-trifluoromethyl- pyrimidin-4-yl)-but-3-yn-2-ol;

(S)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(2-trifluoromethyl- pyrimidin-4-yl)-but-3-yn-2-ol;

(S)-(R)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(2-trifluoromethyl- pyrimidin-4-yl)-but-3-yn-2-ol;

(R)-4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2-(2-trifluoromethyl- pyrimidin-4-yl)-but-3-yn-2-ol;

4-(5-{(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyc lopropyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6- methyl-pyridin-2-yl)-but-3-yn-2-ol;

4-(5-{(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl) -phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl- pyridin-2-yl)-but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-trifluo romethyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2 -yl)- but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-h ydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3 -yn-

2-ol;

4-{5-[(R)-(4-tert-Butyl-phenyl)-(1,3-dimethyl-azetidin-3- yl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)- but-3- yn-2-ol;

4-{5-[(R)-(3-Ethyl-1-methyl-azetidin-3-yl)-hydroxy-(4-tri fluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyri din-

2-yl)-but-3-yn-2-ol;

4-(5-{(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(2,2,2- trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl- pyridin-2-yl)-but-3-yn-2-ol;

4-{5-[(S)-(3-Fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4-is opropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2- yl)- but-3-yn-2-ol;

1-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridazin-3-ylethynyl}-piperidin-1-yl) - ethanone;

N-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridazin-3-yl}-1,1 -dimethyl-prop-2- ynyl)-acetamide; 1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-1,1 -dimethyl-prop-2- ynyl)-pyrrolidin-2-one;

4-{5-[(R)-Hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin -2- yl)-but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-b ut-3- yn-2-ol;

4-{5-[(R)-Hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azetidin- 3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl - pyridin-2-yl)-but-3-yn-2-ol;

4-{5-[(R)-[1-(2,2-Difluoro-ethyl)-3-methyl-azetidin-3-yl] -hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-met hyl- pyridin-2-yl)-but-3-yn-2-ol;

1-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yloxymethyl}-piperidin-1-yl) - ethanone;

4-{5-[(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrid in-

2-yl)-but-3-yn-2-ol;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-(2-isopropyl-pyrimidin-4- yl)- pyrrolidin-2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methyl-thiazol-5-yl)- pyrrolidin-2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-(6-methyl-pyridin-3-yl)- pyrrolidin-2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-(6-isopropyl-pyridin-2-yl )- pyrrolidin-2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-(6-trifluoromethyl-pyridi n-3- yl)-pyrrolidin-2-one;

1 -{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-p henyl)-methyl]-pyridin-3-yl}-4-(1 -methyl-1 H-pyrazol-4-yl)- pyrrolidin-2-one;

1 -{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-4-(1 ,3-dimethyl-1 H-pyrazol-4- yl)-pyrrolidin-2-one;

4-(1-Difluoromethyl-1H-pyrazol-4-yl)-1-{5-[(R)-(1,3-dimet hyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]- pyridin-3-yl}-pyrrolidin-2-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methyl-2H-[1,2,3]triaz ol-

4-yl)-pyrrolidin-2-one;

4-(1-Acetyl-piperidin-4-yl)-1-{5-[(R)-(1,3-dimethyl-azeti din-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-3-y l}- pyrrolidin-2-one; 5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridazin-3-yl}-hexahydro-furo[2,3-c]pyrrol-

4-one;

1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-4-(6-isopropyl-pyridin-2- yl)- pyrrolidin-2-one;

1-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-pyrido[4, 3- d]pyrimidin-6-yl)-ethanone;

1-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-

[1,6]naphthyridin-6-yl)-ethanone;

1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-5-yl)-piper idin- 1-yl]-ethanone; and

1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-4-yl)-piper idin-

1-yl]-ethanone.

35) Another embodiment relates to a compound according to embodiment 1) selected from a group consisting of

(R)-2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-y l)- 1,1,1 -trifluoro-propan-2-ol;

2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propan-2-ol;

2-(3-{5-[(S)-(1-Cyclopropyl-3-fluoro-azetidin-3-yl)-hydro xy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiaz ol-

5-yl)-propan-2-ol; and

2-(3-{5-[(R)-(4-Butyl-phenyl)-(1,3-dimethyl-azetidin-3-yl )-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propa n-2- ol.

36) Another embodiment relates to a compound according to embodiment 1) selected from a group consisting of 4-{5-[(R)-Hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azetidin-3-y l]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl- pyridin-2-yl)-but-3-yn-2-ol;

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-trifluo romethyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2 -yl)- but-3-yn-2-ol;

(S)-4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4 - yl)-but-3-yn-2-ol; and

4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-(4-ethyl-phenyl)-h ydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3 -yn-

2-ol.

37) Another embodiment relates to a compound according to embodiment 1) selected from a group consisting of 1-[4-(3-{5-[(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-hydro xy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone; 1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-1 -yl]-ethanone;

1-[4-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-propyl-phenyl)-methyl] -pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-1 -yl]-ethanone; and

1-[4-(3-{5-[(R)-Hydroxy-(1-isopropyl-3-methyl-azetidin-3- yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadia zol-

5-yl)-piperidin-1-yl]-ethanone.

38) Another aspect of the present invention relates to compounds of embodiment 1), which are also compounds of formula (Ip), wherein

Formula (Ip)

A represents a 6-membered heteroaryl containing from one to three ring nitrogen atom(s) (notably one or two ring nitrogen atoms; especially one or two ring nitrogen atoms in n?efa-position(s) and/or para- position of A with respect to the point of attachment of A to the rest of the molecule), wherein said 6-membered heteroaryl is independently unsubstituted, mono-, di- or tri-substituted (notably mono- or di-substituted in meta- and/or para- position of A with respect to the point of attachment of A to the rest of the molecule), wherein the substituent(s), if any, is(are) independently selected from

> halogen (especially fluorine);

> cyano;

> Ci-4-alkyl (notably methyl, ethyl, propyl, or isopropyl; especially methyl, ethyl, or propyl) which is unsubstituted or mono-substituted with

• Ci-3-alkoxy (especially methoxy);

• fluoro-phenoxy (especially 4-fluoro-phenoxy);

• benzyl-oxy;

• C3-6-cycloalkyl which is optionally fused with a pyridine ring (notably at positions 2 and 3 adjacent to the nitrogen atom of said pyridine ring), wherein said C3-6-cycloalkyl is unsubstituted or mono-substituted with hydroxy (notably at the point of attachment of the C3-6-cycloalkyl to the Ci-4-al kyl);

• pyrazolyl (notably pyrazol-4-yl) which is unsubstituted or mono-substituted with Ci-3-alkyl (especially methyl);

• tetrahydropyranyl (notably tetrahydropyran-4-yl) which is unsubstituted or mono-substituted with hydroxy (especially 4-hydroxy-tetrahydropyran-4-yl); • indolyl (especially indol-2-yl);

• N-(Ci-3-alkyl)-amino-carbonyl-oxy; or

• 1 - (C 1 -4-al ky l-oxy-car bo nyl)-3-hyd roxy azeti d i n-3-y I ;

[in particular such Ci-4-al kyl which is unsubstituted or mono-substituted as defined above is methyl, ethyl, isopropyl, 2-(1-hydroxy-cyclopropyl)-ethyl, 2-(1-hydroxy-cyclobutyl)-ethyl, 2-(1-hydroxy-cyclopentyl)-ethyl, 3- methoxy-propyl, 4-fluoro-phenoxy-methyl, benzyl-oxy-methyl, N-(isopropyl)-amino-carbonyl-oxy-methyl, 2-(1- (tert-butoxy-carbonyl)-3-hydroxyazetidin-3-yl)-ethyl, 2-(1-methyl-pyrazol-4-yl)-ethyl, 2-(tetrahydropyran-4-yl)- ethyl, 2-(4-hydroxy-tetrahydropyran-4-yl)-ethyl, 2-(indol-2-yl)-ethyl, 2-(8-hydroxy-5,6,7,8-tetrahydroquinolin-8- yl)-ethyl, or 2-(7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethyl ]

> C3-5-alkenyl which is unsubstituted (especially isopropenyl) or mono-substituted with hydroxy (especially 4- hydroxy-but-1 -en-2-yl);

> tetrahydropyranyl (especially tetrahydropyran-4-yl);

> hydroxy-Ci- ₆ -alkyl which is optionally further substituted with one or more fluorine atoms (especially 3-hydroxy- propyl, 4-hydroxy-butyl, 3-hydroxy-butyl, 3-hydroxy-3-methyl-butyl, 3-hydroxy-4-methyl-pentyl, or 2,2-difluoro- 3-hydroxy-prop-1-yl);

> C3-5-alkyl (especially n-propyl, n-butyl, or n-pentyl) which is substituted with hydroxy and R ^A1 (notably both substituents at position 3 with respect to the point of attachment of said C3-5-alkyl to the rest of the molecule), wherein

• R ^A1 represents

^■ tetrahydropyranyl (especially tetrahydropyran-4-yl);

^■ phenyl which is unsubstituted or mono-substituted with fluorine (especially 3-fl uoro-pheny I) or Ci-3-alkoxy (especially 2-methoxy-phenyl or 4-methoxy-phenyl); or

^■ 5- or 6-membered heteroaryl containing one or two ring heteroatom(s) being independently selected from nitrogen or sulfur (notably thiazolyl, pyrazolyl, pyridinyl, or pyrimidinyl; especially thiazol-4-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl), wherein said 5- or 6-membered heteroaryl is independently unsubstituted, mono- or di- substituted, and wherein the substituent(s), if any, is(are) independently selected from Ci-3-alkyl (especially methyl) or Ci_3-alkoxy (especially methoxy);

[in particular such C3-5-alkyl which is substituted as defined above is 3-hydroxy-3-(tetrahydropyran-4-yl)-propyl, 3-hydroxy-3-phenyl-propyl, 3-hydroxy-3-phenyl-butyl, 3-hydroxy-3-(m-fluoro-phenyl)-butyl, 3-hydroxy-3-(o- methoxy-phenyl)-butyl, 3-hydroxy-3-(p-methoxy-phenyl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-propyl, 3-hydroxy-3-(2- methyl-thiazol-4-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-butyl, 3-hydroxy-3-(pyrimidin-2-yl)-butyl, 3- hydroxy-3-(6-methoxy-pyrimidin-4-yl)-butyl, 3-hydroxy-3-(1,3-dimethyl-pyrazol-4-yl)-propyl, 3-hydroxy-3-(2- methyl-thiazol-4-yl)-propyl, 3-hydroxy-3-(pyridin-2-yl)-pentyl, or 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pentyl]

> C _3-6 -cycloalkyl which is unsubstituted, mono-, or di-substituted with Ci_ ₃ -alkyl (especially methyl, ethyl, isopropyl), hydroxy or hydroxy-Ci. ₃ -alkyl (especially 1 -hydroxy-1 -methyl-ethyl), wherein optionally one ring carbon atom of said C _3.6 -cycloalkyl is replaced by an oxygen atom;

[in particular such C _3.6 -cycloalkyl which is unsubstituted, mono-, or di-substituted as defined above is cyclopropyl, cyclopentyl, 3-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 3-hydroxy-3-ethyl- cyclopentyl, 3-hydroxy-3-isopropyl-cyclopentyl, 2-(2-hydroxy-isopropyl)-cyclopropyl, 4-hydroxy-4-methyl- cyclohextyl, tetrahydrofuran-3-yl, tetrahydrofuran-2-yl, tetrahydropyran-4-yl, 5-methyl-tetrahydrofuran-2-yl, or 5,5-dimethyl-tetrahydrofuran-2-yl]

> C _4-6 -cycloalkenyl (notably cyclopentenyl; especially cyclopent- 1 -en- 1 -y I) which is unsubstituted, mono-, or di- substituted with Ci_ ₃ -al kyl, oxo (i.e. =0), or hydroxy, wherein optionally one ring carbon atom of said C _4.6 - cycloalkenyl is replaced by an oxygen atom;

[in particular such C _4.6 -cycloalkenyl which is unsubstituted, mono-, or di-substituted as defined above is 3-oxo- cyclopent-1 -en-1 -yl, 3-hydroxy-3-methyl-cyclopent-1-en-1-yl, 2,3-dihydro-furan-3-yl, or 5-methyl-furan-2-yl]

> -0-R°, wherein

• R° represents

^■ Ci- ₄ -alkyl (especially methyl, ethyl, isopropyl, sec-butyl, or isobutyl);

^■ hydroxy-Ci-5-alkyl (especially 2-hydroxy-ethyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, or 3- hydroxy-3-methyl-butyl);

^■ Ci_ ₃ -alkoxy-C _2-3 -alkyl (especially 2-methoxy-ethyl);

^■ C _3-6 -cycloalkyl (especially cyclopentyl or cyclohexyl) which is unsubstituted, mono-, or di-substituted with Ci- ₃ -alkyl (especially methyl), hydroxy or Ci. ₃ -alkoxy (especially methoxy);

^■ tetrahydropyranyl (especially tetrahydropyran-4-yl);

^■ tetrahydropyranyl-Ci- ₃ -alkyl (especially tetrahydropyran-4-yl-methyl);

^■ oxetanyl-Ci- ₃ -alkyl (especially oxetan-3-yl-methyl);

^■ phenyl;

^■ benzyl;

^■ benzy l-oxy-Ci _ ₃ -al kyl (especially 2-(benzyl-oxy)-ethyl);

^■ pyridinyl-Ci_ ₃ -al kyl (especially 2-(pyridin-2-yl)-ethyl);

^■ (3-cyclopropyl-1,2,4-oxadiazol-5-yl)-methyl; or

^■ 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethyl; [in particular such -0-R° is methoxy, ethoxy, isopropoxy, isobutoxy, sec-butoxy, phenoxy, benzyloxy, 2- (benzyloxy)-ethoxy, 2-methoxy-ethoxy, oxetan-3-yl-methoxy, 3-hydroxy-propoxy, cyclohexyl-oxy, 4-hydroxy- cyclohexyl-oxy, 4-methyl-4-hydroxy-cyclohexyl-oxy, 2-hydroxy-2-methyl-propoxy, 2-hydroxy-ethoxy, 3- hydroxy-3-methyl-butoxy, tetrahydropyran-4-yl-oxy, tetrahydropyran-4-yl-methoxy, 3-methoxy-cyclopentyl- oxy, (3-cyclopropyl-1,2,4-oxadiazol-5-yl)-methoxy, or 2-(3,5-dimethyl-1 ,2,4-triazol-1-yl)-ethoxy]

> -CºC-R ^T1 , wherein

> R ^T1 represents

^■ hydroxy-Ci-4-alkyl (especially hydroxy-methyl, 1 -hydroxy-ethyl, 2-hydroxy-ethyl, 1-hydroxy-2-methyl- propyl, or 1 -hydroxy-1 -methyl-ethyl);

^■ Ci_3-alkoxy-Ci_ ₃ -alkyl (especially methoxy-methyl);

^■ C _3-6 -cycloalkyl which is mono-substituted with hydroxy (notably at the point of attachment of the C _3.6 - cycloalkyl to the rest of the molecule; especially 1 -hydroxy-cyclopropyl, 1 -hydroxy-cyclobutyl, or 1- hydroxy-cyclopentyl);

^■ C _3-6 -cycloalkyl (notably cyclopentyl or cyclohexyl) fused with a pyridine ring (notably at positions 2 and 3 of the pyridine ring), wherein said C _3.6 -cycloalkyl is mono-substituted with hydroxy (notably at position 1 of the C _3.6 -cycloalkyl ring) (especially 8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl or 7- hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl);

^■ pyrazolyl (notably pyrazol-4-yl) which is mono- substituted with methyl (especially 1-methyl-pyrazol- 4-yl);

^■ tetrahydropyranyl (especially tetrahydropyran-4-yl) which is unsubstituted or mono-substituted with hydroxy (especially 4-hydroxy-tetrahydropyran-4-yl);

^■ indolyl (notably indol-2-yl); or

^■ hydroxy-azetidinyl (notably 3-hydroxy-azetidin-3-yl) which is N-substituted with C -alkoxy-carbonyl (especially isopropyl-carbonyl or tert-butoxy-carbonyl);

[in particular such -CºC-R ^T1 is 3-hydroxy-prop-1 -yn-1 -yl, 4-hydroxy-but-1 -yn-1 -yl, 3-hydroxy-but-1-yn-1-yl, 3- hydroxy-3-methyl-but-1 -yn-1 -yl, 3-hydroxy-4-methyl-pent-1-yn-1-yl, 3-methoxy-prop-1 -yn-1 -yl, (1-hydroxy- cyclopropyl)-ethynyl, (l-hydroxy-cyclobutyl)-ethynyl, (l-hydroxy-cyclopentyl)-ethynyl, (8-hy d roxy-5, 6,7,8- tetrahydroquinolin-8-yl)-ethynyl, (7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethynyl , (1-methyl- pyrazol-4-yl)-ethynyl, (tetrahydropyran-4-yl)-ethynyl, (4-hydroxy-tetrahydropyran-4-yl)-ethynyl, indol-2-yl- ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl, or (1-(tert-butoxy-carbonyl)-3-hydroxy- azetidin-3-yl)-ethynyl]

> -CºC-C(OH)(R ^T2 )(R ^T3 ), wherein

> R ^T2 represents hydrogen or Ci. ₃ -alkyl (especially methyl or ethyl); > R ^T3 represents

^■ phenyl which is unsubstituted or mono-substituted, wherein the substituent(s), if any, is(are) independently selected from Ci_ ₃ -alkoxy (notably methoxy) or halogen (notably fluorine);

[in particular such phenyl which is unsubstituted or mono-substituted is 3-fluoro-phenyl, 4-methoxy- phenyl, or 2-methoxy-phenyl]

^■ 5- to 6-membered heteroaryl containing one or two ring heteroatom(s) being independently selected from nitrogen or sulfur (notably thiazolyl, pyrazolyl, pyridinyl, or pyrimidinyl; especially thiazol-4-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl), wherein said 5- or 6- membered heteroaryl is independently unsubstituted, mono- or di- substituted, and wherein the substituent(s), if any, is(are) independently selected from Ci_ ₃ -alkyl (especially methyl) and Ci_ ₃ - alkoxy (especially methoxy); or

[in particular such 5- to 6-membered heteroaryl is 1 -methyl-pyrazol-3-yl, 1,3-dimethyl-pyrazol-4-yl, 1,5-dimethyl-pyrazol-3-yl, 2-methyl-thiazol-4-yl, pyridin-2-yl, 6-methoxy-pyridin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, or 1,5-dimethyl-pyrazol-3-yl]

^■ tetrahydropyranyl (especially tetrahydropyran-4-yl);

[in particular such -CºC-C(OH)(R ^T2 )(R ^T3 ) is 3-hydroxy-3-(tetrahydropyran-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3- phenyl-prop-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-prop-1-yn-1-yl, 3-hy droxy-3-(1 , 3-d i methy l-pyrazol- 4-yl)-prop- 1 -y n- 1 -y 1 , 3-hydroxy-3-phenyl-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3- hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1 -methyl-pyrazol-3-yl)-but-1 -yn-1 -yl, 3- hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1 -methyl-pyrazol-3-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(3- fluoro-phenyl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(pyridin-2-yl)- pent-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pent- 1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl, or 3-hydroxy-3-(2-methoxy-phenyl)-but-1-yn-1-yl]

> -NR ^N1 R ^N2 wherein

• R ^N1 represents Ci_3-alkyl (especially methyl);

• R ^N2 represents hy d roxy-C i - ₃ -al ky I (especially 2-hydroxy-ethyl) or 2-(benzyl-oxy)-Ci- ₃ -alkyl (especially 2- (benzyl-oxy)-ethyl);

• or R ^N1 and R ^N2 form, together with the nitrogen to which they are attached, a heterocyclic ring of 4 to 6 members (notably 5 to 6 members), wherein the members needed to complete said heterocyclic ring are each independently selected from -CH ₂ -, -0-, -(C=0)-, -CHR ^X - and -C(R ^Y ) ₂ -; wherein said heterocyclic ring does not contain more than one member independently selected from the group consisting of -0- and -(C=0)-; wherein said heterocyclic ring does not contain more than two members selected from the group consisting of -CHR ^X -; and wherein said heterocyclic ring does not contain more than two members selected from the group consisting of -C(R ^Y ) ₂ -; wherein R ^x independently represents fluorine, methyl, isopropyl, isobutyl, tert-butyl, hydroxy, trifluoromethyl, hydroxy-methyl, 1 -hydroxy-ethyl, 1-hydroxy-1- methyl-ethyl, cyclopropyl, 2-methoxy-ethyl, 4-methyl-thiazol-2-yl, phenyl, benzyl, tetrahydropyran-4-yl, 1,2,4-oxadiazolyl, 3-methyl-1,2,4-oxadiazol-5-yl, pyridin-2-yl, or 1-methoxy-methyl; and wherein R ^Y independently represents fluorine, hydroxy, cyclopropyl, methyl, hydroxy-methyl, or trifluoromethyl [notably such -NR ^N1 R ^N2 is pyrrolidinyl; 2-pyrrolidonyl; oxazolidinonyl (especially 1,3-oxazolidin-2-on-3-yl); piperidinyl; or morpholinyl, optionally independently substituted with one or two substituents independently selected from a group consisting of R ^x and R ¹¹ ];

[in particular such -NR ^N1 R ^N2 is pyrrolidin-1-yl, 3-fluoro-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, 3,4-difluoro- pyrrolidin-1-yl, 3-isopropyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2-methyl- pyrrolidin-1-yl, 3-hydroxy-3-methyl-pyrrolidin-1-yl, 3-(hydroxy-methyl)-pyrrolidin-1-yl, 2-(hydroxy-methyl)- pyrrolidin-1-yl, 3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-hydroxy-3-cyclopropyl-pyrrolidin-1-yl, 3-hydroxy-3- trifluoromethyl-pyrrolidin-1-yl, 3-trifl uoromethy l-pyrrol id i n-1 -yl , 3-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl, 3- (1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-(hydroxy-methyl)-3-methyl-pyrrolidin-1-yl, 1,3-oxazolidin-2-on-3-yl, 5-(tert- butyl)-1 , 3-oxazol idin-2-on-3-y 1 , 5-phenyl-1 ,3-oxazolidin-2-on-3-yl, 5-benzyl-1 , 3-oxazol idin-2-on-3-y 1 , 5- isopropyl-1 ,3-oxazolidin-2-on-3-yl, 5-(tetrahydropyran-4-yl)-1 , 3-oxazol idin-2-on-3-y 1 , 5,5-dimethyl-1 ,3- oxazolid i n-2-on-3-yl , morpholin-4-yl, piperidin-1-yl, 4-hydroxy-piperidin-1-yl, 3-hydroxy-piperidin-1-yl, 3- (tetrahydropyran-4-yl)-pyrrolid-2-on-1-yl, N-methyl-N-(2-(benzyl-oxy)-ethyl)-amino, N-methyl-N-(2-hydroxy- ethyl)-amino, pyrrolid-2-on-1-yl, 4-phenyl-pyrrolid-2-on-1-yl, 4-isopropyl-pyrrolid-2-on-1-yl, 3-isopropyl- pyrrolid-2-on-1-yl, 4,4-dimethyl-pyrrolid-2-on-1-yl, 3-(piperidin-4-yl)-pyrrolid-2-on-1-yl, 4-isobutyl-pyrrolid-2-on- 1-yl, 4-cyclopropyl-pyrrolid-2-on-1-yl, 4-trifluoromethyl-pyrrolid-2-on-1-yl, 3-(2-methoxy-ethyl)-pyrrolid-2-on-1- yl, 4-(2-methoxy-ethy l)-py rrol id-2-on- 1 -y 1 , 2,2,6,6-tetrafluoro-morpholin-4-yl, 2,6-dimethyl-morpholin-4-yl, 2- (methoxy-methyl)-morpholin-4-yl, 3-(3-methy I- 1 , 2, 4-oxadi azol-5-y I )-pyrrol idi n- 1 -y I, 3-(4-methyl-thiazol-2-yl)- pyrrolidin-1-yl, or 3-(phenyl)-pyrrolidin-1-yl]

> -(C=0)-N(R ^N3 )(R ^N4 ), wherein

• R ^N3 represents hydrogen; and

R ^N4 represents C3-6-cycloalkyl (especially cyclopentyl) or tetrahydropyranyl (especially tetrahydropyran-4- yl); or

• R ^N3 and R ^N4 form, together with the nitrogen to which they are attached, pyrrolidinyl;

[in particular such -(C=0)-N(R ^N3 )(R ^N4 ) is N-cyclopentyl-amino-carbonyl, N-(tetrahydropyran-4-yl)-amino- carbonyl, or pyrrolidinyl-carbonyl] > piperidin-4-yl or pyrrolidin-3-yl which independently are mono-substituted at the nitrogen ring atom, wherein the substituent is selected from Ci. ₄ -alkoxy-carbonyl (especially tert-butoxy-carbonyl), pyridinyl (especially pyridin-2-yl), phenyl and (4-methylphenyl)-sulfonyl;

[in particular such piperidin-4-yl or pyrrolidin-3-yl are N-(tert-butoxy-carbonyl)-piperidin-4-yl, N-(tert-butoxy- carbonyl)-pyrrolidin-3-yl, N-(pyridin-2-yl)-piperidin-4-yl, N-(phenyl)-piperidin-4-yl, or N-((4-methylphenyl)- sulfonyl)-piperidin-4-yl]

> 5-membered heteroaryl containing from one to three (notably two or three; especially three) ring heteroatom(s) independently selected from nitrogen, oxygen and sulfur (notably pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl or 1,2,4- oxadiazol-3-yl); wherein said 5-membered heteroaryl is independently unsubstituted, mono-, di-, or tri- substituted (notably mono-substituted; especially mono-substituted in position 3 with respect to the point of attachment of said 5-membered heteroaryl to A), wherein the substituent(s), if any, is(are) independently selected from

> Ci-4-alkyl which is unsubstituted or mono-substituted with hydroxy or C -alkoxy (especially methoxy and tert-butoxy);

[in particular such Ci-4-al kyl which is unsubstituted or mono-substituted as defined above is methyl, 1- hydroxy- 1 -methyl-ethyl , 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1 -dimethyl-ethyl, methoxy-methyl, 2- methoxy-ethyl, 1 -methoxy-1 -methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1 , 1 -dimethyl-ethyl, tert- butoxy-methyl; preferably such Ci_ ₄ -alkyl group is 1 -hydroxy-1 -methyl-ethyl, 2-hydroxy-2-methy l-propy I , or 2-hydroxy-1 , 1 -dimethyl-ethyl]

> amino-Ci-4-alkyl (especially 2-amino-ethyl or 2-amino-2, 2-dimethyl-ethyl), wherein the amino group is mono- or di-substituted (especially mono-substituted) with Ci_3-alkyl (especially methyl), Ci-3-alkyl- carbonyl including deuterated C i -3-al kyl-carbony I (especially acetyl or acetyl-2, 2, 2-d ₃ ), or hydroxy-Ci-3- alkyl-carbonyl (especially hydroxy-methyl-carbonyl);

[in particular such amino-C -alkyl is N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl, N-acetyl- 2-amino-2, 2-dimethyl-ethyl, N-(acetyl-2, 2, 2-d ₃ )-2-amino-2, 2-dimethyl-ethyl, N-methyl-N-(hydroxy-methyl- carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl, or N-methyl-N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl]

> C3_6-cycloalkyl-L ² -, wherein

^■ -L ² - represents a bond (i.e. the C3_6-cycloalkyl is directly attached to the rest of the molecule), oxygen,

Ci_3-alkylene (especially -CH ₂ -, -CH ₂ -CH ₂ -, or -C(CH ₃ ) ₂ -), hydroxy-Ci_ ₂ -alkylene (especially -CH(OH)- ) or oxy-Ci- ₂ -alkylene (especially -0-CH ₂ -) (wherein the C3-6-cycloalkyl is attached to the oxygen atom of said oxy-Ci- ₂ -alkylene); ^■ C3-6-cycloalkyl is unsubstituted, mono-, or di-substituted with fluorine, Cu-alkyl (especially methyl), Ci_3-alkoxy (especially methoxy), hydroxy, hy d roxy-C i _ ₃ -al ky I , or Ci_3-alkoxy-Ci_ ₃ -alkyl; wherein optionally one ring carbon atom of said C3_6-cycloalkyl is replaced by an oxygen atom;

[in particular such C3-6-cycloalkyl-L ² - is oxetan-3-yl, cyclobutoxy-methyl, 1 -hydroxy-cyclopropyl, 1- hydroxy-cyclobutyl, 3-hydroxy-cyclobutyl, 1 -hydroxy-cyclopentyl, 3- hy d roxy-3-methy I -cy cl openty 1 , 1- hydroxy-cyclohexyl, 4-hydroxy-cyclohexyl, (1 -hydroxy-cyclohexyl)-methyl, (1 -hydroxy-cyclobutyl)-methyl, 1 -hydroxy-1 -cyclohexylmethyl, 1 -methoxy-cyclobutyl, 1 -methoxy-cyclopentyl, 1 -(1 -(methoxy-methyl)- cyclopropyl)-methyl, tetrahydrofuran-2-yl-methyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, 4-methyl-tetrahydropyran-4-yl, 2,6-dimethyl-tetrahydropyran- 4-yl, 4-methoxy-tetrahydropyran-4-yl, 4-fl uoro-tetrahy d ropy ran-4-y I , tetrahydropyran-4-yl-methyl, 2- (tetrahydropyran-4-yl)-ethyl, 1-(tetrahydropyran-4-yl)-1-methyl-ethyl, tetrahydropyran-4-yl-oxy-methyl, or (4-methyl-tetrahydropyran-4-yl)-oxy-methyl]

> piperidin-4-yl which is N-substituted with Ci-3-alkyl-carbonyl (especially acetyl), (hydroxy-Ci-3-alkyl)- carbonyl (especially hydroxymethyl-carbonyl), or C3-5-cycloalkyl-sulfonyl;

[in particular such piperidin-4-yl is N-acetyl-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl, or N- (cyclopropyl-sulfonyl)-piperidin-4-yl]

> morpholinyl-L ³ - (notably (morpholin-4-yl)-L ³ -), wherein -L ³ - represents a bond (i.e. the morpholinyl is directly attached to the rest of the molecule) or Ci_2-alkylene; wherein said morpholinyl is unsubstituted or di-substituted with methyl;

[in particular such morpholinyl-L ³ - is morpholin-4-yl, morpholin-4-yl-methyl, or (2,6-dimethyl-morpholin-4- yl)-methyl]

> pyrazolyl-Ci-3-alkyl (especially 2-(pyrazol-1-yl)-ethyl);

> Ci-3-alkyl-sulfonyl-Ci-3-alkyl (especially methyl-sulfonyl-methyl);

> 2,2,2-trifluoro-1 -hydroxy-1 -methyl-ethyl;

> 3-hydroxymethyl-bicyclo[1.1.1]pent-1 -yl;

> 7-oxa-bicyclo[2.2.1]hept-2-yl; and

> 6-oxa-sp i ro [2.5] oct- 1 -y I ;

> 5-oxo-4-oxa-6-azaspiro[2.4]hept-6-yl, 2,2-dimethyl-6-oxo-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-cyclopropyl-6-oxo-

5-oxa-7-azaspiro[3.4]oct-7-yl, 2-oxo-1-oxa-3-azaspiro[4.4]non-3-yl, 8,8-difluoro-2-oxo-1-oxa-3- azaspiro[4.5]dec-3-yl, or 8-oxo-7-oxa-9-azadispiro[3.1.4.1]undec-9-yl;

> 7-aza-bicyclo[2.2.1]hept-7-yl, 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl, or 8- oxa-3-azabicyclo[3.2.1]oct-3-yl; > 5-oxo-6-azaspiro[3.4]oct-6-yl, 3-oxo-2-azaspiro[4.4]non-2-yl, 1-oxo-2-azaspiro[4.5]dec-2-yl, 1-oxo-8-oxa-2- azaspiro[4.5]dec-2-yl, 3-oxo-8-oxa-2-azaspiro[4.5]dec-2-yl, or 4-oxo-hexahydro-5H-furo[2,3-c]pyrrol-5-yl;

> 3-(7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)propyl or 3-(8-hydroxy-5,6,7,8-tetrahydroquinolin-8- yl)propyl); and

> 2-(6,7-dihydro-5H-[1]pyrindin-7-ol)-ethyl or 2-(8-hydroxy-5,6,7,8-tetrahydro-quinolin-8-yl)-ethyl;

B represents phenyl, which is unsubstituted, mono-, di- or tri-substituted (especially mono-substituted in para- position with respect to the point of attachment of B to the rest of molecule), wherein the substituent(s), if any, is(are) independently selected from

> Ci-5-alkyl (especially methyl, ethyl, n-propyl, isopropyl, or tert-butyl; in particular isopropyl);

> Ci_3-alkoxy (especially methoxy, ethoxy, or isopropoxy);

> Ci_3-alkoxy-Ci_4-alkyl (especially 3-methoxy-propyl);

> Ci-3-fluoroalkyl (especially trifluoromethyl);

> C3-5-cycloalkyl (especially cyclopropyl or cyclobutyl) which independently is unsubstituted or mono-substituted (notably at the point of attachment of said C3-5-cycloalkyl to the rest of the molecule) with Ci_3-alkyl (especially methyl) or Ci-3-fluoroalkyl (especially trifluoromethyl);

> C3-5-cycloalkoxy (especially cyclopropoxy or cyclobutoxy); and

> C ₁ - ₃ -f I uo ro al koxy (especially trifluoromethoxy);

[in particular such Bis phenyl, 4-methyl-phenyl, 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-tert-butyl-phenyl, 4-cyclopropyl-phenyl, 4-methoxy-phenyl, 4-ethoxy-phenyl, 4-isopropoxy-phenyl, 4-trifluoromethyl-phenyl, 4-(1-methyl- cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, 4-cyclopropoxy-phenyl, 4-cyclobutoxy-phenyl, 4-(trifluoromethoxy)-phenyl, 4- (3-methoxy-propyl)-phenyl, or 4-(1 -trifluoromethyl-cyclopropyl)-phenyl]

R ¹ represents Ci_3-alkyl (especially methyl), cyano, or halogen (especially fluorine);

R ² represents Ci_4-alkyl (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl or isobutyl), C3-5-cycloalkyl (especially cyclopropyl or cyclobutyl), C3-5-cycloalkyl-Ci-3-alkyl (especially cyclopropyl-methyl), or Ci-3-fluoroalkyl (especially 2,2- difluoroethyl or 2-fluoroethyl).

39) A further embodiment relates to compounds of Formula (IP) according to embodiment 38), wherein the characteristics of any one of embodiments 2) to 32) apply mutatis mutandis.

40) One embodiment of the present invention relates to compounds according to embodiment 38), wherein A represents pyridinyl, pyrimidinyl, pyrazinyl, orpyridazinyl (notably pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, or pyridazin- 4-yl; especially pyridin-3-yl), wherein A is independently unsubstituted, mono-, di- or tri-substituted (notably mono- or di-substituted in meta- and/or para- position of A with respect to the point of attachment of A to the rest of the molecule; especially mono-substituted in eia-position of A with respect to the point of attachment of A to the rest of the molecule), wherein the substituent(s), if any, is(are) as defined in embodiment 38).

41) Another embodiment of the present invention relates to compounds according to embodiment 38), wherein A represents pyridin-3-yl or pyridin-4-yl, wherein A is independently unsubstituted, mono-, di- or tri-substituted (notably mono- or di-substituted in meta- and/or para- position of A with respect to the point of attachment of A to the rest of the molecule; especially mono-substituted in meia-position of A with respect to the point of attachment of A to the rest of the molecule), wherein the substituent(s), if any, is(are) as defined in embodiment 38).

42) Another embodiment of the present invention relates to compounds according to embodiment 38), wherein A is

> unsubstituted;

> mono-substituted (especially in meia-position of A with respect to the point of attachment of A to the rest of the molecule), wherein the substituent is as defined in embodiment 38).

> di-substituted, wherein a first substituent is (notably in meta- position of A with respect to the point of attachment of A to the rest of the molecule) selected from the substituents defined in embodiment 38) (notably excluding halogen (especially fluorine) or cyano); and a second substituent is (notably in para- position of A with respect to the point of attachment of A to the rest of the molecule) selected from halogen (especially fluorine) and cyano.

[In a sub-embodiment of embodiment 4), A is pyridin-3-yl]

43) Another embodiment of the present invention relates to compounds according to any one of embodiments 40) to 42), wherein A is mono-substituted in meia-position of A with respect to the point of attachment of A to the rest of the molecule, wherein the substituent of A is

> 5-membered heteroaryl containing from one to three (notably two or three; especially three) ring heteroatom(s) independently selected from nitrogen, oxygen and sulfur (notably pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl or 1,2,4- oxadiazol-3-yl; preferably 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl); wherein said 5-membered heteroaryl is independently unsubstituted, mono-, di-, or tri-substituted (notably mono-substituted; especially mono- substituted in position 3 with respect to the point of attachment of said 5-membered heteroaryl to A), wherein the substituent(s), if any, is(are) independently selected from

> Ci-4-alkyl which is unsubstituted or mono-substituted with hydroxy or Ci_ ₄ -alkoxy (especially methoxy and tert-butoxy);

[in particular such Ci_ ₄ -al kyl which is unsubstituted or mono-substituted as defined above is methyl, 1- hydroxy- 1 -methyl-ethyl , 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1 -dimethyl-ethyl, methoxy-methyl, 2- methoxy-ethyl, 1 -methoxy-1 -methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1 , 1 -dimethyl-ethyl, tert- butoxy-methyl; preferably such Ci-4-alkyl group is 1 -hydroxy-1 -methyl-ethyl, 2-hydroxy-2-methy l-propy I , or 2-hydroxy-1 , 1 -dimethyl-ethyl]

> amino-Ci-4-alkyl (especially 2-amino-ethyl or 2-amino-2, 2-dimethyl-ethyl), wherein the amino group is mono- or di-substituted (especially mono-substituted) with Cu-alkyl (especially methyl), Ci-3-alkyl- carbonyl including deuterated Ci-3-alkyl-carbonyl (especially acetyl or acetyl-2, 2, 2-d ₃ ) or hydroxy-Ci_3- alkyl-carbonyl (especially hydroxy-methyl-carbonyl);

[in particular such amino-C -alkyl is N -acetyl -2-am i no-ethyl , N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl, N-acetyl- 2-amino-2, 2-dimethyl-ethyl, N-(acetyl-2, 2, 2-d ₃ )-2-amino-2, 2-dimethyl-ethyl, N-methyl-N-(hydroxy-methyl- carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl, or N-methyl-N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl]

> C _3-6 -cycloalkyl-L ² -, wherein

^■ -L ² - represents a bond (i.e. the C _3-6 -cycloalkyl is directly attached to the rest of the molecule), oxygen, Ci-3-alkylene (especially -CH ₂ -, -CH ₂ -CH ₂ -, or -C(CH ₃ ) ₂ -), hydroxy-Ci_ ₂ -alkylene (especially -CH(OH)- ) or oxy-Ci- ₂ -alkylene (especially -0-CH ₂ -) (wherein the C3-6-cycloalkyl is attached to the oxygen atom of said oxy-Ci- ₂ -alkylene); and

^■ the C3-6-cycloalkyl is unsubstituted, mono-, or di-substituted with fluorine, Ci-3-alkyl (especially methyl), Ci_3-alkoxy (especially methoxy), hydroxy, hy droxy-C i -3-al ky I , or C i -3- al koxy-C 1 -3-al ky I ; wherein optionally one ring carbon atom of said C3-6-cycloalkyl is replaced by an oxygen atom;

[in particular such C3-6-cycloalkyl-L ² - is oxetan-3-yl, cyclobutoxy-methyl, 1 -hydroxy-cyclopropyl, 1- hydroxy-cyclobutyl, 3-hydroxy-cyclobutyl, 1 -hydroxy-cyclopentyl, 3- hy d roxy-3-methy I -cy cl openty 1 , 1- hydroxy-cyclohexyl, 4-hydroxy-cyclohexyl, (1 -hydroxy-cyclohexyl)-methyl, (1 -hydroxy-cyclobutyl)-methyl, 1 -hydroxy-1 -cyclohexylmethyl, 1 -methoxy-cyclobutyl, 1 -methoxy-cyclopentyl, 1 -(1 -(methoxy-methyl)- cyclopropyl)-methyl, tetrahy d rof u ran-2-y l-methy I , tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, 4-methyl-tetrahydropyran-4-yl, 2,6-dimethyl-tetrahydropyran- 4-yl, 4-methoxy-tetrahydropyran-4-yl, 4-fl uoro-tetrahy d ropy ran-4-y I , tetrahyd ropy ran-4-y I -methyl , 2- (tetr ahy d ro py r an-4-y I )-ethy 1 , 1 - (tetrahyd ropy r an-4-y I )- 1-methyl-ethyl, tetrahydropyran-4-yl-oxy-methyl, or (4-methyl-tetrahydropyran-4-yl)-oxy-methyl]

> piperidin-4-yl which is N-substituted with Ci-3-alkyl-carbonyl (especially acetyl), (hydroxy-Ci-3-alkyl)- carbonyl (especially hydroxymethyl-carbonyl), or C _3-5 -cycloalkyl-sulfonyl;

[in particular such piperidin-4-yl is N-acety I -pi perid i n-4-y I , N-(hydroxymethyl-carbonyl)-piperidin-4-yl, or N- (cyclopropyl-sulfonyl)-piperidin-4-yl]

> morpholinyl-L ³ - (notably (morpholin-4-yl)-L ³ -), wherein -L ³ - represents a bond (i.e. the morpholinyl is directly attached to the rest of the molecule) or Ci. ₂ -alkylene; wherein said morpholinyl is unsubstituted or di-substituted with methyl; [in particular such morpholinyl-L ³ - is morpholin-4-yl, morpholin-4-yl-methyl, or (2,6-dimethyl-morpholin-4- yl)-methyl]

> pyrazolyl-Ci-3-alkyl (especially 2-(pyrazol-1 -yl)-ethyl);

> Ci-3-alkyl-sulfonyl-Ci-3-alkyl (especially methyl-sulfonyl-methyl);

> 2,2,2-trifluoro-1 -hydroxy-1 -methyl-ethyl;

> 3-hydroxymethyl-bicyclo[1.1.1]pent-1 -yl;

> 7-oxa-bicyclo[2.2.1]hept-2-yl; and

> 6-oxa-spiro[2.5]oct-1-yl.

44) Another embodiment of the present invention relates to compounds according to any one of embodiments 40) to 42), wherein A is mono-substituted in eia-position of A with respect to the point of attachment of A to the rest of the molecule, wherein the substituent of A is

> 5-membered heteroaryl containing from one to three (notably two or three; especially three) ring heteroatom(s) independently selected from nitrogen, oxygen and sulfur (notably pyrazolyl, triazolyl, oxazolyl, thiazolyl, oxadiazolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, oxazol-2-yl, thiazol-2-yl, 1,2,4-oxadiazol-5-yl or 1,2,4- oxadiazol-3-yl; most preferably 1,2,4-oxadiazol-5-yl or 1,2,4-oxadiazol-3-yl); wherein said 5-membered heteroaryl is independently unsubstituted, mono-, di-, or tri-substituted (notably mono-substituted; especially mono-substituted in position 3 with respect to the point of attachment of said 5-membered heteroaryl to A), wherein the substituent(s), if any, is(are) independently selected from

> amino-Ci-4-alkyl (especially 2-amino-ethyl or 2-amino-2, 2-dimethyl-ethyl), wherein the amino group is mono- or di-substituted (especially mono-substituted) with Ci_ ₃ -alkyl (especially methyl), Ci_ ₃ -alkyl- carbonyl including deuterated C i _ ₃ -al kyl-carbony I (especially acetyl or acetyl-2, 2, 2-d ₃ ), or hydroxy-Ci. ₃ - alkyl-carbonyl (especially hydroxy-methyl-carbonyl);

[in particular such amino-C -alkyl is N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl, N-acetyl- 2-amino-2, 2-dimethyl-ethyl, N-(acetyl-2, 2, 2-d ₃ )-2-amino-2, 2-dimethyl-ethyl, N-methyl-N-(hydroxy-methyl- carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl, or N-methyl-N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl]

> piperidin-4-yl which is N-substituted with Ci-3-alkyl-carbonyl (especially acetyl), (hydroxy-Ci-3-alkyl)- carbonyl (especially hydroxymethyl-carbonyl), or C3-5-cycloalkyl-sulfonyl.

[in particular such piperidin-4-yl is N-acetyl-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl, or N- (cyclopropyl-sulfonyl)-piperidin-4-yl]

45) Another embodiment of the present invention relates to compounds according to any one of embodiments 40) to 42), wherein A is mono-substituted in meia-position of A with respect to the point of attachment of A to the rest of the molecule, wherein the substituent is > 1 ,2,4-oxadiazol-3-yl which is mono-substituted, wherein the substituent is independently selected from

> amino-Ci-4-alkyl (especially 2-amino-ethyl or 2-amino-2, 2-dimethyl-ethyl), wherein the amino group is

^■ mono-substituted with Ci_ ₃ -al kyl-carbonyl including deuterated Ci_ ₃ -alkyl-carbonyl (especially acetyl or acetyl-2,2,2-d ₃ );

^■ di-substituted, wherein a first substituent is Ci- ₃ -alkyl (especially methyl) and a second substituent is Ci- ₃ -alkyl-carbonyl (especially acetyl) or Ci- ₃ -alkyl-carbonyl including deuterated Ci-3-alkyl-carbonyl (especially acetyl or acetyl-2,2,2-d ₃ ); or

^■ di-substituted, wherein a first substituent is Ci- ₃ -alkyl (especially methyl) and a second substituent is hydroxy-Ci- ₃ -alkyl-carbonyl (especially hydroxy-methyl-carbonyl);

[in particular such amino-Ci_ ₄ -alkyl is N-acetyl-2-amino-ethyl, N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl, N-acetyl- 2-amino-2, 2-dimethyl-ethyl, N-(acetyl-2, 2, 2-d ₃ )-2-amino-2, 2-dimethyl-ethyl, N-methyl-N-(hydroxy-methyl- carbonyl)-2-amino-ethyl, N-methyl-N-acetyl-2-amino-ethyl, or N-methyl-N-(acetyl-2,2,2-d ₃ )-2-amino-ethyl]

> piperidin-4-yl which is N-substituted with Ci. ₃ -alkyl-carbonyl (especially acetyl), (hydroxy-Ci. ₃ -alkyl)- carbonyl (especially hydroxymethyl-carbonyl), or C _3. 5-cycloalkyl-sulfonyl.

[in particular such piperidin-4-yl is N-acetyl-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl, or N- (cyclopropyl-sulfonyl)-piperidin-4-yl]

46) Another embodiment of the present invention relates to compounds according to any one of embodiments 40) or 42), wherein A represents pyridinyl (especially pyridin-3-yl) which is mono-substituted in eia-position with respect to the point of attachment of A to the rest of the molecule, wherein the substituent is oxadiazolyl (especially 1,2,4- oxadiazol-3-yl) which is mono-substituted, wherein the substituent is Ci_ ₄ -alkyl which is unsubstituted or mono- substituted with hydroxy or Ci_ ₄ -alkoxy (especially such Ci_ ₄ -alkyl is 1 -hydroxy-1 -methyl-ethyl, 2-hydroxy-2-methyl- propyl, or 2-hydroxy-1 , 1 -dimethyl-ethyl).

47) Another embodiment of the present invention relates to compounds according to any one of embodiments 40) to 42), wherein A is mono-substituted in meia-position of A with respect to the point of attachment of A to the rest of the molecule, wherein the substituent of A is

> -CºC-R ^T1 , wherein

> R ^T1 represents

^■ hydroxy-Ci-4-alkyl (especially hydroxy-methyl, 1 -hydroxy-ethyl, 2-hydroxy-ethyl, 1-hydroxy-2-methyl- propyl, or 1 -hydroxy-1 -methyl-ethyl);

^■ Ci_ ₃ -alkoxy-Ci_3-alkyl (especially methoxy-methyl);

^■ C _3-6 -cycloalkyl which is mono-substituted with hydroxy (notably at the point of attachment of the C _3-6 - cycloalkyl to the rest of the molecule; especially 1 -hydroxy-cyclopropyl, 1 -hydroxy-cyclobutyl, or 1- hydroxy-cyclopentyl); ^■ C3-6-cycloalkyl (notably cyclopentyl or cyclohexyl) fused with a pyridine ring (notably at positions 2 and 3 of the pyridine ring), wherein said C _3-6 -cycloalkyl is mono-substituted with hydroxy (notably at position 1 of the C _3-6 -cycloalkyl ring) (especially 8-hydroxy-5,6,7,8-tetrahydroquinolin-8-yl or 7- hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl);

^■ pyrazolyl (notably pyrazol-4-yl) which is mono- substituted with methyl (especially 1-methyl-pyrazol- 4-yl);

^■ tetrahydropyranyl (especially tetrahydropyran-4-yl) which is unsubstituted or mono-substituted with hydroxy (especially 4-hydroxy-tetrahydropyran-4-yl);

^■ indolyl (notably indol-2-yl); or

^■ hydroxy-azetidinyl (notably 3-hydroxy-azetidin-3-yl) which is N-substituted with Ci. ₄ -alkoxy-carbonyl (especially isopropyl-carbonyl or tert-butoxy-carbonyl);

[in particular such -CºC-R ^T1 is 3-hydroxy-prop-1 -yn-1 -yl, 4-hydroxy-but-1 -yn-1 -yl, 3-hydroxy-but-1-yn-1-yl, 3- hydroxy-3-methyl-but-1 -yn-1 -yl, 3-hydroxy-4-methyl-pent-1-yn-1-yl, 3-methoxy-prop-1 -yn-1 -yl, (1-hydroxy- cyclopropyl)-ethynyl, (l-hydroxy-cyclobutyl)-ethynyl, (l-hydroxy-cyclopentyl)-ethynyl, (8-hy d roxy-5, 6,7,8- tetrahydroquinolin-8-yl)-ethynyl, (7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-ethynyl , (1-methyl- pyrazol-4-yl)-ethynyl, (tetrahydropyran-4-yl)-ethynyl, (4-hydroxy-tetrahydropyran-4-yl)-ethynyl, indol-2-yl- ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azetidin-3-yl)-ethynyl, or (1-(tert-butoxy-carbonyl)-3-hydroxy- azetidin-3-yl)-ethynyl]

> -CºC-C(OH)(R ^T2 )(R ^T3 ), wherein

> R ^T2 represents hydrogen or Ci_ ₃ -alkyl (especially methyl or ethyl);

> R ^T3 represents

^■ phenyl which is unsubstituted or mono-substituted, wherein the substituent, if any, is selected from Ci- ₃ -alkoxy (notably methoxy) or halogen (notably fluorine);

[in particular such group is 3-fluoro-phenyl, 4-methoxy-phenyl, or 2-methoxy-phenyl]

^■ 5- to 6-membered heteroaryl containing one or two ring heteroatom(s) being independently selected from nitrogen or sulfur (notably thiazolyl, pyrazolyl, pyridinyl, or pyrimidinyl; especially thiazol-4-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl), wherein said 5- or 6- membered heteroaryl is independently unsubstituted, mono- or di- substituted, and wherein the substituent(s), if any, is(are) independently selected from Ci_ ₃ -alkyl (especially methyl) and Ci_ ₃ - alkoxy (especially methoxy); or [in particular such 5- to 6-membered heteroaryl group is 1 -methyl-pyrazol-3-yl, 1,3-dimethyl-pyrazol- 4-yl, 1,5-dimethyl-pyrazol-3-yl, 2-methyl-thiazol-4-yl, pyridin-2-yl, 6-methoxy-pyridin-2-yl, pyrimidin-2- yl, pyrimidin-4-yl, or 1,5-dimethyl-pyrazol-3-yl]

^■ tetrahydropyranyl (especially tetrahydropyran-4-yl);

[in particular such -CºC-C(OH)(R ^T2 )(R ^T3 ) is 3-hydroxy-3-(tetrahydropyran-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3- phenyl-prop-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazol-4-yl)-prop-1-yn-1-yl, 3-hy droxy-3-(1 , 3-d i methy l-pyrazol- 4-yl)-prop- 1 -y n- 1 -y 1 , 3-hydroxy-3-phenyl-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-but-1-yn-1-yl, 3- hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1 -methyl-pyrazol-3-yl)-but-1 -yn-1 -yl, 3- hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1 -methyl-pyrazol-3-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(3- fluoro-phenyl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-but-1 -yn-1 -yl, 3-hydroxy-3-(pyridin-2-yl)- pent-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pent- 1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl, or 3-hydroxy-3-(2-methoxy-phenyl)-but-1-yn-1-yl]

48) Another embodiment of the present invention relates to compounds according to any one of embodiments 38) to 42), wherein A is mono-substituted in eia-position of A with respect to the point of attachment of A to the rest of the molecule, wherein the substituent of A is as defined in embodiment 42) or 46).

49) Another embodiment of the present invention relates to compounds according to any one of embodiments 38) to

48), wherein B represents phenyl, which is mono-substituted in para- position with respect to the point of attachment of B to the rest of molecule, wherein the substituent is selected from Ci-5-alkyl (especially ethyl, n-propyl, isopropyl, or tert- butyl; in particular isopropyl).

[in particular such B is 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-tert-butyl-phenyl; in particular 4-isopropyl- phenyl]

50) Another embodiment of the present invention relates to compounds according to any one of embodiments 38) to

49), wherein R ¹ represents Ci-3-alkyl (especially methyl).

51) Another embodiment of the present invention relates to compounds according to any one of embodiments 38) to

50), wherein R ² represents Ci-4-alkyl (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl or isobutyl).

52) Another embodiment of the present invention relates to compounds according to embodiment 38), wherein

A represents pyridinyl (especially pyridin-3-yl) which is mono-substituted in meia-position with respect to the point of attachment of A to the rest of the molecule, wherein the substituent is oxadiazolyl (especially 1 ,2,4-oxadiazol-3-yl) which is mono-substituted, wherein the substituent is Ci_ ₄ -alkyl which is unsubstituted or mono-substituted with hydroxy or Ci_4-alkoxy (especially such Ci_ ₄ -alkyl which is unsubstituted or mono-substituted is 1 -hydroxy-1 -methyl-ethyl, 2- hydroxy-2-methyl-propyl, or 2-hydroxy-1 , 1 -dimethyl-ethyl); B represents phenyl which is mono-substituted in para- position with respect to the point of attachment of B to the rest of molecule, wherein the substituent is Ci_ ₅ -alkyl (especially isopropyl);

R ¹ represents Ci_ ₃ -alkyl (especially methyl); and R ² represents C -alkyl (especially methyl).

53) Another embodiment relates to compounds according to any one of embodiments 38) to 52), which are also compounds of Formula (lip) (i.e. the asymmetric carbon atom to which A and B are attached has the absolute configuration depicted in Formula (lip))

Formula (lip)

It is understood that for A being pyridin-3-yl, pyrimidin-5-yl, pyrazin-2-yl, or pyridazin-4-yl (especially pyridin-3-yl), the asymmetric carbon atom to which A and B are attached, as depicted in Formula (lip), has absolute configuration (R). In the case where A represents pyridin-4-yl, the asymmetric carbon atom to which A and B are attached, as depicted in Formula (II), has absolute configuration (S).

Based on the dependencies of the different embodiments 1) to 37) as disclosed hereinabove, the following embodiments are thus possible and intended, and herewith specifically disclosed in individualized form:

2+1, 3+1, 4+1, 11+1, 11+2+1, 11+3+1, 11+4+1, 12+11+1, 12+11+2+1, 12+11+3+1, 12+11+4+1, 13+11+1, 13+11+2+1, 13+11+3+1, 13+11+4+1, 14+11+1, 14+11+2+1, 14+11+3+1, 14+11+4+1, 15+11+1, 15+11+2+1, 15+11+3+1, 15+11+4+1, 16+1, 16+2+1, 16+3+1, 16+4+1, 17+16+1, 17+16+2+1, 17+16+3+1, 17+16+4+1, 18+16+1, 18+16+2+1, 18+16+3+1, 18+16+4+1, 19+16+1, 19+16+2+1, 19+16+3+1, 19+16+4+1, 20+1, 20+2+1, 20+3+1, 20+4+1, 21+20+1, 21+20+2+1, 21+20+3+1, 21+20+4+1, 22+20+1, 22+20+2+1, 22+20+3+1 , 22+20+4+1 , 23+1, 23+2+1, 23+3+1, 23+4+1, 23+5, 23+6, 23+7, 23+8, 23+9, 23+10, 23+11+1, 23+11+2+1, 23+11+3+1, 23+11+4+1, 23+12+11+1, 23+12+11+2+1, 23+12+11+3+1, 23+12+11+4+1, 23+13+11+1, 23+13+11+2+1, 23+13+11+3+1, 23+13+11+4+1, 23+14+11+1, 23+14+11+2+1, 23+14+11+3+1, 23+14+11+4+1, 23+15+11+1, 23+15+11+2+1, 23+15+11+3+1, 23+15+11+4+1, 23+16+1, 23+16+2+1, 23+16+3+1, 23+16+4+1, 23+17+16+1, 23+17+16+2+1, 23+17+16+3+1, 23+17+16+4+1, 23+18+16+1, 23+18+16+2+1, 23+18+16+3+1, 23+18+16+4+1, 23+19+16+1, 23+19+16+2+1, 23+19+16+3+1, 23+19+16+4+1, 23+20+1, 23+20+2+1, 23+20+3+1, 23+20+4+1, 23+21+20+1, 23+21+20+2+1, 23+21+20+3+1, 23+21+20+4+1, 23+22+20+1, 23+22+20+2+1, 23+22+20+3+1, 23+22+20+4+1, 26+1, 26+2+1, 26+3+1, 26+4+1, 26+5, 26+6, 26+7, 26+8, 26+9, 26+10, 26+11+1, 26+11+2+1, 26+11+3+1, 26+11+4+1, 26+12+11+1, 26+12+11+2+1, 26+12+11+3+1, 26+12+11+4+1, 26+13+11+1, 26+13+11+2+1, 26+13+11+3+1, 26+13+11+4+1, 26+14+11+1, 26+14+11+2+1, 26+14+11+3+1, 26+14+11+4+1, 26+15+11+1, 26+15+11+2+1, 26+15+11+3+1, 26+15+11+4+1, 26+16+1, 26+16+2+1, 26+16+3+1, 26+16+4+1, 26+17+16+1, 26+17+16+2+1, 26+17+16+3+1, 26+17+16+4+1, 26+18+16+1, 26+18+16+2+1, 26+18+16+3+1, 26+18+16+4+1, 26+19+16+1, 26+19+16+2+1, 26+19+16+3+1, 26+19+16+4+1, 26+20+1, 26+20+2+1, 26+20+3+1, 26+20+4+1, 26+21+20+1, 26+21+20+2+1, 26+21+20+3+1, 26+21+20+4+1, 26+22+20+1, 26+22+20+2+1, 26+22+20+3+1, 26+22+20+4+1, 26+23+1, 26+23+2+1, 26+23+3+1, 26+23+4+1, 26+23+5, 26+23+6, 26+23+7, 26+23+8, 26+23+9, 26+23+10, 26+23+11+1, 26+23+11+2+1, 26+23+11+3+1, 26+23+11+4+1, 26+23+12+11+1, 26+23+12+11+2+1, 26+23+12+11+3+1, 26+23+12+11+4+1, 26+23+13+11+1, 26+23+13+11+2+1, 26+23+13+11+3+1, 26+23+13+11+4+1, 26+23+14+11+1, 26+23+14+11+2+1, 26+23+14+11+3+1, 26+23+14+11+4+1, 26+23+15+11+1, 26+23+15+11+2+1, 26+23+15+11+3+1, 26+23+15+11+4+1, 26+23+16+1, 26+23+16+2+1, 26+23+16+3+1, 26+23+16+4+1, 26+23+17+16+1, 26+23+17+16+2+1, 26+23+17+16+3+1, 26+23+17+16+4+1, 26+23+18+16+1, 26+23+18+16+2+1, 26+23+18+16+3+1, 26+23+18+16+4+1, 26+23+19+16+1, 26+23+19+16+2+1, 26+23+19+16+3+1, 26+23+19+16+4+1, 26+23+20+1, 26+23+20+2+1, 26+23+20+3+1, 26+23+20+4+1, 26+23+21+20+1, 26+23+21+20+2+1, 26+23+21+20+3+1, 26+23+21+20+4+1, 26+23+22+20+1, 26+23+22+20+2+1, 26+23+22+20+3+1, 26+23+22+20+4+1, 26+24, 26+25, 28+1, 28+2+1, 28+3+1, 28+4+1, 28+5, 28+6, 28+7, 28+8, 28+9, 28+10, 28+11+1, 28+11+2+1, 28+11+3+1, 28+11+4+1, 28+12+11+1, 28+12+11+2+1, 28+12+11+3+1, 28+12+11+4+1, 28+13+11+1, 28+13+11+2+1, 28+13+11+3+1, 28+13+11+4+1, 28+14+11+1, 28+14+11+2+1, 28+14+11+3+1, 28+14+11+4+1, 28+15+11+1, 28+15+11+2+1, 28+15+11+3+1, 28+15+11+4+1, 28+16+1, 28+16+2+1, 28+16+3+1, 28+16+4+1, 28+17+16+1, 28+17+16+2+1, 28+17+16+3+1, 28+17+16+4+1, 28+18+16+1, 28+18+16+2+1, 28+18+16+3+1, 28+18+16+4+1, 28+19+16+1, 28+19+16+2+1, 28+19+16+3+1, 28+19+16+4+1, 28+20+1, 28+20+2+1, 28+20+3+1, 28+20+4+1, 28+21+20+1, 28+21+20+2+1, 28+21+20+3+1, 28+21+20+4+1, 28+22+20+1, 28+22+20+2+1, 28+22+20+3+1, 28+22+20+4+1, 28+23+1, 28+23+2+1, 28+23+3+1, 28+23+4+1, 28+23+5, 28+23+6, 28+23+7, 28+23+8, 28+23+9, 28+23+10, 28+23+11+1, 28+23+11+2+1, 28+23+11+3+1, 28+23+11+4+1, 28+23+12+11+1, 28+23+12+11+2+1, 28+23+12+11+3+1, 28+23+12+11+4+1, 28+23+13+11+1, 28+23+13+11+2+1, 28+23+13+11+3+1, 28+23+13+11+4+1, 28+23+14+11+1, 28+23+14+11+2+1, 28+23+14+11+3+1, 28+23+14+11+4+1, 28+23+15+11+1, 28+23+15+11+2+1, 28+23+15+11+3+1, 28+23+15+11+4+1, 28+23+16+1, 28+23+16+2+1, 28+23+16+3+1, 28+23+16+4+1, 28+23+17+16+1, 28+23+17+16+2+1, 28+23+17+16+3+1, 28+23+17+16+4+1, 28+23+18+16+1, 28+23+18+16+2+1, 28+23+18+16+3+1, 28+23+18+16+4+1, 28+23+19+16+1, 28+23+19+16+2+1, 28+23+19+16+3+1, 28+23+19+16+4+1, 28+23+20+1, 28+23+20+2+1, 28+23+20+3+1, 28+23+20+4+1, 28+23+21+20+1, 28+23+21+20+2+1, 28+23+21+20+3+1, 28+23+21+20+4+1, 28+23+22+20+1, 28+23+22+20+2+1, 28+23+22+20+3+1, 28+23+22+20+4+1, 28+24, 28+25, 28+26+1, 28+26+2+1, 28+26+3+1, 28+26+4+1, 28+26+5, 28+26+6, 28+26+7, 28+26+8, 28+26+9, 28+26+10, 28+26+11+1, 28+26+11+2+1, 28+26+11+3+1, 28+26+11+4+1, 28+26+12+11+1, 28+26+12+11+2+1, 28+26+12+11+3+1, 28+26+12+11+4+1, 28+26+13+11+1, 28+26+13+11+2+1, 28+26+13+11+3+1, 28+26+13+11+4+1, 28+26+14+11+1, 28+26+14+11+2+1, 28+26+14+11+3+1, 28+26+14+11+4+1, 28+26+15+11+1, 28+26+15+11+2+1, 28+26+15+11+3+1, 28+26+15+11+4+1, 28+26+16+1, 28+26+16+2+1, 28+26+16+3+1, 28+26+16+4+1, 28+26+17+16+1, 28+26+17+16+2+1, 28+26+17+16+3+1, 28+26+17+16+4+1, 28+26+18+16+1, 28+26+18+16+2+1, 28+26+18+16+3+1, 28+26+18+16+4+1, 28+26+19+16+1, 28+26+19+16+2+1, 28+26+19+16+3+1, 28+26+19+16+4+1, 28+26+20+1, 28+26+20+2+1, 28+26+20+3+1, 28+26+20+4+1, 28+26+21+20+1, 28+26+21+20+2+1, 28+26+21+20+3+1, 28+26+21+20+4+1, 28+26+22+20+1, 28+26+22+20+2+1, 28+26+22+20+3+1, 28+26+22+20+4+1, 28+26+23+1, 28+26+23+2+1, 28+26+23+3+1, 28+26+23+4+1, 28+26+23+5, 28+26+23+6, 28+26+23+7, 28+26+23+8, 28+26+23+9, 28+26+23+10, 28+26+23+11+1, 28+26+23+11+2+1, 28+26+23+11+3+1, 28+26+23+11+4+1, 28+26+23+12+11+1, 28+26+23+12+11+2+1, 28+26+23+12+11+3+1, 28+26+23+12+11+4+1, 28+26+23+13+11+1, 28+26+23+13+11+2+1, 28+26+23+13+11+3+1, 28+26+23+13+11+4+1, 28+26+23+14+11+1, 28+26+23+14+11+2+1, 28+26+23+14+11+3+1, 28+26+23+14+11+4+1, 28+26+23+15+11+1, 28+26+23+15+11+2+1, 28+26+23+15+11+3+1, 28+26+23+15+11+4+1, 28+26+23+16+1, 28+26+23+16+2+1, 28+26+23+16+3+1, 28+26+23+16+4+1, 28+26+23+17+16+1, 28+26+23+17+16+2+1, 28+26+23+17+16+3+1, 28+26+23+17+16+4+1, 28+26+23+18+16+1, 28+26+23+18+16+2+1, 28+26+23+18+16+3+1,

28+26+23+18+16+4+1, 28+26+23+19+16+1, 28+26+23+19+16+2+1, 28+26+23+19+16+3+1, 28+26+23+19+16+4+1,

28+26+23+20+1, 28+26+23+20+2+1, 28+26+23+20+3+1, 28+26+23+20+4+1, 28+26+23+21+20+1, 28+26+23+21+20+2+1, 28+26+23+21+20+3+1, 28+26+23+21+20+4+1, 28+26+23+22+20+1, 28+26+23+22+20+2+1, 28+26+23+22+20+3+1,

28+26+23+22+20+4+1, or 28+26+24, 28+26+25.

The invention relates to compounds of the Formula (I) as defined in embodiment 1), or to such compounds further limited by the characteristics of any one of embodiments 2) to 53), under consideration of their respective dependencies; to pharmaceutically acceptable salts thereof; and to the use of such compounds as medicaments especially in the treatment of diseases or disorders where CCR6 receptors are involved as described hereinbelow.

The present invention also includes isotopically labelled, especially ² H (deuterium) labelled compounds of Formula (I), which compounds are identical to the compounds of Formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially ² FI (deuterium) labelled compounds of Formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope ² FI (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of Formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of Formula (I) are not isotopically labelled at all. Isotopically labelled compounds of Formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.

Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, pharmaceutical composition, disease or the like.

Any reference to compounds of Formula (I) according to embodiments 1) to 53) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.

The term "pharmaceutically acceptable salts" refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound. For reference see for example "Flandbook of Pharmaceutical Salts. Properties, Selection and Use.”, P. Heinrich Stahl, Camille G. Wermuth (Eds.), Wiley-VCH, 2008; and "Pharmaceutical Salts and Co-crystals”, Johan Wouters and Luc Quere (Eds.), RSC Publishing, 2012.

Definitions provided herein are intended to apply uniformly to the compounds of Formula (I), as defined in any one of embodiments 1) to 53), and, mutatis mutandis, throughout the description and the claims unless an otherwise expressly set out definition provides a broader or narrower definition. It is well understood that a definition or preferred definition of a term defines and may replace the respective term independently of (and in combination with) any definition or preferred definition of any or all other terms as defined herein.

The compounds of Formula (I) may encompass compounds with one or more asymmetric centers, such as one or more asymmetric carbon atoms, which may be present in (R)- as well as (S)-configuration. The compounds of Formula (I) may further encompass compounds with one or more double bonds which are allowed to be present in Z- as well as E- configuration and/or compounds with substituents at a ring system which are allowed to be present, relative to each other, in cis- as well as trans-configuration. The compounds of Formula (I) may thus be present as mixtures of stereoisomers or preferably in stereoisomerically enriched form, especially as essentially pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.

In case a particular compound (or generic structure) is designated as (R)- or (S)-enantiomer, such designation is to be understood as referring to the respective compound (or generic structure) in enriched, especially essentially pure, enantiomeric form. Likewise, in case a specific asymmetric center in a compound is designated as being in (R)- or (S)- configuration or as being in a certain relative configuration, such designation is to be understood as referring to the compound that is in enriched, especially essentially pure, form with regard to the respective configuration of said asymmetric center. In analogy, cis- or trans-designations are to be understood as referring to the respective stereoisomer in enriched, especially essentially pure, form. Likewise, in case a particular compound (or generic structure) is designated as Z- or E-stereoisomer (or in case a specific double bond in a compound is designated as being in Z- or E-configuration), such designation is to be understood as referring to the respective compound (or generic structure) in enriched, especially essentially pure, stereoisomeric form (or to the compound that is in enriched, especially essentially pure, form with regard to the respective configuration of the double bond).

The term "enriched", when used in the context of stereoisomers, is to be understood in the context of the present invention to mean that the respective stereoisomer is present in a ratio of at least 70:30, especially of at least 90:10 (i.e., in a purity of at least 70% by weight, especially of at least 90% by weight), with regard to the respective other stereoisomer / the entirety of the respective other stereoisomers.

The term "essentially pure”, when used in the context of stereoisomers, is to be understood in the context of the present invention to mean that the respective stereoisomer is present in a purity of at least 95% by weight, especially of at least 99% by weight, with regard to the respective other stereoisomer / the entirety of the respective other stereoisomers.

The compounds of Formula (I) according to embodiments 1) to 53) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral) or parenteral administration (including topical application or inhalation).

The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of Formula (I), or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

Whenever the word "between” is used to describe a numerical range, it is to be understood that the end points of the indicated range are explicitly included in the range. For example: if a temperature range is described to be between 40 °C and 80 °C, this means that the end points 40 °C and 80 °C are included in the range; or if a variable is defined as being an integer between 1 and 4, this means that the variable is the integer 1, 2, 3, or 4.

Unless used regarding temperatures, the term "about” (or alternatively the term "around”) placed before a numerical value "X” refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X. In the particular case of temperatures, the term "about” placed before a temperature “Y" refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C.

The compounds of Formula (I) as defined hereinabove are useful for the prevention or treatment of various diseases, conditions or disorders ameliorated by modulating CCR6 receptors. Such diseases, conditions or disorders where CCR6 receptors are involved may be defined as inflammatory and/or autoimmune diseases, conditions or disorders; and cancer .

The compounds of Formula (I) as defined hereinabove are useful for the prevention or treatment of of various diseases, conditions or disorders ameliorated by modulating CCR6 receptors. Such diseases, conditions or disorders where CCR6 receptors are involved may be defined as including rheumatoid arthritis; ankylosing spondylitis; spondyloarthritis; psoriasis; psoriatic arthritis; inflammatory skin disorders such as rosacea; Crohn's disease; ulcerative colitis; inflammatory bowel disease; irritable bowel disease; dry eye disease; multiple sclerosis; systemic lupus erythematosus; Sjogren's disease; autoimmune hepatitis; Primary Sclerosing Cholangitis; Posterior uveitis; allergic conjunctivitis; allergic disease in the gastrointestinal tract; type I diabetes and endometriosis; diseases of the ocular surface in which elevated levels of IL-17A have been recorded such as meibomian gland dysfunction; GVFID; graft-versus host disease; autoimmune keratitis; filamentary keratitis; dry eye syndrome with rheumatic arthritis; dry eye syndrome without systemic disease; Stevens-Johnson syndrome; psoriasis including plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis; autoimmune keratitis; filamentary keratitis; autoimmune uveitis; allergic conjunctivitis; asthma; allergic disease of the gastrointestinal tract; T1D; endometriosis; meibomian gland dysfunction; graft-versus host disease; juvenile arthritis; juvenile rheumatoid arthritis; systemic onset rheumatoid arthritis; pauciarticular rheumatoid arthritis; pauciarticular juvenile rheumatoid arthritis; polyarticular rheumatoid arthritis; enteropathic arthritis; juvenile Reiter's Syndrome; ankylosing spondylitis; juvenile ankylosing spondylitis; SEA Syndrome; reactive arthritis (reactive arthropathy); psoriatic arthropathy; juvenile enteropathic arthritis; polymyalgia rheumatica; enteropathic spondylitis; juvenile idiopathic arthritis (JIA); juvenile psoriatic arthritis; juvenile rheumatoid arthritis; systemic onset juvenile rheumatoid arthritis; acute pancreatitis; chronic pancreatitis; giant cell arteritis; and secondary osteoarthritis from inflammatory diseases.

Further, such diseases, conditions or disorders where CCR6 receptors are involved may be defined as including cancer such as skin cancer e.g. melanoma (superficial spreading, nodular, lentigo maligna and acral lentiginous melanoma); advanced melanoma; metastatic melanoma; Merkel cell carcinoma; Kaposi sarcoma; basal cell carcinoma; squamous cell carcinoma; and pre-cancerous skin lesions such as actinic keratosis; lung cancer including small cell lung cancer and non-small (SCLC, NSCLC) such as squamous and non-squamous NSCLC; pleuropulmonary blastoma and tracheobronchial tumors; bladder cancer including urinary bladder cancer; urothelial cell carcinoma; mesothelioma; renal carcinomas including renal cell carcinoma (RCC) such as clear cell RCC; papillary RCC; chromophobe RCC; non- dear cell RCC; unclassified RCC; metastatic renal cell carcinoma; metastatic renal clear cell carcinoma; renal parenchymal carcinoma; gastro-intestinal cancers including colorectal cancer; metastatic colorectal cancer; familial adenomatous polyposis (FAP); rectum carcinoma; colon carcinoma; colorectal adenoma; colorectal adenocarcinoma; colorectal cancer liver metastases; hereditary non-polyposis colorectal cancer; esophageal cancer; gastric cancer; advanced gastric cancer; gallbladder cancer; cholangiocarcinoma; hepatocellular carcinoma; pancreatic cancer such as pancreatic adenocarcinoma or pancreatic ductal (adeno)carcinoma; pancreatic neuroendocrine tumors; endometrial cancer; ovarian cancer; prostate cancer including castrate-resistant prostate cancer; brain tumors including brain metastases, malignant gliomas, glioblastoma multiforme, medulloblastoma, meningiomas, astrocytoma; peripheral neuroectodermal tumors; oligoastrocytic tumors; oligodendrogliomas; ependymal tumors; anaplastic astrocytoma; pilocytic astrocytoma; craniopharyngioma; spinal cord tumors; brain stem glioma; central nervous system atypical teratoid/rhabdoid tumor; medulloblastoma; central nervous system germ cell tumors; craniopharyngioma; ependymoma; neuroblastoma; head and neck cancer such as esthesioneuroblastoma; cervical cancer; advanced cervical cancer; breast cancer including normal-like, basal-like, claudin-low, HER2 positive, luminal-A, luminal-B and triple negative breast carcinoma; pregnancy breast cancer and male breast cancer; oral tumors; nasopharyngeal tumors; heart tumors; thoracic cancer; lymphomas such as Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma; primary intra-ocular B-Cell lymphoma; diffuse large B-cell lymphoma; primary mediastinal large B-cell lymphoma; mucosa-associated lymphoid tissue (MALT) lymphoma; gastric MALT lymphoma; cutaneous T-cell lymphoma; primary central nervous system lymphoma; Sezary syndrome and Waldenstrom macroglobulinemia; leukemia such as acute lymphoblastic leukemia; acute myeloid leukemia ; chronic lymphocytic leukemia; chronic myelogenous leukemia; hairy cell leukemia; chronic myeloid leukemia; adult T-cell leukemia; carcinomas; adenocarcinomas; thyroid carcinoma including papillary thyroid carcinoma and medullary thyroid carcinoma choriocarcinoma; sarcomas including Ewing's sarcoma; bone cancer such as osteosarcoma; high-grade osteosarcoma; rhabdomyosarcoma; Ewing sarcoma; malignant fibrous histiocytoma of the bone; chordoma; soft tissue sarcoma; myeloma; multiple myelomas; labial carcinoma; larynx carcinoma; hypopharynx carcinoma; tongue carcinoma; salivary gland carcinoma; cervix carcinoma; uterine corpus carcinoma; endometrium carcinoma; chorion carcinoma; testis carcinoma; urinary carcinoma; bronchial carcinoma; basalioma; teratoma; retinoblastoma; choroid melanoma; seminoma; chondrosarcoma; myosarcoma; liposarcoma; fibrosarcoma; plasmacytoma; hepatocarcinoma; advanced liver cancer; gastrointestinal stromal tumors; neuroendocrine tumors; bile duct cancer; appendix cancer; gastrointestinal carcinoid tumor; carcinoid tumor; islet cell tumor; small intestine cancer; stomach cancer; adrenocortical carcinoma; parathyroid cancer; paraganglioma; pheochromocytoma; pituitary tumor; penile cancer; renal pelvis and ureter cancer; testicular cancer; urethral cancer; Wilms tumor; extracranial germ cell tumor; extragonadal germ cell tumor; fallopian tube cancer; gestational trophoblastic tumor; primary peritoneal cancer; vaginal cancer; vulvar cancer; hypopharyngeal cancer; laryngeal cancer; papillomatosis cancer; lip and oral cavity cancer; metastatic squamous neck cancer; mouth cancer; nasopharyngeal cancer; oropharyngeal cancer; paranasal sinus and nasal cavity and paranasal sinus cancer; parathyroid cancer; pharyngeal cancer; throat cancer; chronic myeloproliferative neoplasm; Langerhans cell histiocytosis; plasma cell neoplasm; myelodysplastic syndromes; myeloproliferative neoplasm; midline tract carcinoma; virally induced tumors; and diseases involving CCR6 and/or CCL20 mediated metastasis, chemotaxis, cell adhesion, trans-endothelial migration, cell proliferation and/or survival.

Notably, such diseases, conditions or disorders, where CCR6 receptors are involved refer to rheumatoid arthritis; ankylosing spondylitis; spondyloarthritis; psoriasis; psoriatic arthritis; inflammatory skin disorders e.g. rosacea; Crohn's disease; ulcerative colitis; irritable bowel disease; inflammatory bowel disease; dry eye disease; multiple sclerosis; systemic lupus erythematosus; Sjogren's disease; autoimmune hepatitis; Primary Sclerosing Cholangitis; psoriasis including plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis; autoimmune keratitis; filamentary keratitis; autoimmune uveitis; allergic conjunctivitis; asthma; allergic disease of the gastrointestinal tract; type 1 diabetes (T1D); endometriosis; meibomian gland dysfunction; graft-versus host disease; lymphoma including T cell lymphoma and primary mediastinal B-cell lymphoma; brain cancer including glioma and glioblastoma; breast cancer including triple negative breast cancer; colorectal cancer; hepatocarcinoma; renal cell carcinoma; lung cancer including non-small cell lung cancer and small cell lung cancer; gastric cancer; melanoma including Merkel cell carcinoma, cutaneous squamous cell carcinoma and malignant melanoma; bladder cancer; head and neck cancer including squamous cell head and neck carcinoma; Hodgkin's lymphoma; cervical cancer; endometrial cancer; colon cancer; gastrointestinal stromal tumors; pancreatic cancer; prostatic cancer; leukemia including acute myeloid leukemia; ovarian cancer; oesophageal carcinomas; mesothelioma; neuroblastoma; sarcoma e.g. high-grade osteosarcoma; astrocytoma; myeloma; urothelial cancer including locally advanced and metastatic urothelial cancer; MSI-H or dMMR cancer; rectal cancer; laryngeal cancer; salivary adenocarcinoma; multiple myeloma; cholangiocarcinoma; oral squamous cell carcinoma; thyroid cancer; and esophagogastric junction cancer.

Especially, such diseases, conditions or disorders, where CCR6 receptors are involved are selected from • inflammatory/autoimmune diseases, conditions or disorders such as psoriasis; psoriatic arthritis; rheumatoid arthritis; ankylosing spondylitis; spondyloarthritis; inflammatory skin disorders e.g. rosacea; Crohn's disease; ulcerative colitis; irritable bowel disease; dry eye disease; multiple sclerosis; systemic lupus erythematosus; Sjogren's disease; autoimmune hepatitis; and Primary Sclerosing Cholangitis; In particular, psoriasis or psoriatic arthritis; and/or

• cancer such as lymphoma (e.g. T cell lymphoma); brain cancer (e.g. glioma or glioblastoma); breast cancer; colorectal cancer; hepatocarcinomas; renal cell carcinoma; lung cancer; and gastric cancer.

For avoidance of any doubt, if compounds are described as useful for the prevention or treatment of certain diseases, conditions or disorders, such compounds are likewise suitable for use in the preparation of a medicament for the prevention or treatment of said diseases.

The present invention also relates to a method for the prevention or treatment of diseases, conditions or disorders, mentioned hereinabove and/or hereinbelow comprising administering to a subject a pharmaceutically active amount of a compound as described hereinabove or/and hereinbelow either alone or in combination with other pharmacologically active compounds and/or therapies. The meaning of the term "prevention” may also be understood as "prophylaxis”.

Preparation of compounds of Formula (I)

A further aspect of the invention is a process for the preparation of compounds of Formula (I). Compounds according to Formula (I) of the present invention can be prepared from commercially available or well-known starting materials according to the methods described in the experimental part; by analogous methods; or according to the general sequence of reactions outlined below. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures. In the schemes below, the generic groups A, B, R ¹ and R ² are as defined for the compounds of Formula (I); the number of carbon atoms "n” is 1 . X represents a halogen atom, notably chlorine or bromine. The meaning of the generic group R' is derivable from the compounds of Formula (I) and/or the exemplified embodiments. Other abbreviations used herein are explicitly defined, or are as defined in the experimental section. In some instances, the functional groups described may be incompatible with the assembly illustrated in the schemes and so will require the use of protecting groups (PG). The use of protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups as necessary are in place. The compounds obtained may also be converted into salts, especially pharmaceutically acceptable salts thereof in a manner known perse.

General preparation routes:

Compounds of Formula (I) can be prepared starting from an intermediate of Formula (A1), which is reacted with N,0- dimethylhydroxylamine hydrochloride under standard conditions (e.g. HATU, DIPEA, DMF) to give the Weinreb amide derivative of Formula (A2) (Scheme A). Upon reaction with a compound of Formula (A3) wherein X is iodine or bromine, in presence of n-butyl lithium or n-hexyl lithium in THF at a temperature around -78°C, the ketone derivative of Formula (A4) is produced, which can be further reacted with a compound of Formula (A5) wherein X is a halogen atom, preferably bromine, similarly using n-butyl lithium or n-hexyl lithium in THF at a temperature around -78°C, to provide the tertiary alcohol intermediate of Formula (A6). A chiral separation by HPLC over a chiral stationary phase can be performed at this stage to yield enantiomerically pure intermediates of Formula (A6). Cleavage of the protecting group under standard conditions such as treatment with HCI in dioxane in the case of a Boc protecting group, or treatment with Pd/C (50% water) in EtOH or EA under hydrogen atmosphere in case of a Cbz protecting group, provides the free NH derivative of Formula (A7). A reductive amination step can be performed with an aldehyde of Formula (A8) or a ketone of Formula (A9) under standard conditions such as using NaBFi(OAc) ₃ or NaBFi ₃ CN as reductive agent, in presence of a base such as DIPEA or TEA, or in presence of an acid such as acetic acid, in a solvent such as DCM, MeOFI, THF or dioxane, or a mixture thereof, and at a temperature around RT to provide compounds of Formula (I). Alternatively, the intermediate of Formula (A7) can be coupled to a reactant of Formula (A10) wherein X is iodine or bromine, in presence of a base such as TEA, DIPEA or Cs2C0 ₃ , in a solvent such as MeOFI, THF or DMF, and stirring at a temperature from 0°C to 70°C. Furthermore, the compounds of Formula (I) wherein R ² is cyclopropyl can be prepared by coupling with (1- ethoxycyclopropoxy)trimethysilane, using NaBH(OAc)3 in presence AcOH in EtOH and at RT. For the compounds of Formula (I) wherein R ² is tert-butyl, specific conditions were used that are fully described in the experimental part (Example 12).

Scheme A Alternatively, the compounds of Formula (I) can be prepared following the route described in Scheme B. The protecting group in intermediate (A4) can be removed and the free NH of the resulting intermediate (B1) can be reacted with an aldehyde of structure (A8), a ketone of structure (A9), a reactant of Formula (A10), or (1- ethoxycyclopropoxy)trimethysilane, as previously described. The resulting intermediate of Formula (B2) can be reacted with a compound of Formula (A5) wherein X is a halogen atom, preferably bromine, using conditions described in Scheme A to provide compounds of Formula (I), or using a iPrMgCI-LiCI-mediated halogen-metal exchange protocol in presence of LiCI in THF and heating at around 60°C.

Scheme B

Alternatively, the compounds of Formula (I) can be prepared using the same synthetic strategies as those described in Schemes A and B, with the difference of performing the addition of the compound of Formula (A5) prior to the addition of the compound of Formula (A3) in the synthetic sequence (Scheme C), and using the same conditions as those reported previously.

Scheme C The intermediates of Formula (D1) (see Scheme D) wherein C and/or D are/is a nitrogen atom and R is a protecting group, or wherein C and/or D are/is a nitrogen atom and R is R ² , can be prepared starting from the appropriate compound of Formula (A5) wherein A contains a cyano group in meta position to the halogen atom X, X being iodine or bromine, following the route described in Scheme A for the synthesis of intermediates of Formula (A6), or of Formula (I), respectively. Alternatively, an intermediate of Formula (D1) can be prepared starting from a compound of Formula (A5) wherein A contains a bromine atom in meta position to the halogen atom X, X being iodine or bromine, and using the same conditions as described above. The bromine atom may be further transformed into a cyano group using zinc cyanide, in presence of zinc and Pd ₂ (dba) ₃ , using a ligand such as 1,T-bis(diphenylphosphino)ferrocene, in a solvent such as DMF and heating at around 150°C. An intermediate of Formula (D1) can be transformed into a hydroxy-amidine derivative of Formula (D2) by reaction with hydroxylamine hydrochloride in a solvent such as EtOH or DMSO, in presence of a base such as TEA or K2CO3, and at a temperature between 80°C and 100°C. The resulting hydroxy- amidine intermediate (D2) can be further reacted with a carboxylic acid of Formula (D3) to form an oxadiazole-containing derivative of Formula (D4) if R is a protecting group, or a compound of Formula (I) if R is R ² , using a coupling agent such as HATU, PyBOP, EDC combined with HOBt, CDI, in presence of a base such as DIPEA or K3PO4, optionally in presence of molecular sieves 3A, in a solvent such as dioxane, DMSO or DMF, and heating at a temperature between 80°C and 100°C. Alternatively, the formation of the oxadiazole ring can be performed in two steps (i) coupling with the carboxylic acid partner of Formula (D3) as described before at RT and (ii) heating at a temperature between 80°C and 100°C in presence of molecular sieves 3A. Moreover, a compound of Formula (D2) can be reacted with trimethyl orthoformate, in presence of boron trifluoride and TEA, in a solvent such as DMA, and heating at around 50°C to provide a compound of Formula (D4) wherein R' is hydrogen. The intermediate of Formula (D4) can be further transformed into a compound of Formula (I) following the two-step protocol described in Scheme A.

Scheme D

The intermediates of Formula (E1) (see Scheme E) wherein C and/or D are/is a nitrogen atom and R is a protecting group, or wherein C and/or D are/is a nitrogen atom and R is R ² , can be prepared starting from the appropriate compound of Formula (A5) wherein A contains a protected acid function such as a tert-butyl carboxylic acid moiety in meta position to the halogen atom X, following the route described in Scheme A for the synthesis of intermediates of Formula (A6), or compounds of Formula (I), respectively. An intermediate of Formula (E1) can be transformed into an intermediate of Formula (E3) wherein R is a protecting group, or into a compound of Formula (I) wherein R is R ² , by reaction with a hydroxyamidine derivative of Formula (E2) using conditions described in Scheme (D). Hydroxyamidine derivatives of Formula (E2), if not commercially available, can be prepared using the same protocol as described in Scheme (D). Scheme E

Furthermore, the intermediates of Formula (D4) and (E3) wherein R is R ² and R' contains a protected amine function can be transformed into compounds of formula (I) following a two-step protocol. Firstly, the amine protecting group can be cleaved using standard conditions such as treatment with HCI in dioxane in the case of a Boo protecting group. The resulting amine-containing intermediate can be subsequently engaged in a coupling reaction, with an acid chloride reactant, in presence of a base such as DIPEA, in a suitable solvent such as THF; or with an acid-containing reactant of formula (D3), using FIATU as coupling agent, in presence of a base such as DBU, in a suitable solvent such as DMF; or with a sulfonyl chloride reactant, in presence of a base such as DIPEA, in a suitable solvent such as DCM. In case diacylation was observed during the coupling reaction, subsequent treatment with K2CO3 in MeOFI can provide the desired compound of formula (I).

The intermediates of Formula (F1) (see Scheme F) wherein X is a chlorine atom, C is CH, and D is nitrogen; or wherein X is a chlorine atom, C and D are nitrogen atoms; or wherein X is a bromine atom, C is a nitrogen atom, and D is CH; can be prepared following the route described in Scheme B using the appropriate derivative of Formula (A5).

Compounds of Formula (I) can be prepared by reacting an intermediate of Formula (F1) wherein X is a bromine atom, C is a nitrogen atom, and D is CH; or wherein X is a chlorine atom, and C and D are nitrogen atoms; with an NH- containing reagent of Formula (F2), using standard conditions for a Buchwald type reaction, using a palladium catalyst such as Pd2(dba)3, in presence of a ligand such as Xantphos, RuPhos, or BINAP, in presence of a base such as NaOtBu, in toluene, and heating at a temperature around 100°C. Alternatively, the coupling reaction can be performed using a copper catalyst such as Cul, in presence of a ligand such as L-proline, in presence of a base such as K ₂ C0 ₃ , in a solvent such as DMSO and heating at a temperature around 100°C.

Furthermore, compounds of Formula (I) can be prepared by reacting an intermediate of Formula (F1), wherein X is a chlorine atom, and C and D are nitrogen atoms; or wherein X is a chlorine atom, C is CH, and D is a nitrogen atom; with an NH-containing reagent of Formula (F2), using standard conditions for an aromatic nucleophilic substitution type reaction, optionally in presence of a base such as DIPEA, and heating at a temperature between 100°C and 150°C in a solvent such as n-butanol, NMP, or dioxane.

An intermediate of Formula (F1) wherein X is a bromine atom, C is a nitrogen atom, and D is CH; or wherein X is a chlorine atom, and C and D are nitrogen atoms; can be further reacted with an amide-containing reagent of Formula (F3), or with a carbamate-containing reagent of Formula (F4), using a copper catalyst such as Cul, in presence of a ligand such as N,N-dimethylenediamine, in presence of a base such as K2CO3, in a solvent such as dioxane, and heating at a temperature around 110°C.

In addition, an intermediate of Formula (F1) wherein X is a chlorine atom, C is CH, and D is nitrogen; or wherein X is a bromine atom, C is nitrogen, and D is CH; or wherein X is a bromine atom, and C and D are CH can be reacted with an alkyne-containing reagent of Formula (F5), using standard conditions for a Sonogashira type reaction, using a palladium catalyst such as Pd(PPfi3)4, Pd(OAc)2, or PdCl2(PPfi3)2, optionally combined with a copper catalyst such as Cul, optionally in presence of a ligand such as PPh ₃ , in presence of a base such as piperidine, Et ₂ NH, or K3PO4, in a solvent such as THF, DMF, or DMSO/toluene mixture, and heating at a temperature between 60°C and 80°C. The alkyne (F5) reagents are either commercially available or accessible via multistep synthesis as described in the experimental part.

The resulting alkyne-containing compound of Formula (I) can be further transformed by hydrogenation of the alkyne functionality into an alkane chain using Pd/C (50% water) in EtOH or MeOFI and under a hydrogen atmosphere.

Furthermore, an intermediate of Formula (F1) wherein X is a chlorine atom, C is CH, and D is nitrogen; or wherein X is a bromine atom, C is nitrogen, and D is CH; or wherein X is a bromine atom, and C and D are CH can be reacted with an boronic acid or boronate ester reagent of Formula (F6) using standard conditions for a Suzuki type reaction, using a palladium catalyst such as Pd(PPfi3)4, Pd(dppf)2Cl2 or PdCl2(PPfi3)2, in presence of a base such as Na2C03 or K3PO4, in a solvent such as MeCN/water, DME/water or dioxane/water mixture, and heating at a temperature around 80°C.

An intermediate of Formula (F1) wherein X is bromine can be converted by Miyaura borylation using standard conditions to the corresponding boronic acid or ester of Formula (F10) and subsequently treated with a reagent of Formula (F9) in a Suzuki type reaction as described previously. In addition, an intermediate of Formula (F1) wherein X is a chlorine atom, C is CH, and D is nitrogen; or wherein X is a bromine atom, C is nitrogen, and D is CH can be reacted with a alkyl zinc reagent of Formula (F7) using standard conditions for a Negishi type reaction, using a palladium catalyst such as Pd(dppf) ₂ CI ₂ , in a solvent such as toluene, and heating at a temperature around 70°C.

Furthermore, compounds of Formula (I) can be prepared by reacting an intermediate of Formula (F1) wherein X is a chlorine atom, C is CH, and D is a nitrogen atom, with an alcohol reagent of Formula (F8), using standard conditions for an aromatic nucleophilic substitution type reaction, in presence of a base such as NaH, and heating at a temperature between 100°C and 110°C, optionally in a solvent such as dioxane.

It will be understood by one skilled in the art that the steps described in Scheme (F) can be performed with the protected azetidine ring (n=1) prior to the introduction of the R ² group, and following the two-step protocol from the intermediate (A6) described in Scheme (A) to yield compounds of Formula (I).

Scheme F

The intermediates of Formula (G1) (see Scheme G) wherein C is CH, and D is a nitrogen atom; or wherein C is a nitrogen atom, and D is CH can be prepared following the route described in Scheme B using the appropriate derivative of Formula (A5) that contains a protected phenol group in the form of a benzyloxy or methyloxy functionality. Deprotection using Pd/C in EtOH under hydrogen atmosphere, or 2-diethylamino-ethanethiol and KOtBu in DMF, respectively, provides the intermediates of Formula (G1). Such intermediates of Formula (G1) can be transformed into compounds of Formula (I) by performing a Mitsunobu type reaction with a hydroxy-containing derivative of Formula (G2), using conditions such as cyanomethyltributylphosphorane in toluene and heating at a temperature around 110 °C. It will be understood by one skilled in the art that the Mitsunobu reaction can be performed with the protected azetidine ring (n=1) prior to the introduction of the R ² group, and following the synthetic sequence from the intermediate (A6) described in Scheme (A) to yield compounds of Formula (I).

(01) (G2) (I)

Scheme G

The intermediates of Formula (A5) (see Scheme H) wherein C is CH, and D is a nitrogen atom; or wherein C is a nitrogen atom, and D is CH can be prepared via a two-step procedure: (i) treatment of an appropriate nitrile of Formula (H1) with hydroxylamine hydrochloride in a solvent such as EtOH or DMSO, in presence of a base such as K ₂ C0 ₃ or

TEA, and at a temperature between 80°C and 100°C and (ii) subsequent treatment of the resulting hydroxy-amidine derivative of Formula (H2) with a carboxylic acid of Formula (D3) using a coupling agent such as HATU, PyBOP, EDC combined with HOBt, or CDI in possible presence of a base such as DIPEA or K3PO4, in a solvent such as dioxane, DMF or DMSO, and heating at a temperature between 80°C and 100°C.

Scheme H

The intermediates of Formula (J1) (see Scheme J) can be prepared following the route described in Scheme A using the appropriate derivative of Formula (A3) that contains a bromo-phenyl group. Such intermediates of Formula (J1) can be transformed into compounds of Formula (I) wherein R represents an appropriate Ci-5-alkyl, C -fluoroalkyl, or C2-4- alkenyl group by Suzuki cross coupling with boron species of Formula (J2) wherein R represents an appropriate C1-5- alkyl, Ci_ ₃ -alkoxy-Ci_ ₄ -alkyl, Ci_ ₄ -fluoroalkyl, C ₂ -4-alkenyl group and BX represents BF ₃ K, Bpin or B(OH) ₂ in the presence of a suitable palladium catalyst such as cataCXium®A Pd G3 and a suitable base such as Cs ₂ C0 ₃ and heating in a suitable solvent such as a mixture of toluene and water at temperatures around 100°C. Alternatively, intermediates of Formula (J1) can be transformed into intermediate of Formula (J3) by Miyaura borylation using standard conditions such as treatment with bis(pinacolato)diboron in the presence of a suitable palladium catalyst such as Pd(dppf)CI ₂ .DCM and a suitable base such as KOAc and heating in a suitable solvent such as dioxane at temperatures around 80°C.

Such intermediates of Formula (J3) can be transformed into compounds of Formula (I) wherein R represents a trifluoromethyl group by copper catalyzed perfluoroalkylation with a trifluoromethylation reagent of Formula (J4) such as (phen)CuCF3 in the optional presence of a suitable base such as KF and heating in a suitable solvent such as DMF at temperatures around 50°C.

Alternatively, intermediates of Formula (J3) can be transformed into compounds of Formula (I) wherein R represents a Ci_3-alkoxy or C ₃ -5-cycloalkoxy group via a two-step procedure: (i) treatment with an aq. solution of hydrogen peroxide in the presence of NaOFI in a solvent such as THF at temperatures between 0°C and RT and (ii) subsequent treatment of the resulting phenol intermediate of Formula (J5) with an appropriate Ci_ ₃ -al kyl or C ₃ -5-cycloalkyl halide of formula (J6) in the presence of suitable base such as HGCCh and heating in a suitable solvent such as DMF at temperatures around 100°C.

Scheme J

Reactants of Formula (A3), (A5), (A8), (A9), (D3), (E2), (F2) to (F9), (G2), (J2), (J4) and (J6) are either commercially available or can be synthesized according to published protocols. Whenever the compounds of Formula (I) are obtained in the form of mixtures of enantiomers, the enantiomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase. Enantiomeric separation may be performed at the stage of intermediate (A6) or with compounds of Formula (I). Experimental section:

Abbrevations (as used herein and in the description above):

Ac acetyl aq. aqueous

BINAP (2, 2'-bis(diphenylphosphino)-1,1 '-binaphthyl)

Boc ferf.-butyloxycarbonyl

BSA Bovine serum albumin

Brine saturated aqueous NaCI solution

Bu butyl cataCXium ^® A Pd G3 mesylate[(di(1-adamantyl)-n-butylphosphine)-2-(2'-amino-1,1' -biphenyl)]palladium(ll)

Cbz benzyloxycarbonyl

CC column chromatography on silica gel

CDI 1 , 1 '-carbonyldiimidazole

CV column volume dba dibenzylideneacetone

DCM dichloromethane

DBU 1 ,8-diazabicyclo[5.4.0]undec-7-ene

DIPEA W-ethyldiisopropylamine

DMA N,N-Dimethylacetamide

DME 1,2-dimethoxyethane

DMAP 4-dimethylaminophenol

DMEM Dulbecco's modified eagle media

DMF dimethylformamide

DMP Dess Martin periodinane

DMSO dimethylsulfoxide dppf 1 , 1 '-bis(diphenylphosphino)ferrocene

EA ethyl acetate

EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide eq Equivalent

Et ethyl

FCS fetal calf serum

FLIPR Fluorescent imaging plate reader

Fluo-8-AM acetyloxymethyl 2-[W-[2-(acetyloxymethoxy)-2-oxoethyl]-4-[3-(acetyloxymethox y)-6-oxoxanthen-9- yl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]pheno xy]ethoxy]anilino]acetate h hour(s)

HATU 2-(7-Aza-1 H-benzotri azole-1 -yl)-1 , 1 ,3,3-tetramethyluronium

HEK Human embryonic kidney

Hep heptanes

HOBt hydroxybenzotriazole

HV high vacuo

HPLC high performance liquid chromatography

LC liquid chromatography

LiHMDS lithium-bis(trimethylsilyl)amide

M molarity [mol L· ¹ ]

Me methyl

MS mass spectrometry min minute(s)

MTBE methyl tert-butyl ether

NMP N-methyl-2-pyrrolidone

NMR nuclear magnetic resonance spectroscopy org. organic

Pd/C palladium on carbon

PG protecting group

Ph phenyl phen phenanthroline pin pinacol

Prep preparative

PyBOP (benzotriazoM-yloxy)tripyrrolidinophosphonium hexafluorophosphate rpm rotations per minute

RT room temperature

RuPhos 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl sat. saturated t tert

TBAF tetrabutylammoniumfluorid

TEA triethylamine

TFA trifluoroacetic acid

THF tetrahydrofuran

TLC Thin layer chromatography tR retention time

UPLC Ultra performance liquid chromatography

Xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

I. Chemistry

The following Examples illustrate the preparation of compounds of the invention but do not at all limit the scope thereof.

General: All temperatures are stated in degrees Celsius (°C). Unless otherwise indicated, the reactions take place at RT under an argon atmosphere and are run in a flame dried round-bottomed flask or sealable tube equipped with a magnetic stir bar.

Characterization methods used:

The LC-MS retention times have been obtained using the following elution conditions:

I) LC-MS (A):

Zorbax RRHD SB-Aq, 1.8 Dm, 2.1x50mm column thermostated at 40°C. The two elution solvents were as follows: solvent A= water + 0.04%TFA; solvent B = MeCN. The eluent flow rate was 0.8 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the table below (a linear gradient being used between two consecutive time points):

I) LC-MS (B):

Acquity UPLC CSH C18 1.7 urn, 2.1x50 mm from Waters thermostated at 60°C. The two elution solvents were as follows: solvent A= water + 0.05% HCOOH; solvent B = MeCN + 0.045% HCOOH. The eluent flow rate was 1 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the table below (a linear gradient being used between two consecutive time points):

The chiral SFC or HPLC retention times have been obtained using the following elution conditions: I) Chiral SFC (A): CHIRALCEL OD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 92% (A) / 8% (B).

II) Chiral SFC (B):

CHIRALCEL OZ-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH + 0.1% DEA. The eluent flow rate was 4 mL/min, the duration of the run was 4min and the isocratic solvent proportion was 85% (A) / 15% (B).

III) Chiral SFC (C):

CHIRALPAK AD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 3min and the isocratic solvent proportion was 80% (A) / 20% (B).

IV) Chiral SFC (D):

CHIRALPAK IB, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 85% (A) / 15% (B).

V) Chiral SFC (E):

CHIRALPAK IC, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH + 0.1% DEA. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 60% (A) / 40% (B).

VI) Chiral SFC (F):

CHIRALPAK IB, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH. The eluent flow rate was 4 mL/min, the duration of the run was 4min and the isocratic solvent proportion was 90% (A) / 10% (B).

VII) Chiral SFC (G):

CHIRALPAK AD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 4min and the isocratic solvent proportion was 75% (A) / 25% (B).

VIII) Chiral SFC (H):

CHIRALCEL OZ-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH + 0.1% DEA. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 85% (A) / 15% (B). IX) Chiral SFC (I):

CHIRALCEL OD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= CO2; solvent B = MeOH. The eluent flow rate was 4 mL/min, the duration of the run was 3.5min and the isocratic solvent proportion was 90% (A) / 10% (B).

X) Chiral SFC (J):

CFIIRALPAK AD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeCN/EtOF1 1/1 + 0.1%DEA. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 75% (A) / 25% (B).

XI) Chiral SFC (K):

CFIIRALPAK AS-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeCN/EtOFI + 0.1%DEA. The eluent flow rate was 4 mL/min, the duration of the run was 3min and the isocratic solvent proportion was 70% (A) / 30% (B).

XII) Chiral SFC (L):

CHIRALCEL OD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH + 0.1% DEA. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 85% (A) / 15% (B).

XIII) Chiral SFC (M):

CHIRALPAK AD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH + 1%DEA. The eluent flow rate was 4 mL/min, the duration of the run was 3min and the isocratic solvent proportion was 75% (A) / 25%(B).

XIV) Chiral SFC (N):

REGIS (R,R) Whelk-01, 5 Dm, 4.6x250mm column thermostated at 40°C. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = DCM/MeOH 1/1 + 0.1%DEA. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 70% (A) / 30% (B).

XV) Chiral SFC (O):

CHIRALPAK ID, 5 Dm, 4.6x250mm column thermostated at 40°C. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeCN/EtOH 1/1 + 0.1%DEA. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 65% (A) / 35% (B).

XVI) Chiral SFC (P): CHIRALPAK IB, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH+0.1%DEA. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 90% (A) / 10% (B).

XVII) Chiral SFC (Q):

CHIRALPAK IB, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH. The eluent flow rate was 4 mL/min, the duration of the run was 2.50min and the isocratic solvent proportion was 80% (A) / 20% (B).

XVIII) Chiral SFC (R):

CHIRALPAK IH, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeCN + EtOH 1/1. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 85% (A) / 15% (B).

XIX) Chiral HPLC (S):

CHIRALPAK AY-H, 5 Dm, 4.6x250mm column thermostated at 25°C was used. The two elution solvents were as follows: solvent A= Hept; solvent B = 2-Propanol. The eluent flow rate was 1 mL/min, the duration of the run was 15min and the isocratic solvent proportion was 80% (A) / 20% (B).

XX) Chiral SFC (T):

CHIRALPAK IH, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = Hept + EtOH 1/1 . The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 85% (A) / 15% (B).

XXI) Chiral SFC (U):

CHIRALCEL OD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 2.5min and the isocratic solvent proportion was 80% (A) / 20% (B).

XXII) Chiral SFC (V):

CHIRALPAK AD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C02; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 85% (A) / 15% (B).

XXIII) Chiral SFC (W):

CHIRALPAK AD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 3.5min and the isocratic solvent proportion was 90% (A) / 10% (B). XXIV) Chiral HPLC (X):

CHIRALCEL OD-H, 5 Dm, 4.6x250mm column thermostated at 25°C was used. The two elution solvents were as follows: solvent A= Heptane; solvent B = EtOH. The eluent flow rate was 0.8 mL/min, the duration of the run was 20min and the isocratic solvent proportion was 80% (A) / 20% (B).

XXV) Chiral HPLC (Y):

CHIRALPAK IG, 5 Dm, 4.6x250mm column thermostated at 25°C was used. The two elution solvents were as follows: solvent A= Hept + 0.05%DEA; solvent B = MeOH/EtOH 1/1 + 0.05%DEA. The eluent flow rate was 1 mL/min, the duration of the run was 15min and the isocratic solvent proportion was 30% (A) / 70% (B).

XXVI) Chiral SFC (Z):

CHIRALCEL OD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= CO2; solvent B = MeOH. The eluent flow rate was 4 mL/min, the duration of the run was 2.5min and the isocratic solvent proportion was 75% (A) / 25% (B).

XXVII) Chiral SFC (AA):

A (R,R) Whelk-01, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeCN/iPrOH 1/1. The eluent flow rate was 4 mL/min, the duration of the run was 3.5min and the isocratic solvent proportion was 80% (A) / 20% (B).

XXVIII) Chiral SFC (AB):

A Chiralpak AD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH. The eluent flow rate was 4 mL/min, the duration of the run was 3.5min and the isocratic solvent proportion was 85% (A) / 15% (B).

XXIX) Chiral SFC (AC):

A Chiralpak IB, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeCN/EtOH 1/1 . The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 70% (A) / 30% (B).

XXX) Chiral SFC (AD):

A Chiralpak IG, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 3min and the isocratic solvent proportion was 85% (A) / 15% (B).

XXXI) Chiral SFC (AE): CHIRALCEL OD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOH. The eluent flow rate was 4 mL/min, the duration of the run was 5.0min and the isocratic solvent proportion was 90% (A) / 10% (B).

XXXII) Chiral SFC (AF):

CHIRALCEL OD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= CO2; solvent B = MeOH. The eluent flow rate was 4 mL/min, the duration of the run was 5.0min and the isocratic solvent proportion was 80% (A) / 20% (B).

XXXIII) Chiral SFC (AG):

CHIRALPAK AD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 5 mL/min, the duration of the run was 3.5min and the isocratic solvent proportion was 95% (A) / 5% (B).

XXXIV) Chiral HPLC (AH):

CHIRALPAK AY-H, 5 Dm, 4.6x250mm column thermostated at 25°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 1 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 90% (A) / 10% (B).

XXXV) Chiral SFC (Al):

CHIRALPAK IC, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 90% (A) / 10% (B).

XXXVI) Chiral SFC (AJ):

CHIRALPAK IC, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = ACN/EtOH 1/1 . The eluent flow rate was 4 mL/min, the duration of the run was 3.5min and the isocratic solvent proportion was 90% (A) / 10% (B).

XXXVII) Chiral HPLC (AK):

CHIRALPAK AY-H, 5 Dm, 4.6x250mm column thermostated at 25°C was used. The two elution solvents were as follows: solvent A= Hept; solvent B = EtOH. The eluent flow rate was 0.8 mL/min, the duration of the run was 10min and the isocratic solvent proportion was 75% (A) / 25% (B).

XXXVIII) Chiral HPLC (AL):

CHIRALPAK IC, 5 Dm, 4.6x250mm column thermostated at 25°C was used. The two elution solvents were as follows: solvent A= Hept; solvent B = EtOH. The eluent flow rate was 0.8 mL/min, the duration of the run was 20min and the isocratic solvent proportion was 95% (A) / 5% (B). (XXXIX) Chiral SFC (AM):

CHIRALCEL OZ-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= CO2; solvent B = MeOH. The eluent flow rate was 4 mL/min, the duration of the run was 4min and the isocratic solvent proportion was 70% (A) / 30% (B).

(XL) Chiral SFC (AN):

CFIIRALPAK AD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH + 1%DEA. The eluent flow rate was 4 mL/min, the duration of the run was 3min and the isocratic solvent proportion was 85% (A) / 15%(B).

(XL I) Chiral SFC (AO):

A REGIS (R,R) Whelk 01, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= CO2; solvent B = MeCN/iPrOH 1/1 . The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 80% (A) / 20% (B).

(XLI I) Chiral SFC (AP):

CFIIRALPAK OD-H, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeOFI + 0.1%DEA. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 90% (A) / 10%(B).

(XLIII) Chiral SFC (AQ):

CFIIRALPAK IC, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= CO2; solvent B = MeOFI. The eluent flow rate was 4 mL/min, the duration of the run was 3.5min and the isocratic solvent proportion was 80% (A) / 20%(B).

(XLIV) Chiral SFC (AR):

A CFIIRALPAK IB, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= CO2; solvent B = MeCN/MeOF1 1/1. The eluent flow rate was 4 mL/min, the duration of the run was 3.5min and the isocratic solvent proportion was 80% (A) / 20% (B).

(XLV) Chiral HPLC (AS):

CFIIRALPAK IE, 5 Dm, 4.6x250mm column thermostated at 25°C was used. The two elution solvents were as follows: solvent A= Hept; solvent B = EtOH. The eluent flow rate was 0.8mL/min, the duration of the run was 15min and the isocratic solvent proportion was 10% (A) / 90%(B).

(XL VI) Chiral HPLC (AT): CHIRALCEL OZ-H, 5 Dm, 4.6x250mm column thermostated at 25°C was used. The two elution solvents were as follows: solvent A= Hept; solvent B = EtOH. The eluent flow rate was 0.8mL/min, the duration of the run was 20min and the isocratic solvent proportion was 10% (A) / 90%(B).

(XLVI I) Chiral HPLC (AU):

CHIRALPAK AD-H, 5 Dm, 4.6x250mm column thermostated at 25°C was used. The two elution solvents were as follows: solvent A= Hept; solvent B = EtOH. The eluent flow rate was 0.8mL/min, the duration of the run was 20min and the isocratic solvent proportion was 80% (A) / 20%(B).

(XLVI 11) Chiral SFC (AV):

A CHIRALPAK IB, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeCN/MeOH 1/1. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 85% (A) / 15% (B).

(XL IX) Chiral SFC (AW):

A CHIRALPAK IB, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeCN/MeOH 1/1. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 75% (A) / 25% (B).

(L) Chiral SFC (AX):

A CHIRALPAK IE, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 60% (A) / 40% (B).

(LI) Chiral SFC (AY):

A REGIS (R,R) Whelk 01, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = MeCN/EtOH 1/1. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 85% (A) / 15% (B).

(LI I) Chiral SFC (AZ):

A CHIRALPAK IB, 5 Dm, 4.6x250mm column thermostated at 40°C was used. The two elution solvents were as follows: solvent A= C0 ₂ ; solvent B = EtOH. The eluent flow rate was 4 mL/min, the duration of the run was 5min and the isocratic solvent proportion was 70% (A) / 30% (B).

Compound purity and identity was further confirmed by NMR spectroscopy (Bruker Avance II 400 MHz UltrashieldTM or Bruker AscendTM 500 equipped with a 5mm DCH cryoprobe), 1 H (400 MHz or 500 MHz). The chemical shifts are reported in parts per million (ppm) relative to tetramethylsilane (TMS), and multiplicities are given as s (singlet), d (doublet), t (triplet), or m (multiplet). Preparative LC-MS methods used:

The purifications by preparative LC-MS have been performed using the conditions described hereafter.

I) Prep LC-MS (I): AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = MeCN; solvent B = water + 0.5% NH ₄ OH (25%). The eluent flow rate and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points): AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points): A Zorbax column (SB-AQ, 7miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = MeCN; solvent B = water + 0.5% NH ₄ OH (25%). The eluent flow rate and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

V) Prep LC-MS (V):

A X-Bridge column (Waters C18, 10miti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

VI) Prep LC-MS (VI):

A X-Bridge column (Waters C18, 10miti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

VII) Prep LC-MS (VII):

X-Bridge column (Waters C18, 10miti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

VIII) Prep LC-MS (VIII):

X-Bridge column (Waters C18, IOmiti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

X) Prep LC-MS (IX):

An Agilent column (Zorbax SB-Aq, 5miti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

X) Prep LC-MS (X):

AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = MeCN; solvent B = water + 0.5% NH ₄ OH (25%). The eluent flow rate and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XI) Prep LC-MS (XI): AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = MeCN; solvent B = water + 0.5% NH ₄ OH (25%). The eluent flow rate and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points): XII) Prep LC-MS (XII):

A Zorbax SB-Aq column (Agilent, 5miti, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points): XIII) Prep LC-MS (XIII):

A X-Bridge column (Waters C18, 10miti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points): XIV) Prep LC-MS (XIV):

An Agilent column (Zorbax SB-Aq, 5miti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XV) Prep LC-MS (XV):

A X-Bridge column (Waters C18, IOmiti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XVI) Prep LC-MS (XVI):

AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = MeCN; solvent B = water + 0.5% NH ₄ OH (25%). The eluent flow rate and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XVII) Prep LC-MS (XVII):

A Zorbax column (SB-AQ, 7miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XVIII) Prep LC-MS (XVIII): A X-Bridge column (Waters C18, IOmiti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points): XIX) Prep LC-MS (XIX):

AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = MeCN; solvent B = water + 0.5% formic acid. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points): XX) Prep LC-MS (XX):

An Agilent column (Zorbax SB-Aq, 5miti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points): XXI) Prep LC-MS (XXI):

A X-Bridge column (Waters C18, 10miti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXII) Prep LC-MS (XXII):

An Agilent column (Zorbax SB-Aq, dmiti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXIII) Prep LC-MS (XXIII):

An Agilent column (Zorbax SB-Aq, dmiti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXIV) Prep LC-MS (XXIV):

A Zorbax column (SB-AQ, 7miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid; solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXV) Prep LC-MS (XXV): AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXVI) Prep LC-MS (XXVI):

A Zorbax column (SB-AQ, 7miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = MeCN; solvent B = water + 0.5% formic acid. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXVII) Prep LC-MS (XXVII):

AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXVIII) Prep LC-MS (XXVIII)

AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid ; solvent B = MeCN. The eluent flow rate and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXIX) Prep LC-MS (XXIX):

A X-Bridge column (Waters C18, IOmiti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid ; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXX) Prep LC-MS (XXX):

A X-Bridge column (Waters C18, 10miti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid ; solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXXI) Prep LC-MS (XXXI)

AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points): XXXII) Prep LC-MS (XXXII):

A X-Bridge column (Waters C18, IOmiti OBD, 30x75 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The eluent flow rate was 75 mL/min and the characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXXIII) Prep LC-MS (XXXIII): acidic large scale (Zorbax 50x150 mm, 7 urn), 90%Water_150ml_to 75%_8min_RT_0,49

A Zorbax column (SB-AQ, 7miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = MeCN; solvent B = water + 0.5% formic acid. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXXIV) Prep LC-MS (XXXIV):

A Zorbax column (SB-AQ, 7miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = MeCN; solvent B = water + 0.5% formic acid. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXXV) Prep LC-MS (XXXV):

A Zorbax column (SB-AQ, 7miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid (25%); solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXXVI) Prep LC-MS (XXXV ):

A Zorbax column (SB-AQ, 7miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% formic acid (25%); solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

XXXVII) Prep LC-MS (XXXVII):

AX-Bridge column (Waters C18, 10miti OBD, 50x150 mm) was used. The two elution solvents were as follows: solvent A = water + 0.5% NH ₄ OH (25%); solvent B = MeCN. The characteristics of the eluting mixture proportion in function of the time t from start of the elution are summarized in the tables below (a linear gradient being used between two consecutive time points):

Preparative chiral HPLC and SFC methods used: The purifications by preparative chiral HPLC or SFC have been performed using the conditions described hereafter. I) Prep chiral SFC (I): A ChiralCel OD-H column (5Dm, 30x250mm) thermostated at 40°C was used. The elution solvent was C02/MeOH 92/8, the run lasted for 6.50min and at a flow rate of 160mL/min.

II) Prep chiral SFC (II):

A ChiralCel OZ-H column (5Dm, 30x250mm) thermostated at 40°C was used. The elution solvent was CO2/MeOH+0.1%DEA 85/15, the run lasted for 5.50min and at a flow rate of 160mL/min.

III) Prep chiral SFC (III):

A ChiralPak AD-H column (5Dm, 30x250mm) thermostated at 40°C was used. The elution solvent was C02/EtOH 80/20, the run lasted for 5min and at a flow rate of 160mL/min.

IV) Prep chiral SFC (IV):

A ChiralPak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/EtOH 85/15, run for 3.90min and at a flow rate of 160mL/min.

V) Prep chiral SFC (V):

A ChiralPak IC (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO2/MeOFI+0.1%DEA 60/40, run for 5min and at a flow rate of 160mL/min.

VI) Prep chiral SFC (VI):

A ChiralPak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /MeOFI 90/10, run for 4min and at a flow rate of 160mL/min.

VII) Prep chiral SFC (VII):

A ChiralPak AD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /EtOH 75/25, run for 5min and at a flow rate of 160mL/min.

VIII) Prep chiral SFC (VIII):

A ChiralCel OD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/MeOFI 90/10, run for 6min and at a flow rate of 160mL/min.

IX) Prep chiral SFC (IX):

A ChiralPak AD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO2/50%MeCN- 50%EtOH-0.1 %DEA 75/25, run for 5.5min and at a flow rate of 160mL/min.

X) Prep chiral SFC (X):

A ChiralPak AS-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO2/50%MeCN- 50%EtOH-0.1 %DEA 72/28, run for 4.5min and at a flow rate of 160mL/min.

XI) Prep chiral SFC (XI):

A ChiralPak AS-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO2/50%MeCN- 50%EtOH-0.1%DEA 70/30, run for 4min and at a flow rate of 160mL/min. XII) Prep chiral SFC (XII):

A ChiralPak OD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO ₂ /MeOH+0.1%DEA 85/15, run for 9.30min and at a flow rate of 160mL/min.

XIII) Prep chiral SFC (XIII):

A ChiralPak AD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO ₂ /EtOH+0.1%DEA 75/25, run for 4min and at a flow rate of 160mL/min.

XIV) Prep chiral SFC (XIV):

A (R,R) Whelk (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO ₂ /50%DCM- 50%MeOPI-0.1%DEA 70/30, run for 7.9min and at a flow rate of 160mL/min.

XV) Prep chiral SFC (XV):

A ChiralPak ID (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO ₂ /50%MeCN- 50%EtOH-0.1%DEA 65/35, run for 4.75min and at a flow rate of 160mL/min.

XVI) Prep chiral SFC (XVI):

A ChiralPak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO ₂ /MeOFI+0.1%DEA 90/10, run for 4.50min and at a flow rate of 160mL/min.

XVII) Prep chiral SFC (XVII):

A ChiralPak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /MeOPI 80/20, run for 4min and at a flow rate of 160mL/min.

XVIII) Prep chiral SFC (XVIII):

A ChiralPak IH (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO ₂ /50%MeCN- 50%EtOH 85/15, run for 6min and at a flow rate of 160mL/min.

XIX) Prep chiral SFC (XIX):

A ChiralPak AD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /EtOH 85/15, run for 5min and at a flow rate of 160mL/min.

XX) Prep chiral SFC (XX):

A ChiralPak AD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /EtOH 90/10, run for 4.8min and at a flow rate of 160mL/min.

XXI) Prep chiral HPLC (XXI):

A ChiralPak AY-H (5Dm, 30x250mm) column thermostated at 25°C was used. The elution solvent was Hept/2-Propanol 80/20, run for 12min and at a flow rate of 38mL/min.

XXII) Prep chiral SFC (XXII): A ChiralPak IH (50m, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO2/50%Hept- 50%EtOH 85/15, run for 3.5min and at a flow rate of 160mL/min.

XXIII) Prep chiral SFC (XXIII):

A ChiralCel OD-H column (50m, 30x250mm) thermostated at 40°C was used. The elution solvent was C02/EtOH 80/20, the run lasted for 3.50min and at a flow rate of 160mL/min.

XXIV) Prep chiral SFC (XXIV):

A ChiralCel OD-H (50m, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/MeOH 85/15, run for 6min and at a flow rate of 160mL/min.

XXV) Prep chiral SFC (XXV)

A Chiralpak AD-H (50m, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /EtOH 95/5, run for 5.5min and at a flow rate of 160mL/min.

XXVI) Prep chiral HPLC (XXVI):

A ChiralPak IG (50m, 20x250mm) column thermostated at 25°C was used. The elution solvent was Hept/50%MeOH- 50%EtOH-0.1%DEA 30/70, run for 14min and at a flow rate of 20mL/min.

XXVII) Prep chiral SFC (XXVII):

A ChiralCel OD-H (50m, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /MeOH 75/25, run for 4min and at a flow rate of 160mL/min.

XXVIII) Prep chiral SFC (XXVIII):

A (R,R) Whelk-01 (50m, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO ₂ /50%iPrOH- 50%MeCN 80/20, run for 4min and at a flow rate of 160mL/min.

XXIX) Prep chiral SFC (XXIX):

A Chiralpak AD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/MeOH 85/15, run for 4min and at a flow rate of 160mL/min.

XXX) Prep chiral SFC (XXX):

A Chiralpak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/MeOH 70/30, run for 6min and at a flow rate of 160mL/min.

XXXI) Prep chiral SFC (XXXI):

A ChiralPak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /MeOH 90/10, run for 3.5min and at a flow rate of 160mL/min.

XXXII) Prep chiral SFC (XXXII):

A ChiralPak ID (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO ₂ /EtOH-0.1%DEA 60/40, run for 6min and at a flow rate of 160mL/min.

XXXIII) Prep chiral SFC (XXXIII): A ChiralPak IC (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO2EtOH-0.1%DEA 60/40, run for 6min and at a flow rate of 160mL/min.

XXXIV) Prep chiral SFC (XXXIV):

A ChiralPak IH (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/EtOH 55/45, run for 3.5min and at a flow rate of 160mL/min.

XXXV) Prep chiral SFC (XXXV):

A ChiralPak IG (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/EtOH 85/15, run for 6min and at a flow rate of 160mL/min.

XXXVI) Prep chiral SFC (XXXVI):

A ChiralPak IC (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /EtOH 75/25, run for 3.5min and at a flow rate of 160mL/min.

XXXVII) Prep chiral SFC (XXXVII):

A Chiralpak AY-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /EtOH 90/10, run for 3.4min and at a flow rate of 160mL/min.

XXXVIII) Prep chiral SFC (XXXVIII):

A ChiralPak IC (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /EtOH 90/10, run for 2.5min and at a flow rate of 160mL/min.

XXXIX) Prep chiral SFC (XXXIX):

A ChiralPak IC (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/ACN:EtOF1 1:1 90/10, run for 4.4min and at a flow rate of 160mL/min.

XL) Prep chiral HPLC (XL):

A ChiralPak AY-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was Hep/EtOH 75/25, run for 11min and at a flow rate of 38mL/min.

XLI) Prep chiral HPLC (XLI):

A ChiralPak IC (5Dm, 20x250mm) column thermostated at 40°C was used. The elution solvent was heptane/EtOH 95/5, run for 11.6min and at a flow rate of 16mL/min.

XLII) Prep chiral SFC (XLII):

A ChiralPak AD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/EtOH 90/10, run for 5.0min and at a flow rate of 160mL/min.

XLIII) Prep chiral HPLC (XLIII):

A ChiralCel OJ-H column (5Dm, 20x250mm) thermostated at 40°C was used. The elution solvent was Hept/EtOH 80/20, the run lasted for 10.5min and at a flow rate of 16mL/min. XLIV) Prep chiral SFC (XLIV):

A ChiralCel OJ-H column (5Dm, 30x250mm) thermostated at 40°C was used. The elution solvent was C0 ₂ /Me0H 90/10, the run lasted for 4min and at a flow rate of 16mL/min.

XLV) Prep chiral SFC (XLV):

A ChiralCel OZ-H column (5Dm, 30x250mm) thermostated at 40°C was used. The elution solvent was C02/Me0FI 70/30, the run lasted for 4min and at a flow rate of 160mL/min.

XL VI) Prep chiral SFC (XLVI):

A ChiralPak AD-H (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was CO2/EtOH-0.1% DEA 85/15, run for 5.0min and at a flow rate of 160mL/min.

XLVI I) Prep chiral SFC (XLVII):

A Chiralpak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /(MeCN:EtOFI 1 :1) 70/30, run for 6min and at a flow rate of 160mL/min.

XLVI 11) Prep chiral SFC (XLVIII):

A Regis (R,R)-Whelk 01 (50m, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/(MeCN:iPrOF1 1 :1) 80/20, run for 5min and at a flow rate of 160mL/min.

XLIX) Prep chiral SFC (XLIX):

A ChiralPak OD-H (50m, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/MeOH- 0.1% DEA 90/10, run for 9.0min and at a flow rate of 160mL/min.

L) Prep chiral SFC (L):

A ChiralPak IC (50m, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/MeOPI 80/20, run for 4min and at a flow rate of 160mL/min.

LI) Prep chiral SFC (LI):

A Chiralpak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/(MeCN:MeOPI 1 :1) 80/20, run for 6min and at a flow rate of 160mL/min.

Lll) Prep chiral HPLC (Lll):

A ChiralPak IE (5Dm, 30x250mm) column thermostated at 25°C was used. The elution solvent was Hept/EtOH 10/90, run for 12.0min and at a flow rate of 34mL/min.

LIN) Prep chiral HPLC (LIN):

A Chiralcel OZ-H (5Dm, 30x250mm) column thermostated at 25°C was used. The elution solvent was Hept/EtOH 10/90, run for 14.0min and at a flow rate of 34mL/min.

LIV) Prep chiral HPLC (LIV): A Chiralpak AD-H (5Dm, 30x250mm) column thermostated at 25°C was used. The elution solvent was Hept/EtOH 80/20, run for lO.Omin and at a flow rate of 34mL/min.

LV) Prep chiral SFC (LV):

A Chiralpak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/(MeCN:MeOH 1 :1) 85/15, run for 6min and at a flow rate of 160mL/min.

LVI) Prep chiral SFC (LVI):

A Chiralpak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /(MeCI\l:MeOH 1 :1) 75/25, run for 7min and at a flow rate of 160mL/min.

LVI I) Prep chiral SFC (LVII):

A Chiralpak IE (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/EtOH 60/40, run for 5min and at a flow rate of 160mL/min.

LVI 11) Prep chiral SFC (LVIII):

A Regis (R,R)-Whelk 01 (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C02/(MeCN:EtOH 1 :1) 85/15, run for 8min and at a flow rate of 160mL/min.

LIX) Prep chiral SFC (LIX):

A Chiralpak IB (5Dm, 30x250mm) column thermostated at 40°C was used. The elution solvent was C0 ₂ /EtOH 70/30, run for 6min and at a flow rate of 160mL/min.

Preparation of Intermediate Examples of Formula (A3), (A4), (A5), (A6), (A7), (B2), (C1), (C3), (D1), (D2), (D3), (D4), (D5), (E1), (E2), (F1), (F3), (F4), (F5), (G1), (J3) and (J5)

Example A3.1 : 5-Bromo-1,3-difluoro-2-isopropylbenzene A3. 1. 1: 2-(4-Bromo-2, 6-difluoro-phenyl)-propan-2-ol

To a solution of 4-bromo-2,6-difluorobenzoic acid methyl ester (1 eq) in THF (6.4 mL/mmol) was added at 0°C, a 3M solution of methylmagnesium bromide in Et ₂ 0 (3 eq). The ice bath was removed, and the reaction mixture was stirred for 1.5 h at RT. It was quenched with a half sat. solution of NH ₄ CI and extracted with EA. The combined org. phases were dried over MgS04 and concentrated in vacuo. The crude was purified by CC using Sfar prepacked cartridges from Biotage and eluting with Hept/EA to afford the title compound as colorless liquid. ¹ H NMR (500 MHz, DMSO) d : 7.34 (m, 2 H), 5.32 (s, 1 H), 1.56 (t, 0 = 2.0 Hz, 6 H).

A3. 1.2: 5-Bromo-1,3-difluoro-2-isopropylbenzene

To a solution of 2-(4-bromo-2,6-difluoro-phenyl)-propan-2-ol (1 eq) and triethylsilane (1.1 eq) in DCM (7.8 mL/mmol) was added at 0°C, TFA (11 eq). The ice bath was removed, and the reaction mixture was stirred for 3h at RT. It was quenched with a half sat. solution of NaHC03 and extracted with DCM. The combined org. phases were dried over MgS0 ₄ and concentrated in vacuo. The crude was purified by CC using Sfar prepacked cartridges from Biotage and eluting with pentane/EA to afford the title compound as colorless liquid. ¹ H NMR (500 MHz, DMSO) d : 7.40 (m, 2 H), 3.22-3.31 (m, 1 H), 1 .27 (d, 0 = 7.1 Hz, 6 H).

Example A4.1: 3-Methyl-3-(4-trifluoromethoxy-benzoyl)-azetidine-1-carboxyl ic acid tert-butyl ester A4.1.1. 3-(Methoxy-methy/-carbamoy/)-3-methy/-azetidine-1 -carboxylic acid tert-butyl ester To a pale yellow solution of 1-Boc-3-methylazetidine-3-carboxylic acid (20g) in DCM (500mL) were added N,O- dimethylhydroxylamine hydrochloride (8.97g) and DIPEA (54mL). The mixture was then cooled at 0°C and propylphosphonic anhydride solution in EA (50% w/w, 68mL) was slowly added. The resulting pale yellow solution was stirred 18h at RT and quenched with aq. sat. NaHC03 solution. The org. layer was washed with citric acid (10%) and water. The combined org. layers were dried (MgS04), filtered off and evaporated to dryness to afford 24.1g of the title compound as yellowish resin which was used without further purification. LC-MS (A): t _R = 0.78min; [M+H] ⁺ : 259.32.

A4. 1.2. 3-Methyl-3-(4-trifluoromethoxy-benzoyl)-azetidine-1 -carboxylic acid tert-butyl ester To a solution of 1-bromo-4-(trifluoromethoxy)benzene (12.2mL) in anhydrous THF (150mL) under argon cooled down to -78°C was added n-BuLi (2.5M in hexane, 29.7mL) dropwise over 45min so that the internal temperature did not rise above -70°C. The resulting mixture was stirred at -78°C for 20min. A solution of Example A4.1.1 (16g) in anhydrous THF (50mL) was added dropwise keeping the internal temperature below -70°C. The resulting dark yellow solution was allowed to warm up to RT and was stirred overnight. The reaction mixture was quenched with water and extracted with DCM. The org. layers were washed with brine, dried (MgS04), filtered off and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 340g, solvent A: Hep; solvent B: EA; gradient in %B: 10 over 2CV, 10 to 30 over 3CV, 30 over 2CV) to afford 18g of the title compound as yellow foam. LC-MS (A): t _R = 1.07min; [M- Me+H] ⁺ : 345.11.

Example A4.2 to Example A4.11 were synthesized starting from the appropriate Weinreb amide of Formula (A2) and bromo derivative of Formula (A3) and following the procedure described in Example A4.1. LC-MS data of Example A4.2 to Example A4.11 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example A4.12: 3-Cyano-3-(4-trifluoromethoxy-benzoyl)-azetidine-1-carboxyli c acid tert-butyl ester To a solution of 3-cyano-3-(methoxy-methyl-carbamoyl)-azetidine-1 -carboxylic acid tert-butyl ester (1.4g) in anhydrous THF (40mL) under argon cooled down to 0°C was added 4-(trifluoromethoxy)phenylmagnesium bromide (0.5M in THF, 20.8mL) dropwise. The resulting mixture was stirred at 0°C for 30 min, allowed to warm up to RT and stirred overnight.

The reaction mixture was quenched with sat. aq. NFUCI, stirred for 15min and extracted with EA /water. The aq. layer was back extracted twice with EA. The org. layers were dried (MgS04), filtered off and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 100g, solvent A: Hep; solvent B: EA; gradient in %B: 0 over 3CV, 0 to 10 over 5CV, 10 over 10CV) to afford 1.2g of the title compound as yellow solid. LC-MS (A): t _R = 1.06min; [M+H] ⁺ : 371.15.

Example A4.13: 3-Fluoro-3-(4-isopropyl-benzoyl)-azetidine-1 -carboxylic acid tert-butyl ester To a solution of 1-[(tert-butoxy)carbonyl]-3-fluoroazetidine-3-carboxylic acid (500mg) in DCM (16mL) were added N,O- dimethylhydroxylamine hydrochloride (221 mg), DIPEA (1.36mL) and propylphosphonic anhydride solution in DCM (50% w/w, 1.64mL). The resulting mixture was stirred 40min at RT. Then it was diluted with DCM and washed once with aq. sat. NaPICOs solution. The org. layer was washed with citric acid (10%) and brine. The aq. layers were back extracted with twice DCM. The combined org. layers were dried (MgS04), filtered off, evaporated and dried at HV to afford 630mg of the title compound as yellow oil. LC-MS (A): t _R = 0.62min; [M+Fi] ⁺ : 263.13. Example A4.14 to A4.18, A4.20, A4.22 to A.4.33 were synthesized starting from the appropriate Weinreb amide of Formula (A2) and the appropriate bromo derivative of Formula (A3) and following the procedure described in Example A4.1. LC-MS data of Example A4.14 to A4.18, A4.20, and A4.22 to A4.33 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example A4.19: 3-methyl-3-(4-(pentafluoro- 6-sulfaneyl)benzoyl)azetidine-1-carboxylic acid tert-butyl ester A4.19.1: 3-Formyl-3-methyl-azetidine-1-carboxylic acid tert-butyl ester

To a solution of Example A4.1.1 (1 eq) in THF (6.7 mL/mmol) was added dropwise at -78°C, a 1M solution of diisobutylaluminium hydride in DCM (1.2 eq). The reaction mixture was stirred for 30 min at -78°C, quenched with MeOFI and partitioned between a sat. solution of potassium sodium tartrate tetrahydrate and DCM. The org. phase was dried over MgS0 ₄ and concentrated in vacuo to provide the crude title compound as yellowish oil. ¹ FI NMR (400 MHz, DMSO) 5: 9.69 (s, 1 H), 4.04 (d, 0= 8.1 Hz, 2 H), 3.59 (d, 0= 8.2 Hz, 2 H), 1.39 (s, 9 H), 1.35 (s, 3 H)

A4.19.2: 3-(Hydroxy(4-(pentafluoro- 6-sulfaneyl)phenyl)methyl)-3-methylazetidine-1 -carboxylic acid tert-butyl ester To a solution of 4-bromophenylsulphur pentafluoride (1.5 eq) in anhydrous Et ₂ 0 (7.5 mL/mmol) under argon and cooled to -78°C, was added dropwise a 1 ,6M solution of tBuLi (1.1 eq). The reaction mixture was stirred for 5 min and a solution of 3-formyl-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester (1 eq) in anhydrous THF (2 mL/mmol) was added dropwise. The resulting dark yellow solution was stirred for 45 min at -78°C, the dry ice bath was removed, and the reaction mixture was additionally stirred for 45 min. It was quenched with water and extracted with EA. The org. phase was washed with brine, dried over MgS0 ₄ and concentrated in vacuo. The crude was purified by CC using Sfar prepacked cartridges from Biotage and eluting with Hept/EA to afford the title compound as white solid. LC-MS (A): tR = 1.03 min; [M+H] ⁺ : 403.91 A4.19.3: 3-Methyl-3-(4-(pentafluoro- 6-sulfaneyl)benzoyl)azetidine-1 -carboxylic acid tert-butyl ester

To a solution of 3-(hydroxy(4-(pentafluoro- 6-sulfaneyl)phenyl)methyl)-3-methylazetidine-1-carboxylic acid tert-butyl ester (1 eq) in DCM (3.5 mL/mmol) was added at RT, DMP (1 .2 eq). The reaction mixture was stirred for 15 min at RT, diluted with DCM, quenched with water and filtered. The filtrate was washed with a sat. solution of NaHC0 ₃ and the org. phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC using Sfar prepacked cartridges from Biotage and eluting with Hept/EA to afford the title compound as colorless sticky oil. LC-MS (A): tR = 1.12 min; [M+H] ⁺ : 401.73

Example A4.21: 3-(Benzo[b]thiophene-5-carbonyl)-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from the appropriate Weinreb amide of Formula (A2) and the appropriate bromo derivative of Formula (A3) and following the procedure described in Example A4.1. It was isolated from the resulting mixture of 3-(benzo[b]thiophene-2-carbonyl)-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester and 3- (benzo[b]thiophene-5-carbonyl)-3-methyl-azetidine-1-carboxyl ic acid tert-butyl ester by Prep chiral SFC (III). LC-MS (A): t _R = 1.07 min; [M+H] ⁺ : 332.04.

Example A4.343-Ethyl-3-(4-trifluoromethoxy-benzoyl)-azetidine-1 -carboxylic acid tert-butyl ester A4.34.1 3-Ethyl-azetidine-1,3-dicarboxylic acid 1 -tert-butyl ester 3-ethyl ester

To a solution of ethyl 1-Boc-azetidine-3-carboxylate (993 mg) and iodoethane (0.338 mL) in THF (10 mL) was added potassium bis(trimethylsilyl)amide (1.55 mL) as a solution in toluene (10 mL) at -78°C. The reaction was stirred overnight and allowed to slowly warm up to RT. The reaction was quenched by the addition of aqueous aq. sat. NH ₄ CI (20 mL) and diluted with water (20 mL) and EA (20 mL). The phases were separated and the aqueous phase was extracted with EA (3x, 30 mL). The combined organic phases were washed with brine, dried over MgS0 ₄ and concentrated in vacuo. The product was obtained as 677mg yellow oil. LC-MS (A) tR = 0.88min; [M+H] ⁺ : 257.16 A4.34.23-Ethyl-azetidine-1,3-dicarboxyHc acid mono-tert-butyl ester

To the solution of A4.34.1 (676 mg) in water (3.72 mL) and dioxane (3.72 mL) was added lithium hydroxide monohydrate (780 mg) and the mixture was heated to 70°C (bath temperature) for 3h. The reaction was diluted in water (ca. 20 mL) and EA (ca. 20 mL) and acidified (ca. pH = 4) with aqueous HCI (2 M). The phases were separated, the aqueous phase was extracted with EA (3x, 15 mL), the combined organic phases were washed with brine, dried over MgS0 ₄ and concentrated in vacuo to give the pure product as 555mg yellowish solid. LC-MS (A) t _R = 0.65min, [M+H] ⁺ : 229.13

A4.34.33-Ethyl-3-(methoxy-methyl-carbamoyl)-azetidine-1-c arboxylic acid tert-butyl ester To a suspension of A4.34.2 (550 mg), N,O-dimethylhydroxylamine hydrochloride (468 mg) and DMAP (2.93 mg) in DCM (9 mL) was added N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (929 mg) and triethylamine (1.35 mL). The mixture was stirred at RT for 2h. The reaction was diluted with water (10 mL) and and EA (10 mL) and the pH was adjusted to 1 . The phases were separated and the aqueous phase was extracted with EA (3x, 10 mL). The combined organic phases were washed with brine, dried over MgSC>4 and concentrated in vacuo to yield the product as 570mg yellowish oil. LC-MS (A) t _R = 0.77min; [M+H] ⁺ : 272.17

A4.34.43-Ethyl-3-(4-trifluoromethoxy-benzoyl)-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was synthesized from Example A4.34.3 and following the procedure described in Example A4.1 step A4.1.2 . LC-MS (A): t _R = 0.99min; [M+H] ⁺ : 373.15.

Example A4.353-Methyl-3-[4-(2, 2, 2-trifluoro-ethyl)-benzoyl]-azetidine-1 -carboxylic acid tert-butyl ester

A flask was charged with A4.8 (647mg), CSCO3 (1803mg), H2O (782pL) and toluene (9.13mL). The suspension was degassed with argon in ultrasonic bath for 5min, then 14,4,5,5-Tetramethyl-2-(2,2,2-trifluoroethyl)-1 ,3,2-dioxaborolane (486 L) and cataCXium A Pd G3 (140mg) were added under argon. The flask was 3x evacuated and backfilled with argon. The resulting suspension was stirred at 100°C under argon overnight. The reaction mixture was allowed to cool down, filtrated, the filter was washed with EA, the filtrate was evaporated to dryness and purified by CC (Biotage, 25g sphere duo, A: Hept, B: EA, gradient (in %B): 10 for 3CV, 10 to 30 over 1CV, 30 for 3CV, 30 to 50 over 2CV, 50 for 1CV) to give 569mg brown solid. LC-MS (A) t _R = 1.06min; [M+H]"·: 358.06

Example A5.1: 2-[3-(5-Bromo-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan-2- ol H2.1 : 5-Bromo-N-hydroxy-nicotinamidine

To a solution of 5-bromonicotinonitrile (2g) in DMF (10mL) were sequentially added hydroxylamine hydrochloride (1.14g) and TEA (3.05 mL). The reaction mixture was heated to 85°C for 1 h, cooled to RT and quenched with water (20mL). The resulting precipitate was filtered off and dried at 65°C under vacuo to afford 2.1g of the title compound as white solid. LC-MS (A): t _R = 0.36 min; [M+H] ⁺ : 215.98.

A5.1 : 2-[3-(5-Bromo-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-propan-2-ol

To a solution of CDI (11 ,6g) in DMF (35mL) under argon, was added dropwise at RT a solution of 2-hydroxyisobutiric acid (7.23g) in DMF (15mL). After stirring for 30 min, a suspension of intermediate H2.1 (10g) in DMF (50mL) was added slowly at RT. The mixture was heated to 90°C, stirred for 18h and cooled to RT. It was quenched with dropwise addition of water (100mL) at 0°C and aged for 30 min at 0°C. The resulting precipitate was filtered and dried at 65°C under vacuo to afford 9.1g of the title compound as white solid. LC-MS (A): t _R = 0.77 min; [M+H]-: 283.98.

Example A5.2: 1-{4-[3-(5-Bromo-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperi din-1-yl}-ethanone

The title compound was synthesized following the procedure described in Example A5.1 except that 2-hydroxyisobutiric acid was replaced by 1-acetyl-4-piperidinecarboxylic acid in the second step. LC-MS (A): t _R = 0.84 min; [M+H]-: 350.91.

Examples A6.1 to A6.25

Intermediate A6.1.1 to A6.30.1 were synthesized starting from the appropriate precursor of Formula (A4) and the appropriate bromo derivative of Formula (A5) and following the procedure described in Example A7.1 step A7.1.1 except that nBuLi was replaced by HexLi. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example A6.1.1 to A6.25.1 were purified by Prep chiral SFC or HPLC to afford the title compound of Formula (A6) as pure enantiomer. The Prep chiral SFC or HPLC conditions and chiral SFC or HPLC data are listed in the table below

Example A6.26 to Example A6.28 were synthesized following the procedure described in Example A7.1 step A7.1.1 using the ketone precursor and 3,5-dibromopyridine. The ketone precursor, LC-MS (A) data, prep LC-MS method, chiral preparative and analytical SFC data are listed in the table below.

Example A6.293-[(R)-(5-Bromo-pyridin-3-yl)-hydroxy-(4-trifluoromethy l-phenyl)-methyl]-3-methyl-azetidine-1- carboxylic acid tert-butyl ester was synthesized following the procedure described Example A7.1 step A7.1.1 using A4.5 and 3,5-dibromopyridine, purified by prep LC-MS (XXV) and chiral separation conditions (XU I). LC-MS (A) t _R = 1.07min; [M+H] ⁺ : 501.13; chiral SFC (W) t _R = 1.792min.

Example A7.1: (R)-(3-Methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl )-(4-trifluoromethoxy-phenyl)-methanol, hydrochloride salt

A7.1.1. 3-[Hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluorometh oxy-phenyl)-methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester To a solution of Example A4.1 (15g) and 3-bromo-5-pyrrolidinopyridine (12.6g) in anhydrous THF (150mL) under argon cooled down to -78°C was added n-BuLi (2.5M in hexane, 20.04mL) dropwise over 20min so that the internal temperature did not rise above -65°C. The resulting dark yellow solution was stirred at -78°C for 1h30 and allowed to warm up to RT. The reaction mixture was quenched with water and extracted with DCM. The org. layers were dried (MgS0 ₄ ), filtered off and evaporated to dryness. The resulting crude material was taken up in MeCN/MeOH (9/1 v/v) and filtrated off. The solution was purified by Prep LC-MS (IV) to afford 6.67g of the title compound as yellow solid. LC- MS (A): t _R = 0.9 min; [M+H] ⁺ : 508.31. A7.1.2 3-[(R)-Hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoro methoxy-phenyl)-methyl]-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

Example A7.1.1 (6.67g) was purified by Prep chiral SFC (II) to afford the title compound as pure enantiomer (3.35g) as yellow solid. LC-MS (A): tR = 0.89min; [M+H] ⁺ : 508.31. Chiral SFC (A): tR = 2.8min. The absolute configuration of the compound of Example A7.1.2 was determined to be (R)- by obtaining a suitable crystal of one of the two separated enantiomers (solvent: methylcyclohexane) and performing single crystal X-ray diffraction experiment.

A7.1.3. (R)-(3-Methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl )-(4-trifluoromethoxy-phenyl)-methanol, hydrochloride salt

A pale-yellow solution of Example A7.1.2 (3.25g) in HCI in dioxane (4M, 15mL) was stirred 1h at RT. The crude was evaporated to dryness to give the title compound as yellow solid. LC-MS (A): tR = 0.60min; [M+H]-: 408.33. Example A7.2 and Example A7.3 were synthesized starting from the appropriate Example of Formula (A4) and following the procedure described in Example A7.1 but omitting the chiral separation step A7.1.2. LC-MS data of Example A7.2 and Example A7.3 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example A7.4 to Example A7.33 were synthesized starting from the appropriate precursor of Formula (A6) and following the procedure described in Example A7.1 step A7.1.3 except that the reaction mixture was stirred for 18h at RT. LC-MS data of Example A7.4 to Example A7.33 are listed in the table below. The LC-MS conditions used were LC- MS (A).

Example A7.34 (RS)-4-{5-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-azetid in-3-yl)-methyl]-pyridin-3-yl}-2-(6-methyl- pyridin-2-yl)-but-3-yn-2-ol

A7.34.1-[(R)-Hydroxy-{5-[(RS)-3-hydroxy-3-(6-methyl-pyrid in-2-yl)-but-1-ynyl]-pyridin-3-yl}-(4-isopropyl-phenyl)- methyl]-3-methyl-azetidine- 1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from F1.11 using Example F5.27, and following the procedure described in Example 15, where the amount of Pd(PPh3)4 was adjusted to 0.1 eq and the base was changed to pyrrolidine (3.5eq). Purified with prep LC-MS method (V). LC-MS (A) t _R = 0.89; [M1H] ^÷ : 556.24

A7.34.2 (RS)-4-{5-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-azetid in-3-yl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin- 2-yl)-but-3-yn-2-ol

To a solution of A7.34.1 (250mg)in dioxane (2mL) was added HCI 4M in dioxane (473mI_) dropwise at RT. The resulting suspension was stirred for 23h before neutralized basified to pH=10 by the dropwise addition of NaOF1 1 M, diluted with water and DCM, extracted using a phase separator and was re-extracted 2x with DCM. The org layer was concentrated in vacuo and dried in HV to give 191 mg yellowish solid. LC-MS (A) t _R = 0.61 min; [M+H] ⁺ : 465.22 Example A7.35 to Example A7.37 were synthesized from the protected amine listed in the table below following the procedure in Example 309 step 309.2. The LC-MS date can be found in the table below. The method used was LC- MS (A).

Example A7.38: (R)-(5-Bromo-pyridin-3-yl)-(3-methyl-azetidin-3-yl)-(4-trifl uoromethyl-phenyl)-methanol The title compound was synthesized following the procedure described in Example 309 step 309.2 using Example A6.29. Instead of evaporation the reaction mixture was cooled with an ice-bath and slowly basified to pH=8 with aq. sat. NaHC0 ₃ and extracted with 3x DCM. The combined org. layers were dried over MgS0 ₄ , filtrated off, evaporated and dried at HV to give 1.59g light yellow foam. LC-MS (A) tR = 0.71 min; [M+H] ⁺ : 403.17

Example B2.1 : (1 ,3-Dimethyl-azetidin-3-yl)-(4-trifluoromethoxy-phenyl)-metha none

B2.1.1. (3-Methyl-azetidin-3-yl)-(4-trifluoromethoxy-phenyl)-methano ne; as hydrochloric salt

A pale yellow solution of Example A4.1.2 (2g) in HCI in dioxane (4M, 10mL) was stirred for 30min at RT. The crude was evaporated to dryness and used in the next step without further purification. LC-MS (A): t _R = 0.66min; [M+H] ⁺ : 260.29.

B2.1.2. ( 1,3-Dimethyl-azetidin-3-yl)-(4-trifluoromethoxy-phenyl)-meth anone

To a light yellow solution of Example B2.1.1 (1.5g) in MeOH (35mL) was added AcOH (3.5mL), followed successively by formaldehyde (37% in water, 2.27mL) and NaBH(OAc) ₃ (2.22g). The resulting solution was stirred for 30min at RT and evaporated in vacuo. The residue was diluted with water and the resulting mixture was basified with aq. sat. NaHCCh solution, and extracted with DCM. The org. layers were dried (MgS04), filtered off and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 50g, solvent A: DCM; solvent B: MeOH; gradient in %B: 0 over 3CV, 0 to 3 over 5CV, 3 over 5CV) to afford 950mg of the title compound as yellow sticky glue. LC-MS (A): tp = 0.67min; [M+H] ⁺ : 274.02

Example B2.2 and Example B2.3 were synthesized following the procedure described in Example B2.1, but using THF instead of MeOH as solvent in the reductive amination step for the synthesis of Example B2.3. LC-MS data of Example B2.2 and Example B2.3 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example C1.1 : 3-Methyl-3-(5-pyrrolidin-1-yl-pyridine-3-carbonyl)-azetidine -1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from 3-bromo-5-pyrrolidinopyridine and Example A4.1.1, following the synthesis procedure described in Example A7.1 step A7.1.1, and was purified by Prep LC-MS (I). LC-MS (A): tR = 0.79min; [M+H] ⁺ : 346.24

Example C1.2: 3-(5-Ethoxy-pyridine-3-carbonyl)-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from 3-bromo-5-ethoxypyridine and Example A4.1.1, following the synthesis procedure described in Example A7.1 step A7.1.1, and was purified by CC (Biotage, SNAP 50g, solvent A: Hep; solvent B: EA; gradient in %B: 0 over 2CV, 0 to 30 over 3CV, 30 over 5CV). LC-MS (A): tR = 0.94min; [M+H] ⁺ : 321.19.

Example C3.1 : (1,3-Dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl )-methanone C3.1.1. (3-Methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-me thanone, hydrochloride salt

A yellowish solution of Example C1 .1 (1 .45 g) in HCI in dioxane (4M, 10ml_) was stirred at RT for 45min and evaporated in vacuo to afford the title compound (1 ,2g) as yellow solid. LC-MS (A): t _R = 0.44min; [M+H] ⁺ : 246.34.

C3.1.2. ( 1,3-Dimethyl-azetidin-3-yl)-(5-pyrroHdin-1-yl-pyridin-3-yl)- methanone

The title compound (170mg, yellow resin) was prepared starting from Example C3.1.1 (1.12g), and following the procedure described in Example B2.1 step B2.1.2. The crude material was purified by Prep LC-MS (XXIII). LC-MS (A): t _R = 1.09min; [M+H] ⁺ : 422.40.

Example D1.1 : 5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]-nicotinonitrile

D1.1.1. 3-[(5-Bromo-pyridin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-3-methyl-azetidine-1-carboxyHc acid tert-butyl ester

The title compound was synthesized starting from Example A4.2 and 3,5-dibromopyridine, following the synthesis procedure described in Example A7.1 step A7.1.1, and was purified by CC (Biotage, SNAP 100g, solvent A: Hep; solvent B: EA; gradient in %B: 0 over 3CV, 0 to 60 over 15CV). LC-MS (A): t _R = 1.12min; [M+H] ⁺ : 475.22.

D1.1.2. 3-[(5-Cyano-pyiidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-3-methyl-azetidine-1-carboxylic acid tert-butyl ester

To a solution of Example D1.1.1 (11g) in anhydrous DMF (113mL) under argon atmosphere were sequentially added zinc (powder, 268mg), zinc cyanide (4.44g), Pd2(dba)3 (1.48g) and 1,T-bis(diphenylphosphino)ferrocene (7.37g). The reaction mixture was refluxed for 20h, cooled down to RT, quenched with water and extracted with EA. The combined org. layers were dried over Na2S04, filtered off and evaporated to dryness. The crude was purified by CC (Biotage, SNAP 100g, solvent A: Hep; solvent B: EA; gradient in %B: 10 over 4.4CV, 10 to 22 over 2CV, 22 over 4CV, 22 to 40 over 1CV, 40 over 5.3CV) and by Prep LC-MS (XIX) to afford the title product as white solid (5.8g). LC-MS (A): t _R = 1.09min; [M+H] ^÷ : 422.40.

D1.1.3. 3-[(R)-(5-Cyano-pyiidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-m ethyl]-3-methyl-azetidine-1-carboxylic acid tert- butyl ester

Example D1.1.2 (4.5g) was purified by Prep chiral SFC (VIII) to afford the title compound as pure enantiomer (1.85g). Chiral SFC (I): t _R = 2.53min.

D1.1.4. 5-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-azetidin-3-yl) -methyl]-nicotinonitrile, hydrochloride salt Example D1.1.3 (1.5g) was dissolved in EA (15mL) and HCI in dioxane (4M, 8.9mL) was added. The reaction mixture was stirred overnight at RT, concentrated in vacuo and dried under HV. The residue was directly used in the next step without further purification. LC-MS (A): t _R = 0.69min; [M+H]-: 321.99.

D1.1.5. 5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]-nicotinonitrile To a solution of Example D1.1.4 (1 ,27g) in dioxane (26mL) were added TEA (1 ,49mL) and formaldehyde (37% in water, 0.93mL), followed by NaBH(OAc)3 (1.17g). The reaction mixture was stirred at RT until completion of the reaction, filtered off, and the filtrate was purified by Prep LC-MS (XVI) to afford the title product as white powder (970mg). LC- MS (A): tp = 0.70min; [M+H] ⁺ : 336.13.

Example D1.2: 3-{(R)-(5-Cyano-pyridin-3-yl)-hydroxy-[4-(2,2,2-trifluoro-et hyl)-phenyl]-methyl}-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example D1.3 and 4,4,5,5-tetramethyl-2-(2,2,2-trifluoroethyl)-1,3,2- dioxaborolane, following the synthesis procedure described in Example 572, and was purified by Prep LC-MS (XXIX). LC-MS (A): t _R = 1.03 min; [M+H] ⁺ : 462.15.

Example D1.3: 3-[(R)-(4-Bromo-phenyl)-(5-cyano-pyridin-3-yl)-hydroxy-methy l]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

D1.3.1: 3-[(4-Bromo-phenyl)-(5-cyano-pyridin-3-yl)-hydroxy-methyl]-3 -methyl-azetidine-1-carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example A4.8 and 5-bromonicotinonitrile, following the synthesis procedure described in Example A7.1 step A7.1.1 except that nBuLi was replaced by HexLi, and was purified by Prep LC-MS (XXVIII). LC-MS (A): t _R = 1.02 min; [M+H] ⁺ : 459.87.

D1.3.2: 3-[(R)-(4-Bromo-phenyl)-(5-cyano-pyridin-3-yl)-hydroxy-methy l]-3-methyl-azetidine-1-carboxylic acid tert-butyl ester

Example D1.3.1 was purified by Prep chiral SFC (XXVII) to afford the title compound as pure enantiomer. Chiral SFC (Z): t _R = 1.72 min.

Example D1.4: 3-{(5-Cyano-pyridin-3-yl)-hydroxy-[4-(1,2,2,2-tetrafluoro-1- trifluoromethyl-ethyl)-phenyl]-methyl}-3- methyl-azetidine-1-carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example A4.18 and 5-bromonicotinonitrile, following the synthesis procedure described in Example A7.1 step A7.1.1 except that nBuLi was replaced by HexLi, and was purified by CC (Biotage, SNAP, solvent A: Hep; solvent B: EA; gradient in %B: 10 over 3CV, 10 to 50 over 13CV). LC-MS (A): t _R = 1.11 min; [M+H] ⁺ : 547.88.

Example D1.5: 3-((5-cyanopyridin-3-yl)(hydroxy)(4-(pentafluoro- 6-sulfaneyl)phenyl)methyl)-3-methylazetidine-1- carboxylic acid tert-butyl ester The title compound was synthesized starting from Example A4.19 and 5-bromonicotinonitrile, following the synthesis procedure described in Example A7.1 step A7.1.1 except that nBuLi was replaced by HexLi, and was purified by CC (Biotage, Sfar, solvent A: Hep; solvent B: EA; gradient in %B: 12 over 1CV, 12 to 100 over 10CV). LC-MS (A): t _R = 1.05 min; [M+H] ⁺ : 505.86.

Example D2.1 : 5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-N-hydroxy-nicotinamidine To a solution of Example D1.1 (970 mg) in EtOH (19 mL) were sequentially added K ₂ CO ₃ (1.60 g) and hydroxylamine hydrochloride (609 mg). The reaction mixture was refluxed for 45 min, cooled down to RT, and filtered off. The resulting solution was evaporated in vacuo to afford 1.12 g of the title compound as off-white solid. LC-MS (A): t _R = 0.53min; [M+H] ⁺ : 369.25.

Example D2.2: 3-[(R)-Hydroxy-[5-(N-hydroxycarbamimidoyl)-pyridin-3-yl]-(4- isopropyl-phenyl)-methyl]-3-methyl- azetidine-1-carboxylic acid tert-butyl ester

The title compound was obtained starting from Example D1.1.3 and following the procedure described in Example D2.1 , but stirring the reaction mixture at RT. LC-MS (A): t _R = 0.81 min; [M+H] ⁺ : 455.03.

Example D2.3: 3-{(R)-(4-Bromo-phenyl)-hydroxy-[5-(N-hydroxycarbamimidoyl)- pyridin-3-yl]-methyl}-3-methyl- azetidine-1-carboxylic acid tert-butyl ester

The title compound was obtained starting from Example D1.3 and following the procedure described in Example D2.1. LC-MS (A): t _R = 0.74min; [M+H] ⁺ : 492.95.

Example D2.4: 3-{Hydroxy-[5-(N-hydroxycarbamimidoyl)-pyridin-3-yl]-[4-(1,2 ,2,2-tetrafluoro-1-trifluoromethyl-ethyl)- phenyl]-methyl}-3-methyl-azetidine-1-carboxylic acid tert-butyl ester

The title compound was obtained starting from Example D1.4 and following the procedure described in Example D2.1. LC-MS (A): t _R = 0.87min; [M+H] ⁺ : 580.89.

Example D2.5: 3-(hydroxy(5-(N'-hydroxycarbamimidoyl)pyridin-3-yl)(4-(penta fluoro- 6-sulfaneyl)phenyl)methyl)-3- methylazetidine-1 -carboxylic acid tert-butyl ester

The title compound was obtained starting from Example D1.5 and following the procedure described in Example D2.1. LC-MS (A): t _R = 0.81 min; [M+H] ⁺ : 538.93.

Example D2.6: 3-{(R)-Hydroxy-[5-(N-hydroxycarbamimidoyl)-pyridin-3-yl]-[4- (2,2,2-trifluoro-ethyl)-phenyl]-methyl}-3- methyl-azetidine-1-carboxylic acid tert-butyl ester

The title compound was obtained starting from Example D1.2 and following the procedure described in Example D2.1. LC-MS (A): t _R = 0.79 min; [M+H] ⁺ : 495.03.

Example D3.1: 1 -(acetamido-2, 2, 2-d3)cyclopropane-1 -carboxylic acid D3. 1. 1 1-tert-Butoxycarbonylamino-cyclopropanecarboxylic acid benzyl ester To a solution of Boc-1-aminocyclopropane-1 -carboxylic acid (100mg) in DCM (2mL) were added DCC (155mg) and DMAP (31 mg) followed by benzyl alcohol (51.5mI_). The resulting solution was stirred overnight at RT. The resulting mixture was filtrated then basified with aq. sat. NaHC0 ₃ solution and extracted with DCM. The org. layers were dried (MgS04), filtered off and evaporated to dryness. LC-MS (A): tR = 0.94min; [M+H]"·: 291.93.

D3.1.2 1-Amino-cyclopropanecarboxylic acid benzyl ester, hydrochloride salt

A solution of Example D3.1 .1 (145mg) in HCI in dioxane (4M, 2mL) was stirred 30min at RT. The crude was evaporated to dryness and used in the next step without further purification. LC-MS (A): tR = 0.51 min; [M+H]-: 192.25.

D3.1.3 Benzyl 1-(acetamido-2,2,2-d3)cyclopropane-1-carboxylate

To a solution of of Example D3.1.2 (113mg) in DCM (2mL) were added DIPEA (257 mί), HOBt (81.1mg) and EDC.HCI (115mg) followed by acetic acid-2, 2, 2-d3 (43 L). The resulting solution was stirred overnight at RT. Crude was basified with aq. sat. NaHC0 ₃ solution and extracted with DCM over phase separator. The resulting solution was evaporated to dryness. LC-MS (A): t _R = 0.66min; [M+H] ⁺ : 237.1.

D3.1.4 1 -(acetamido-2, 2, 2-d3)cyclopropane-1 -carboxylic acid

To a solution of Example D3.1.3 (117mg) in EA (2mL) was added Pd/C (10% w/w, 50% water, 41.3mg). The resulting solution was stirred under hb atmosphere was at RT for 5h, filtered over a glass paper fiber filter and the filtrate was concentrated in vacuo and dried under HV. LC-MS (A): tR = 0.41 min.

Example D3.2: 1 -(N-methylacetamido-2, 2, 2-d3)cyclopropane-1 -carboxylic acid D3.2.1 1-(tert-Butoxycarbonyl-methyl-amino)-cyclopropanecarboxylic acid benzyl ester

To a solution of 1-((tert-Butoxycarbonyl)(methyl)amino)cyclopropanecarboxylic acid (100mg) in DMF (1mL) were added K2C0 ₃ (62.3mg) followed by benzyl bromide (54.6 L). The resulting solution was stirred overnight at RT. The resulting mixture was extracted with water and DCM. The org. layers were dried (MgS04), filtered off and evaporated to dryness. LC-MS (A): t _R = 1.02min; [M+H] ⁺ : 305.93.

D3.2.2 1-( N-methylacetamido-2, 2, 2-d3)cyclopropane- 1 -carboxylic acid

The title compound was synthesized starting from Example D3.2.1 following the three-step procedure described in Example D3.1 steps D3.1.2 to D3.1.4. LC-MS (A): t _R = 0.4min; [M+H] ⁺ : 161.15.

Example D3.3 to Example D3.8 and Example D3.12 were synthesized starting from the appropriate commercial amine and acid reagents following the procedure described in Example D3.2. LC-MS data of Example D3.3 to Example D3.8 and Example D3.12 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example D3.9: (S)-1-Acetyl-pyrrolidine-3-carboxylic acid

D3.9.1 (S)-Pyrrolidine-1,3-dicarboxylic acid 3-benzyl ester 1-tert-butyl ester

The title compound (275mg) was synthesized starting from (S)-l-N-Boc-beta-proline (200mg) following the procedure described in Example D3.2 steps D3.2.1. LC-MS (A): t _R = 0.99min; [M+H]-: 305.84.

D3.9.2 (S)-Pyrrolidine-3-carboxylic acid benzyl ester

A solution of Example D3.9.1 (275mg) in HCI in dioxane (4M, 3mL) was stirred 2h at RT. The crude was evaporated to dryness and used in the next step without further purification. LC-MS (A): t _R = 0.52min; [M+H]-: 206.19.

D3.9.3 (S)-1-Acetyl-pyrrolidine-3-carboxylic acid benzyl ester To a solution of Example D3.9.2 (185mg) in THF (3mL) were added DIPEA (308 L) and acetyl chloride (64.7 L), mixture was stirred 2h at RT. The crude was evaporated to dryness and placed under HV. LC-MS (A): t _R = 0.76min; [M+H]"·: 248.13.

D3.9.4 (S ) - 1 - Acety l-pyrrolidine-3-carboxylic acid

The title compound (141.6mg) was synthesized starting from Example D3.9.3 (223mg) following the procedure described in Example D3.1 step D3.1.4. LC-MS (A): t _R = 0.36min; [M+H]-: 158.17.

Example D3.10 and Example D3.11 were synthesized starting from the appropriate commercially available acid following the procedure described in Example D3.9. LC-MS data of Example D3.10 and Example D3.11 are listed in the table below. The LC-MS conditions used were LC-MS (A). Example D3.13: 1-Acetyl-4-hydroxy-piperidine-4-carboxylic acid D3.13.1 4-Hydroxy-piperidine-4-carboxylic acid, hydrochloride salt

N-Boc-4-hydroxy-4-piperidinecarboxylic acid (124 mg) was treated with a solution of HCI in dioxane (4 M, 1 .25 mL) and stirred at RT for 2.5 h. The mixture was concentrated and dried under HV to give the desired product as a white solid (87 mg). LC-MS (A): t _R = 0.17 min; [M+H] ⁺ : 146.09.

D3.13.2 1-Acetyl-4-hydroxy-piperidine-4-carboxylic acid

To a mixture of Example D3.13.1 (87 mg) and 4-dimethylaminopyridine (59 mg) in THF (0.5 mL) was added acetic anhydride (55 mg) and NEt3 (0.20 mL). The mixture was heated at 60 °C for 90 min. After cooling to RT, the reaction was treated with aq. HCI (1 M) and extracted with EA/MeOH (9:1) five times. The combined organic layers were dried over MgS0 ₄ , filtered, concentrated and dried under HV to give the title compound as a white solid (87 mg). LC-MS (A): t _R = 0.47 min; [M+MeCN+H] ^÷ : 230.19.

Example D3.14: 1-Acetyl-3-methoxy-piperidine-4-carboxylic acid D3.14. 1 3-Methoxy-piperidine-4-carboxylic acid

1-[(tert-butoxy)carbonyl]-3-methoxypiperidine-4-carboxyli c acid (200 mg) was treated with a solution of HCI in dioxane (4 M, 2 mL) and stirred for 30 min. The reaction mixture was concentrated under vacuo to give the desired product as a slightly yellow solid (193 mg). LC-MS (A): U = 0.19 min; [M+H] ⁺ : 160.12.

D3.14.2 1-Acetyl-3-methoxy-piperidine-4-carboxylic acid

To a mixture of Example D3.14.1 (193 mg) and EtsN (0.16 mL) in DCM (2.5 mL) was added acetic anhydride (0.11 mL). The reaction was stirred at RT for 2 h, then concentrated under vacuo. The crude was recrystallized from hot EtOH to give the title compound as white crystals (61 mg). LC-MS (A): t _R = 0.38 min; [M+H] ⁺ : 202.32.

Example D3.15: (R)- or (S)-1-Methyl-5-oxo-pyrrolidine-3-carboxylic acid D3.15. 1 (R)- or (S)-1-Methyl-5-oxo-pyrrolidine-3-carboxylic acid ethyl ester

A mixture of rac-1-methyl-5-oxopyrrolidine-3-carboxylic acid (500 mg), H ₂ SO ₄ (0.5 mL) in EtOH (5 mL) was stirred at RT for 1 h. The solvent was evaporated and the residue was purified by prep LC-MS (XXXIII) to give the racemic mixture. To obtain the enantiomeric pure compound the racemate was subjected to prep chiral SFC (XXXV). The second eluting product was isolated to give the title compound. LC-MS (A): t _R = 0.50 min; [M+H] ⁺ : 172.06. Chiral SFC (AD): t _R = 2.23 min.

D3.15.2 (R)- or (S)-1-Methyl-5-oxo-pyrrolidine-3-carboxyHc acid

To a solution of Example D3.15.1 (34 mg) in THF (1 mL) was added a solution of LiOH in H ₂ 0 (0.8 mL). The mixture was stirred at RT for 16 h, extracted with DCM and EA. The combined organic layers were concentrated and the residue was used in the next step without further purification. LC-MS (A): t _R = 0.32 min; [M+H] ⁺ : 144.12.

Example D3.16: rac- 1 - Ethy l-5-oxo-pyrrol idine-3-carboxy I ic acid Example D3.16 was synthesized from rac-1-Ethyl-5-oxo-pyrrolidine-3-carboxylic acid methyl ester through saponification, which is described for Example D3.15, without chiral separation. LC-MS (A): t _R = 0.38 min; [M+H]-: 158.10.

Example D3.17: (S)- or (R)-1-lsopropyl-5-oxo-pyrrolidine-3-carboxylic acid

Example D3.17 was synthesized from rac-5-oxo-1-(propan-2-yl)pyrrolidine-3-carboxylic acid, analogously to the 2-step procedure described for Example D3.15. The racemic ester in step 1 was purified by prep LC-MS (XV + XXXIV), the enantiomers were separated by prep chiral SFC (XXXVI). The ester of the title compound was the first eluting enantiomer. LC-MS (A): t _R = 0.44 min; [M+H]-: 171.99.

Example D3.18: (R)- or (S)-1-lsopropyl-5-oxo-pyrrolidine-3-carboxylic acid

Example D3.18 was synthesized from rac-5-oxo-1-(propan-2-yl)pyrrolidine-3-carboxylic acid, analogously to the 2-step procedure described for D3.15. The racemic ester in step 1 was purified by prep LC-MS (XV + XXXIV), the enantiomers were separated by prep chiral SFC (XXXVI). The ester of the title compound was the second eluting enantiomer. LC- MS (A): t _R = 0.44 min; [M+H] ⁺ : 172.00.

Example D3.19: ((S)-1-Acetyl-pyrrolidin-3-yl)-acetic acid D3.19.1 (S)-Pyrrolidin-3-yl-acetic acid, hydrochloride salt

(S)-(1-Boc-pyrrolidin-3-yl)-acetic acid (325 mg) was treated with a solution of HCI in dioxane (4 M, 3.5 mL) and stirred at RT for 1 h. The reaction was diluted with EA and stirred for 30 min. The suspension was filtered and washed with EA to give the desired compound as a white solid (182 mg). LC-MS (A): t _R = 0.22 min; [M+H]" ^· : 130.07.

D3.19.2 ((S)-1-Acetyl-pyrrolidin-3-yl)-acetic acid

To a suspension of Example D3.19.1 (60 mg) in THF (2 mL) was added acetyl chloride (30 mg) and NEt ₃ (0.10 mL). The resulting mixture was stirred at RT for 30 min. The reaction was filtered, the residue was washed with EA/dioxane (3:1) and the combined filtrates were purified by prep LC-MS (IX) to give the title compound as a white solid (27 mg). LC-MS (A): t _R = 0.42 min; [M+H] ⁺ : 172.02.

Example D4.1: 3-((R)-(4-Bromo-phenyl)-hydroxy-{5-[5-(1 -hydroxy-1 -methyl-ethyl)-[1, 2, 4]oxadiazol-3-yl]-pyridin-3-yl}- methy l)-3-methy I -azetidi ne- 1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example D2.3 and 2-hydroxyisobutiric acid, following the procedure described in Example 134, and was purified by CC (Biotage, Sfar, solvent A: Hep; solvent B: EA; gradient in %B: 18 over 1CV, 18 to 100 over 6CV). LC-MS (A): t _R = 0.99 min; [M+H] ⁺ : 558.98.

Example D4.2: 3-{(R)-Hydroxy-{5-[5-(1 -hydroxy-1 -methyl-ethyl)-[1, 2, 4]oxadiazol-3-yl]-pyridin-3-yl}-[4-(1, 2,2,2- tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-methyl}-3-methy l-azetidine-1 -carboxylic acid tert-butyl ester

D4.2.1 3-{Hydroxy-{5-[5-( 1 -hydroxy- 1 -methyl-ethyl)-[1 , 2,4]oxadiazol-3-yl]-pyridin-3-yl}-[4-( 1,2,2, 2-tetrafluoro-1- trifluoromethyl-ethyl)-phenyl]-methyl}-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester The title compound was synthesized starting from Example D2.4 and 2-hydroxyisobutiric acid, following the procedure described in Example 134, and was purified by by Prep LC-MS (XI). LC-MS (A): t _R = 1.09 min; [M+H]" ^· : 649.04.

D4.2.2 3-{(R)-Hydroxy-{5-[5-( 1 -hydroxy- 1 -methyl-ethyl)-[ 1, 2,4]oxadiazol-3-yl]-pyhdin-3-yl}-[4-( 1,2,2, 2-tetrafluoro-1- trifluoromethyl-ethyl)-phenyl]-methyl}-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

Example D4.2.1 was purified by Prep chiral SFC (XXVIII) to afford the title compound as pure enantiomer. Chiral SFC

(AA): t _R = 1.79 min.

Example D4.3: (R)-3-(hydroxy(5-(5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3 -yl)pyridin-3-yl)(4-(pentafluoro- 6- sulfaneyl)phenyl)methyl)-3-methylazetidine-1-carboxylic acid tert-butyl ester

D4.3.1 3-(hydroxy(5-(5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl) pyridin-3-yl)(4-(pentafluoro-A6- sulfaneyljphenyl) methyl)-3-methylazetidine-1-carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example D2.5 and 2-hydroxyisobutiric acid, following the procedure described in Example 134, and was purified by by Prep LC-MS (VI). LC-MS (A): t _R = 1.03 min; [M+H]-: 607.04.

D4.3.2 (R)-3-(hydroxy(5-(5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3 -yl)pyridin-3-yl)(4-(pentafluoro-A6-sulfaneyl) phenyl)methyl)-3-methylazetidine-1 -carboxylic acid tert-butyl ester

Example D4.3.1 was purified by Prep chiral SFC (XXIX) to afford the title compound as pure enantiomer. Chiral SFC

(AB): t _R = 1.14 min.

Example D4.4: 3-[(R)-{5-[5-(1-Acetyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl ]-pyridin-3-yl}-(4-bromo-phenyl)-hydroxy- methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example D2.3 and 1 -acetyl-4-piperidinecarboxylic acid, following the procedure described in Example 134, and was purified by CC (Biotage, SNAP, solvent A: DCM; solvent B: MeOH; gradient in %B: 1 over 1CV, 1 to 5 over 10CV5 over 3CV). LC-MS (A): t _R = 1.03 min; [M+H] ⁺ : 627.99.

Example D4.5: 3-{(R)-Hydroxy-{5-[5-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazo l-3-yl]-pyridin-3-yl}-[4-(2,2,2-trifluoro- ethyl)-phenyl]-methyl}-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example D2.6 and tetrahydropyran-4-carboxylic acid, following the procedure described in Example 134, and was purified by by Prep LC-MS (XXX). LC-MS (A): t _R = 1.07 min; [M+H]-: 589.18.

Example D5.1 : 2-(3-{5-[(R)-(4-Bromo-phenyl)-hydroxy-(3-methyl-azetidin-3-y l)-methyl]-pyridin-3-yl}-[1 ,2,4]oxadiazol- 5-yl)-propan-2-ol, hydrochloride salt

The title compound was obtained starting from Example D4.1 and following the procedure described in Example A7.1 step A7.1.3 except that the reaction mixture was stirred for 18h at RT. LC-MS (A): t _R = 0.62 min; [M+H]-: 458.95. Example D5.2: 2-[3-(5-{(R)-Hydroxy-(3-methyl-azetidin-3-yl)-[4-(1,2,2,2-te trafluoro-1-trifluoromethyl-ethyl)-phenyl]- methyl}-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-propan-2-ol, hydrochloride salt

The title compound was obtained starting from Example D4.2 and following the procedure described in Example A7.1 step A7.1.3 except that the reaction mixture was stirred for 18h at RT. LC-MS (A): t _R = 0.74 min; [M+H] ⁺ : 548.97.

Example D5.3: (R)-2-(3-(5-(hydroxy(3-methylazetidin-3-yl)(4-(pentafluoro- 6-sulfaneyl)phenyl)methyl)pyridin-3-yl)- 1,2,4-oxadiazol-5-yl)propan-2-ol, hydrochloride salt

The title compound was obtained starting from Example D4.3 and following the procedure described in Example A7.1 step A7.1.3 except that the reaction mixture was stirred for 18h at RT. LC-MS (A): t _R = 0.69 min; [M+H] ⁺ : 506.93.

Example D5.4: 1-[4-(3-{5-[(R)-(4-Bromo-phenyl)-hydroxy-(3-methyl-azetidin- 3-yl)-methyl]-pyridin-3-yl}-[1,2,4] oxadiazol-5-yl)-piperidin-1-yl]-ethanone, hydrochloride salt

The title compound was obtained starting from Example D4.4 and following the procedure described in Example A7.1 step A7.1.3 except that the reaction mixture was stirred for 18h at RT. LC-MS (A): t _R = 0.66 min; [M+H]-: 525.84. Example D5.5: (R)-(3-Methyl-azetidin-3-yl)-{5-[5-(tetrahydro-pyran-4-yl)-[ 1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-[4-(2,2,2- trifluoro-ethyl)-phenyl]-methanol, hydrochloride salt

The title compound was obtained starting from Example D4.5 and following the procedure described in Example A7.1 step A7.1.3 except that the reaction mixture was stirred for 18h at RT. LC-MS (A): t _R = 0.70 min; [M+H] ⁺ : 489.12.

Example E1.1: 5-[(R)-(1-tert-Butoxycarbonyl-3-methyl-azetidin-3-yl)-hydrox y-(4-isopropyl-phenyl)-methyl]-nicotinic acid

El.1.1. 5-[(1-tert-Butoxycarbonyl-3-methyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-nicotinic acid tert-butyl ester

The title compound was synthesized starting from Example A4.2 and tert-butyl 5-bromonicotinate, following the synthesis procedure described in Example A4.1 step A4.1.2, and purified twice by CC (Biotage, SNAP 330g, solvent A: Hep; solvent B: EA; gradient in %B: 0 over 2min, 0 to 10 over 3min, 10 over 5min, 10 to 100 over 25min, 100 over 5min) followed by Prep LC-MS (II). LC-MS (A): t _R = 1.14min; [M+H] ⁺ : 497.26.

E1.1.2. 5-[(R)-( 1 -tert-Butoxycarbonyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-nicotinic acid tert- butyl ester

Example E1.1.1 (14.8g) was purified by Prep chiral SFC (I) to afford the title compound as pure enantiomer (5.97g) as beige solid. LC-MS (A): t _R = 1.14min; [M+H] ⁺ : 497.26. Chiral SFC (A): t _R = 2.795 min.

El.1.3. (R)-5-(hydroxy(4-isopropylphenyl)(3-methylazetidin-3-yl)meth yl)nicotinic acid, hydrochloride salt A solution of Example E1.1.2 (5.97g) in HCI in dioxane (4M, 120mL) was stirred at RT until completion of the reaction. The mixture was concentrated to dryness and dried under HV. The resulting white solid (5g) was directly used in the next step without further purification. LC-MS (A): t _R = 0.58min; [M+H]-: 341.17.

El.1.4. 5-[(R)-( 1 -tert-Butoxycarbonyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-nicotinic acid To a suspension of Example E1.1.3 (5g) and di-tert-butyl dicarbonate (3.23g) in THF (60mL) was added dropwise TEA (3.4mL). The reaction mixture was stirred at RT for 1h and concentrated in vacuo. The residue was purified by Prep LC-MS (III) to afford the desired compound as white solid (4g). LC-MS (A): t _R = 0.92min; [M+H] ⁺ : 441.2.

Example E1.2 to Example E1.3 were synthesized starting from the appropriate compound of Formula (A4) and following the four-step procedure described in Example E1.1. LC-MS data of Example E1.2 to Example E1.3 are listed in the table below. The LC-MS conditions used were LC-MS (A). The preparative and chiral SFC methods used in the second step, and the preparative LC-MS methods used in the last step are indicated in the table below.

Example E2.1: N-Hydroxy-tetrahydro-pyran-4-carboxamidine

To a solution of 4-cyanotetrahydro-4H-pyran (389mg) in EtOH (9mL) and water (2mL) were sequentially added K ₂ C0 ₃ (726mg) and hydroxylamine hydrochloride (730mg). The reaction mixture was refluxed for 20h, cooled down to RT, and filtered off. The solid was further washed with EtOH and the resulting solution was concentrated in vacuo. EA was added to the residue and the resulting mixture was concentrated and dried under HV to afford the title compound as yellow solid (494mg). LC-MS (A): t _R = 0.21 min; [M+H]+: 145.27.

Example E2.2 to Example E2.13 were synthesized starting from the appropriate cyano derivative and following the procedure described in Example E2.1. LC-MS data of Example E2.2 to Example E2.13 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example E2.14: 4-(N-Hydroxycarbamimidoyl)-piperidine-1-carboxylic acid benzyl ester

To a solution of 1-N-Cbz-4-cyanopiperidine (100mg) in EtOH (4mL) were added hydroxylamine hydrochloride (42.2mg) and DIPEA (110pL), mixture was stirred 41 h at 80°C. Reaction mixture was evaporated to dryness, resulting crude was extracted with EA and water, organic phase was washed with brine. The combined org. layers were dried (MgS04), filtrated off, evaporated and dried under HV to give 104mg of the title compound as a pale yellow resin. LC-MS (A): t _R = 0.59min; [M+H] ⁺ : 278.17.

Example E2.15: (E)-1 -acetyl-N'-hydroxypiperidine-4-carboximidamide To a solution of 1-acetylpiperidine-4-carbonitrile (955mg) in DMSO (5mL) were added hydroxylamine hydrochloride (621 mg) and Et3N (1.66mL), the resulting mixture was stirred 10h at 90°C and filtrated. Filtrate was lyophilisated, resulting oil was stripped in MeCN, resulting precipitate was filtered and washed with MeCN. The title compound was obtained as 620mg of an off-white solid. LC-MS (A): tR = 0.24min; [M+H] ⁺ : 186.28.

Example E2.16: 4,N-Dihydroxy-tetrahydro-pyran-4-carboxamidine

To a solution of 4-hydroxy-4-carbonitrile (200 mg) in EtOH (8 mL) were added hydroxylamine hydrochloride (315 mg) and K ₂ C0 ₃ (826 mg). The mixture was stirred at 80 °C for 40 h, cooled to RT, filtered, concentrated and dried under HV to give the title compound as a pale sticky solid (231 mg). LC-MS (A): tR = 0.19 min; [M+H]"-: 161.07.

Example E2.17 to Example E2.20 were synthesized according to the procedure described for Example E2.16 from the corresponding nitriles. If necessary, purification was performed with prep LC-MS. Retention times and observed masses of the products, as well as purification methods (if applicable) are given in the table below.

Example E2.21 : 1-[2-(tert-Butyl-diphenyl-silanyloxy)-acetyl]-N-hydroxy-pipe ridine-4-carboxamidine E2.21.1 Piperidine-4-carbonitrile, hydrochloride salt

N-Boc-piperidine-4-carbonitrile (600 mg) was treated with a solution of HCI in dioxane (4 M, 7.2 mL) and stirred at RT for 2 h. The reaction mixture was concentrated and dried under HV to give the desired product as a pale solid (455 mg). LC-MS (A): t _R = 0.20 min; [M+H] ⁺ : 111.17.

E2.21.2 (tert-Butyl-diphenyl-silanyloxy)-acetic acid

To a solution of glycolic acid (2.00 g), N,N-dimethyl-4-aminopyridine (318 mg)and NEt3 (10.9 mL) in THF (100 mL) was added tert-butyl(chloro)diphenylsilane (7.6 mL) dropwise at 0 °C. The mixture was allowed to warm to RT and was stirred for 16 h. The reaction mixture was acidified with aq. HCI (1 M) until pH 1 was reached. The solution was extracted with Et20 (3 times) and the combined organic layers were dried over MgS04, filtered and concentrated under vacuo to give a colorless oil, which was purified by CC (CombiFlash, RediSep 330 g, gradient of n-Heptane/EA 100:0 to 70:30 over 25 min at 200 mL/min) to yield the desired product as a colorless oil (7.05 g). LC-MS (A): tR = 1.05 min; product mass was not observed; ¹ H-NMR (500 MHz, DMSO-d6): d = 12.56 (br s, 1 H), 7.67-7.63 (m, 4 H), 7.51-7.41 (m, 6 H), 4.19 (s, 2 H), 1.02 (s, 9 H) ppm. E2.21.3 1-[2-( tert-Butyl-diphenyl-silanyloxy) -acetyl]-piperidine-4-carbonitrile

To a suspension of Example E2.21.1 (455 mg), Example E2.21.2 (1.27 g) and HATU (1.89 g) in THF (8.5 mL) was added DIPEA (1.59 mL). The reaction was stirred at RT for 4 h. Then it was diluted with EA, washed with aq. HCI (1 M), sat. aq. NaHC0 ₃ , water and brine, dried over Na2S04, filtered and concentrated under vacuo. The residue was purified by CC (CombiFlash, RediSep 220 g, gradient of n-Heptane/EA 100:0 to 0:100 over 30 min at 150 mL/min) to give the desired product as a colorless oil (968 mg). LC-MS (A): tR = 1.09 min; [M+H] ⁺ : 407.27.

E2.21.4 1-[2-(tert-Butyl-diphenyl-silanyloxy)-acetyl]-N-hydroxy-pipe ridine-4-carboxamidine To a solution of Example E2.21.3 (968 mg) in EtOH (8 mL) were added hydrodxyl amine hydrochloride (501 mg) and K ₂ CO ₃ (1.32 g). The reaction mixture was stirred at 80 °C for 16 h. The reaction mixture was concentrated under vacuo to give a yellow oil, which was purified by prep LC-MS (XIV) to give the title compound as a white solid (79 mg). LC-MS (A): t _R = 0.83 min; [M+H] ⁺ : 440.32.

Example E2.22: 2-(1-Acetyl-azetidin-3-yl)-N-hydroxy-acetamidine E2.22.1 Azetidin-3-yl-acetonitrile, hydrochloride salt

3-Cyanomethyl-azetidine-1 -carboxylic acid tert-butyl ester (500 mg) was treated with a solution of HCI in dioxane (4 M, 6.1 mL). The mixture was stirred for 1 h, concentrated and dried under HV to give the desired product as a yellow viscous oil (474 mg). ¹ H-NMR (500 MHz, DMSO-d6): d = 9.18 (br s, 2 H) 4.06-3.98 (m, 2 H), 3.75-3.67 (m, 2 H), 3.10 (hept, J = 7.6 Hz, 1 H), 2.93 (d, J = 7.0 Hz, 2 H) ppm.

E2.22.2 (1-Acetyl-azetidin-3-yl)-acetonitrile

A mixture of Example E2.22.1 (231 mg) and K ₂ C0 ₃ in THF (5 mL) was cooled to 0 °C before acetyl chloride (138 mg) was added dropwise. The reaction was allowed to warm to RT and was stirred for 1 h. The mixture was filtered, the residue was washed with THF, suspended in MeOH, sonicated and filtered. The filtrate was concentrated under vacuo to give the desired product as an orange sticky solid (226 mg). It was used for the next step without further purification. LC-MS (A): t _R = 0.36 min; [M+H] ⁺ : 139.14.

E2.22.3 2-(1-Acetyl-azetidin-3-yl)-N-hydroxy-acetamidine

The title compound was synthesized from Example E2.22.2 according to the procedure described for Example E2.16. A yellow sticky solid was obtained. LC-MS (A): t _R = 0.21 min; [M+H] ⁺ : 171.87.

Example F1.1: (5-Bromo-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopr opyl-phenyl)-methanol FI. 1. 1. (5-Bromo-pyridin-3-yl)-(4-isopropyl-phenyl)-(3-methyl-azetid in-3-yl)-methanol

A pale yellow solution of Example D1.1.1 (2.15g) in HCI in dioxane (4M, 10mL) was stirred for 2h at RT. The reaction mixture was cooled at 0°C, slowly basified with aq. sat. NaHC0 ₃ solution and extracted with DCM. The org. phases were dried (MgS04), filtrated off and evaporated to dryness to give the title compound (1 .76 g). LC-MS (A): t _R = 0.74min; [M+H] ⁺ : 375.19.

FI. 1.2. (5-Bromo-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopr opyl-phenyl)-methanol To a light yellow solution of Example F1.1.1 (1.75g) in THF (40mL), AcOH (0.4mL) was added at RT, followed successively by formaldehyde (37% in water, 0.695 mL) and NaBH(OAc) ₃ (1.53g). The resulting solution was stirred for 1 h 10 at RT, was basified with aq. sat. NaHC0 ₃ solution, diluted with water, and extracted with EA. The org. layers were dried (MgS04), filtered off, and evaporated to dryness to afford 1 .91 g of the title compound as beige solid. LC-MS (A): t _R = 0.76min; [M+H] ⁺ : 389.22.

Example F1.2: (R)-(5-Bromo-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-i sopropyl-phenyl)-methanol

F1.2.1. 3-[(R)-(5-Bromo-pyridin-3-yl)-hydroxy-(4-isopropyl-phenyl)-m ethyl]-3-methyl-azetidine-1 -carboxylic acid tert- butyl ester

The title compound was obtained by chiral separation of Example D1.1.1 using Prep chiral SFC (III). LC-MS (A): t _R = 1.12min; [M+H] ⁺ : 475.20; Chiral SFC (C): 1.4min.

F1.2.2. (R)-(5-Bromo-pyridin-3-yl)-(4-isopropyl-phenyl)-(3-methyl-az etidin-3-yl)-methanol, dihydrocloride salt

A pale yellow solution of Example F1.2.1 (3.7g) in HCI in dioxane (4M, 27mL) was stirred 2h at RT and evaporated to dryness to give the title compound (3.98g) as white solid. LC-MS (A): t _R = 0.73min; [M+H] ⁺ : 375.13

F1.2.3. (R)-(5-Bromo-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-i sopropyl-phenyl)-methanol

The title compound was synthesized starting from Example F1.2.2 and following the synthesis procedure described in

Example F1.1 step F1.1.2, additional equivalents of formaldehyde and NaBH(OAc) ₃ were added until completion of the reaction. LC-MS (A): t _R = 0.74min; [M+H] ⁺ : 389.18.

Example F1.3: (2-Chloro-pyridin-4-yl)-(1 ,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol

F1.3.1. 3-[(2-Chloro-pyridin-4-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-3-methyl-azetidine-1-carboxylic acid tert-butyl ester

The title compound (516mg, colorless foam) was synthesized starting from Example A4.2 (415mg) and 4-bromo-2- chloropyridine (200 L), and following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by CC (Biotage, SNAP 40g, solvent A: Hep; solvent B: EA; gradient in %B: 0 to 50 over 20min). LC-MS (A): t _R = 1.12min; [M+H] ⁺ : 431.31.

F1.3.2. (2-Chloro-pyridin-4-yl)-(4-isopropyl-phenyl)-(3-methyl-azeti din-3-yl)-methanol, hydrochloride salt

A solution of Example F1.3.1 (644mg) in HCI in dioxane (4M, 5mL) and MeOH (2.5mL) was stirred at RT for 15min and evaporated in vacuo. The resulting residue was triturated in Et ₃ 0 and the solvent was evaporated in vacuo to afford the title compound (650mg) as yellow foam. LC-MS (A): t _R = 0.72min; [M+H] ⁺ : 331.27.

F1.3.3. ( 2-Chloro-pyridin-4-yl) -( 1 ,3-dimethyl-azetidin-3-yl) -( 4-isopropyl-phenyl) -methanol

The title compound (483mg, beige foam) was synthesized starting from Example F1.3.2 (650mg), and following the procedure described in Example F1.1 step F1.1.2. LC-MS (A): t _R = 0.75min; [M+H] ⁺ : 345.27. Example F1.4: 3-[(S)-(2-Chloro-pyridin-4-yl)-hydroxy-(4-isopropyl-phenyl)- methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was obtained by chiral separation of Example F1.3.1 using Prep Chiral SFC (XVII). LC-MS (A): tR = 1.12min; [M+H] ⁺ : 431.36; Chiral SFC (Q): 1.31min.

Example F1.5: (S)-(2-Chloro-pyridin-4-yl)-(1,3-dimethyl-azetidin-3-yl)-(4- isopropyl-phenyl)-methanol The title compound (852mg, white solid) was synthesized starting from Example F1.4 (1.1g), and following the procedure described in Example F1.3 step F1.3.2 and F1.3.3. The crude material was purified by Prep LC-MS (XIII). LC-MS (A): t _R = 0.74min; [M+H] ⁺ : 345.16.

Example F1.6: (R)-(6-Chloro-pyridazin-4-yl)-(1 ,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol

FI.6.1. 3-[(6-Chloro-pyridazin-4-yl)-hydroxy-(4-isopropyl-phenyl)-me thyl]-3-methyl-azetidine-1 -carboxylic acid tert- butyl ester

The title compound (4.34g, brown solid) was synthesized starting from Example A4.2 (8.5g) and 5-bromo-3- chloropyridazine (6g), and following the procedure described in Example A7.1 step A7.1.1, however using toluene instead of THF as solvent. The crude material was purified by CC (Biotage, SNAP 330g, solvent A: Hep; solvent B: EA; gradient in %B: 0 to 50 over 40 min). LC-MS (A): t _R = 1.06min; [M+H] ⁺ : 432.22.

F1.6.2. 3-[(R)-(6-Chloro-pyridazin-4-yl)-hydroxy-(4-isopropyl-phenyl )-methyl]-3-methyl-azetidine-1 -carboxylic acid tert- butyl ester

The title compound was obtained by chiral separation of Example F1.6.1 using Prep Chiral SFC (XVIII). LC-MS (A): t _R = 1.05min; [M+H] ⁺ : 432.22; Chiral SFC (R): 1.26min.

FI.6.3. (R)-(6-Chloro-pyridazin-4-yl)-(4-isopropyl-phenyl)-(3-methyl -azetidin-3-yl)-methanol, hydrochloric salt A solution of Example F1.6.2 (377mg) in HCI in dioxane (4M, 7mL) was stirred at RT for 2h and evaporated in vacuo. The crude material was evaporated to dryness to give 351 mg of the title compound as yellow solid. LC-MS (A): t _R = 0.67min; [M+H] ^÷ : 332.13.

F1.6.4. (R)-(6-Chloro-pyridazin-4-yl)-(1,3-dimethyl-azetidin-3-yl)-( 4-isopropyl-phenyl)-methanol

The title compound (215mg, beige foam) was synthesized starting from Example F1.6.3, and following the procedure described in Example F1.1 step F1.1.2, however additional equivalents of formaldehyde and NaBH(OAc) ₃ were added until completion of the reaction. LC-MS (A): t _R = 0.67min; [M+H] ⁺ : 346.10.

Example F1.7 to Example F1.10 were synthesized starting from appropriate compound of Formula (A4) and 3,5- dibromopyridine, following the four-step procedure described in Example F1 .6. Chiral Prep SFC conditions used in step 2 , Prep LC-MS conditions used in step 4 and LC-MS data of Example F1.7 to Example F1.10 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example F1.11: 3-[(R)-(5-Bromo-pyridin-3-yl)-hydroxy-(4-isopropyl-phenyl)-m ethyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

Example D1.1.1 (9g) was purified by Prep chiral SFC (III) to afford the title compound as pure enantiomer (4.31g). Chiral SFC (C): t _R = 1.377min. LC-MS (A): t _R = 1.12min; [M+H] ⁺ : 475.20. Example F1.12 to Example F1.14 were synthesized starting from appropriate compound of Formula (A7) following the procedure described in Example D1.1 step D1.1.5. The LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A). Example F1.15 (R)-(5-Bromo-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-t rifluoromethyl-phenyl)-methanol was synthesized starting from Example A7.38 following the procedure described in Example D1.1 step D1.1.5 and purified by prep LC-MS (VI). LC-MS (A) t _R = 0.72min; [M+H] ⁺ : 415.22.

Example F3.1 (for synthesis, see F4.10): 4-(2-Methoxy-ethyl)-pyrrolidin-2-one

Example F3.2: 4-(2-lsopropyl-pyrimidin-4-yl)-pyrrolidin-2-one

F3.2.1. (E)-3-(2-lsopropyl-pyrimidin-4-yl)-acrylic acid ethyl ester

To an ice-cold suspension of NaH (60% in mineral oil, 250mg) in DMF (5.5L) was added triethyl phosphonoacetate (0.36mL) and the resulting mixture was stirred for 30 min at 0°C. A solution of 2-isopropyl-4-pyrimidinecarbaldehyde (250mg) in DMF (0.5mL) was added and the resulting suspension was stirred for 1h30 at RT. The reaction mixture was quenched and diluted with water and extracted with EA (3x). The combined org. layers were washed with brine, dried (MgSC>4), filtered off and evaporated to dryness. The resulting crude material (417mg) was used without further purification. LC-MS (A): t _R = 0.89min; [M+H] ⁺ : 221.11.

F3.2.2. 3-(2-lsopropyl-pyrimidin-4-yl)-4-nitro-butyric acid ethyl ester

To a solution of Example F.3.2.1 (232mg) in nitromethane (0.2mL) was added tetramethylguanidine (25 mg) at 0°C and the reaction mixture was allowed to reach RT. After stirring for 27h, the reaction mixture was diluted with EA and water, and extracted with EA. The combined org. layers were washed with brine, dried (MgS04), filtered off and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 10g, solvent A: DCM; solvent B: DCM/MeOH 8/2; gradient in %B: 0 over 3CV, 0 to 25 over 8CV, 25 for 2CV, 25 to 50 over 3CV, 50 for 2CV) to afford 65mg of the title compound as yellow oil. LC-MS (A): t _R = 0.88min; [M+H] ⁺ : 282.1.

F3.2.3. 4-(2-lsopropyl-pyrimidin-4-yl)-pyrrolidin-2-one

To a flask charged with Pd/C (30mg) were added a solution of Example F3.2.2 (65mg) in EtOH (0.5mL) and ammonium formate (94mg) at RT under argon and the resulting suspension was stirred at 80°C for 1h30. The reaction mixture was allowed to cool down, filtrated through a syringe filter, and the filtrate evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 10g, solvent A: DCM; solvent B: DCM/MeOH 8/2; gradient in %B: 0 over 3CV, 0 to 25 over 7CV, 25 for 2CV) to afford 16mg of the title compound as colorless oil. LC-MS (A): t _R = 0.52min; [M+H] ⁺ : 206.17.

Example F3.3: 4-(2-Methyl-thiazol-5-yl)-pyrrolidin-2-one

F3.3.1. (E)-3-(2-Methyl-thiazol-5-yl)-acrylic acid octyl ester

To a solution of 5-bromo-2-methylthiazole (250mg) in DMF (7.5mL) were added successively n-octyl acrylate (388mg), DABCO (6.6mg), K ₂ C0 ₃ (194mg), Pd(OAc) ₂ (6.4mg). The resulting brown suspension was stirred at 120°C for 21 h. After cooling to RT, the reaction mixture was diluted with water, and extracted with DCM (3x), and the filtrate evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 10g, solvent A: EA; solvent B: Hept; gradient in %B: 0 over 3CV, 0 to 15 over 3CV, 15 to 30 over 3CV, 30 over 3CV) to afford 57mg of the title compound as orange resin. LC-MS (A): t _R = 1.22min; [M+H]"·: 282.16.

F3.3.2. 3-(2-Methyl-thiazol-5-yl)-4-nitro-butyric acid octyl ester.

The title compound (27mg, orange resin) was synthesized starting from Example F3.3.1, and following the procedure described in Example F3.2 step 2, however running the reaction under higher dilution (1.5 mL nitromethane). LC-MS (A): t _R = 1.12min; [M+H] ⁺ : 343.05.

F3.3.3. 4-( 2-Methyl-thiazol-5-yl)-pyrrolidin-2-one

The title compound (6mg, beige solid) was synthesized starting from Example F3.3.2, and following the procedure described in Example F3.2 step 3. Further addition of 3eq ammonium formate and 0.03eq Pd/C were required to advance the reaction conversion. LC-MS (A): t _R = 0.4min; [M+H]-: 183.14.

Example F3.4 to Example F3.10 were synthesized starting from the appropriate heteroaryl bromide derivative, following the three-step procedure described in Example F3.3, omitting the addition of ammonium formate and Pd/C in step 3. If the cyclization was sluggish, 10 eq of TEA was added. The purification (CC, Biotage, (solumn size) SNAP solvent A: DCM, solvent B: DCM/MeOH 8/2), gradients in %B and the LC-MS (A) data can be found in the table below. Example F4.1: 5-Benzyl-oxazolidin-2-one

1-Amino-3-phenylpropan-2-ol (150mg) and CDI (268mg) were dissolved in THF (30mL). The resulting mixture was stirred for 16h30 at RT and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 10g, solvent A: Hep; solvent B: EA; gradient in %B: 50 over 4CV, 50 to 100 over 5CV, 100 over 1CV) to afford 57mg of the title compound as yellow solid. LC-MS (A): tR = 0.65min; [M+H] ⁺ : 178.40.

Example F4.2: 5-lsopropyl-oxazolidin-2-one

To a solution of 1-amino-3-methyl-2-butanol hydrochloride (150mg) and DIPEA (69.9mI_) in THF (3mL) cooled at 0°C was added a solution of bis(trichloromethyl)carbonate (101 mg) in THF (2mL) and the resulting suspension was stirred for 40min at 0°C. The reaction mixture was diluted with EA, washed with aq. sat. NaHC0 ₃ solution, water and brine. The org. layers were dried (MgS0 ₄ ), filtrated off and evaporate to dryness. The resulting crude material was purified by CC (Biotage, SNAP 10g, solvent A: Hep; solvent B: EA; gradient in %B: 0 over 2CV, 0 to 100 over 10CV, 100 over 2CV) to afford 16mg of the title compound as yellow solid. LC-MS (A): tR = 0.49min; [M+H] ⁺ : 130.30.

Example F4.3 to Example F4.5 were synthesized starting from the appropriate amine and carbonate reagents, following the procedure described in Example F4.2 and using solvents and bases listed in the table below. Prep LC- MS conditions and LC-MS data of Example F4.3 to Example F4.5 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example F4.6: 8,8-Difluoro-1-oxa-3-aza-spiro[4.5]decan-2-one F4.6.1. 4,4-Difluoro-1-trimethylsilanyloxy-cyclohexanecarbonitrile To an ice-cold solution of 4,4-difluorocyclohexanone (5g) in DCM (100mL) were added TMSCN (5.71mL) followed by Znl (119mg). The reaction mixture was stirred for 2h30 at 0°C, was quenched with Na ₂ C0 ₃ solution (10%) and extracted with DCM. The org. layers were dried (MgS04), filtrated off and evaporated to dryness to give 8.26g of yellow oil.

F4.6.2. 1-Aminomethyl-4,4-difluoro-cyclohexanol, hydrochloride salt To an ice-cold solution of LiAIH4 in THF (1M, 53.1mL) in Et20 (28mL) was added dropwise a solution of Example F4.6.1 (8.26g) in Et ₂ 0 (14mL). The reaction mixture was stirred for 45min at RT, cooled down to 0°C and ice-cold water (4.25mL) followed by NaOFI (1M, 4.25mL) were added. The resulting mixture was stirred for 30min, diluted with Et ₂ 0, filtered off and evaporated to dryness. The residue was dissolved in Et ₂ 0 (67mL) and HCI in dioxane (4M, 34mL) was added dropwise at 0°C. The mixture was stirred for 1h at 0°C and filtered off. The resulting precipitate was dried under HV to give 5.5g of the title compound as white solid. LC-MS (A): tR = 0.27min; [M+FI] ⁺ :207.27.

F4.6.3. 8, 8-Difluoro- 1 -oxa-3-aza-spiro[4.5 ]decan-2-one

A solution of Example F4.6.2 (250mg) and TEA (174mI_) in DCM (7mL) was stirred for 15min at RT. Carbonic acid di- 2-pyridyl ester (274mg) was added and the mixture was stirred overnight at RT, diluted with water and extracted with DCM. The org. layers were dried (MgS0 ₄ ), filtrated off, and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 10g, solvent A: DCM; solvent B: MeOFI; gradient in %B: 3 over 5CV, 3 to 5 over 2CV, 5 over 2CV) to afford 208mg of the title compound as white solid. LC-MS (A): t _R = 0.57min; [M+Fi]-: 192.36.

Example F4.7 to Example F4.9 were synthesized starting from the appropriate ketone derivative, and following the three-step procedure described in Example F4.6. LC-MS data of Example F4.7 to Example F4.9 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example F4.10: 4-(2-Methoxy-ethyl)-pyrrolidin-2-one F4.10.1. (E)-5-Methoxy-pent-2-enoic acid ethyl ester

To an ice-cold suspension of NaH (60% in mineral oil, 440mg) in THF (24mL) was added triethyl phosphonoacetate (2.26mL) and the resulting mixture was stirred for 20 min at 0°C. A solution of 3-methoxy-propionaldehyde (1g) in THF (14mL) was added dropwise over 15min and the resulting solution was stirred for 1h15 at 0°C. The reaction mixture was diluted with Et ₂ 0 and water and extracted with Et ₂ 0. The org. phases were washed with brine, dried (MgS04), filtered off and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 50g, solvent A: Hep; solvent B: EA; gradient in %B: 0 over 1CV, 0 to 10 over 2CV, 10 over 2CV, 10 to 30 over 2CV, 30 over 1CV, 30 to 50 over 1CV, 50 to 70 over 1CV) to afford 1.02g of the title compound as colourless oil. LC-MS (A): t _R = 0.72min; [M+Fi]-: 159.18.

F4.10.2. 5-Methoxy-3-nitromethyl-pentanoic acid ethyl ester To an ice-cold solution of Example F4.10.1 (564mg) and nitromethane (274mI_) was added DBU (426mI_). The reaction mixture was stirred for 17h at RT, cooled down to 0°C, quenched with water and extracted with DCM. The org. layers were washed with aq. HCI solution (1 M) and brine, dried (MgS0 ₄ ), filtrated off and evaporated to dryness to give 377mg of the title compound as yellow oil. LC-MS (A): tR = 0.79min; [M+H]"-: 220.22.

F 4. 10.3. 4-(2-Methoxy-ethyl)-pyrrolidin-2-one

To a solution of Example F4.10.2 (50mg) and TEA (31.7mI_) in EtOH (0.5mL) was added Pd(OH)2/C (20%, 8.01mg) and the resulting mixture was stirred for 23h at RT under hydrogen atmosphere. The reaction mixture was filtered off and evaporated to dryness. The resulting crude material was dissolved in EtOH (1mL) and stirred for 22h at 40°C then for 7 days at RT. The reaction mixture was evaporated to dryness to give 24mg of the title compound as yellow oil. LC- MS (A): t _R = 0.41 min; [M+H]"-: 144.21.

Example F5.1: 1-(Tetrahydro-pyran-4-yl)-prop-2-yn-1-ol

F5. 1. 1. 1-(Tetrahydro-pyran-4-yl)-3-trimethylsilanyl-prop-2-yn-1-ol

To an ice-cold solution of trimethylsilylacetylene (637mί) in THF (10mL) was added dropwise n-BuLi in hexane (2.5M, 2mL). The resulting mixture was stirred for 1h at 0°C and a solution of 4-formyltetrahydropyran (500mg) in THF (2mL) was added. The reaction mixture was stirred for 30min at 0°C and for 1h at RT. Water was added and the mixture was extracted with Et20. The org. layer was evaporated to dryness to give 875mg of the title compound as white solid. LC- MS (A): tp = 0.83min; [M+H] ⁺ : 213.33.

F5. 1.2. 1-(Tetrahydro-pyran-4-yl)-prop-2-yn-1-ol

To a solution of Example F5.1.1 (875mg) in MeOH (30mL) was added K2C03(1.14g). The resulting mixture was stirred overnight at RT, concentrated, diluted with EΪ20, and washed successively with 1 M HCI solution, 1 M NaHC03 solution and brine. The org. phases were dried (MgS04), filtrated off and evaporated to dryness to afford 384mg of the title compound as white solid. ¹ H-NMR (DMSO) : 5.36 (d, 1 H); 4.00 (m, 1 H); 3.86 (m, 2H); 3.28 (d, 1 H); 3.25 (m, 2H); 1.63 (m,3H); 1.29 (m,2H).

Example F5.2 to Example F5.17

Example F5.2 to Example F5.17 were synthesized starting from the appropriate ketone or aldehyde, and following the procedure described in Example F5.1. Prep LC-MS conditions and LC-MS data of Example F5.2 to Example F5.17 are listed in the tables below. The LC-MS conditions used were LC-MS (A).

To a solution of 3-ethynyl-3-hydroxyazetidine trifluoroacetate (100mg) and TEA (132mI_) in DCM (2mL) was added dropwise isobutyryl chloride (48.1 mί) at RT. The resulting mixture was stirred for 25min at RT, diluted with water and basified with aq. sat. NaHC03 solution. The org. layers were dried (MgS04), filtrated off and evaporated to dryness. The residue was purified by CC (Biotage SNAP 10g, solvent A: DCM; solvent B: MeOH; gradient in %B: 3 over 2CV, 3 to 5 over 2CV, 5 over 3CV) to afford 37mg of the title compound as yellow oil. LC-MS (A): t _R = 0.48min; [M+H]-: 168.05.

Example F5.19: 3-(6-Methyl-pyrimidin-4-yl)-pent-1-yn-3-ol

F5.19. 1 6-Methyl-pyrimidine-4-carboxylic acid methoxy-methyl-amide To a solution of 6-methylpyrimidine-4-carboxylic acid (500mg) in DCM (50mL) were added N,O-dimethylhydroxylamine hydrochloride (342mg), DIPEA (2.06mL) and propylphosphonic anhydride solution in DCM (50% w/w, 2.54mL). The resulting mixture was stirred 2h at RT and quenched with aq. sat. NaHC0 ₃ solution. The org. layer was washed with citric acid (10%) and water. The combined org. layers were dried (MgS04), filtered off and evaporated to dryness to afford 453mg of the title compound as brown oil which was used without further purification. LC-MS (A): t _R = 0.48min; [M+H] ⁺ : 182.22.

F5.19.2 1-(6-Methyl-pyrimidin-4-yl)-propan-1-one

To a yellow solution of Example F5.19.1 (445mg) cooled at -78°C under argon was added ethylmagnesium bromide in THF (1M, 4.91 mL) and the resulting suspension was stirred 1 h. The resulting crude was quenched with aq. sat. NH ₄ CI solution, diluted with water and extracted with DCM. The combined org. layers were dried (MgS04), filtrated off and evaporated to dryness. The residue was purified by CC (Biotage, snaplOg, solvent A: Hep; solvent B: EA; gradient in %B: 30 over 3CV, 30 to 70 over 6CV, 70 over 2CV to afford 77mg of the title compound as yellow solid. LC-MS (A): t _R = 0.63min; [M+H] ⁺ : 151.16.

F5.19.33-(6-Methyl-pyrimidin-4-yl)-pent-1-yn-3-ol

The title compound (45mg, yellow oil) was synthesized from Example F5.19.2 (73mg) and trimethylsilylacetylene (74.4 L) and following the two-step procedure described in Example F5.1. LC-MS (A): t _R = 0.56min; [M+H] ⁺ : 177.27.

Example F5.20 to Example F5.30 were synthesized starting from the appropriate commercially available ketone or aldehyde reagent, and following the two-step procedure described in Example F5.1. Prep LC-MS and Chiral Prep (SFC & HPLC) conditions, Chiral HPLC & SFC and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

The absolute configuration for the Example F5.20 was assessed by single crystal X-ray diffraction (suitable crystal obtained through diffusion of heptane into a solution of the compound in EA) and proved to be in absolute (S)- configuration. Consequently, the absolute configuration for the Example F5.21 was assigned (R). Example F5.31 to Example F5.42 were synthesized using the commercially available ketone following the procedure described in Example F5.1. CC (Biotage) gradients and column size, if CC was made, and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example F5.42 rac-2-(6-Cyclopropyl-pyrimidin-4-yl)-but-3-yn-2-ol F5.42. 1 1-(6-Cyclopropyl-pyrimidin-4-yl)-ethanone

A vial was charged with Bis(triphenylphosphine)palladium(ll) dichloride (34.2mg), 4-bromo-6-cyclopropylpyrimidine (100mg), toluene (200mitiI_) and tributyl(1-ethoxyvinyl)tin (216mί) at RT, sealed and shaken at 95°C overnight. After evaporation to dryness the residue was taken up in dioxane (900mI_) and HCI 2N (169mI_) to be stirred for 6h at RT. The reaction mixture was diluted with EA and washed 2x with water and 1x with brine. Afterwards the aq. layers were re-extracted with 2x EA. The combined org. layers were dried over MgS04, filtrated off, evaporated and purified by CC (Biotage, 10g snap, solvent A: heptane, solvent B: EA, gradient (in %B): 10 for 3CV, 10 to 100 over 10CV, 100 for 2CV) to give 82mg light yellow oil. LC-MS (A) t _R = 0.69min; [M+H] ⁺ 163.10.

F5.42.2 rac-2-( 6-Cyclopropyl-pyrimidin-4-yl)-but-3-yn-2-ol

The title compound was synthesized starting from Example F5.42.1 following the two-step procedure described in Example F5.1, EA was used instead of Et ₂ 0 for extraction. Furthermore, instead of quenching in step 2 the work-up was skipped and the mixture was filtered and evaporated to dryness and the crude purified by CC (Biotage, 10 g, gradients: A:DCM B: DCM/MeOH 0 for 2CV, 0 to 25 for 6CV, 25 for 2CV, 25 to 50 over 3CV, 50 for 2CV. LC-MS (A) t _R = 0.59min; [M+H] ⁺ 189.20.

Example F5.43 to Example F5.53 were synthesized using the appropriate ketone following the procedure described in Example F5.1. CC (Biotage) gradients and column size, if CC was made, and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A). For chiral separated compounds the prep LC-MS and chiral separation method is listed in the table below. The ketones are listed in the table below unless commercially available.

Precursors ketones for alkynes Examples F5.43 to F5.53

Example F5.K1 1-(6-Methoxy-pyrimidin-4-yl)-ethanone

F5.K1.1 6-Methoxy-pyrimidine-4-carboxylic acid methoxy-methyl-amide

The title compound was synthesized following the procedure described in Example F5.19.1, except the washing with citric acid (10%), which was left out, starting from 6-methoxypyrimidine-4-carboxylic acid. LC-MS (A) tR = 0.53min, [M+H] ⁺ : 198.16

F5.K1.2 1-( 6-Methoxy-pyrimidin-4-yl)-ethanone

A solution of F5.K1.1 (600mg) in THF abs. (10mL) was 3x evacuated and backfilled with argon, then cooled to -78°C. Then a methylmagnesium bromide solution (230mI_, 3.0M in diethyl ether) was added dropwise under argon at -78°C. After stirring for 15min at RT, the mixture was quenched with aq. sat. NH4CI, diluted with water and extracted with 3x DCM (phase separator). The combined org. layers were evaporated to dryness and purified by CC (Biotage, SNAP 25g, solvent A: heptane, solvent B: EA 0 to 15 over 2CV, 15 for 2CV, 15 to 30 over 2CV, 30 for 2CV, 30 to 70 over 3CV, 70 for 3CV) to give 290mg yellowish solid. LC-MS (A) t _R = 0.62min; [M+H] ⁺ : 153.10.

Example F5.K2 1-(2-Methoxy-pyrimidin-4-yl)-ethanone

F5.K2. 1 2-Methoxy-pyrimidine-4-carboxyHc acid methoxy-methyl-amide

The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.1, using 2- methoxypyrimidine-4-carboxylic acid. LC-MS (A) t _R = 0.53min, [M+H] ⁺ : 198.16 F5. K2.2 1 -( 2-Methoxy-pyrimidin-4-yl)-ethanone

The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.2, using F5.K2.1, purified by CC (Biotage, 25g SNAP, solvent A: Hept, solvent B: EA, gradient (in %B): 0 to 15 over 2CV, 15 for 2CV, 15 to 30 over 2CV, 30 for 2CV, 30 to 70 over 3CV, 70 for 3CV). LC-MS (A) t _R = 0.61min, [M+H] ⁺ : 153.12

Example F5.K3 1-(2,6-Dimethyl-pyrimidin-4-yl)-ethanone

F5.K3. 1 2, 6-Dimethyl-pyrimidine-4-carboxylic acid methoxy-methyl-amide

The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.1, starting from 2,6-dimethylpyrimidine-4-carboxylic acid. LC-MS (A) t _R = 0.49min, [M+H] ⁺ : 196.19

F5. K3.2 1 -(2, 6-Dimethyl-pyrimidin-4-yl)-ethanone The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.2, using F5.K3.1, purified by CC (Biotage, 10g SNAP, solvent A. Hept, solvent B: EA, gradient (in %B): 15 for 3CV, 15 to 30 over 5CV, 30 for 5CV. LC-MS (A) t _R = 0.58min, [M+H] ⁺ : 151.15

Example F5.K4 1-(2-Chloro-6-methoxy-pyrimidin-4-yl)-ethanone F5.K4.1 2-Chloro-6-methoxy-pyrimidine-4-carboxylic acid methyl ester

To a suspension of methyl 2,4-dichloropyrimidine-6-carboxylate (1000mg) in MeOH abs. (20ml) was added sodium methoxide solution 0.5M in MeOH (9.46mL) slowly at 0°C under argon. The resulting suspension was stirred at 0°C under argon overnight, allowed to reach RT. AcOH was added to the reaction mixture and stirred for 10min, then the mixture was evaporated to dryness. The residue was taken up in EA and washed with 1x aq. sat. NaHC03 and 1x brine. Afterwards the aq. layers were 2x re-extracted with EA. The combined org. layers were dried over MgS04, filtrated off, evaporated and dried at HV to 826mg off-white solid. LC-MS (A) t _R = 0.72; [M+H] ⁺ : 203.09 F5.K4.22-chloro-6-methoxy-pyrimidine-4-carboxylic acid, as sodium salt

To solution of Example F5.K4.1 (803mg) in MeOH (4mL), THF (2mL) and DCM (500mί) was added NaOH 1N (3.96mL) at RT and the solution was stirred for 3h at RT. The reaction mixture was evaporated and dried at HV to give 865mg beige solid. LC-MS (A) t _R = 0.54min, [M+H] ⁺ : 189.09.

F5.K4.32-Chloro-6-methoxy-pyrimidine-4-carboxylic acid methoxy-methyl-amide

The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.1 using

Example F5.K4.2. LC-MS (A) t _R = 0.49min, [M+H] ⁺ : 196.19

F5. K4.4 1 -( 2-Chloro-6-methoxy-pyrimidin-4-yl)-ethanone

The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.2, using F5.K4.3. LC-MS (A) t _R = 0.79min, [M+H] ⁺ : 187.13 Example F5.K51-(2-Methoxy-6-methyl-pyrimidin-4-yl)-ethanone F5.K5.1 2-Methoxy-b-methyl-pyrimidine-4-carboxyHc acid

Methyl 2-chloro-methylpyrimidine-4-carboxylate (5.0g) was suspended in MeOH (67mL) and NaOH 1N (67mL) was added. The mixture was stirred for 1h at RT, then MeOH was evaporated off. At 0°C the mixture was acidified to pH=2 with HCI (25%). The crystals were filtrated, washed with water and heptane and dried at HV at 35°C overnight to give 3.0g beige crystals 1H NMR (400 MHz, DMSO) d: 13.67-13.76 (m, 1 H), 7.52 (s, 1 H), 3.94 (s, 3 H), 2.50 (s, 3 H)

F5.K5.22-Methoxy-b-methyl-pyrimidine-4-carboxyHc acid methoxy-methyl-amide

The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.1 using

Example F5.K5.1. LC-MS (A) t _R = 0.57min, [M+H] ⁺ : 212.13

F5.K5.3 1-(2-Methoxy-6-methyl-pyrimidin-4-yl)-ethanone The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.2, using Example F5.K5.2. LC-MS (A) t _R = 0.68min, [M+H] ⁺ : 167.06

Example F5.K6 1-(6-Methoxy-2-methyl-pyrimidin-4-yl)-ethanone F5.K6.1 6-Methoxy-2-methyl-pyrimidine-4-carboxylic acid methyl ester

A flask was charged with Example F5.K4.1 (787mg), Pd(PPh ₃ )4 (227mg) and THF abs. (60mL) at RT under argon. To this solution trimethylaluminum solution 2M in toluene (3.89mL) was added in one portion at RT. The resulting solution was stirred at 75°C ET under argon over weekend. The mixture was poured slowly into 1 M NaH ₂ P0 ₄ and extracted with 3x DCM. The combined org. layers were dried over MgS04, filtrated, evaporated and purified by CC (Biotage, 10g snap, solvent A: heptane , B: EA, Gradient (in %B): 50 for 3CV, 50 to 70 over 2CV, 70 for 1CV) to give 507mg brown solid. LC-MS (A) t _R = 0.62min; [M+H] ⁺ : 183.17 F5.K6.26-methoxy-2-methyl-pyrimidine-4-carboxylic acid, sodium salt

The title compound was synthesized following the procedure described in Example F5.K4, step F5.K4.2 using

Example F5.K6.1. LC-MS (A) t _R = 0.33min, [M+H] ⁺ : 169.01

F5.K6.36-Methoxy-2-methyl-pyrimidine-4-carboxylic acid methoxy-methyl-amide

The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.1 using

Example F5.K6.2. LC-MS (A) t _R = 0.56min, [M+H] ⁺ : 212.13

F5. K6.4 1 -( 6-Methoxy-2-methyl-pyrimidin-4-yl)-ethanone

The title compound was synthesized following the procedure described in Example F5.K1, step F5.K1.2, using F5.K6.3. LC-MS (A) t _R = 0.64min, [M+H] ⁺ : 167.05 Example F5.541-(4-Ethynyl-piperidin-1-yl)-ethanone

To a suspension of the 4-ethynylpiperidine hydrochloride (125mg) in EA (2.5ml) and aq. sat. NaHC0 ₃ (2.5ml) was added acetic anhydride (157pL) at RT and the mixture was stirred for 1 h. Then the phases were separated. The aq. layer was extracted with 1x EA and the aq. layers were washed with 1x brine. The combined org. layers were dried over MgS0 ₄ , filtrated off, evaporated and dried at HV to give 136mg colourless oil. LC-MS (A) t _R = 0.61 min; [M+H]-: 152.16.

Example F5.551-((S)-2-Ethynyl-2-methyl-pyrrolidin-1-yl)-ethanone

The title compound was synthesized following the procedure described in Example F5.54 using (2S)-2-ethynyl-2- methylpyrrolidine hydrochloride as amine. LC-MS (A) t _R = 0.59min; [M+H] ⁺ : 152.15.

Example F5.56 1-(4-Prop-2-ynyl-piperidin-1-yl)-ethanone F5.56.1 4-Prop-2-ynyl-piperidine-1-carboxylic acid tert-butyl ester To a suspension N-BOC-4-piperidineacetaldehyde (250mg) in MeOH (5mL) were added K2C03 (456mg) and dimethyl (diazomethyl)phosphonate (191 mg) at RT. The resulting suspension was stirred at RT under argon. After 1h45 the mixture was diluted with DCM, filtrated over celite and evaporated to dryness. The crude was purified by CC (Biotage), 25g SNAP, A: Hep, B: EA Gradient (%B) 0 for 3CV, 0 to 15 over 3CV, 15 for 3CV, 15 to 30 over 3CV, 30 for 3CV to give 158mg colorless resin. LC-MS (A) tR = 0.99min; [M+H]-: 224.12.

F5.56.24-(prop-2-yn-1-yl)piperidine, hydrochloride salt

A colorless solution of Example F5.56.1 (155mg) in 4M HCI in dioxane (1.5mL) was stirred at RT for 2h30. Then the reaction mixture was evaporated to dryness to give 130mg off-white solid. ¹ H-NMR (400 MHz, CDCI3) d: 9.58-9.80 (m,

1 H), 9.31-9.46 (m, 1 H), 3.47-3.60 (m, 2 H), 2.81-2.96 (m, 2 H), 2.16-2.34 (m, 2 H), 1.97-2.12 (m, 3 H), 1.74-1.90 (m,

4 H)

F5.56.3 1 -(4-Prop-2-ynyl-piperidin- 1 -yl) -ethanone

The title compound was synthesized following the procedure described in Example F5.54 using F5.56.2 as amine. LC- MS (A) t _R = 0.69min; [M+H] ⁺ : 166.10.

Example F5.57 rac-1 -[4-(1-Hydroxy-prop-2-ynyl)-4-methyl-piperidin-1-yl]-ethanon e F5.57. 1 rac-1 -(4-Methyl-piperidin-4-yl)-prop-2-yn-1-ol, hydrochloride salt

The title compound was synthesized following the procedure described in Example F5.56, step 2 using F5.34 as Boc- protected amine. ¹ H-NMR (400 MHz, MeOD) d: 1.16 (s, 3 H), 1.64 (d, J = 15.4 Hz, 1 H), 1.69-1.74 (m, 1 H), 1.88-1.98

(m, 2 H), 2.94 (d, J = 1.4 Hz, 1 H), 3.11-3.19 (m, 2 H), 3.30 (m, 2 H), 4.14 (d, J = 1.3 Hz, 1 H)

F5.57.2 rac-1 -[4-( 1 -Flydroxy-prop-2-ynyl)-4-methyl-piperidin-1-yl]-ethanone

The title compound was synthesized following the procedure described in Example F5.54 using F5.57.1 as amine. LC- MS (A) t _R = 0.56min; [M+H] ⁺ : 196.20.

Example F5.58 1-(4-Ethynyl-4-methyl-piperidin-1-yl)-ethanone F5.58.1 4-Ethynyl-4-methyl-piperidine, hydrochloride salt

The title compound was synthesized following the procedure described in Example F5.56, step 2 using tert-butyl 4- ethynyl-4-methylpiperdidine-1-carboxylate. LC-MS (A) t _R = 0.39min; [M+H] ⁺ : 124.21 F5.58.2 1 -(4-Ethynyl-4-methyl-piperidin-1-yl)-ethanone

The title compound was synthesized following the procedure described in Example F5.54 using F5.58.1 as amine. LC- MS (A) t _R = 0.71 min; [M+H] ⁺ : 166.11.

Example F5.59 rac-1 , 1 , 1 -T rifluoro-2-methyl-but-3-yn-2-ol

To a solution of ethyl magnesium bromide solution 0.5M in THF (863mI) at 0°C was added 1,1,1 -trifluoroacetone (399mI). After stirring for 1 h, the mixture was quenched with HCI 1 N, diluted with water and extracted with 3x diethyl ether. The combined org. layers were dried over MgS04, filtrated off and evaporated to dryness to afford 520mg yellowish resin. 1H NMR (500 MHz, CDCI3) d: 2.63 (s, 1 H), 1.67 (m, 4 H).

Example F5.60 to F5.62 were synthesized following the procedure described in Example F5.18 using 2-methyl-3-butyn- 2-amine and the appropriate commercially available acid chloride. The CC (Biotage, SNAP, 10g, solvent A: heptane, solvent B: EA) gradients can be found in the table below, if a CC was necessary. The LC-MS conditions used were LC- MS (A).

Example F5.633-(1,1-Dimethyl-prop-2-ynyl)-oxazolidin-2-one F5.63.1 (1,1 -Dimethyl-prop-2-ynyl)-carbamic acid 2-chloro-ethyl ester

K ₂ CO ₃ was added to a solution 2-methyl-3-butyn-2-amine (250mg) in MeCN (10ml) at 0°C. Then a solution of 2- chloroethyl chloroformate (336mI_) in MeCN (5ml) was added dropwise within 5min at 0°C. The resulting white susp was stirred at 0°C and allowed to warm up to RT for 2h. The reaction mixture was evaporated and the residue was extracted with EA/water. The org. layer was washed one with brine. The aq. layers were back extracted with twice EA. The combined org. layers were dried over MgS04, filtrated off and evaporated to dryness to give 594mg of a colorless oil.

LC-MS (A) t _R = 0.75min; [M+H] ⁺ : 190.13

F5.63.2 3-( 1, 1 -Dimethyl-prop-2-ynyl)-oxazolidin-2-one

To a solution of Example F5.63.1 in THF (12ml) and treated with NaH (60% dispersion in mineral oil, 357mg) at RT for 1 h. The reaction mixture was quenched with HCI 1N (approx. 1ml), diluted with water and with 3x EA. The org. phases were washed with 1x brine, combined, dried over MgS04, filtrated off and evaporated to dryness. The crude was purified by CC (Biotage, 10g snap, solvent A: Heptane, solvent B: EA, gradient in %B: 10 for 3CV, 10 to 30 over 2CV, 30 for 3CV, 30 to 50 over 1CV, 50 for 1CV ) to give 528mg pale grey oil. LC-MS (A) t _R = 0.58min; [M+H] ⁺ : 154.12

Example F5.64 1-(1,1-Dimethyl-prop-2-ynyl)-pyrrolidin-2-one F5.64.1 4-Chloro-N-( 1, 1 -dimethyl-prop-2-ynyl)-butyramide The title compound was synthesized following the procedure described in Example F5.63.1 using 2-methyl-3-butyn-2- amine. LC-MS (A) t _R = 0.69min; [M+H] ⁺ : 188.20.

F5.64.2 1-(1, 1-Dimethyl-prop-2-ynyl)-pyrrolidin-2-one

The title compound was synthesized following the procedure described in Example F5.63.2 using the Example F5.64.1, while the purification by CC was omitted. LC-MS (A) t _R = 0.62min; [M+H]-: 152.13 Example F5.65 1-(1,1-Dimethyl-prop-2-ynyl)-imidazolidin-2-one Example F5.65. 1 1 -(2-Chloro-ethyl)-3-( 1, 1 -dimethyl-prop-2-ynyl)-urea

The title compound was synthesized using the procedure described in F5.55.1 using 2-methyl-3-butyn-2-amine and purified by CC (Biotage, 10g SNAP, A: DCM, B: DCM/MeOH 8/2, Gradient (in %B): 0 for 3CV, 0 to 15 over 6CV, 15 for 1CV). LC-MS (A) t _R = 0.63min; [M+H] ⁺ :189.18.

F5.65.2 1-(1, 1-Dimethyl-prop-2-ynyl)-imidazolidin-2-one

The title compound was synthesized following the procedure described in Example F5.63.2 using Example F5.65.1, while the purification by CC was omitted. LC-MS (A) t _R = 0.56min; [M+H] ⁺ : 153.13 Example F5.66 1 -(1 , 1 -Dimethyl-prop-2-ynyl)-3-methyl-imidazolidin-2-one

Example F5.65 (70mg) was dissolved in THF abs. (1mL) and cooled to 0°C, then NaH (60% dispersion in mineral oil, 22.1 mg) was added under argon and the susp was stirred for 5min at 0°C under argon, then iodomethane(28.9pL) was added and the susp was stirred at 0°C under argon, for 1h30.The reaction mixture was quenched with aq. sat. NH4CI, diluted with water and extracted with 3x DCM (phase separator). The combined org. layers were evaporated and dried at HV. 75mg yellow oil. LC-MS (A) t _R = 0.64min; [M+H] ^÷ : 167.08 Example F5.67 3-(1-Ethynyl-cyclopropyl)-oxazolidin-2-one F5.67.1 (1 -Ethynyl-cyclopropylj-carbamic acid 2-chloro-ethyl ester

The title compound was synthesized following the procedure described in Example F5.63, step 1 using 1-ethynyl- cyclopropylamine hydrochloride as amine. LC-MS (A) t _R = 0.68min; [M+H]-: 188.13 F5.67.2 3-(1-Ethynyl-cyclopropyl)-oxazolidin-2-one

The title compound was synthesized following the procedure described in Example F5.66, step 2 using Example F5.69.1

. The used gradient (in %B) is: 0 for 3CV, 0 to 10 over 8CV, 10 for 3CV, 10 to 100 over 10CV, 100 for 2CV LC-MS (A) t _R = 0.53min; [M+H] ⁺ : 152.09

Example F5.682-(1-Ethynyl-cyclopropyl)-pyridine

F5.68. 1 (1-Pyridin-2-yl-cyclopropyl)-methanol

A suspension of the 1-(pyridine-2-yl)cyclopropanecarboxylic acid (300mg) in diethyl ether abs. (3.6mL) was cooled to 0°C under argon, then LiAIH ₄ 1 M in THF (2.14mL) was added slowly. The resulting suspension was stirred at RT under argon overnight. The reaction mixture was quenched by adding 89mI_ water, 89 mI_ NaOH (15%) and 267 mI_ water. The mixture was stirred for 20min, then filtrated off and evaporated to dryness. 218mg yellow oil. LC-MS (A) t _R = 0.21min; [M+H] ⁺ : 150.14

F5.68.2 1-Pyridin-2-y/-cyc/opropanecarba/dehyde

To a solution of F5.68.1 (100mg) and DIPEA (950mI_) in DCM (2mL) was added a solution of sulfur trioxide pyridine complex 45% (308mg) in DMSO (2mL) at 0°C dropwise. The resulting solution was stirred for 30min at 0°C. After 2h the reaction mixture was quenched with 5ml cold water.The two layers were separated (phase separator) and the aq. layer was extracted twice with DCM. The combined org. layers were evaporated to dryness. 273mg orange liquid. LC- MS (A) t _R = 0.28min; [M+H] ⁺ : 148.18 F5.68.32-(1-Ethyny/-cyc/opropy/)-pyridine

The title compound was synthesized following the procedure described in Example F5.56, step 1 using F5.68.2 aldehyde. Filtration over plug of celite with DCM/MeOH 9 was carried out instead of CC. LC-MS (A) t _R = 0.47min; [M+H]-: 144.20.

Example F5.694-(1-Ethynyl-cyclopropyl)-6-methyl-pyrimidine F5.69.1 (6-Methyl-pyrimidin-4-yl)-acetic acid methyl ester

To a solution of methyl 2-(6-chloropyrimidin-4-yl)acetate (600mg) and bis(tri-tert-butylphosphine)palladium(0) (82.2mg) in THF abs. (10mL) was added dropwise at 0 °C a dimethylzinc solution (345mί, 2.0 M in toluene) under argon. The reaction mixture was further stirred at RT overnight. The reaction mixture was quenched with water, extracted 3x with DCM and purified by CC (Biotage, 25g SNAP, solvent A: DCM, solvent B: DCM/MeOH 8/2, gradient (in %B) 0 for 3CV, 0 to 15 over 5CV, 15 for 5CV) to give 485mg orange resin. LC-MS (A) t _R = 0.52min; [M+H] ⁺ : 167.04 F5.69.2 1-(6-Methyl-pyrimidin-4-yl)-cyclopropanecarboxylic acid methyl ester

To a solution of F5.69.1 (485mg) in DMF abs. (20mL) was added at 0°C NaH (60% dispersion in mineral oil) (70mg) and the mixture stirred at 0°C for 10min. Subsequently, 1,2-dibromoethane (267mί) was added and the mixture stirred for additional 5min. Again, NaH (60% dispersion in mineral oil) (70mg) was added and stirring continued at 0°C for 4h. The reaction was quenched by the addition of NH ₄ CI aq. sat. and extracted with DCM 3x, dried over MgS0 ₄ , concentrated in vacuo, and purified by CC (Biotage, 25g SNAP, solvent A: DCM, solvent B: DCM/MeOH 8/2, gradient (in %B): 0 for 3CV, 0 to 15 over 10CV, 15 for 5CV) to give 280mg yellowish resin. LC-MS (A) t _R = 0.64min, [M+H] ⁺ : 193.13

F5.69.23 [1-(6-Methyl-pyrimidin-4-yl)-cyclopropyl]-methanol

A lithium borohydride solution (10.4mL, 2.0 M in THF) was added dropwise at RT under argon to a solution of F5.69.2 (180mg) in MeOH abs. (3.5mL) and stirred overnight. The mixture was cooled to 0°C and carefully quenched by the dropwise addition of HCI 2N to adjust the pH to 7, and the aq. phase was extracted with DCM 3x.The combined org. phases were evaporated to dryness and the crude purified by CC (Biotage, 10g SNAP, solvent A: DCM, solvent B: DCM/MeOH 8/2, gradient (%B) 0 for 3CV, 0 to 15 over 5CV, 15 for 5CV) to give 68mg yellowish resin. LC-MS (A) t _R = 0.42min; [M+H] ⁺ : 165.09

F5.69.3 1 -( 6-Methyl-pyrimidin-4-yl)-cyclopropanecarbaldehyde

To solution of F5.69.2 (48mg) in DCM abs. (2.5mL) were added molecular sieves (3A) and Dess-Martin periodinane (248mg) at RT under argon. The resulting suspension was stirred at RT for 30min. The mixture was filtrated over silica, evaporated and purified by CC (Biotage, 10g SNAP, solvent A: DCM, solvent B: DCM/MeOH 8/2, gradient (%B): 0 for 3CV, O to 15 over 5CV, 15 for 5CV to give 110mg yellowish wax. LC-MS (A) t _R = 0.54min, [M+H] ⁺ :163.12 F5.69.4 4-(1-Ethynyl-cyclopropyl)-6-methyl-pyrimidine

The title compound was synthesized following the procedure described in Example F5.56.1 using F5.69.3 as aldehyde. CC (Biotage), 10g SNAP, A: DCM ,B: DCM/MeOH 8/2 0 for 3CV, 0 to 15 over 5CV, 15 for 5CV, 15 to 50 over 3CV, 50 for 5CV. LC-MS (A) t _R = 0.74min; [M+H] ⁺ : 159.15.

Example F5.704-Ethynyl-1 -methanesulfonyl-piperidine

To a suspension of the 4-ethynylpiperidine hydrochloride (70mg) and TEA (324pL) in DCM (1.5mL) was added slowly methanesulfonyl chloride (54.7 L) at 0°C and the suspension was stirred under argon overnight. The reaction mixture was quenched with water and the phases were separated with a phase separator. The aq. layer was 1x re-extracted with DCM. The combined org. layers were evaporated to dryness and purified by CC (Biotage, 10g SNAP, solvent A: heptane, solvent B: EA; 30 for 3CV, 30 to 50 over 2CV, 50 for 1CV) to give 68mg white powder. ¹ H-NMR (500 MHz, CDCI3) d: 3.41 (m, 2 H), 3.23 (m, 2 H), 2.81 (s, 3 H), 2.69 (m, 1 H), 2.17 (d, J = 2.5 Hz, 1 H), 1.95 (m, 2 H), 1.82 (m, 2 H).

Example F5.71 4-Ethynyl-4-methyl-piperidine-1 -sulfonic acid methylamide

The title compound was synthesized following the procedure described in Example F5.70 using F5.58.1. CC (Biotage, 10g SNAP, solvent A: heptane, solvent B: EA; 30 for 3CV, 30 to 50 over 3CV, 50 for 2CV). LC-MS (A) t _R = 0.76min; [M+H] ⁺ : 217.11.

Example F5.724 (2-Methyl-but-3-yne-2-sulfonyl)-cyclopropane

To a suspension of sodium cyclopropanesulfinate (150mg), CuCI (9.08mg), 3-chloro-3-methyl-1-butyne in DMF (500 L) was stirred at 40°C overnight. The mixture was allowed to cool to RT, diluted with EA/water and extracted with EA. The combined org. layers were washed with brine, dried over MgS0 ₄ , filtrated off, evaporated to dryness. The crude was purified by CC (Biotage, 10g snap, solvent A: Hp, solvent B: EA, Gradient (in %B): 30 for 3CV, 30 to 100 over 10CV, 100 for 2CV) to give 57mg pale yellow oil. LC-MS (A) t _R = 0.85min; [M+H] ⁺ : 214.09

Example F5.73 rac-2-(1 -Cyclopropyl-1 H-pyrazol-3-yl)-but-3-yn-2-ol F5. 73.1 1-(1 -Cyclopropyl- 1 FI-pyrazol-3-yl) -ethanone A mixture of 1-(1H-pyrazol-3-yl)ethan-1-one (200mg), cyclopropylboronic acid (306mg), 2,2'-bipyridyl (550mg), Na2C03 (185mg), copper(ll) acetate (313mg) and toluene (16mL) was stirred at 100°C under argon overnight.

The reaction mixture was diluted with water and extracted with 3x DCM. The org. layers were washed with 1x brine, combined, dried over MgSC>4, filtrated off, evaporated. The crude was purified by CC (Biotage, 25g snap, solvent A: heptane, solvent B: EA, Gradient (in %B): 0 for 3CV, 0 to 30 over 7CV, 30 for 2CV), followed by a second CC (Biotage, 10g snap, solvent A: heptane, solvent B: EA, gradient (in %B): 10 for 3CV, 10 to 30 over 4CV, 30 for 2CV) to give 50mg pale yellow oil. LC-MS (A) t _R = 0.64min, [M+H] ⁺ : 151.16

F5. 73.2 rac-2-(1 -Cyclopropyl-1 H-pyrazol-3-yl)-but-3-yn-2-ol

To a solution of ethynyl magnesium bromide (918mI_, 0.5M in THF) at 0°C was added dropwise a solution of F5.73.1

(46mg) in THF (800mI_) under argon and reaction mixture stirred at 50°C overnight. The mixture was allowed to cool down to RT, quenched with aq. sat. NH ₄ CI, diluted with water and extracted with 3x DCM. The combined org. layers were dried over MgS04, filtrated off, evaporated and purified by CC (Biotage, 10g snap, solvent A: heptane, B: EA,

Gradient (in %B): 30 for 3CV, 30 to 50 for 2CV, 50 for 2CV, 50 to 70 over 2CV, 70 for 2CV) to give 22mg pale yellow oil. LC-MS (A) t _R = 0.57min; [M+H] ⁺ : 177.24

Example F5.74 rac-2-(6-Trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol

F5. 74. 1 6-Tiifluoromethyl-pyrimidine-4-carboxylic acid methoxy-methyl-amide

The title compound was synthesized following the procedure described Example F5.K1 step 1 using 6- trifluoromethyl)pyrimidine-4-carboxylic acid. LC-MS (A) t _R = 0.70min, [M+H] ⁺ : 235.97

F5.74.2 1-(6-Tiifluoromethyl-pyrimidin-4-yl)-3-triisopropylsilanyl-p ropynone

To a solution of the Weinreb amide F5.74.1 (452mg) in THF abs. (9mL) and (triisopropylsilyl)acetylene (578mί) in a heated-out flask was added LiHMDS 1 M (2.5mL) dropwise at -78°C under argon. The resulting solution was stirred at -78°C under argon for 45min, before it was allowed to warm up to RT, to be quenched with aq. sat. NaHC03 and extracted with 3x EA. Afterwards the org. layers were washed with 1x brine, combined, dried over MgS04, filtrated off, evaporated and dried at HV to give 712mg dark brown oil. LC-MS (A) t _R = 1.29min, [M+H] ⁺ : 357.01.

F5. 74.3 rac-2-f 6-Trifluoromethyl-pyrimidin-4-yl)-4-triisopropylsilanyl-but- 3-yn-2-ol

To a solution of F5.74.2 (723mg) in THF abs. (7mL) was added dropwise methylmagnesium bromide solution (810mί, 3.0M in diethyl ether) at 0°C under argon. The resulting solution was stirred at 0°C under argon for 1h30.The reaction mixture was quenched with aq. sat. NH ₄ CI at 0°C, diluted with water and extracted with 3x DCM. The combined org. layers were dried over MgS0 ₄ , filtrated off, purified by CC (Biotage, 25g sphere, A: Hp, B: EA, 10 for 3CV, 10 to 30 over 3CV, 30 for 2CV) to give 507mg brown oil. LC-MS (A) t _R = 1.24min, [M+H] ⁺ : 373.10

F5. 74.4 rac-2-( 6-Tiifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol To a solution of the F5.74.3 (499mg) in THF abs. (5mL) was added TBAF (1.47mL) at 0°C. After stirring for 30min at 0°C under argon the reaction mixture was quenched and diluted with aq. sat. NH ₄ CI and extracted with 2x DCM. Afterwards the aq. layers were washed with 1x aq. sat. NH ₄ CI and 1x brine. The combined org. layers were dried over MgSC>4, filtrated, evaporated and purified by Prep LC-MS (XVI, then IX) to give 99mg pale brown oil. LC-MS (A) tR = 0.70min, [M+H] ⁺ : 217.07

Example F5.75 rac-2-(6-Difluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol F5. 75. 1 6-Difluoromethyl-pyrimidine-4-carboxylic acid methoxy-methyl-amide

The title compound was synthesized following the procedure described Example F5.K1 step F5.K1.1 using 6- (difluoromethyl)pyrimidine-4-carboxylic acid. LC-MS (A) tR = 0.58min, [M+PI]"·: 218.09.

F5.75.2 1-(6-Difluoromethyl-pyrimidin-4-yl)-3-triisopropylsilanyl-pr opynone

The title compound was synthesized following the procedure described Example F5.75 step F5.75.2 using F5.75.1 . LC- MS (A) t _R = 1.24min, [M+H] ⁺ : 339.10.

F5. 75.3 rac-2-( 6-Difluoromethyl-pyrimidin-4-yl)-4-triisopropylsilanyl-but-3 -yn-2-ol

The title compound was synthesized following the procedure described Example F5.75 step F5.75.3 using F5.75.2. The compound was purified by CC (Biotage, 25g SPHERE, 10 for 4CV, 10 to 30 over 2CV, 30 for 1CV ) LC-MS (A) t _R = 1.17min, [M+H] ⁺ : 355.06.

F5. 75.4 rac-2-( 6-Difluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol

The title compound was synthesized following the procedure described Example F5.75 step F5.75.4 starting from Example F5.75.3. The compound was purified by CC (Biotage, 25g SPHERE, A: heptane, B: EA), gradient (in %B): 10 for 3CV, 10 to 30 over 3CV, 30 for 3CV). LC-MS (A) tR = 0.57min, [M+H] ⁺ : 199.16.

Example F5.76 (R)- or (S)-2-(2-Trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol F5. 76. 1 N-methoxy-N-methyl-2-(trifluoromethyl)pyrimidine-4-carboxami de

The title compound was synthesized following the procedure described Example F5.K1 step F5.K1.1 using 2- (trifluoromethyl)pyrimidine-4-carboxylic acid. LC-MS (A) tR = 0.72min, [M+Fi] ⁺ : 235.82.

F5.76.2 1-(2-Tiifluoromethyl-pyrimidin-4-yl)-3-triisopropylsilanyl-p ropynone

The title compound was synthesized following the procedure described Example F5.75 step F5.75.2 starting from Example F5.76.1. LC-MS (A) t _R = 1.25min, [M+H] ⁺ : 357.75.

F5. 76.3 rac-2-(2-Trifluoromethyl-pyrimidin-4-yl)-4-triisopropylsilan yl-but-3-yn-2-ol

The title compound was synthesized following the procedure described Example F5.75 step F5.75.3 using F5.76.2. The compound was purified by CC (Biotage, 25g SPHERE, 0 for 2CV, 0 to 10 over 3CV, 10 for 3CV, 10 to 30 over 3CV) L- C-MS (A): t _R = 1.20min, [M+H] ⁺ : 373.10. F5. 76.4 (R)- or (S)-2-(2-Trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol

The title compound was synthesized following the procedure described Example F5.75 step F5.75.4 using F5.76.3. The compound was purified by Chiral prep (XU II) / Analytical (X): 7.0 min. LC-MS (A): tR = 0.72min. ¹ H-NMR (400 MHz, MeOD) d: 9.00 (d, J = 5.2 Hz, 1 H), 8.04 (d, J = 5.2 Hz, 1 H), 3.07 (s, 1 H), 1.83 (s, 3 H). Example F5.77 (S)- or (R)-2-(2-Trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol

The title compound was synthesized following the procedure described Example F5.75 step F5.75.4 using F5.76.3. The compound was purified by Chiral prep (XLIII) / Analytical (X): 8.9 min. LC-MS (A): t _R = 0.72min. ¹ H-NMR (400 MHz, MeOD) d: 9.00 (d, J = 5.2 Hz, 1 H), 8.04 (d, J = 5.2 Hz, 1 H), 3.07 (s, 1 H), 1.83 (s, 3 H).

Example F5.782-(3-Methyl-isoxazol-5-yl)-but-3-yn-2-ol A heated-out flask was charged with a solution of trimethylsilylacetylene (361 mί) in THF abs. (4mL) and cooled to 0°C, then n-BuLi 2.5 M in hexanes (11.14mL) was added slowly under argon. The solution was stirred for 1h at 0°C under argon, then a solution of 1-(3-methyl-5-isoxazolyl)ethanone (250mg) in THF abs. (5mL) was added slowly at 0°C under argon. The resulting solution was further stirred at 0°C under argon for 45min. The reaction mixture was quenched by dropwise addition of MeOH (5mL), allowed to warm up to RT, then K2CO3 (262mg) was added. The resulting suspension was stirred at RT for 20min, before filtrated off, evaporated to dryness and purified by CC (Biotage, 10g Snap, A: Hep, B: EA, gradient (in %B): 30 for 3CV, 30 to 50 over 2CV, 50 for 2CV) to give 200mg yellow oil. LC-MS (A): t _R = 0.57min _; [M+H]-:152.14.

Example F5.79 to Example F5.81 were synthesized following the procedure described in Example F5.78. The LC- MS data and the CC gradients (in %B) are listed in the table below. The LC-MS conditions used were LC-MS (A). Example G1.1 : 5-[(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-ol

G1. 1. 1. 3-[Hydroxy-(4-isopropyl-phenyl)-(5-methoxy-pyridin-3-yl)-met hyl]-3-methyl-azetidine-1 -carboxylic acid tert- butyl ester

A flask was charged with 3-bromo-5-methoxypyridine (5.35g), THF (20mL) and iPrMgCI.LiCI (1.3M in THF, 24mL) under argon at RT and the resulting brown solution was stirred at 60°C for 30min. A solution of Example A4.2 (3.98g) in THF (20mL) was added dropwise and the resulting mixture was stirred at RT for 3h15, quenched with aq. sat. NFUCI solution and water, and extracted with DCM. The org. layers were evaporated in vacuo to afford 6.45g of dark-orange resin. LC- MS (A): t _R = 0.90min; [M+H] ⁺ : 427.33.

G1.1.2. ( 4-lsopropyl-phenyl)-( 5-methoxy-pyridin-3-yl) -( 3-methyl-azetidin-3-yl)-methanol

A solution of Example G1.1.1 (6.45g) in HCI in dioxane (4M, 30mL) was stirred for 40min, diluted with water and extracted with EA. The aq. layer was basified to pH12 with aq. NaOFI solution (1 M) and extracted with EA. The org. layers were dried (MgS04) and evaporated to dryness to give 5.4g of the title compound as orange solid. LC-MS (A): tp = 0.59min; [M+H] ⁺ : 327.25.

G1.1.3. (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-methoxy -pyridin-3-yl)-methanol Example G1.1.3 was synthesized starting from Example G1.1.2 (5.4g), and following the procedure described in Example B2.1 step B2.1.2. The resulting crude material was purified by CC (Biotage, SNAP 100g, solvent A: DCM; solvent B: MeOFI; gradient in %B: 0 over 3CV, 0 to 3 over 5CV, 3 over 5CV, 3 to 6 over 5CV, 6 to 10 over 3CV, 10 over 5CV, 10 to 20 over 2CV, 20% over 5CV) to afford 1.98g of the title compound as orange solid. LC-MS (A): t _R = 0.61 min; [M-t-H]-: 341.25.

G1.1.4. 5-[(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridin-3-ol

To a solution of Example G1 .1 .3 (50mg) in DMF (0.5mL) were added 2-diethylamino-ethanethiol hydrochloride (31 ,2mg) and KOtBu (43.4mg) and the resulting mixture was stirred at reflux for 1 h. Aq. sat. NaPICOs solution was added dropwise at RT, the resulting mixture was diluted with water and extracted with EA. The org. layers were dried (MgS04) and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 10g, solvent A: MeOFI; gradient in %A: 100 over 15CV). The isolated fractions were evaporated off and the residue was dissolved in THF. The resulting mixture was filtrated off and the solvent was evaporated to dryness to afford 15mg of the title compound as yellow resin. LC-MS (A): t _R = 0.52 min; [M+H] ⁺ : 327.25.

Example G1.2: 5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-ol G1.2.1. 3-[(5-Benzyloxy-pyridin-3-yl)-hydroxy-(4-isopropyl-phenyl)-m ethyl]-3-methyl-azetidine-1-carboxylic acid tert- butyl ester

The title compound was synthesized starting from Example A4.2 (3.9g) and 3-(benzyloxy)-5-bromopyridine (4.39g), and following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by Prep LC-MS (II) to afford 4.79g of the title compound as white solid. LC-MS (A): tR = 1 .01 min; [M+H] ⁺ : 503.30.

G1.2.2. 3-[(R)-(5-Benzyloxy-pyridin-3-yl)-hydroxy-(4-isopropyl-pheny l)-methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was obtained by chiral separation of Example G1.2.1 (4.79g) by Prep chiral SFC (VII). LC-MS (A): tp = 1.01min; [M+H] ⁺ : 503.16; chiral SFC (G): 2.7min.

G1.2.3. (R)-(5-Benzyloxy-pyridin-3-yl)-(4-isopropyl-phenyl)-(3-methy l-azetidin-3-yl)-methanol, hydrochloride salt

A solution of Example G1.2.2 (1.99g) in HCI in dioxane (4M, 15mL) was stirred for 1h and evaporated to dryness to give 2.05g of the title compound as off-white solid. LC-MS (A): tR = 0.73min; [M+H] ⁺ : 403.12.

G1.2.4. (R)-(5-Benzyloxy-pyridin-3-yl)-(1,3-dimethyl-azetidin-3-yl)- (4-isopropyl-phenyl)-methanol

The title compound was synthesized starting from Example G1.2.3, and following the procedure described in Example B2.1 step B2.1.2. LC-MS (B): t _R = 0.783min; [M+H] ⁺ : 417.4.

G1.2.5. 5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]-pyridin-3-ol A mixture of Example G1 .2.4 (1 ,62g) and Pd/C (10% w/w, 50% water, 206mg) in EtOH (40mL) was stirred at RT under hydrogen atmosphere for 2h and filtered off over a celite plug. The resulting solution was evaporated to dryness to provide the title compound (1.04g) as pale yellow solid. LC-MS (A): t _R = 0.52min; [M+H]-: 327.16.

Example J3.1: 2-[3-(5-{(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-[4-(4,4,5, 5-tetramethyl-[1,3,2]dioxaborolan-2-yl)- phenyl]-methyl}-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-propan- 2-ol

A mixture of Example 532 (1 eq), bis(pinacolato)diboron (1.1 eq), Pd(dppf)Cl2.DCM (0.03 eq) and KOAc (3 eq) in dioxane (5 mL/mmol) was flushed with argon, heated at 80°C in a sealed vial and stirred for 18h. It was filtered over

Celite, the cake was washed with EA and the filtrate was concentrated in vacuo. The crude was purified by Prep LC-

MS (XV) to afford the title compound as brown oil. LC-MS (A): tR = 0.70 min; [M+H] ⁺ : 521.08

Example J5.1: 4-((R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-{5-[5-(1 -hydroxy-1 -methyl-ethyl)-[1, 2, 4]oxadiazol-3-yl]- pyridin-3-yl}-methyl)-phenol

To a solution of boronic ester intermediate (J3.1) (1 eq) in THF (31 mL/mmol) was added at 0°C, NaOH (2.5 eq) and a 30% aq. solution of hydrogen peroxide (2.5 eq). The mixture was stirred at RT for 1h and quenched with a half sat. solution of NH4CI. It was acidified to pH 0 with 1M HCI and washed with EA. The aq. phase was basified to pH 10 with a 1 M NaOH and extracted with EA/MeOH 99/1 then EA/MeOH 95/5. The combined org. phases were dried over MgS04 and concentrated in vacuo. The crude was purified by Prep LC-MS (XV) to afford the title compound as white solid. LC- MS (A): t _R = 0.52 min; [M+H] ⁺ : 411.08

Depending on the purification conditions, the title compounds/intermediates in Intermediate Examples of Formula (A3), (A4), (A5), (A6), (A7), (B2), (C1), (C3), (D1), (D2), (D3), (D4), (D5), (E1), (E2), (F1), (F3), (F4), (F5), (G1), (J3) and (J5) may be isolated as free bases or as salts such as formate salts, or hydrochloride salts, or sodium salts. Whenever isolating a title compound/intermediate as a salt, formate salt or hydrochloride salt or sodium salt is indicated at the end of the chemical name and can refer to a mono-, di- or tri-formate salt; or a mono-, di-, or tri-hydrochloride salt; or a mono-, or di-sodium salt.

Preparation of Examples of Formula (I)

Example 1: (3-Fluoro-1-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin -3-yl)-(4-trifluoromethoxy-phenyl)-methanol

To a light-yellow solution of Example A7.3 (45mg) in DCM (1mL) was added formaldehyde (26.2mI_, 37% in water) followed by NaBH(OAc)3 (33.6mg). The resulting solution was stirred for 30min at RT and was basified with aq. sat. NaHCCh solution. The resulting mixture was extracted with DCM and the org. layers were dried (MgS04), filtered off and evaporated to dryness. The resulting crude material was purified by Prep LC-MS (VI) to afford 17mg of the title compound as white solid. LC-MS (A): t _R = 0.63min; [M+H]"·: 426.21.

Example 2: 3-[Hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluorometh oxy-phenyl)-methyl]-1-methyl-azetidine-3- carbonitrile

Example 2 was synthesized starting from Example A7.2 and following the procedure described in Example B2.1 step B2.1.2. The material was purified by Prep LC-MS (V). LC-MS (A): t _R = 0.63min; [M+H] ⁺ : 433.15.

Example 3: (R)-(1-Ethyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyri din-3-yl)-(4-trifluoromethoxy-phenyl)-methanol

To a light-yellow solution of Example A7.1 (20mg) in MeOH (0.5mL), AcOH (0.05mL) was added at RT, followed successively by acetaldehyde (15.2 L) and NaBH(OAc)3 (19.7mg). The resulting solution was stirred 17h at RT. Acetaldehyde (5 L) and NaBH(OAc)3 (9.85mg) were added again and the reaction mixture was stirred for 4 days. The mixture was quenched with water, filtered off and evaporated to dryness. The resulting crude material was purified by Prep LC-MS (VII) to afford 6mg of the title compound as white solid. LC-MS (A): t _R = 0.64min; [M+H]-: 436.29.

Example 4 to Example 8 were synthesized starting from the appropriate aldehyde or ketone, following the procedure described in Example 3. LC-MS data of Example 4 to Example 9 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 9: (R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-y l-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)- methanol

To a light yellow solution of Example A7.1 (20mg) in EtOH (0.5mL), AcOH (0.05mL) was added at RT, followed successively by (l-ethoxycyclopropoxy)trimethysilane (91.5 mI_) and sodium cyanoborohydride (28.3mg). The resulting solution was stirred for 17h at RT. 1-Ethoxycyclopropoxy)trimethysilane (45.7 L) and sodium cyanoborohydride (14.1 mg) were added again and the reaction mixture was stirred for 4 days. The mixture was quenched with water and evaporated to dryness. The resulting crude material was purified by Prep LC-MS (VII) to afford 4mg of the title compound as white solid. LC-MS (A): t _R = 0.65min; [M+H] ⁺ : 448.28.

Example 10: (R)-[1-(2-Fluoro-ethyl)-3-methyl-azetidin-3-yl]-(5-pyrrolidi n-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)- methanol

To a light yellow solution of Example A7.1 (20mg) in MeOH (0.5mL), TEA (13.8 L) was added, followed by 1-fluoro-2- iodo-ethane (17.4 L). The reaction mixture was stirred at reflux for 22h. 1-Fluoro-2-iodo-ethane (3.95 L) and TEA (3.14 L) were added and the mixture was stirred at reflux for 48h. The resulting crude material was filtered off and purified by Prep LC-MS (V) to afford 5mg of the title compound as white solid. LC-MS (A): t _R = 0.63min; [M+H] ⁺ : 454.24. Example 11: (R)-[1-(2,2-Difluoro-ethyl)-3-methyl-azetidin-3-yl]-(5-pyrro lidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy- phenyl)-methanol

The title compound was synthesized starting from Example A7.1 and 1 , 1 -difluoro-2-iodoethane, following the synthesis procedure described in Example 10. LC-MS (A): t _R = 0.65min; [M+H] ⁺ : 472.2.

Example 12: (R)-(1-tert-Butyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl -pyridin-3-yl)-(4-trifluoromethoxy-phenyl)- methanol

12.1. (R)-(1 -lsopropenyl-3-methyl-azetidin-3-yl) -( 5-pyrrolidin- 1 -yl-pyridin-3-yl) -( 4-trifluoromethoxy-phenyl) -methanol

To a light yellow solution of Example A7.1 (20mg) and acetone (19.9 L) in water (0.5mL) was added dropwise at 0°C a solution of KCN (18.1 mg) in water (0.5mL). The resulting mixture was stirred for 69h at RT, was diluted with water and extracted with EA. The org. layers were washed with brine, dried (MgS04), filtrated off and evaporated to dryness to afford 80mg of the title compound. LC-MS (A): t _R = 0.62min; [M+H]-: 448.26.

12.2 (R)-(1-tert-Butyl-3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl -pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol To a solution of Example 12.1 (77mg) in THF (1.5mL) was added dropwise methylmagnesium bromide (3M in diethyl ether, 573mI_) at 0°C. The resulting mixture was stirred for 10min at 0°C then at 60°C overnight. The reaction mixture was cooled down, quenched by addition of aq. sat. NH ₄ CI solution, diluted with water and extracted with EA. The org. layers were washed with water and brine, dried (MgS0 ₄ ), filtrated off and evaporated to dryness. The resulting crude material was first purified by Prep LC-MS (VIII) then by Prep LC-MS (IX) to afford 9mg of the title compound as white powder. LC-MS (A): t _R = 0.65min; [M+H] ⁺ : 464.29.

Example 13: (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-meth oxy-prop-1-ynyl)-pyridin-3-yl]-methanol

To a solution of Example F1.1 (100mg) in DMSO (2mL) and toluene (0.3mL), methyl propargyl ether (33.5mg) was added at RT followed by palladium(ll) acetate (2.89mg), triphenylphosphine (83.7mg) and KsP0 ₄ (65.4mg). The resulting solution was stirred for 66h at 80°C, was allowed to cool down, was diluted with MeOH and water, filtered off and purified by Prep LC-MS (VII) to afford 32mg of the title compound as purple powder. LC-MS (A): t _R = 0.75min; [M+H]-: 379.34.

Example 14: 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-prop-1-yn-1-ol Example 14 was synthesized starting from Example F1.2 and propargyl alcohol following the procedure described in Example 13. The crude material was purified by Prep LC-MS (VI). LC-MS (A): t _R = 0.65min; [M+H]-: 365.25.

Example 15: 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-2-methyl-but-3- yn-2-ol

To a solution of Example F1.2 (70mg) in THF (2.5mL) was added 2-methyl-3-butyn-2-ol (24 L) followed by Cul (0.86mg), tetrakis(triphenylphosphine)pailadium(0) (83.2mg) and piperidine (93 mί). The resulting reaction mixture was stirred for 2h at 80°C, cooled down, diluted with MeOH and water, filtrated through a syringe filter and purified by Prep LC-MS (VI) then by Prep LC-MS (XIII) to afford 38mg of the title compound as white powder. LC-MS (A): t _R = 0.69min; [M+H] ⁺ : 393.33.

Example 16 to Example 46 were synthesized starting from Example F1.2 and the appropriate alkyne of Formula (F5), and following the procedure described in Example 15. The alkyne precursors of Formula (F5) are indicated in the table below unless commercially available. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

47.1. (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-tri methylsilanylethynyl-pyridin-3-yl)-methanol

Example 47.1 was synthesized starting from Example F1.2 and trimethylsilylacetylene and following the procedure described in Example 15. The crude material was purified by Prep LC-MS (V). LC-MS (A): t _R = 0.89min; [M+H]"·: 407.22. 47.2. (R)-(1,3-Dimethyl-azetidin-3-yl)-(5-ethynyl-pyridin-3-yl)-(4 -isopropyl-phenyl)-methanol

To a solution of Example 47.1 (24mg) in MeOH (0.5mL) was added K ₂ C0 ₃ (8.16mg). The resulting mixture was stirred for 2h30 at RT, diluted with EA, washed with water and brine. The org. layers were dried (MgS04), filtrated off, and evaporated to dryness to afford 21 mg of the title compound as brown solid. LC-MS (A): t _R = 0.73min; [M+H]-: 335.19. 47.3. (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(1H-indol-2-ylethynyl)-p yridin-3-yl]-(4-isopropyl-phenyl)-methanol The title compound was synthesized starting from Example 47.2 and 2-iodo-1 H-indole, following the procedure described in Example 15. The crude material was purified by Prep LC-MS (VII). LC-MS (A): t _R = 0.88min; [M+H]-: 449.82.

Example 48: (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-meth oxy-propyl)-pyridin-3-yl]-methanol A solution of Example 13 (29mg) was dissolved in EtOH (2mL), Pd/C (10% w/w, 50% water, 8.12mg) was added and resulting mixture was stirred for 41 h under hydrogen. The reaction mixture was filtered off and evaporated to dryness to afford 21 mg of the title compound as brown resin. LC-MS (A): t _R = 0.6min; [M+H]-: 383.36.

Example 49 to Example 81 were synthesized starting from the appropriate alkyne-containing Example and following the procedure described in Example 48. Precursor alkyne-containing Examples, Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A). yl]-pyridin-3-yl}-methanol

82.1. 3-((R)-(4-Cyclopropyl-phenyl)-hydroxy-{5-[3-(tetrahydro-pyra n-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methyl)-3- methyl-azetidine-1 -carboxylic acid tert-butyl ester A vial was charged with Example E1.2 (50mg), Example E2.1 (24.7mg), and H0Bt.H ₂ 0 (23.4mg). Dioxane (1.1 mL) and DIPEA (0.039mL) were added followed by EDC.HCI (28.7mg). The reaction mixture was heated at 90°C until completion of the reaction. The reaction mixture was cooled down to RT and partitioned between DCM and sat. aq. NaHCCh. The org. layer was filtered over a phase separator and concentrated in vacuo. The residue (105mg) was purified by Prep LC-MS (XII) to afford the title product as a white solid (27.5mg). LC-MS (A): t _R = 1.09min; [M+H]+: 547.25. 82.2. (R)-(4-Cyclopropyl-phenyl)-(3-methyl-azetidin-3-yl)-{5-[3-(t etrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3- yl}-methanol, hydrochloride salt

Example 82.1 (27.5mg) was dissolved with HCI in dioxane (4M, 0.13mL). The reaction mixture was stirred at RT until completion, was concentrated in vacuo, dried under HV and used without further purification. LC-MS (A): t _R = 0.74min; [M+H]+: 447.33. 82.3. (R)-(4-Cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[ 3-(tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]- pyridin-3-yl}-methanol The title compound was prepared starting from Example 82.2, and following the procedure described in Example D1.1 step D1.1.5. LC-MS (B): t _R = 0.68min; [M+H]+: 461.40.

Example 83 to Example 93 were synthesized starting from the appropriate compounds of Formula (E1) and (E2) and following the three-step procedure described in Example 82, and were purified by Prep LC-MS at the end of the sequence if needed. The precursors of Formula (E1) and (E2) are indicated in the table below unless commercially available. The Prep LC-MS methods and the LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B) except for Example 92 where the LC-MS conditions used were LC-MS (A).

Example 94: (R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3-morpho lin-4-yl-[1 ,2,4]oxadiazol-5-yl)-pyridin-3- yl]-methanol

94.1. 3-[(R)-[5-(3-Amino-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-hydr oxy-(4-isopropyl-phenyl)-methyl]-3-methyl-azetidine-1- carboxylic acid tert-butyl ester The title compound was prepared starting from Example E1.1 and N-hydroxyguanidine sulfate and using the conditions described in Example 82 step 82.1. The material was purified by Prep LC-MS (VI). LC-MS (A): t _R = lOOmin; [M+H]+: 480.39.

94.2. (R)-[5-(3-Chloro-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(4-iso propyl-phenyl)-(3-methyl-azeticlin-3-yl)-methanol

To an ice-cold solution of Example 94.1 (9mg) in cone. HCI (37% fuming, O.lmL) was added a solution of sodium nitrite (1.31 mg) in water (0.05mL). The reaction mixture was stirred at 0°C for 1 h, diluted with water and quenched with solid

NaHC0 ₃ . The mixture was extracted with DCM and the combined org. layers were filtered over a phase separator, concentrated in vacuo and dried under HV to afford the title compound (7.5mg) that was used without further purification. LC-MS (A): t _R = 0.77min; [M+H]+: 399.28.

94.3. (R)-[5-(3-Chloro-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]-(1,3-d imethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol The title compound was synthesized starting from Example 94.3 and using the conditions described in Example F1.1 step F1.1.2. LC-MS (A): t _R = 0.79min; [M+H]+: 413.3.

94.4. (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3- morphoHn-4-yl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]- methanol

Example 94.3 (7.7mg) was dissolved in EtOH (0.1mL) and transferred in a sealed vial. Morpholine (33.2 L) and DIPEA (64.4 L) were added and the reaction mixture was heated at 90°C for 4h. The mixture was cooled down to RT, diluted in MeCN and purified by Prep LC-MS (IX) to afford the title compound as white solid (0.5mg). LC-MS (A): tR = 0.76min; [M+H]+: 464.4.

Example 95: (R)-(4-Cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[ 3-(4-methoxy-tetrahydro-pyran-4-yl)- [1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-methanol

95.1. 3-((R)-(4-Cyclopropyl-phenyl)-hydroxy-{5-[3-(4-methoxy-tetra hydro-pyran-4-yl)-[1,2,4]oxadiazol-5-yl]-pyiidin-3- yl}-methyl)-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

A sealed vial was charged with Example E1.2 (100mg) and DMF (2.2mL) was added, followed by DIPEA (0.12mL) and PyBOP (182mg). After stirring at RT for 15min, Example E2.3 (79.4mg) and K3PO4 (198mg) were added. The reaction mixture was heated overnight at 100°C. The mixture was cooled down to RT, partitioned between DCM and water/sat. aq. NaHCCh. The phases were separated, and the aq. layer was extracted twice with DCM. The org. layers were filtered over a phase separator and concentrated to dryness. The residue was purified by Prep LC-MS (XII) to afford the desired product as white solid (94.7mg). LC-MS (A): tR = 1.08min; [M+H]+: 577.21.

95.2. (R)-(4-Cyclopropyl-phenyl)-{5-[3-(4-methoxy-tetrahydro-pyran -4-yl)-[1,2,4]oxadiazol-5-yl]-pyridin-3-yl}-(3-methyl- azetidin-3-yl)-methanol, hydrochloride salt

Example 95.2 was prepared starting from Example 95.1 and following the procedure described in Example 82 step

82.2. LC-MS (A): t _R = 0.72min; [M+H]+: 477.28.

95.3. (R)-(4-Cyclopropyl-phenyl)-(1,3-dimethyl-azetidin-3-yl)-{5-[ 3-(4-methoxy-tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol- 5-yl]-pyridin-3-yl}-methanol

Example 95.3 was prepared starting from Example 95.2 and following the procedure described in Example D1.1 step D1.1.5. The material was purified by Prep LC-MS (IX). LC-MS (B): t _R = 0.693min; [M+H]+: 491.3.

Example 96 to Example 102 were synthesized starting from the appropriate compounds of Formula (E1) and (E2) and following the three-step procedure described in Example 95, and were purified by Prep LC-MS at the end of the sequence if needed. The precursors of Formula (E1) and (E2) are indicated in the table below unless commercially available. The Prep LC-MS methods and the LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

Example 103: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5- methanesulfonylmethyl-[1,2,4]oxadiazol-3- yl)-pyridin-3-yl]-methanol

A mixture of Example D2.1 (25.4mg), 2-(methylsulfonyl)acetic acid (10.7mg), PyBOP (53.9mg), K3PO4 (29.8mg) and DIPEA (18mI_) in DMF (0.8mL) was heated at 85°C for 16h, cooled down to RT, and water (200mI_) was added. The resulting solution was purified by Prep LC-MS (IX) then (V) to afford the desired product. LC-MS (B): tR = 0.646min; [M+H] ⁺ : 471.3.

Example 104 to Example 133 were synthesized starting from Example D2.1 and the appropriate carboxylic acid of Formula (D3), and following the procedure described in Example 103. The Prep LC-MS methods used are indicated in the table below. LC-MS data of Example 104 to 133 are listed in the table below. The LC-MS conditions used were LC- MS (B).

Example 134: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5- (2-methoxy-1,1 -dimethyl-ethyl)- [1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol A mixture of Example D2.1 (40mg), 3-methoxy-2,2-dimethylpropanoic acid (15.8mg), PyBOP (86.8mg), K3P04(92.2mg) and DIPEA (55.8 L) in DMF (1 mL) was heated at 80°C for 20h, cooled down to RT, quenched with water and extracted with DCM. The combined organic layers were dried (MgS0 ₄ ), filtered off and concentrated in vacuo. The residue was purified by Prep LC-MS (XVIII) and (VIII) to afford 25mg of the desired product. LC-MS (B): tR = 0.834min; [M+H]-: 465.3.

Example 135 to 138 were synthesized starting from Example D2.1 and the appropriate carboxylic acid of Formula (D3), and following the procedure described in Example 134. LC-MS data of Example 135 to 138 are listed in the table below. The LC-MS conditions used were LC-MS (B). The Prep LC-MS methods used are indicated in the table below. pyridin-3-yl}-methanol

The title compound was obtained starting from Example D2.1 and 3-(1H-pyrazol-1-yl)propanoic acid, and following the procedure described in Example 82 step 82.1, but heating the reaction mixture at 100°C. The crude material was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.75min; [M+H] ⁺ : 473.3.

Example 140: (R)-N-(2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopr opylphenyl)methyl)pyridin-3-yl)-1,2,4- oxadiazol-5-yl)ethyl)acetamide-2,2,2-d3

140.1. 3-[(R)-{5-[5-(2-Benzyloxycarbonylamino-ethyl)-[1,2,4]oxadiaz ol-3-yl]-pyridin-3-yl}-hydroxy-(4-isopropyl-phenyl)- methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester The title compound was obtained starting from Example D2.2 and Cbz-beta-Alanine, and following the procedure described in Example 134. LC-MS (A): t _R = 1.12min; [M+H] ⁺ : 642.18.

140.2. 3-[(R)-{5-[5-(2-Amino-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridin- 3-yl}-hydroxy-(4-isopropyl-phenyl)-methyl]-3-methyl- azetidine-1 -carboxylic acid tert-butyl ester

A mixture of Example 140.1 (76.4mg) and Pd/C (9.88mg) in EtOH (2mL) under Eh atmosphere was stirred at RT for 6h, filtered over a glass paper fiber filter and the filtrate was concentrated in vacuo and dried under HV to afford 30.2 mg of the title compound. LC-MS (A): t _R = 0.81 min; [M+H] ⁺ : 508.01 .

140.3. tert-Butyl (R)-3-((5-(5-(2-(acetamido-2,2,2-d3)ethyl)-1,2,4-oxadiazol-3 -yl)pyridin-3-yl)(hydroxy)(4- isopropylphenyl)methyl)-3-methylazetidine- 1 -carboxylate

A mixture of Example 140.2 (30.2mg), acetic acid-2, 2, 2-d ₃ (99 atom % D, 10.2pL), HOBt (9.65mg), DIPEA (30.6 L) and EDC.HCI (13.7mg) in DCM (1mL) was stirred overnight at RT, quenched with aq. sat. NaHC0 ₃ and extracted with DCM. The combined org. layers were dried (MgS0 ₄ ), filtered off and concentrated in vacuo to afford 32.9mg of the title compound. LC-MS (A): t _R = 0.99min; [M+H]-: 533.25.

140.4. (R)-N-(2-(3-(5-(hydroxy(4-isopropylphenyl)(3-methylazetidin- 3-yl)methyl)pyridin-3-yl)-1, 2, 4-oxadiazol-5- yl)ethyl)acetamide-2,2,2-d ₃ , hydrochloride salt

A solution of Example 140.3 (32.9mg) in HCI in dioxane (4M, 2mL) was stirred at RT for 30min, concentrated in vacuo and dried under HV to afford 29.1 mg of the title compound. LC-MS (A): t _R = 0.66min; [M+H] ⁺ : 453.06.

140.5. (R)-N-(2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopr opylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5- yl)ethyl)acetamide-2, 2, 2-d ₃

The title compound was obtained starting from Example 140.4, and following the procedure described in Example D1.1 step D 1.1 .5. The reaction mixture was filtered off and the filtrate was purified by Prep LC-MS (IX) and (V) to afford the desired compound (6.9mg) as a white powder. LC-MS (B): t _R = 0.617min; [M+H] ⁺ : 467.3.

Example 141 to Example 143 were synthesized starting from Example D2.2, and following the five-step procedure described in Example 140, using the appropriate carboxylic acid derivative of Formula (D3) in the first step. The Prep LC-MS methods and the LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

[1.2.4]oxadiazol-5-yl)-ethyl]-2-hydroxy-N-methyl-acetamid e

144.1. 3-(tert-Butoxycarbonyl-methyl-amino)-propionic acid benzyl ester

To a solution of 3-[(tert-butoxycarbonyl)(methyl)amino]propanoic acid (100mg) in DMF (1mL) were added benzyl bromide (58.4mI_) and K ₂ CO ₃ (66.6mg). The reaction mixture was stirred at RT for 2h, quenched with water and extracted with EA. The org. layer was dried (MgS0 ₄ ), filtered off, concentrated in vacuo and dried under HV to afford 141 mg of the title compound. LC-MS (A): t _R = 0.99min; [M+H]-: 294.1.

144.2. 3-Methylamino-propionic acid benzyl ester, hydrochloride salt

A solution of Example 144.1 (141 mg) in HCI in dioxane (4M, 3mL) was stirred at RT for 30min, concentrated in vacuo and dried under HV to afford 46.6mg of the title compound. LC-MS (A): t _R = 0.51 min; [M+H] ⁺ : 194.21.

144.3. 3-[(2-Hydroxy-acetyl)-methyl-amino]-propionic acid benzyl ester

The title compound was obtained starting from Example 144.2 and glycolic acid, and following the procedure described in Example 140 step 140.3. LC-MS (A): t _R = 0.67min; [M+H] ⁺ : 252.07.

144.4. 3-[(2-Hydroxy-acetyl)-methyl-amino]-propionic acid

A mixture of Example 144.3 (60.6mg) and Pd/C (19.9mg) in EA (1mL) under H ₂ atmosphere was stirred at RT for 3h. Additional Pd/C was added and the reaction mixture was stirred overnight at RT, filtered over a glass paper fiber filter. The filtrate was concentrated in vacuo and dried under HV to afford 19.4mg of the desired compound. LC-MS (A): t _R = 0.26min; [M+H] ⁺ : 162.2.

144.5. 3-[(R)-Hydroxy-[5-(5-{2-[(2-hydroxy-acetyl)-methyl-amino]-et hyl}-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-(4- isopropyl-phenyl)-methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was obtained starting from Example D2.2 and Example 144.4, and following the procedure described in Example 134, but with a second addition of reagents after the night and an additional night of stirring. LC- MS (A): t _R = 0.97min; [M+H] ⁺ : 580.01.

144.6. 2-Hydroxy-N-[2-(3-{5-[(R)-hydroxy-(4-isopropyl-phenyl)-(3-me thyl-azetidin-3-yl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-ethyl]-N-methyl-acetamide, hydrochloride salt A solution of Example 144.5 (68.4mg) in HCI in dioxane (4M, 2mL) was stirred at RT for 1 h, concentrated in vacuo and dried under HV to afford 60.9mg of the title compound. LC-MS (A): t _R = 0.65min; [M+H]-: 480.0.

144.7. N-[2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5-yl)-ethyl]-2-hydroxy-N-methyl-acetamide The title compound was obtained starting from Example 144.6, and following the procedure described in Example 82 step 82.3, with a direct filtration of the reaction mixture and purification by Prep LC-MS (IX) and (VI) to afford 6.2mg of the desired compound. LC-MS (B): t _R = 0.616min; [M+H]"·: 494.4.

Example 145: (R)-N-(2-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopr opylphenyl)methyl)pyridin-3-yl)-1,2,4- oxadiazol-5-yl)ethyl)-N-methylacetamide-d3 The title compound was obtained starting from Example 144.2, and following the procedure described in Example 144 step 144.3 to 144.7, using acetic acid-2, 2, 2-d ₃ instead of glycolic acid in step 144.3. The crude material was purified by Prep LC-MS (IX) and (VI). LC-MS (B): t _R = 0.651 min; [M+H] ⁺ : 481.3.

Example 146: (1,3-Dimethyl-azetidin-3-yl)-(6-methoxy-pyridin-3-yl)-(4-tri fluoromethoxy-phenyl)-methanol 5-Bromo-2-methoxypyridine (110 L) and iPrMgCI.LiCI (1.3M in THF, 704 L) were dissolved in THF (0.5mL) and the resulting solution was stirred for 2h at 60°C. A solution of Example B2.1 (100mg) in THF (0.5mL) was added, the resulting mixture was stirred for 4h at RT and was quenched with aq. sat. NH4CI, diluted with water and extracted with DCM. The org. layers were evaporated to dryness. The resulting crude material was purified by Prep LC-MS (VI) to afford 50mg of the title compound as brown solid. LC-MS (A): t _R = 0.74min; [M+H]+: 383.20.

Example 147 to Example 149 were synthesized starting from the appropriate commercially available bromo derivative and following the procedure described in Example 146. Prep LC-MS conditions and LC-MS data of Example 147 to Example 149 are listed in the table below. The LC-MS conditions used were LC-MS (A). An additional purification step was performed with Example 147 (Preparative TLC, 0.5mm, 254nm, eluent DCM/MeOH 95/5 +0.1% TEA). 150.1. 3-[Hydroxy-(4-propyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl )-methyl]-3-methyl-azetidine-1 -carboxylic acidtert- butyl ester

The title compound was synthesized starting from Example C1.1 and 1-bromo-4-propylbenzene, following the procedure described in Example 146. The resulting crude material was purified by Prep LC-MS (VII). LC-MS (A): t _R = 0.92min; [M+H] ⁺ : 466.13.

150.2. (3-Methyl-azetidin-3-yl)-(4-propyl-phenyl)-(5-pyrrolidin-1-y l-pyridin-3-yl)-methanol

A solution of Example 150.1 (11 mg) in MeOH (0.1 mL) and HCI in dioxane (4M, 0.5mL) was stirred for 4h, was basified with 1 M NaOH solution, diluted with water and extracted with DCM. The org. layers were evaporated to dryness to give 14mg of the title compound as white solid. LC-MS (A): t _R = 0.62min; [M+H]-: 366.35. 150.3. (1,3-Dimethyl-azetidin-3-yl)-(4-propyl-phenyl)-(5-pyrrolidin -1-yl-pyridin-3-yl)-methanol

The title compound was synthesized starting from Example 150.2 and following the procedure described in Example F1.1 step F1.1.2. LC-MS (A): t _R = 0.62min; [M+H] ⁺ : 380.41.

Example 151 to Example 157 were synthesized starting from the appropriate commercially available bromo derivative and following the three-step procedure described in Example 150. Prep LC-MS conditions and LC-MS data of Example 151 to Example 157 are listed in the table below. The LC-MS conditions used were LC-MS (A). Example 158 to Example 161 were synthesized starting from Example C3.1 and the appropriate bromo derivative, following the procedure described in Example A4.1 step A4.1.2. Prep LC-MS conditions and LC-MS data of Example 158 to Example 161 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 162: (S)-[2-(3,3-Difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3-dim ethyl-azetidin-3-yl)-(4-isopropyl-phenyl)- methanol

162.1. 3-[(S)-[2-(3,3-Difluoro-pyrroHdin-1-yl)-pyridin-4-yl]-hydrox y-(4-isopropyl-phenyl)-methyl]-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

Example F1.4 (35mg) and 3,3-difluoropyrrolidine (18.3mg) were suspended in toluene (1mL), and BINAP (3.03mg), Pd2(dba)3 (1.53mg) and NaOtBu (24.1 mg) were added. The reaction mixture was stirred for 4h at 100°C, cooled down to RT, filtered off and evaporated to dryness. The residue was purified by Prep LC-MS (XIV) to afford 33.5mg of the title compound as white solid. LC-MS (A): tR = 0.89min; [M+H] ⁺ : 502.31.

162.2. (S)-[2-(3, 3-Difluoro-pyrroHdin-1-yl)-pyridin-4-yl]-(4-isopropyl-phenyl )-(3-methyl-azetidin-3-yl)-methanol, hydrochloride salt

Example 162.1 (32.5mg) was dissolved in HCI in dioxane (4M, 0.5mL) and the reaction mixture was stirred for 4h at RT and evaporated to dryness to give 42.7mg of the title compound as colorless oil which was used without purification. LC-MS (A): t _R = 0.59min; [M+H] ⁺ : 402.00.

162.3. (S)-[2-(3,3-Difluoro-pyrroHdin-1-yl)-pyridin-4-yl]-(1,3-dime thyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol

The title compound was synthesized starting from Example 162.2, and following the procedure described in Example F1.1 step F1.1.2. The crude material was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.61 min; [M+H] ⁺ : 416.25. Example 163: (S)-[2-((3R,4S)-3,4-Difluoro-pyrrolidin-1-yl)-pyridin-4-yl]- (1,3-dimethyl-azetidin-3-yl)-(4-isopropyl- phenyl)-methanol 163.1. 3-[(S)-[2-( ( 3R, 4S) -3, 4-Difluoro-pyrrolidin- 1 -yl) -pyridin-4-yl]-hydroxy-( 4-isopropyl-phenyl) -methyl]-3-methyl- azehdine-1-carboxy\\c acid tert-butyl ester

Example F1.7 (40mg), cis-3,4-difluoropyrrolidine hydrochloride (68.7mg) and DIPEA (159mI_) were dissolved in NMP (2mL) and the mixture was stirred for 22h at 150°C. DIPEA (159mI_) and cis-3,4-difluoropyrrolidine hydrochloride (68.7mg) were added, the mixture was further stirred for 2h at 150°C, and the solvent was evaporated in vacuo. The residue was purified by Prep LC-MS (IX) to afford 11 ,7mg of the title compound as beige solid. LC-MS (A): t _R = 0.89min; [M+H]-: 502.32.

163.2. (S)-[2-(( 3R, 4S) -3, 4-Difluoro-pyrrolidin- 1 -yl)-pyridin-4-yl]-( 4-isopropyl-phenyl) -( 3-methyl-azetidin-3-yl) -methanol, hydrochloride salt

Example 163.1 (11.7mg) was dissolved in HCI in dioxane (4M, 0.2mL) and the mixture was stirred for 1h at RT and evaporated to dryness to give 13mg of the title compound as colorless oil, which was used without further purification. LC-MS (A): t _R = 0.58min; [M+H] ⁺ : 402.01.

163.3. (S)-[2-((3R,4S)-3,4-Difluoro-pyrrolidin-1-yl)-pyhdin-4-yl]-( 1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)- methanol

The title compound was synthesized starting from Example 163.2 and following the procedure described in Example F1.1 step F1.1.2. The resulting crude material was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.61min; [M+H]-: 416.25.

Example 164: (S)-(1,3-Dimethyl-azetidin-3-yl)-(2-isobutoxy-pyridin-4-yl)- (4-isopropyl-phenyl)-methanol

164.1. (S)-(2-lsobutoxy-pyridin-4-yl)-(4-isopropyl-phenyl)-(3-methy l-azetidin-3-yl)-methanol

To a solution of Example F1.4 (40mg) in 2-methyl-1 -propanol (1mL) was added NaH (60% in mineral oil, 26.7mg) and the resulting mixture was stirred for 70h at 110°C. After cooling down, the mixture was diluted with MeCN/water and purified by Prep LC-MS (XIV) to afford 25.3mg of the title compound as white solid. LC-MS (A): t _R = 0.82min; [M+H]-: 369.14.

164.2. (S)-(1,3-Dimethyl-azetidin-3-yl)-(2-isobutoxy-pyridin-4-yl)- (4-isopropyl-phenyl)-methanol

The title compound was synthesized starting from Example 164.1 (25.3mg) and following the procedure described in Example F1.1 step F1.1.2. The resulting crude material was purified by Prep LC-MS (VIII). LC-MS (A): t _R = 0.84min; [M+H]"·: 383.23.

Example 165: 4-{4-[(S)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-2-yl}-2-methyl- butan-2-ol

165.1. 3-[(S)-Hydroxy-[2-(3-hydroxy-3-methyl-but-1-ynyl)-pyridin-4- yl]-(4-isopropyl-phenyl)-methyl]-3-methyl-azetidine- 1-carboxy\\c acid tert-butyl ester Example F1.4 (40mg) and 2-methyl-3-butyn-2-ol (13.8mI_) were dissolved in DMF (1mL). Cul (0.884mg), PPh3 (5.13mg), Pd(PPh) ₃ CI ₂ (3.29mg), and Et ₂ NH (150mί) were added and the reaction mixture was stirred for 17h at 60°C. After cooling down, DCM was added and the resulting mixture was washed with water and brine, dried (MgS0 ₄ ), filtered off and evaporated to dryness. The residue was purified by Prep LC-MS (XX) to afford 38.2mg of the title compound as white solid. LC-MS (A): t _R = 0.82min; [M+H] ⁺ : 479.32.

165.2. 3-[(S)-Hydroxy-[2-(3-hydroxy-3-methyl-butyl)-pyridin-4-yl]-( 4-isopropyl-phenyl)-methyl]-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example 165.1, and following the procedure described in Example 48. LC-MS (A): t _R = 0.85min; [M+H] ⁺ : 483.34.

165.3. 4-{4-[(S)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-azetidin-3- yl)-methyl]-pyridin-2-yl}-2-methyl-butan-2-ol, hydrochloride salt

Example 165.2 (34.4mg) was dissolved in HCI in dioxane (4M, 0.6mL), the mixture was stirred for 1 h at RT and was evaporated to dryness to give the title compound (43.6mg) as yellow oil. LC-MS (A): t _R = 0.54min; [M+H]-: 383.24.

165.4. 4-{4-[(S)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-2-yl}-2-methyl-butan-2-ol The title compound was synthesized starting from Example 165.3, and following the procedure described in Example F1.1 step F1.1.2. The crude material was purified by Prep LC-MS (XIV). LC-MS (A): t _R = 0.55min; [M+H] ⁺ : 397.28. Example 166: (R)-[6-(3,3-Difluoro-pyrrolidin-1-yl)-pyridazin-4-yl]-(1,3-d imethyl-azetidin-3-yl)-(4-isopropyl-phenyl)- methanol

Example F1.6 (35mg) was dissolved in dioxane (1mL), and DIPEA (55.6 L) and 3,3-difluoropyrrolidine (22mg) were added. The reaction mixture was stirred for 48h at 100°C. After cooling down, MeCN/water was added and the resulting material was first purified by Prep LC-MS (VI) then by Prep LC-MS (IX) to afford the title compound (5.1 mg) as white solid. LC-MS (A): t _R = 0.65min; [M+H] ⁺ : 417.10.

Example 167: (S)-5-tert-Butyl-3-{5-[(R)-(1 ,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}- oxazolidin-2-one

167.1. 5-tert-Butyl-3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-oxazolidin- 2-one

Example F1.2 (50mg) and Example F4.5 (18.4mg) were dissolved in dioxane (2.5mL), K ₂ C0 ₃ (35.5mg), N,N- dimethylethylenediamine (14 L) and Cul (24.6mg) were added and the reaction mixture was stirred for 44h at 110°C. The reaction mixture was allowed to cool down to RT, was filtrated off and evaporated to dryness. The residue was purified by Prep LC-MS (VII) to afford 33mg of the title compound as white solid. LC-MS (A): t _R = 0.77min; [M+H] ⁺ : 452.31. 167.2. (S)-5-tert-Butyl-3-{5-[(R)-( 1, 3-dimethyl-azetidin-3-yl)-hyclroxy-(4-isopropyl-phenyl)-meth yl]-pyriclin-3-yl}- oxazolidin-2-one

The title compound (3mg) was obtained by Prep chiral SFC (XIV) of Example 167.1 (20.9mg) followed by Prep LC-MS (VI). The stereochemistry at the oxazolidinone ring was arbitrarily assigned. LC-MS (B): t _R = 0.767min; [M-HH]-: 452.5; Chiral SFC (N): 4.0min.

Example 168: (R)-1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3- ol

168.1. (3R)-1-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylp henyl)methyl)pyridin-3-yl)pyrrolidin-3-ol

The title compound was synthesized starting from Example F1.1 and (R)-3-pyrrolidinol, following the procedure described in Example 162 step 162.1. The crude material was purified by Prep LC-MS (V) to afford 40mg of the title compound as white solid. LC-MS (A): t _R = 0.54min; [M+Fi]-: 396.40.

168.2. (R)-1-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-pyrrolidin-3-ol The title compound was obtained by Prep chiral SFC (X) of Example 168.1. LC-MS (A): tR = 0.54min; [M+H]-: 396.41. Chiral SFC (K): t _R = 1.3min.

Example 169 and Example 170 were synthesized starting from Example F1.1 and the appropriate amine reagent, and following the two-step procedure described in Example 168. Chiral Prep SFC conditions, Chiral SFC and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

Example 171 to Example 188 were synthesized starting from the appropriate compound of -ormula (F1) and amine reactant, and following the procedure described in Example 162 step 162.1. Prep LC-MS conditions, compounds of

Formula (F1) and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

The title compound (192mg, white powder) was synthesized starting from Example A7.1 (339mg), and following the procedure described in Example F1.1 step F1.1.2. The crude material was purified by Prep LC-MS (VI). LC-MS (A): t _R = 0.61 min; [M+H] ⁺ : 422.30. Example 190: (R)-{5-[5-(1-Cyclopropanesulfonyl-piperidin-4-yl)-[1, 2, 4]oxadiazol-3-yl]-pyridin-3-yl}-(1, 3-dimethyl- azetidin-3-yl)-(4-isopropyl-phenyl)-methanol 190.1. 4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- yl)-piperidine-1 -carboxylic acid tert-butyl ester

The title compound (750mg, white powder) was obtained starting from Example D2.1 (1.01g) and N-Boc-isonipecotic acid (1.02g), and following the procedure described in Example 134. The crude material was however purified by prep LC-MS (XXIV) and (XXV). LC-MS (A): t _R = 0.88min; [M+H] ⁺ : 561.90.

190.2. (R)-(1,3-dimethylazetidin-3-yl)(4-isopropylphenyl)(5-(5-(pip eridin-4-yl)-1,2,4-oxadiazol-3-yl)pyridin-3- yljmethanol, hydrochloride salt

A solution of Example 190.1 (750mg) in HCI in dioxane (4M, 15mL) was stirred at RT for 2h, concentrated in vacuo and dried under HV to afford 714mg of the title compound. LC-MS (A): t _R = 0.57min; [M+H] ⁺ : 462.12.

190.3. (R)-{5-[5-( 1 -Cyclopropanesulfonyl-piperidin-4-yl)-[ 1,2, 4]oxadiazol-3-yl]-pyridin-3-yl}-( 1, 3-dimethyl-azetidin-3-yl)- (4-isopropyl-phenyl)-methanol

A solution of Example 190.2 (29.8mg) and DIPEA (38 L) in DCM (1mL) was stirred at -20°C for 1 h. Cyclopropanesulfonyl chloride (5.7 L) was added, the resulting mixture was stirred overnight at RT and evaporated in vacuo. The crude material was purified by Prep LC-MS (XIV) followed by Prep LC-MS (VI) to afford the title compound (12mg) as white powder. LC-MS (A): t _R = 0.80min; [M+H]"-: 566.03.

Example 191 : 2-({5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-methyl- amino)-ethanol

Example 183 (25mg) was dissolved in EtOH (1mL), and TEA (13.4 L) and Pd/C (10% w/w, 50% water, 2.55mg) were added and the reaction mixture was stirred at RT under hydrogen for 18h. The same amounts of TEA and Pd/C were added again and the mixture was further stirred at RT under hydrogen for 24h. The mixture was filtered off and the same amount of Pd/C was added to the resulting solution. The mixture was stirred under hydrogen for 17h. The same procedure was repeated 3 times and the mixture was finally filtered off and evaporated in vacuo. The residue was purified by Prep LC-MS (IX) to afford 4mg of the title compound as white solid. LC-MS (B): t _R = 0.396min; [M+H]-: 384.40.

Example 192: (R)-1-((S)-1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}- pyrrolidin-3-yl)-ethanol

192.1. (S)-1-Pyrrolidin-3-yl-ethanone, hydrochloride salt

Tert-butyl-(3S)-3-acetylpyrrolidine-1-carboxylate (100mg) was dissolved in HCI in dioxane (4M, 1mL), the reaction mixture was stirred for 1h30 at RT and evaporated to dryness to give 69mg of the title compound as brown oil which was used without further purification. LC-MS (A): t _R = 0.2min; [M+H] ⁺ : 114.24.

192.2. 1-((S)-1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)- ethanone The title compound was synthesized starting from Example F1.2 and Example 192.1, and following the procedure described in Example 162 step 162.1. The crude material was purified by Prep LC-MS (VI) to afford. LC-MS (A): t _R = 0.6min; [M+H] ⁺ : 422.38.

192.3. (R)-1-((S)-1 -{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-pyrroHdin-3- yl) -ethanol

Example 192.2 (41 mg) was dissolved in MeOH (0.5mL) and NaBEU (3.86mg) was added at 0°C. The reaction mixture was stirred for 3h at 0°C then for 70h at RT. The reaction mixture was diluted with water, extracted with DCM, and the org. layers were evaporated to dryness. The residue was purified by Prep LC-MS (V) to afford the title compound as first eluting peak (11 mg) as white solid. The stereochemistry at the a-carbon to the secondary hydroxy group was arbitrarily assigned to (R). LC-MS (B): t _R = 0.458min; [M+H] ⁺ : 424.4.

Example 193 to Example 221 were synthesized from Example F1.2 and the appropriate compound of Formula (F3) or Formula (F4), following the procedure described in Example 167 step 167.1. Compounds of Formula (F3) or Formula (F4), unless commercially available, Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

Example 222: 1-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridazin-3-yl}-pyrrolidin-2- one

The title compound was synthesized starting from Example F1.6 and 2-pyrrolidone, and following the procedure described in Example 167 step 167.1. The crude material was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.68min; [M+H] ⁺ : 395.19.

Example 223: (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((R)-3- isopropyl-pyrrolidin-1-yl)-pyridin-3-yl]- methanol

223.1. 3-Hydroxy-3-isopropenyl-pyrrolidine-1 -carboxylic acid tert-butyl ester

To a solution of N-Boc-3-pyrrolidinone (1g) in THF (7mL) was added at RT isopropenylmagnesium bromide in THF (0.5M, 11.7mL). The resulting mixture was stirred for 15min at 70°C, allowed to cool down to RT, poured into aq. sat.

NH ₄ CI solution and extracted with EA. The org. layers were dried (MgS0 ₄ ), filtrated off and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 50g, solvent A: Hep; solvent B: EA; gradient in %B: 30 over 3CV, 30 to 50 over 3CV, 50 over 2CV) to afford 249mg of the title compound as yellow oil. LC-MS (A): t _R = 0.78min; [M+H] ⁺ : 228.20 223.2. 3-lsopropyl-pyrrolidine- 1 -carboxylic acid tert-butyl ester

A mixture of Example 223.1 (243mg) and Pd/C (10% w/w, 50% water, 113mg) in MeOH (3.5mL) was stirred for 1h30 at RT under hydrogen atmosphere, filtrated off and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAP 10g, solvent A: Hep; solvent B: EA; gradient in %B: 10 over 2CV, 10 to 50 over 10CV, 50 over 2CV) to afford 50mg of the title compound as yellow oil. LC-MS (A): t _R = 1.02min; [M+H] ⁺ : 214.36. 223.3. 3-lsopropyl-pyrrolidine, hydrochloride salt A mixture of Example 223.2 (47mg) in HCI in dioxane (4M, 0.5mL) was stirred for 1 h at RT and evaporated to dryness under HV to give 38mg of the title compound as brown solid. LC-MS (A): t _R = 0.42min; [M+H] ⁺ : 114.28.

223.4. (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-((R)-3- isopropyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol Example F1.2 (50mg) and Example 223.3 (20.2mg) were dissolved in toluene (1mL), XantPhos (3.83mg), Pd2(dba)3 (6.06mg) and NaOtBu (27.4mg) were added and the resulting mixture was stirred for 18h at 100°C. The reaction mixture was allowed to cool down to RT, filtrated off and evaporated to dryness. The residue was purified by Prep LC-MS (VII) then by Prep LC-MS (IX) to afford 6mg of the title compound as white solid. LC-MS (B): t _R = 0.665min; [M+H] ⁺ : 422.5. Example 224 to Example 244 were synthesized from the appropriate amine reactant and compound of Formula (F1), and following the procedure described in Example 223 step 223.4. Compounds of Formula (F1), Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

The title compound was synthesized following the four-step procedure described in Example G1.2 step G1.2.1 to step G1.2.4. LC-MS (B): t _R = 0.783min; [M+H] ⁺ : 417.40.

Example 246: (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(2-pyri din-2-yl-ethoxy)-pyridin-3-yl]-methanol To a solution of Example G1.1 (30mg) and 2-(2-hydroxyethyl)pyridine (19.3mί) in toluene (1mL) was added cyanomethyltributylphosphorane (44.4mg). The reaction mixture was stirred for 23h at 110°C and evaporated to dryness. The residue was purified by Prep LC-MS (VI) then by Prep LC-MS (IX) to afford 8mg of the title compound as off-white solid. LC-MS (B): t _R = 0.532min; [M+H] ⁺ : 432.40.

Example 247 to Example 259 were synthesized from the appropriate compounds of Formula (G1) and (G2), and following the procedure described in Example 246. Compounds of Formula (G1), Prep LC-MS conditions, and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

Example 260: 2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yloxy}-ethano A mixture of Example 258 (9mg) and Pd(OH)2/C (20%, 0.686mg) in MeOH (0.5mL) was stirred for 55h at RT under hydrogen atmosphere, was filtered off and evaporated to dryness. The resulting crude material was redissolved in MeOH (0.5mL), the same amount of Pd(OH) ₂ /C was added, and the resulting mixture was stirred for 21 h at RT under hydrogen atmosphere, filtered off, evaporated to dryness and purified by Prep LC-MS (V) to afford 1mg of the title compound as white solid. LC-MS (B): tR = 0.512min; [M+H] ⁺ : 371.40.

Example 261 : 4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yloxy}- cyclohexanol

261.1. (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(1,4-dioxa-spiro[4.5]dec -8-yloxy)-pyhdin-3-yl]-(4-isopropyl-phenyl)-methanol

The title compound was synthesized from 1 ,4-dioxaspiro[4,5]decan-8-ol and Example G1 .2, and following the procedure described in Example 246. The crude material was purified by Prep LC-MS (VI). LC-MS (A): tR = 0.69min; [M+H] ⁺ : 467.18.

261.24-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-is opropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanone

To an ice-cold solution of Example 261.1 (58mg) in dioxane (0.6mL) were added H ₂ SO ₄ (0.12mL) and water (0.12mL). The resulting mixture was stirred for 4h at 0°C, basified with aq. sat. NaHC03 solution, diluted with water and extracted with DCM. The org. phases were dried (MgS0 ₄ ), filtrated off and evaporated to dryness to give 31 mg of the title compound as white solid. LC-MS (A): t _R = 0.65min; [M+H] ⁺ : 423.19.

261.34-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-is opropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanol

To an ice-cold solution of Example 261.2 (10mg) in MeOH (0.3mL) was added NaBH ₄ (0.94mg). The resulting mixture was stirred for 1h at 0°C, quenched with water and extracted with DCM. The org. phases were dried (MgS0 ₄ ), filtrated off, evaporated to dryness and purified by Prep LC-MS (V) to give 5mg of the title compound as white solid. LC-MS (A): t _R = 0.61min; [M+H] ⁺ : 425.22.

Example 262: 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yloxy}-1 -methyl- cyclohexanol

To a solution of Example 261.2 (16mg) in THF (0.5mL) was added dropwise methylmagnesium bromide in Et ₂ 0 (3M, 44.3 L). The resulting mixture was stirred for 1h25 at RT, quenched with aq. sat. NH ₄ CI solution and extracted with DCM. The org. layers were dried (MgS0 ₄ ), filtrated off and evaporated to dryness. The resulting crude material was purified by Prep LC-MS (VI) to afford 7mg of the title compound as white powder. LC-MS (A): tR = 0.63min; [M+H] ⁺ : 439.22.

Example 263 to Example 265 were synthesized starting from Example B2.1 and the appropriate bromoderivative of Formula (A5), and following the procedure described in Example A7.1 step A7.1.1. Prep LC-MS conditions and LC-MS data of Example 263 to Example 265 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 266: (1 ,3-Dimethyl-azetidin-3-yl)-(6-fluoro-5-pyrrolidin-1-yl-pyrid in-3-yl)-(4-trifluoromethoxy-phenyl)- methanol

266.1. 5-Bromo-2-fluoro-3-pyrrolidin-1-yl-pyridine

To an ice-cold solution of 3-amino-5-bromo-2-fluoropyridne (200mg) in THF (4m L) and MeOH (4mL) was added H2SO4 (222mI_) in water (1.78mL), followed by 2,5-dimethoxytetrahydrofuran (403mί) and finally NaBH ₄ portionwise (115mg).

The resulting mixture was stirred for 21 h at RT, diluted with water and basified with aq. sat. NaHC0 ₃ solution. The org. layer was washed with water and brine, dried (MgS0 ₄ ), filtrated off and evaporated to dryness. The residue was purified by CC (Biotage, SNAP 10g, solvent A: Hep; solvent B: EA; gradient in %B: O over 1CV, 0 to 10 over6CV, 10 over 2CV), followed by Prep LC-MS (VII) to afford 31 mg of the title compound as white solid. LC-MS (A): tR = 0.99min; [M+H]-: 245.21.

266.2. (1,3-Dimethyl-azetidin-3-yl)-(6-fluoro-5-pyrrolidin-1-yl-pyr idin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol

The title compound was synthesized starting from Example B2.1 (34mg) and Example 266.1 (30.5mg), and following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by Prep LC-MS (VII) then by Prep LC-MS (XIV) to afford 4mg of the title compound as white solid. LC-MS (B): tR = 0.803min; [M+H] ⁺ : 440.40. Example 267: 5-[(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy- phenyl)-methyl]-3-pyrrolidin-1-yl-pyridine-2- carbonitrile

267.1. 5-Bromo-3-pyrrolidin-1-yl-pyridine-2-carbonitrile

To a solution of 5-bromo-3-fluoropicolinonitrile (186mg) in THF (4.5ml) was added DIPEA (317pL) and pyrrolidine (77.6 L). The resulting solution was stirred overnight at RT, diluted with EA and washed with water and brine. The org. phases were dried (MgS0 ₄ ), filtrated off and evaporated to dryness. The residue was purified by CC (Biotage, snapl Og, solvent A: Hep; solvent B: EA; gradient in %B: 10 over 2CV, 10 to 30 over 3CV, 30 over 2CV) to afford 223mg of the title compound as pale yellow solid. LC-MS (A): tR = 0.93min; [M+H] ⁺ : 252.19.

267.2. 5-[(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-trifluoromethoxy- phenyl)-methyl]-3-pyrrolidin-1-yl-pyridine-2- carbonitrile The title compound was synthesized starting from Example B2.1 (50mg) and Example 267.1 (46.1 mg), following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by Prep LC-MS (VI) to afford 2mg of the title compound as pale yellow solid. LC-MS (A): t _R = 0.82min; [M+H]-: 447.26.

Example 268: (1,3-Dimethyl-azetidin-3-yl)-[6-(tetrahydro-pyran-4-yloxy)-p yridin-3-yl]-(4-trifluoromethoxy-phenyl)- methanol

268.1. 5-Bromo-2-(tetrahydro-pyran-4-yloxy)-pyridine

To a solution of 5-bromo-2-chloropyridine (250mg) in THF (1.5mL) was added KOtBu(152mg) and tetrahydro-4-pyranol (132 L) and the resulting solution was stirred under microwave conditions for 30min at 120°C. The reaction mixture was diluted with EA and washed with water and brine. The org. phases were dried (MgS04), filtrated off and evaporated to dryness. The residue was purified by CC (Biotage, SNAPIOg, solvent A: Hep; solvent B: EA; gradient in %B: 5 over 2CV, 5 to 10 over 2CV, 10 over 2CV) to afford 240mg of the title compound as white solid. LC-MS (A): t _R = 0.89min; [M+H] ⁺ : 260.16.

268.2. (1,3-Dimethyl-azetidin-3-yl)-[6-(tetrahydro-pyran-4-yloxy)-p yridin-3-yl]-(4-trifluoromethoxy-phenyl)-methanol

The title compound was synthesized starting from Example B2.1 (50mg) and Example 268.1 (104mg), and following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by Prep LC-MS (VI) then Prep LC-MS (IX) to afford 7mg of the title compound as white solid. LC-MS (A): t _R = 0.77min; [M+H] ⁺ : 453.14.

Example 269: (1,3-Dimethyl-azetidin-3-yl)-[6-(oxetan-3-ylmethoxy)-pyridin -3-yl]-(4-trifluoromethoxy-phenyl)-methanol The title compound (11mg, white solid) was synthesized following the two-step procedure described in Example 268, using oxetan-3-yl-methanol instead of tetrahydro-4-pyranol. The crude material was purified by Prep LC-MS (VI) to afford 11 mg of the title compound as white solid. LC-MS (A): t _R = 0.73min; [M+H] ⁺ : 439.16.

Example 270: (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(4-meth yl-thiazol-2-yl)-pyridin-3-yl]-methanol

270.1. 3-Bromo-5-(4-methyl-thiazol-2-yl) -pyridine

A suspension of 5-bromopyridine-3-carbothioamide (150mg) and chloroacetone (66 L) in EtOH (5mL) was stirred for 5 days at 80°C and evaporated to dryness. The resulting residue was purified by CC (Biotage, SNAPIOg, solvent A: Hep; solvent B: EA; gradient in %B: 10 over 2CV, 10 to 30 over 2CV, 30 over 2CV) to afford 121 mg of the title compound as brown solid. LC-MS (A): t _R = 0.89min; [M+H] ⁺ : 257.13.

270.2. (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(4-meth yl-thiazol-2-yl)-pyridin-3-yl]-methanol

The title compound was synthesized starting from Example B2.2 (50mg) and Example 270.1 (71.7mg), and following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by Prep LC-MS (VII) then Prep LC-MS (IX) to afford 5mg of the title compound as white solid. LC-MS (A): t _R = 0.79min; [M+H] ⁺ : 408.32.

Example 271 : (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-meth yl-thiazol-2-yl)-pyridin-3-yl]-methanol 271.1. 3-Bromo-5-(5-methyl-thiazol-2-yl)-pyridine A suspension of 5-bromopyridine-3-carbothioamide (150mg) and 2-bromo-1,1-diethoxypropane (139mg) in AcOH (1.5mL) was stirred for 4h at 120°C and was evaporated to dryness. The resulting residue was taken up in aq. sat. NaHC0 ₃ solution. The org. layers were washed with water and brine, dried (MgS0 ₄ ), filtrated off and evaporated to dryness. The resulting crude material was purified by CC (Biotage, SNAPIOg, solvent A: Hep; solvent B: EA; gradient in %B: 10 over 2CV, 10 to 30 over 2CV, 30 over 2CV) to afford 82mg of the title compound as brown solid. LC-MS (A): t _R = 0.92min; [M+H] ⁺ : 257.13.

271.2. (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5-meth yl-thiazol-2-yl)-pyridin-3-yl]-methanol

The title compound was synthesized starting from Example B2.2 (50mg) and Example 271.1 (71.7mg), and following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by Prep LC-MS (VII) then Prep LC-MS (XIV) to afford 5mg of the title compound as white solid. LC-MS (B): t _R = 0.734min; [M+H] ⁺ : 408.4.

Example 272: (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-methoxy -pyrimidin-5-yl)-methanol The title compound was synthesized starting from Example B2.2 (50mg) and 5-bromo-2-methoxypyrimidine (41.7mg), and following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by Prep LC-MS (VI) then Prep LC-MS (IX) to afford 2mg of the title compound as white solid. LC-MS (A): t _R = 0.80min; [M+H] ⁺ : 342.19. Example 273: (S)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyr rolidin-1-yl-pyridin-4-yl)-methanol 273.1. (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyrroli din-1-yl-pyridin-4-yl)-methanol Example F1.5 (75mg) and pyrrolidine (100 L) were dissolved in Dioxane (1mL) and the reaction mixture was stirred for 20h at 110°C. Pyrrolidine (100 L) was added and the mixture was stirred for 70h at 110°C. The mixture was allowed to cool down, was diluted with MeCN and purified by Prep LC-MS (XIV). The solvent of collected fractions was evaporated and the resulting aq. layer was basified with 1 M NaOH solution and extracted with EA. The org. layers were washed with brine, dried (MgS04), filtered off and evaporated to dryness. The residue was purified by Prep LC-MS (VII) to afford 17.7mg of the title compound as yellow oil. LC-MS (B): t _R = 0.58min; [M+H] ⁺ : 380.27.

273.2 (S)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyr rolidin-1-yl-pyridin-4-yl)-methanol

The title compound (9mg) was obtained by Prep chiral SFC (IX) of Example 273.1 (17.7mg). LC-MS (A): t _R = 0.58min;

[M+H] ⁺ : 380.22; Chiral SFC (J): 2.8min.

Example 274 to Example 276 were synthesized starting from the appropriate amine reagent of Formula (F2), and following the procedure described in Example 273 step 273.1, but using different solvents and bases listed in the table below. Prep LC-MS conditions and LC-MS data of Example 274 to Example 276 are listed in the table below. The LC- MS conditions used were LC-MS (A).

Example 277: (S)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[2-(te trahydro-pyran-4-y methoxy)-pyridin-4-yl]- methanol

Example F1.5 (35mg) and tetrahydro-2H-pyran-4-yl-methanol (52mg) were dissolved in dioxane (1mL) and NaH (60% in mineral oil, 17.1mg) was added. The reaction mixture was stirred for 7h at 100°C. DMF (1mL) was added and the mixture was stirred for 72h at 130°C. After cooling down to RT, the mixture was diluted with MeCN/water and purified by Prep LC-MS (IX) to afford the title compound (4.5mg) as white solid. LC-MS (A): tR = 0.78min; [M+H] ⁺ : 425.31. Example 278: (S)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[2-(2- methoxy-ethoxy)-pyridin-4-yl]-methanol

The title compound (7.4mg, white solid) was prepared following the procedure described in Example 277, and using 2- methoxy-ethanol instead of tetrahydro-2H-pyran-4-yl-methanol. LC-MS (A): tR = 0.74min; [M+H] ⁺ : 385.14. Example 279: (S)-(1,3-Dimethyl-azetidin-3-yl)-(2-ethyl-pyridin-4-yl)-(4-i sopropyl-phenyl)-methanol

To a solution of Example F1.5 (30mg) in dioxane (0.5mL) was added diethylzinc solution in toluene (15%, 104 L) and Pd(dppf)Cl2 (1.12mg) and the mixture was stirred for 5h30 at 70°C. Diethylzinc solution in toluene (15%, 104 L) was added again and the mixture was further stirred for 6h30 at 70°C. The reaction mixture was quenched by careful addition of water, diluted with MeOH and filtered off. The resulting crude material was purified by Prep LC-MS (V) then by Prep LC-MS (XIV) to afford 1.3mg of the title compound as white solid. LC-MS (A): tR = 0.54min; [M+H] ⁺ : 339.25.

Example 280: (S)-(2-Cyclopentyl-pyridin-4-yl)-(1,3-dimethyl-azetidin-3-yl )-(4-isopropyl-phenyl)-methanol

280. 1. (S)-(2-Cyclopent-1-enyl-pyridin-4-yl)-( 1, 3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol

To a solution of Example F1.5 (50mg) and cyclopentene-1-yl-boronic acid (16.1mg) in MeCN (0.5mL) were added Na2C03 (1M, 0.5mL) and Pd(PPh)3C (4.49mg), and the mixture was stirred for 3h30 at 80°C. The reaction mixture was cooled down to RT, diluted with MeOH, filtered off and purified by Prep LC-MS (V) to afford 30mg of the title compound as white solid. LC-MS (A): tR = 0.63min; [M+H] ⁺ : 377.33.

280.2. (S)-(2-Cyclopentyl-pyridin-4-yl)-(1,3-dimethyl-azetidin-3-yl )-(4-isopropyl-phenyl)-methanol The title compound (23mg, white solid) was synthetized starting from Example 280.1 (27mg), and following the procedure described in Example 48. LC-MS (A): t _R = 0.62min; [M+H]"·: 379.35.

Example 281 : (R)-(1,3-Dimethyl-azetidin-3-yl)-(5-pyrrolidin-1-yl-pyridin- 3-yl)-(4-trifluoromethyl-phenyl)-methanol

281.1. 3-[Hydroxy-( 5-pyrrolidin- 1 -yl-pyridin-3-yl) -( 4-trifluoromethyl-phenyl) -methyl]-3-methyl-azetidine- 1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example A4.5 (1.13g) and 3-bromo-5-pyrrolidinopyridine (990mg), and following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by Prep LC-MS (IV) to afford 480mg of the title compound as light yellow solid. LC-MS (A): t _R = 0.89min; [M+H]-: 492.32.

281.2. 3-[(R)-Hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoro methyl-phenyl)-methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was obtained by Prep chiral SFC (II) of Example 281.1. LC-MS (A): t _R = 0.87min; [M+H]-: 492.29; Chiral SFC (H): 3.0min.

281.3. (R)-(3-Methyl-azetidin-3-yl)-(5-pyrroHdin-1-yl-pyridin-3-yl) -(4-trifluoromethyl-phenyl)-methanol, hydrochloride salt

A solution of Example 281.2 (215mg) in HCI in dioxane (4M, 2mL) was stirred for 1h45. The mixture was evaporated to dryness to give 210mg of the title compound as orange solid. LC-MS (A): t _R = 0.60min; [M+H]-: 392.33.

281.4. ((R)-(1,3-Dimethyl-azetidin-3-yl)-(5-pyrroHdin-1-yl-pyridin- 3-yl)-(4-trifluoromethyl-phenyl)-methanol

The title compound was synthesized starting from Example 281.3 (50mg), and following the procedure described in Example B2.1 step B2.1.2 (16mg, colorless resin). LC-MS (B): t _R = 0.488min; [M+H]-: 406.4.

Example 282: (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-((R)-3-hydroxymethyl-3-m ethyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4- isopropyl-phenyl)-methanol

282.1. (R)-3-Methyl-pyrrolidine-3-carboxylic acid methyl ester, hydrochloride salt

To an ice-cold MeOH solution (20mL) was added dropwise SOCI2 (1mL), followed 30min later by (R)-3-methyl- pyrrolidine-3-carboxylic acid (500mg) and the resulting suspension was stirred for 65h at RT. The reaction mixture was evaporated to dryness to afford 784 mg of the title compound as brown solid. LC-MS (A): t _R = 0.31 min; [M+H]-: 144.27.

282.2. (R)-3-Methyl-pyrrolidine-1,3-dicarboxyHc acid 1 -tert-butyl ester 3-methyl ester

To a solution of Example 282.1 (768mg) in DCM (30mL) were successively added TEA (1.79mL) and B0C2O (952mg). The resulting mixture was stirred for 1h10 at RT, diluted with water and extracted with DCM. The org. layers were dried (MgS0 ₄ ), filtrated off, and evaporated to dryness to afford 832mg of the title compound as brown oil. LC-MS (A): t _R = 0.87min; [M+H] ⁺ : 244.34.

282.3. (R)-3-Hydroxymethyl-3-methyl-pyrrolidine-1 -carboxylic acid tert-butyl ester To an ice-cold solution of Example 282.2 (820mg) in THF (30mL) was LiAlhU in THF (2M, 1 .01 mL). The resulting mixture was stirred for 1h at 0°C, carefully quenched with ice-water then with aq. sat. NaHC0 ₃ solution, and extracted with EA. The org. layers were washed with water and brine, dried (MgS0 ₄ ), filtrated off, and evaporated to dryness to afford 716mg of the title compound as yellow oil. LC-MS (A): tR = 0.72min; [M+H]"·: 216.22.

282.4. ((R)-3-Methyl-pyrrolidin-3-yl)-methanol, hydrochloride salt

A solution of Example 282.4 (715mg) in HCI in dioxane (4M, 7mL) was stirred for 1 h50 at RT and evaporated to dryness to give 377mg of the title compound as brown solid. LC-MS (A): tR = 0.2min; [M+H]-: 116.30.

282.5. (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-((R)-3-hydroxymethyl-3-m ethyl-pyrroHdin-1-yl)-pyridin-3-yl]-(4-isopropyl- phenylj-methanol

To a solution of Example F1.2 (50mg) and Example 282.4 (97.4mg) in DMSO (1mL), were added K ₂ C0 ₃ (54.1mg), L- proline (16.3mg) and Cul (13.2mg) and the resulting mixture was stirred for 44h at 100°C, cooled down to RT, filtrated off and evaporated to dryness. The residue was purified by Prep LC-MS (IX) then by Prep LC-MS (VI) to afford 14mg of the title compound as white solid. LC-MS (B): tR = 0.475min; [M+H]-: 424.4.

Example 283: (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-((S)-3-fluoro-pyrrolidin -1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)- methanol

To a solution of Example F1 .2 (50mg) and (S)-(+)-3-fluoropyrrolidne hydrochloride (41 ,5mg) in toluene (1 mL) was added RuPhos (6.29mg), Pd ₂ (dba) ₃ (6.05mg) and NaOtBu (57.1 mg). The reaction mixture was stirred for 1h at 110°C, cooled down to RT, diluted with water and extracted with DCM. The org. layers were dried (MgS0 ₄ ) and evaporated to dryness. The residue was purified by Prep LC-MS (VI) to afford 71 mg of the title compound as white solid. LC-MS (B): t _R = 0.493min; [M+H] ⁺ : 398.40.

Example 284: (R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[4-(tetra hydro-pyran-4-yl)-[1,2,3]triazol-1-yl]- pyridin-3-yl}-methanol

To a solution of Example F1.2 (50mg) in EtOH (0.7mL) were added 4-ethynyloxane (70.7mg), sodium azide (16.9mg), (+)-Sodium L-ascorbate (2.57mg), N, N-dimethylethylenediamine (4.23 L) and Cul (4.92mg). The resulting mixture was stirred for 20h20 at 90°C. 4-Ethynyloxane (70.7mg) was added again and the mixture was stirred for 5h30 at 90°C, diluted with water, MeOH and DMF, filtrated off and purified by Prep LC-MS (VI) to afford 1mg of the title compound as white solid. LC-MS (B): t _R = 0.66min; [M+H] ⁺ : 462.40.

Example 285 to Example 288 were synthesized starting from Example F1.1 and the appropriate boronic acid reagent of Formula (F6), following the procedure described in Example 280 step 280.1. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 289: 3-{5-[(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yr -pyridin-3-yl}-cyclopent-2-enol

289.1. 3-{5-[(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phen yl)-methyl]-pyriclin-3-yl}-cyclopent-2-enone The title compound was synthesized starting from Example F1.1 (250mg) and 3-(4, 4,5, 5-tetramethy I - 1 , 3, 2- dioxaborolan-2-yl)cyclopent-2-en-1-one (140mg), following the procedure described in Example 280 step 280.1. The crude material was purified by Prep LC-MS (XIV) to afford 122mg of the title compound as off-white powder. LC-MS (A): t _R = 0.7min; [M+H] ⁺ : 391.32.

289.23-{5-[( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-cyclopent-2-enol

To an ice-cold suspension of Example 289.1 (122mg) in THF (18mL) and MeOH (1.8mL) was added NaBH ₄ (47.3mg) portionwise and the resulting mixture was stirred for 19h30 at RT. NaBH ₄ (47.3mg) was added and the mixture was stirred for 3h30 at RT then for 45h at 40°C and for 6h at 65°C. NaBH ₄ (23.6mg) was added and the mixture was stirred for 18h at 65°C. The reaction mixture was allowed to cool down to RT, quenched with aq. sat. NH ₄ CI and extracted with EA. The org. layers were washed with aq. sat. NH ₄ CI and brine, dried (MgS0 ₄ ), filtrated off, and evaporated to dryness. The residue was purified by Prep LC-MS (IX) to afford 5mg of the title compound as white solid. LC-MS (B): tR = 0.576min; [M+H] ⁺ : 393.40.

Example 290 to Example 293 were synthesized from the appropriate precursor, following the procedure described in Example 48 and using the solvents listed in the table below. Precursors and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

Example 294: 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-cyclopent-2- enone

The title compound (182mg, off-white solid) was synthesized following the procedure described in Example 289 step

289.1, but starting from Example F1.2 (250mg). The crude material was purified by Prep LC-MS (V) then by Prep LC- MS (IX). LC-MS (B): t _R = 0.612min; [M+H] ⁺ : 391.32.

Example 295: 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-1-methyl- cyclopent-2-enol

The title compound (18mg, yellow powder) was synthesized starting from Example 294 (50mg), and following the procedure described in Example 262. The crude material was purified by Prep LC-MS (V). LC-MS (B): t _R = 0.614min; [M+H] ⁺ : 407.40.

Example 296: (3S)-3-(5-((R)-(1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopro pylphenyl)methyl)pyridin-3-yl)-1- methylcyclopentan-1-ol

The title compound (mixture of two diastereomers, 8mg, white powder) was synthesized starting from Example 295 (22mg), and following the procedure described in Example 48. The crude material was purified by Prep LC-MS (VI). The chirality at carbon atom 3 of the cyclopentyl ring was arbitrarily assigned to (S). The chirality at carbon atom 1 of the cyclopentyl ring is undefined. LC-MS (B): t _R = 0.531 min; [M+H]-: 409.5.

Example 297: (3R)-3-(5-((R)-(1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopro pylphenyl)methyl)pyridin-3-yl)-1- methylcyclopentan-1-ol

The title compound (mixture of two diastereomers, 5mg, white powder) was isolated as second eluting compound from Prep LC-MS (VI) of Example 296. The chirality at carbon atom 3 of the cyclopentyl ring was arbitrarily assigned to (R). The chirality at carbon atom 1 of the cyclopentyl ring is undefined. LC-MS (B): t _R = 0.558min; [M+H] ⁺ : 409.5.

Example 298: 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-1-ethyl- cyclopentanol

298.1. 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-1-ethyl-cyclopent-2- enol The title compound (as mixture of diastereomers, 10mg, white powder) was synthesized starting from Example 294 (64mg) and ethylmagnesium bromide solution in THF (1M, 513mI_), following the procedure described in Example 262. The crude material was purified by Prep LC-MS (VI). LC-MS (A): t _R = 0.64min; [M+H]-: 421.34.

298.23-{5-[(R)-(1,3-Dimethy/-azetidin-3-y/)-hydroxy-(4-is opropy/-pheny/)-methy/]-pyridin-3-y/}-1-ethy/-cyc/opentano/ The title compound (10 mg, white powder) was synthesized from Example 298.1 (10mg), and following the procedure described in Example 48. The crude material was purified by Prep LC-MS (VI). LC-MS (B): t _R = 0.584min; [M+H] ⁺ : 423.50.

Example 299: 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-1-isopropyl- cyclopentanol

The title compound was synthesized starting from isopropylmagnesiumbromide solution in THF, and following the two- step procedure described in Example 298. LC-MS (A): t _R = 0.67min; [M+H] ⁺ : 437.40.

Example 300: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(4- methyl-oxazol-2-yl)-pyridin-3-yl]-methanol To a solution of 4-methyloxazole (25mg) in THF (0.5mL) cooled down to -78°C was added dropwise n-BuLi in hexane (2.5M, 143 L), followed by ZnCh in 2-methyltetrahydrofuran (1.9M, 235 L). The resulting solution was stirred for 50min at RT. Example F1.2 (116mg) and Pd(PPfi3)4 (35.1 mg) were added and the mixture was stirred for 18h at 60°C, cooled down to RT, diluted with EA and washed with water and brine. The org. layers were dried (MgS04), filtrated off and evaporated to dryness. The residue was purified by Prep LC-MS (VI) to afford 14mg of the title compound as white powder. LC-MS (B): t _R = 0.692min; [M+H] ⁺ : 392.40.

Example 301 : (R)-(1 ,3-Dimethyl-azetidin-3-yl)-(5-ethyl-pyridin-3-yl)-(4-isoprop yl-phenyl)-methanol

The title compound (8mg, brown solid) was synthesized starting from Example F1.2 (50mg), following the procedure described in Example 279. The crude material was purified by Prep LC-MS (VI). LC-MS (A): t _R = 0.58min; [M+H] ⁺ :

339.30.

Example 302: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-met hyl-pyridin-3-yl)-methanol The title compound (14mg, white solid) was synthesized starting from Example F1.2 (50mg) and methylboronic acid (8.72mg), following the procedure described in Example 280 step 280.1. The crude material was purified by Prep LC- MS (VI) then by Prep LC-MS (XXI). LC-MS (A): tR = 0.54min; [M+H]+: 325.33.

Example 303: (R)-[5-(4,5-Dihydro-furan-3-yl)-pyridin-3-yl]-(1,3-dimethyl- azetidin-3-yl)-(4-isopropyl-phenyl)-methanol To a solution of Example F1 .2 (50mg) and 4,5-dihydrofuran-3-boronic acid pinacol ester (52.5mg) in dioxane (1mL) and water (0.25mL) were added K ₃ P0 ₄ (81.8mg) and [1,T-bis(diphenylphosphino)ferrocene]dichloropalladium (II) complex with DCM (21 mg), and the resulting mixture was stirred for 1h at 80°C. It was then allowed to cool down to RT, diluted with MeCN and water and filtrated off. The resulting solution was purified by Prep LC-MS (VI) then by Prep LC-MS (IX) to afford 25mg of the title compound as white solid. LC-MS (B): t _R = 0.604min; [M+H] ⁺ : 379.40. Example 304: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(te trahydro-furan-3-yl)-pyridin-3-yl]-methanol Example 303 (21 mg) was dissolved in EtOH with 1% toluene (10mL) and the reaction was conducted in a HCube®- Pro equipped with a 10% (w/w) Pd/C cartridge (7 cm long) under a flow of 1.0mL/min, a hydrogen pressure of 3 bar and a temperature of 30°C. After reaction completion, the solvent was evaporated and the residue was purified by Prep LC-MS (V) to afford 5.5mg of the title compound as colorless solid. LC-MS (B): tR = 0.551 min; [M+H]"·: 381 .40. Example 305: 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-but-3-en-1-ol The title compound (35mg, off-white solid) was synthesized starting from Example F1.2 (50mg) and 3-buten-1-ol-3- boronic acid pinacol ester (50.9mg), and following the procedure described in Example 303. The crude material was purified by Prep LC-MS (VI). LC-MS (B): t _R = 0.561 min; [M+H] ⁺ : 381.40.

Example 306: N-Cyclopentyl-5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-nicotinamide

306.1. 3-[(R)-(5-Cyclopentylcarbamoyl-pyridin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

A mixture of Example E1.1 (50mg), HATU (56.1 mg) and DIPEA (58.3 L) in DCM (0.6mL) was stirred at RT for 15 min and cyclopentylamine (14.7 L) was added. The reaction mixture was stirred at RT for 2h, quenched with aq. sat. NaHC03 and extracted with DCM. The combined organic extracts were dried (MgS04), filtered off and concentrated in vacuo. The crude was purified by Prep LC-MS (VII) to afford the title compound as white solid (45.5mg). LC-MS (A): t _R = 1.06min; [M+H] ⁺ : 508.43.

306.2. N-Cyclopentyl-5-[(R)-hydroxy-(4-isopropyl-phenyl)-(3-methyl- azetidin-3-yl)-methyl]-nicotinamide, hydrochloride salt

A solution of Example 306.1 (43mg) in HCI in dioxane (4M, 0.21 mL) was stirred at RT for 2h30, concentrated in vacuo and dried under HV to afford 37.6mg of the title compound. LC-MS (A): t _R = 0.72min; [M+H]-: 408.26.

306.3. N-Cyclopentyl-5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-nicotinamide Example 306.3 was obtained starting from Example 306.2 (37.6mg) and following the procedure described in Example D1.1 step D1.1.5, with a direct filtration of the reaction mixture through a syringue filter and purification by Prep LC-MS (IX) to afford the title product as a white solid (29.2mg). LC-MS (B): t _R = 0.701 min; [M+H]-: 422.5.

Example 307 and Example 308 were synthesized starting from Example E1.1 and the appropriate amine reagent, and following the three-step procedure described in Example 306. The Prep LC-MS methods and the LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

309.1. 3-[(4-Bromo-phenyl)-hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl) -methyl]-3-methyl-azetidine-1-carboxylic acid tert- butyl ester

The title compound (180mg) was prepared starting from Example C1.1 (150mg) and 1,4-dibromobenzene (73.8mI_), and following the procedure described in Example A4.1 step A4.1.2. LC-MS (A): tR = 0.88min; [M+H] ⁺ : 502.28.

309.2. (4-Bromo-phenyl)-(3-methyl-azetidin-3-yl)-(5-pyrrolidin-1-yl -pyridin-3-yl)-methanol, hydrochloride salt

A solution of Example 309.1 (175mg) in HCI in dioxane (4M, 5mL) was stirred for 30min at RT and evaporated to dryness to afford 170mg of the title compound as yellow solid. LC-MS (A): t _R = 0.57min; [M+H]-:402.03.

309.3. (4-Bromo-phenyl)-(1,3-dimethyl-azetidin-3-yl)-(5-pyrroHdin-1 -yl-pyridin-3-yl)-methanol The title compound (138mg, beige solid) was synthesized starting from Example 309.2 (170mg), and following the procedure described in Example B2.1 step B2.1.2. LC-MS (A): t _R = 0.57min; [M+H]"·: 416.29.

309.4. (1,3-Dimethyl-azetidin-3-yl)-[4-((E)-3-methoxy-propenyl)-phe nyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol

The title compound (30mg, white solid) was synthesized starting from Example 309.3 (50mg) and trans-3-methoxy-1- propenylboronic acid pinacol ester (53.7pL), following the procedure described in Example 303. The crude material was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.57min; [M+H] ⁺ : 408.43.

309.5. (1,3-Dimethyl-azetidin-3-yl)-[4-(3-methoxy-propyl)-phenyl]-( 5-pyrrolidin-1-yl-pyridin-3-yl)-methanol

The title compound (11 mg, yellow solid) was synthesized starting from Example 309.4 (28mg), and following the procedure described in Example 48. The crude material was purified by Prep LC-MS (XIV). LC-MS (B): t _R = 0.445min; [M+H]-: 410.5. Example 310 and Example 311 were synthesized starting from Example 309.3 and the appropriate boronic acid reagent, and following the procedure described in Example 303. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

Example 312: 5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]-3',4',5',6'-tetrahydro-2'H- [3, 4']bipyridinyl-1 '-carboxylic acid tert-butyl ester

312.1. 5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]-3',6'-dihydro-2'H-[3,4]bipyridinyl-1'- carboxylic acid tert-butyl ester The title compound was synthesized starting from Example F1.2 (50mg) and 3,6-dihydro-2H-pyridine-1-N-Boc-4- boronic acid, pinacol ester (81 mg), and following the procedure described in Example 303. The crude material was purified by Prep LC-MS (V) to give 33mg of the title compound as white solid. LC-MS (A): t _R = 0.76min; [M+H] ⁺ : 492.34.

312.2. 5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]-3',4',5',6'-tetrahydro-2'H- [3, 4]bipyridiny 1-1 '-carboxylic acid tert-butyl ester The title compound was synthesized from Example 312.1 (30mg) and following the procedure described in Example 48. The crude material was purified by Prep LC-MS (XV) to give 11 mg of the title compound as white solid. LC-MS (B): t _R = 0.77min; [M+H] ⁺ : 494.50.

Example 313 and Example 314 were synthesized from Example F1.2 and the appropriate boronic ester following the two-step procedure described in Example 312. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

Example 315: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3',4' ,5',6'-tetrahydro-2'H-[2,1';4',3"]terpyridin-5"- yl)-methanol

315.1. (R)-(3’,G’-Dihydro-2’H-[2,1’;4’,3”]terpyridine-5 ”-yl)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-me thanol The title compound was synthesized starting from Example F1.2 (43mg) and 4-(4, 4, 5, 5-tetramethy I- 1 , 3,2-dioxaborolan- 2-yl)-3,6-dihydro-2H-1,2'-bipyridine (32.6mg), and following the procedure described in Example 303. The crude material was purified by Prep LC-MS (XIII) to afford 35mg of the title compound as white powder. LC-MS (A): t _R = 0.56min; [M+H] ^÷ : 469.21. 315.2. (R)-(1 _l 3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(3' _l 4' _l 5' _l 6'-tetrahydro-2'H-[2 _l 1';4' _l 3"]terpyridin-5"-yl)- methanol

The title compound was synthesized starting from Example 315.1 (33mg), and following the procedure described in Example 48 but using MeOH as solvent. The crude material was purified by Prep LC-MS (XXI) to afford 6mg of the title compound as white solid. LC-MS (B): t _R = 0.466min; [M+H] ⁺ : 471.5. Example 316 and Example 317 were synthesized starting from Example F1.2 and the appropriate boronic ester, and following the two-step procedure described in Example 315. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 318: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(te trahydro-furan-2-yl)-pyridin-3-yl]-methanol 318.1. 3-{(R)-Hydroxy-(4-isopropyl-phenyl)-[5-(tetrahydro-furan-2-y l)-pyridin-3-yl]-methyl}-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

To a vial equipped with a magnetic stirring bar, Example F1.11 (100mg), [4,4'-bis(1,1-dimethylethyl)-2,2'-bipyridine- N1,NT]bis[3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl-N] phenyl-C]iridium(lll) hexafluorophosphate (2.36mg), NiCL-glyme (4.72mg), 4,4'-di-tert-butyl-2,2'-dipyridyl (8.64mg) and Cs ₂ C0 ₃ (208mg) were added. The vial was placed under nitrogen and dry DMF (10mL) was added followed by tetrahydro-2-furoic acid (60.6 L). The solution was degassed for 15min by sparging with nitrogen and was irradiated with a 34W blue LED placed approximately 8 cm away from the vial. The reaction mixture was stirred for 17h under irradiation, , was diluted with aq. sat. NaHC0 ₃ and extracted with Et ₂ 0 (3 times). The combined org. layers were washed with water and brine, dried (MgS04) and concentrated in vacuo. The residue was purified by CC (Biotage, SNAP 4g, solvent A: Hep; solvent B: EA; gradient in %B: 0 over 1 min, 0 to 100 over 12min, 100 over 8min) and by Prep LC-MS (VII) to afford the title product as white solid (7.2mg). LC-MS (A): t _R = 0.90min; [M+H] ⁺ : 467.36.

318.2. (R)-(4-lsopropyl-phenyl)-(3-methyl-azetidin-3-yl)-[5-(tetrah ydro-furan-2-yl)-pyridin-3-yl]-methanol, hydrochloride salt The title compound was obtained starting from Example 318.1, and following the protocol described in Example 309 step 309.2. LC-MS (A): t _R = 0.59min; [M+H] ⁺ : 367.27.

318.3. (R) -( 1 ,3-Dimethyl-azetidin-3-yl) -( 4-isopropyl-phenyl) -[5-( tetrahydro-furan-2-yl) -pyridin-3-yl]-methanol

The title compound was obtained starting from Example 318.2 (9.3mg), and following the procedure described in Example F1.1 step F1.1.2. Prep LC-MS (XIV) afforded 2.4mg of colorless oil. LC-MS (B): t _R = 0.60min; [M+H] ⁺ : 381.4. Example 319 to Example 320 were synthesized starting from Example F1.11 and the appropriate carboxylic acid, and following the three-step procedure described in Example 318. The Prep LC-MS methods and the LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (B).

Example 321 : 3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-2,2-difluoro- propan-1 -ol 321.1. 3-[(R)-[5-(2-Ethoxycarbonyl-2,2-difluoro-ethyl)-pyridin-3-yl ]-hydroxy-(4-isopropyl-phenyl)-methyl]-3-methyl- azehdine-1-carboxy\\c acid tert-butyl ester

To a vial equipped with a stirring bar were added (4,4'-di-tert-butyl-2,2'-bipyridine)bis[3,5-difluoro-2-[5-tr ifluoromethyl-2- pyridinyl-N)phenyl-C]iridium(lll) hexafluorophosphate (2.36mg), Example F1.11 (100mg), ethyl 3-bromo-2,2- difluoropropionate (96.1 mg), tris(trimethylsilyl)silane (0.1 mL) and LiOH (10.3mg). The vial was sealed, purged with nitrogen, and MeCN (1mL) was added. To a separate vial were added nickel(ll) chloride ethylene glycol dimethyl ether complex (2.36mg) and 4,4'-di-tert-butyl-2,2'-dipyridyl (2.82mg). The vial was sealed, purged with nitrogen, MeCN (1mL) was added and after sonicating the resulting solution for 5 minutes, 0.1 mL were added to the first vial. The resulting mixture was degassed by sparging with nitrogen and irradiated in a photoreactor device (Penn PhD M2, 100% irradiation) at RT for 4h. The mixture was purified by CC (Biotage, SNAP 12g, solvent A: Hep; solvent B: EA; gradient in %B: 0 over 1 min, 0 to 100 over 12min, 100 over 20min) and by Prep LC-MS (XX) to afford the title compound as a beige solid (12.5mg). LC-MS (A): t _R = 1.01 min; [M+H] ⁺ : 533.24.

321.2. 3-[(R)-[5-(2,2-Difluoro-3-hydroxy-propyl)-pyridin-3-yl]-hydr oxy-(4-isopropyl-phenyl)-methyl]-3-methyl-azetidine- 1-carhoxy\\c acid tert-butyl ester

To a suspension of NaBhU (0.66mg) in EtOH (0.5mL) was added dropwise a solution of Example 321.1 (12.5mg) in EtOH (1mL). The reaction mixture was stirred at RT for 3h, concentrated in vacuo and aq. sat. NH4CI was added. The mixture was extracted with EA and the org. layer was dried (MgS04), filtered off, and concentrated in vacuo to afford 10 mg as white solid. LC-MS (A): t _R = 0.85min; [M+H] ⁺ : 491.27.

321.3. 2,2-Difluoro-3-{5-[(R)-hydroxy-(4-isopropyl-phenyl)-(3-methy l-azetidin-3-yl)-methyl]-pyridin-3-yl}-propan-1-ol, hydrochloride salt

A solution of Example 321.2 (10mg) in HCI in dioxane (4M, 0.2mL) was stirred at RT for 1 h, and concentrated in vacuo to afford 11 mg of title compound as oil. LC-MS (A): t _R = 0.57min; [M+H] ⁺ : 391.22.

321.4. 3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-2,2-difluoro-propan-1-ol The title compound (1.2 mg, white solid) was obtained starting from Example 321.3 (11.1 mg), and following the procedure described in Example F1.1 step F1.1.2. The crude was purified by Prep LC-MS (IX). LC-MS (B): t _R = 0.566min; [M+H] ⁺ : 405.4.

Example 322: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5- methyl-oxazol-2-yl)-pyridin-3-yl]-methanol

322.1. 5-Bromo-N-prop-2-ynyl-nicotinamide

To a solution of 5-bromopyridine-3-carboxylic acid (500mg) in THF (12mL) were added HATU (1.66g), DIPEA (0.831 mL) and propargylamine (0.19mL) at RT. The resulting mixture was stirred at 50°C for 1h40, cooled down to RT, diluted with EA and washed with water and brine. The org. layer was dried (MgS04), filtered off and concentrated in vacuo. The crude material was purified by CC (Biotage, SNAP 50g, solvent A: Hep; solvent B: EA; gradient in %B: 50 over 4CV, 50 to 70 over 2CV, 70 over 2CV) to afford the title compound as white solid (513mg). LC-MS (A): t _R = 0.65min; [M+H]"-: 239.15.

322.2. 3-Bromo-5-(5-methylene-4, 5-dihydro-oxazol-2-yl)-pyridine

To a white suspension of Example 322.1 (488mg) in DCM (20mL) was added AuCb (61.9mg). The resulting light yellow suspension was stirred at RT for 1 fi30, diluted with DCM and washed with aq. sat. NaHC03. The aq. layer was extracted with DCM. The combined org. layers were dried (MgS04), filtered off, and concentrated in vacuo. The crude material was purified by CC (Biotage, SNAP 25g, solvent A: Hep; solvent B: EA; gradient in %B: 10 over 3CV, 10 to 30 over 2CV, 30 over 2CV) to afford the title compound as white solid (340mg). LC-MS (A): t _R = 0.82min; [M+H]-: 239.01.

322.3. 3-Bromo-5-(5-methy/-oxazo/-2-y/)-pyridine To a solution of Example 322.2 (340mg) in toluene (14mL) was added DBU (0.263mL). The resulting mixture was heated at 80°C for 2h, cooled down to RT and quenched with aq. sat. NH ₄ CI. The org. layer was washed with aq. sat. NH ₄ CI, dried (MgS0 ₄ ), filtered off, and concentrated in vacuo to afford the title compound as yellow solid (222mg). LC- MS (A): t _R = 0.85min; [M+H] ⁺ : 241.16.

322.4. 3-{Hydroxy-( 4-isopropyl-phenyl) -[5-( 5-methyl-oxazol-2-yl) -pyridin-3-yl]-methyl}-3-methyl-azeticline- 1 -carboxylic acid tert-butyl ester

The title compound was obtained starting from Example A4.2 (125mg) and Example 322.3 (122mg), and following the procedure described in Example A7.1 step A7.1.1. The crude material was purified by Prep LC-MS (VI) and (XII). The resulting material was dissolved in DCM and the solution was washed with aq. sat. NaHC03. The aq. layer was extracted twice with DCM and the combined org. extracts were dried (MgS0 ₄ ), filtered off, and concentrated in vacuo to afford the title compound as yellow solid (39mg). LC-MS (A): t _R = 1.13min; [M+H]-: 478.32.

322.5. 3-{(R)-Hydroxy-(4-isopropyl-phenyl)-[5-(5-methyl-oxazol-2-yl )-pyridin-3-yl]-methyl}-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

Example 322.4 (39mg) was purified by Prep chiral SFC (XVI) to afford the title compound as pure enantiomer (14mg). Chiral SFC (P): t _R = 3.217 min. LC-MS (A): t _R = 1.13min; [M+H] ⁺ : 478.33.

322.6. (R)-(4-lsopropyl-phenyl)-(3-methyl-azetidin-3-yl)-[5-(5-meth yl-oxazol-2-yl)-pyridin-3-yl]-methanol

A solution of Example 322.5 (13mg) in HCI in dioxane (4M, 0.4mL) was stirred at RT for 2h, cooled down to 0°C, basified with aq. sat. NaHC03 and extracted with DCM. The combined org. extracts were dried (MgS0 ₄ ), filtered off, and concentrated in vacuo to afford 7 mg of the title compound as yellow solid. LC-MS (A): t _R = 0.74min; [M+H]-: 378.35.

322.7. (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5- methyl-oxazol-2-yl)-pyridin-3-yl]-methanol

The title compound (2mg, white solid) was obtained starting from Example 322.6 (7mg), and following the procedure described in Example F1.1 step F1.1.2. However, the reaction mixture was basified with aq. sat. NaHC03, filtered through a syringue filter and purified by Prep LC-MS (VI). LC-MS (B): t _R = 0.69min; [M+H] ⁺ : 392.4.

Example 323: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5- (tetrahydro-pyran-4-yl)-oxazol-2-yl]-pyridin- 3-yl}-methanol

323.1. 3-((R)-Hydroxy-(4-isopropyl-phenyl)-{5-[2-oxo-2-(tetrahydro- pyran-4-yl)-ethylcarbamoyl]-pyridin-3-yl}-methyl)-3- methyl-azetidine-1 -carboxylic acid tert-butyl ester

To a solution of Example E1.1 (75mg) and HATU (86.8mg) in DCM (0.85mL) was added DIPEA (87.4 L). The resulting mixture was stirred at RT for 15 min and 2-amino-1-(oxan-4-yl)ethan-1-one hydrochloride (41.9mg) was added. The reaction mixture was stirred at RT, quenched with aq. sat. NaHC03 and extracted with DCM. The org. layers were dried (MgS0 ₄ ), filtered off and concentrated in vacuo. The crude material was purified by CC (Biotage, SNAP 24g, solvent A: DCM; solvent B: 9:1 DCM/MeOH; gradient in %B: O over 1 min, 0 to 10 over 3min, 10 over 5min, 10 to 100 over 20 min, 100 over 5min) to afford the title compound as a white glass (99.8mg). LC-MS (A): t _R = 0.96min; [M+H]-: 566.26.

323.2. 3-(( R)-Hydroxy-( 4-isopropyl-phenyl) -{5-[5-( tetrahydro-pyran-4-yl) -oxazol-2-yl]-pyridin-3-yl}-methyl) -3-methyl- azehdine-1-carboxy\\c acid tert-butyl ester

A solution of Example 323.1 (99.8mg) in pyridine (0.466mL) containing molecular sieves (3A powder, 170mg) was treated with phosphorus(V) oxychloride (81.6mI_). The reaction mixture was stirred at RT for 5h30, diluted with EA and poured into an ice-chilled solution of aq. sat. NaHCOs.The two layers were separated and the aq. phase was extracted twice with EA. The combined org. layers were dried (MgS04), filtered off and concentrated in vacuo. The crude was purified by Prep LC-MS (XXII) to afford the title compound as beige solid (9.7mg). LC-MS (A): t _R = 1.16min; [M+H] ⁺ : 548.13.

323.3. (R)-(4-lsopropyl-phenyl)-(3-methyl-azetidin-3-yl)-{5-[5-(tet rahydro-pyran-4-yl)-oxazol-2-yl]-pyridin-3-yl}- methanol, hydrochloride salt

A solution of Example 323.2 (9.7mg) in HCI (4M in dioxane, 0.1 mL) was stirred at RT for 2h, concentrated in vacuo and dried under HV to afford the title compound (9.2mg) as beige solid. LC-MS (A): t _R = 0.76min; [M+H]-: 448.35.

323.4. (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5- (tetrahydro-pyran-4-yl)-oxazol-2-yl]-pyridin-3-yl}- methanol

The title compound (3mg, white solid) was obtained starting from Example 323.3 (9.2mg), and following the procedure described in Example D1.1 step D1.1.5. However, the reaction mixture was filtered through a syringue filter and purified by Prep LC-MS (IX). LC-MS (B): t _R = 0.712min; [M+H] ⁺ : 462.4.

Example 324: (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(4-fluoro-phenoxymethyl) -pyridin-3-yl]-(4-isopropyl-phenyl)-methanol

324.1. 3-{(R)-Hydroxy-(4-isopropyl-phenyl)-[5-(methoxy-methyl-carba moyl)-pyridin-3-yl]-methyl}-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

To a suspension of Example E1.1 (500mg) in DCM (6mL) were added N,O-dimethylhydroxylamine hydrochloride (128mg) and DIPEA (0.68mL). The mixture was cooled down to 0°C and propylphosphonic anhydride (50% w/w in EA, 0.88mL) was slowly added. The resulting solution was stirred 1 h at RT and quenched with aq. sat. NaHC0 ₃ solution. The aq. layer was extracted twice with DCM and the combined org. layers were dried (MgS04), filtered off and evaporated to dryness to afford 596mg of the title compound as white foam. LC-MS (A): t _R = 0.98min; [M+H] ⁺ : 483.99.

324.2. 3-[(R)-(5-Formyl-pyridin-3-yl)-hydroxy-(4-isopropyl-phenyl)- methyl]-3-methyl-azetidine-1 -carboxylic acid tert- butyl ester

To an ice-cold solution of Example 324.1 (596mg) in dry THF (6mL) was added dropwise UAIH4 (2M in THF, 1.9mL). The reaction mixture was stirred for 1h at -78°C and quenched by dropwise addition of aq. sat. NH4CI solution. The mixture was allowed to warm to RT and EA was added. The solids were filtered off, washed with EA and water, and the filtrate was transferred in a separatory funnel. The layers were separated and the aq. phase was extracted twice with EA. The combined org. layers were dried (MgS0 ₄ ), filtered off and concentrated to dryness to afford the title compound as light yellow foam (494 mg). LC-MS (A): t _R = 1.04min; [M+H]"·: 425.19.

324.3. 3-[(R)-Hydroxy-(5-hydroxymethyl-pyridin-3-yl)-(4-isopropyl-p henyl)-methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

A solution of Example 324.2 (494mg) in dry MeOH (5.8mL) under nitrogen atmosphere was cooled down to 0°C and treated with NaBEU (53.9mg). The reaction mixture was stirred at 0°C for 5min and at RT for 30min, quenched with aq. sat. NaHCCh solution, and extracted with EA. The combined org. layers were dried (MgS04), filtered off, and concentrated in vacuo to afford 516.6mg of the title compound as light yellow foam. LC-MS (A): t _R = 0.79min; [M+H]-: 427.19.

324.4. 3-[(R)-[5-(4-Fluoro-phenoxymethyl)-pyridin-3-yl]-hydroxy-(4- isopropyl-phenyl)-methyl]-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

To an ice-chilled mixture of Example 324.3 (100mg), 4-fluorophenol (58.4mg) and triphenylphosphine polymer bound (3mmol/g, 313mg) in THF (1.2mL) under nitrogen atmosphere was added diisopropyl azodicarboxylate (0.188mL). The reaction mixture was stirred at RT for 17h, filtered off, and concentrated. The resulting solution was filtered through a syringue filter and purified by Prep LC-MS (XX) to afford 11 ,5mg of the title compound as white solid. LC-MS (A): t _R = 1 .01 min; [M+H] ⁺ : 521.17.

324.5. (R)-[5-(4-Fluoro-phenoxymethyl)-pyridin-3-yl]-(4-isopropyl-p henyl)-(3-methyl-azetidin-3-yl)-methanol, hydrochloride salt

A solution of Example 324.4 (11.5mg) in HCI (4M in Dioxane, 0.1 mL) was stirred at RT for 1h and concentrated in vacuo to afford the title compound (10.5mg) as oil. LC-MS (A): t _R = 0.74min; [M+H]-: 421.20.

324.6. (R)-( 1, 3-Dimethyl-azetidin-3-yl)-[5-(4-fluoro-phenoxymethyl)-pyridi n-3-yl]-(4-isopropyl-phenyl)-methanol

The title compound (4.5mg, white solid) was obtained starting from Example 324.5 (10.9mg), and following the procedure described in Example D1.1 step D1.1.5. The reaction mixture was however diluted with MeCN, filtered through a syringue filter and purified by Prep LC-MS (VI). LC-MS (B): t _R = 0.782min; [M+H]-: 435.4.

Example 325: Isopropyl-carbamic acid 5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]- pyridin-3-ylmethyl ester

325.1. 3-[(R)-Flydroxy-(5-isopropylcarbamoyloxymethyl-pyridin-3-yl) -(4-isopropyl-phenyl)-methyl]-3-methyl-azetidine- 1-carboxy\\c acid tert-butyl ester

To an ice-cold solution of Example 324.3 (100mg) and 4-dimethylaminopyridine (63mg) in DCM (1.2mL) was added isopropyl isocyanate (51 ,7 L). The reaction mixture was stirred at 45°C for 17h, cooled down to RT, quenched with aq. sat. NaHC03 solution and extracted with DCM. The combined org. extracts were dried (MgS04), filtered off, concentrated in vacuo and the residue was purified by Prep LC-MS (XIV) to afford 74mg of the title compound as white solid. LC-MS (A): t _R = 0.93min; [M+H] ⁺ : 512.22.

325.2. Isopropyl-carbamic acid 5-[(R)-hydroxy-(4-isopropyl-phenyl)-(3-methyl-azetidin-3-yl) -methyl]-pyridin-3-ylmethyl ester

A solution of Example 325.1 (73.6mg) in HCI (4M in Dioxane, 0.36mL) was stirred at RT for 1 h, concentrated in vacuo and dried under HV to afford 70mg of the title compound as oil. LC-MS (A): t _R = 0.64min; [M+H] ⁺ : 412.22.

325.3. Isopropyl-carbamic acid 5-[(R)-( 1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-met hyl]-pyridin-3- ylmethyl ester

The title compound (47.2mg, white solid) was obtained starting from Example 325.2 (69.7mg), and following the procedure described in Example D1.1 step D1.1.5. The reaction mixture was however diluted with MeCN, filtered through a syringe filter and purified by Prep LC-MS (V). LC-MS (B): t _R = 0.656min; [M+H]-: 426.4.

Example 326: (R)-[5-(2-Benzyloxy-ethyl)-pyridin-3-yl]-(1,3-dimethyl-azeti din-3-yl)-(4-isopropyl-phenyl)-methanol To a solution of Example F1.2 (50mg) and potassium (2-benzyloxyethyl)trifluoroborate (32.6mg) in toluene (1 ,5mL) and water (0.5mL) were added CS2CO3 (126mg), Pd(OAc)2 (1.44mg) and RuPhos (6.31 mg). The resulting mixture was stirred for 23h at 95°C, allowed to cool down to RT, diluted with water and extracted with EA. The org. layers were dried (MgS04), filtrated off and evaporated to dryness. The crude material was purified by Prep LC-MS (VII) to give 30mg of the title compound as white solid. LC-MS (B): t _R = 0.728min; [M+H] ⁺ : 445.50.

Example 327: 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-1-methyl- cyclohexanol

327. 1. (R)-( 1,3-Dimethyl-azetidin-3-yl)-[5-( 1,4-dioxa-spiro[4.5]dec-7-en-8-yl)-pyridin-3-yl]-(4-isopropy l-phenyl)- methanol

The title compound (174mg, white solid) was synthesized starting from Example F1.2 (400mg) and 1,4-dioxa- spiro[4,5]dec-7-en-8-boronic acid pinacol ester (558mg), and following the procedure described in Example 303. The crude material was however purified by CC (Biotage, SNAP 25g, solvent A: DCM; solvent B: MeOH; gradient in %B: 0 over 2CV, 0 to 5 over 5CV, 5 over 2CV, 5 to 10 over 3CV; 10 over 2CV, 10 to 20 over 2CV, 20 over 2CV, 100 over 5CV and 100 % MeOH +0.1%TEA over 10CV). LC-MS (A): t _R = 0.65min; [M+H] ⁺ : 449.1.

327.2. (R)-(1,3-Dimethyl-azetidin-3-yl)-[5-(1,4-dioxaspiro[4.5]dec- 8-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol The title compound (116mg, brown solid) was synthesized starting from Example 327.1 (172mg), and following the procedure described in Example 48. LC-MS (A): t _R = 0.62min; [M+H] ⁺ : 451.08.

327.3. 4-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-cyclohexanone

To an ice-cold solution of Example 327.2 (89mg) in dioxane (1mL) were added water (0.2mL) and H ₂ SO ₄ (0.2mL). The resulting solution was stirred for 3h at 0°C, basified with aq. sat. NaHC03 solution, diluted with water and extracted with DCM. The org. layers were dried (MgS04), filtrated off, and evaporated to dryness to give 72mg of the title compound as brown solid. LC-MS (A): t _R = 0.58min; [M+H] ⁺ : 407.14.

327.4. 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-1-methyl-cyclohexanol The title compound (9mg, white powder) was synthesized starting from Example 327.3 (30mg), and following the procedure described in Example 262. The crude material was purified by Prep LC-MS (VII). LC-MS (B): t _R = 0.591 min; [M+H] ⁺ : 423.5.

Example 328: 2-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-cyclopropyl)- propan-2-ol

328.1. 2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-cyclopropanecarboxylic acid ethyl ester

The title compound (10mg, yellow solid) was synthesized starting from Example F1.2 (250mg) and (2- (ethoxycarbonyl)cyclopropyl)boronic acid pinacol ester, and following the procedure described in Example 280 step

280.1. The crude material was purified by Prep LC-MS (XV). LC-MS (A): t _R = 0.69min; [M+H] ⁺ : 423.22.

328.2. 2-(2-{5-[(R)-(1,3-Dimethy/-azetidin-3-y/)-hydroxy-(4-isoprop y/-pheny/)-methy/]-pyridin-3-y/}-cyc/opropy/)-propan- 2-ol

The title compound (3.4mg, white solid) was synthesized starting from Example 328.1 (10mg), and following the procedure described in Example 262. The crude material was purified by Prep LC-MS (IX). LC-MS (B): t _R = 0.566min; [M+H]"·: 409.5.

Example 329: (S)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{2-[5-(tetra hydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]- pyridin-4-yl}-methanol

329.1. 3-[(2-Cyano-pyridin-4-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-3-methyl-azetidine-1-carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example A4.2 and 4-bromopyridine-2-carbonitrile, and following the procedure described in Example A7.1 step A7.1.1. LC-MS (A): t _R = 1.07min; [M+H]-: 422.31.

329.2. 4-[Hydroxy-(4-isopropyl-phenyl)-(3-methyl-azetidin-3-yl)-met hyl]-pyridine-2-carbonitrile, hydrochloride salt

A solution of Example 329.1 (4.5g) in dioxane (25mL) and HCI in dioxane (4M, 25mL) was stirred for 2h. The solution was lyophilized to give 3.8g of the title compound as light brown solid. LC-MS (A): t _R = 0.70min; [M+H]-: 322.00.

329.3. 4-[(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-pyridine-2-carbonitrile

The title compound (1.92g, off-white solid) was synthesized starting from Example 329.2, and following the procedure described in Example D1.1 step D1.1.5. The resulting crude material was purified by Prep LC-MS (XVI). LC-MS (A): t _R = 0.72min; [M+H] ⁺ : 336.23.

329.4. 4-[(S)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phe nyl)-methyl]-pyridine-2-carbonitrile The title compound (0.8g, off-white powder) was obtained by chiral separation of Example 329.3 (1.92g) using Prep chiral SFC (V) method. LC-MS (A): t _R = 0.72min; [M+H] ⁺ : 336.12, Chiral SFC (E): 2.1 min.

329.5. 4-[(S)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-N-hydroxy-pyridine-2-carboxamidine The title compound (27mg, beige solid) was synthesized starting from Example 329.4 (25mg), and following the procedure described in Example E2.1. LC-MS (A): t _R = 0.59min; [M+H]-: 369.18.

329.6. (S)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{2-[5- (tetrahydro-pyran-4-yl)-[1,2,4]oxadiazol-3-yl]-pyridin- 4-yl}-methanol

The title compound (6mg, white solid) was synthesized starting from Example 329.5 (27mg), and following the procedure described in Example 95 step 95.1. The crude material was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.75min; [M+H] ⁺ : 463.29.

Example 330: (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyrroli din-1-yl-pyrimidin-5-yl)-methanol

330.1. 3-[Hydroxy-(4-isopropyl-phenyl)-(2-pyrrolidin-1-yl-pyrimidin -5-yl)-methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example A4.2 and 5-bromo-2-(pyrrolidin-1-yl)pyrimidine, and following the procedure described in Example A4.1 step A4.1.2. LC-MS (A): t _R = 0.97min; [M+H] ⁺ : 467.11.

330.2. (4-lsopropylphenyl)(3-methylazetidin-3-yl)(2-(pyrrolidin-1-y l)pyrimidin-5-yl)methanol, hydrochloride salt

The title compound was synthesized starting from Example 330.1, and following the procedure described in Example 309. LC-MS (A): t _R = 0.67min; [M+H] ⁺ : 367.18.

330.3. (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(2-pyrroli din-1-yl-pyrimidin-5-yl)-methanol

The title compound (54mg, white powder) was synthesized starting from Example 330.2 (110mg), and following the procedure described in Example D1.1 step D1.1.5. The crude material was purified by Prep LC-MS (IX) and Prep LC- MS (VII). LC-MS (A): t _R = 0.69min; [M+H] ⁺ : 381.2.

Example 331 : (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(6-pyrroli din-1-yl-pyrazin-2-yl)-methanol

331.1. 2-Bromo-6-pyrrolidin-1-yl-pyrazine

To a solution of 2,6-dibromopyrazine (500mg) in MeOH (5mL) was added pyrrolidine ( 0.52mL). The reaction mixture was stirred at RT overnight, quenched with water and extracted with DCM. The organic layer was filtered over a phase separator and concentrated under reduced pressure. The resulting residue was purified Prep-LC-MS (V) affording the title compound (406mg) as yellow solid. LC-MS (A): t _R = 0.88min; [M+H] ⁺ : 228.1.

331.2. (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(6-pyrroli din-1-yl-pyrazin-2-yl)-methanol

The title compound was synthesized starting from Example A4.2 and Example 331.1, and following the procedure described in Example 330 steps 330.1 to 330.3. The crude material was purified twice by Prep LC-MS (IX). LC-MS (A): t _R = 0.80min; [M+H] ⁺ : 381.22. Depending on the purification conditions, the title compounds/intermediates in Example 1 to 331 may be isolated as free bases or as salts such as formate salts, or hydrochloride salts. Whenever isolating a title compound/intermediate as a salt, formate salt or hydrochloride salt is indicated at the end of the chemical name and can refer to a mono-, di- or tri-formate salt, or mono-, di-, or tri-hydrochloride salt. Example 332: (R)-N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopr opylphenyl)methyl)pyridin-3-yl)-1,2,4- oxadiazol-5-yl)cyclopropyl)acetamide-2,2,2-d3

332. 1 tert-butyl (R)-3-((5-(5-(1-(acetamido-2,2,2-d3)cyclopropyl)-1,2,4-oxadi azol-3-yl)pyridin-3-yl)(hydroxy)(4- isopropylphenyl)methyl)-3-methylazetidine- 1 -carboxylate

The title compound (80.2mg) was synthesized starting from Example D2.2 (64.5mg) and Example D3.1 (22.8mg), and following the procedure described in Example 134. Crude was extracted with water and DCM over phase separator, resulting solution was evaporated to dryness. LC-MS (A): tR = 0.98min; [M+H] ⁺ : 565.01.

332.2 (R)-N-(1 -( 3-( 5-( hydroxy ( 4-isopropylphenyl) ( 3-methylazetidin-3-yl)methyl)pyridin-3-yl) -1,2, 4-oxadiazol-5- yl)cyclopropyl)acetamide-2,2,2-d3, hydrochloride salt

A solution of Example 332.1 (80.2mg) in HCI in dioxane (4M, 4mL) was stirred 1h at RT. The crude was evaporated to dryness and used in the next step without further purification. LC-MS (A): t _R = 0.67min; [M+H]-: 464.99.

332.3 (R)-N-(1-(3-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopr opylphenyl)methyl)pyridin-3-yl)-1,2,4-oxadiazol-5- yl) cyclopropyl) acetamide-2, 2, 2-d3

The title compound (0.2mg, white powder) was synthesized from Example 332.2 (66mg), and following the procedure described in Example D1.1 step D.1.1.5. The crude was filtered off, and the filtrate was purified by Prep LC-MS (IX) and (V). LC-MS (A): t _R = 0.69min; [M+H] ⁺ : 479.18.

Example 333 to Example 336 were synthesized starting from Example D2.2 and the appropriate acid of formula (D3), following the three-step procedure described in Example 332. The acid precursors of formula (D3) are indicated in the table below. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 337: 1-(3-{5-[(R)-Hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-2-methyl-propan-2-ol

337.1 3-[(R)-Hydroxy-{5-[5-(2-hydroxy-2-methyl-propyl)-[1,2,4]oxad iazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)- methyl]-3-methyl-azetidine- 1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example D2.2 (1.023g) and 3-hydroxy-3-methylbutanoic acid (348mg) following the procedure described in Example 134. The crude material was purified by Prep LC-MS (XXVI) to afford 560mg of a yellow solid. LC-MS (A): t _R = 1 ,03min; [M+H]-: 537.29.

337.2 1-(3-{5-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-azetidin -3-yl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-2- methyl-propan-2-ol, hydrochloride salt

A solution of Example 337.1 (560mg) in HCI in dioxane (4M, 4mL) and dioxane (4mL) was stirred 1h at RT. HCI in dioxane (4M, 4mL) was added again and mixture further stirred over weekend. The crude was evaporated to dryness to give 450mg of the title compound. LC-MS (A): t _R = 0.7min; [M+H]-: 437.21.

337.3 1 -(3-{5-[(R)-Hydroxy-( 1 -isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-2-methyl-propan-2-ol

To a solution of Example 337.2 (47.6mg) in dioxane (2mL) and EtOH (1mL) were added Et ₃ N (45.5 L) and acetone (56.1 mί), followed by NaBH(OAc)3 (35.7mg). The reaction mixture was stirred at RT until completion of the reaction, filtered off, and the filtrate was purified by Prep LC-MS (IX) and (VI) to afford the title product as off-white solid (14mg). LC-MS (A): t _R = 0.76min; [M+H] ⁺ : 479.1. Example 338: 1-(3-{5-[(R)-(1-Ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-yl)-2-methyl-propan-2-ol

To a solution of Example 337.2 (47.6mg) in dioxane (2mL) and EtOH (1mL) were added Et ₃ N (45,5 L) and acetaldehyde (43.1 L), followed by NaBH(OAc) ₃ (35.7mg). The reaction mixture was stirred at RT until completion of the reaction, filtered off, and the filtrate was purified by Prep LC-MS (IX) and (VI) to afford the title product as off-white solid (16mg). LC-MS (A): t _R = 0.74min; [M+H] ⁺ : 465.07.

Example 339: 2-(3-{5-[(R)-Hydroxy-(1-isopropyl-3-methyl-azetidin-3-yl)-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-yl)-propan-2-ol

339.1 3-[(R)-Hydroxy-{5-[5-(1-hydroxy-1-methyl-ethyl)-[1,2,4]oxadi azol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methyl]- 3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound was synthesized starting from Example D2.2 (1.02 g) and 2-hydroxy-2-methylpropanoic acid (291 mg) following the procedure described in Example 134. The crude material was purified by Prep LC-MS (XVII) to afford 580 mg of a yellow solid. LC-MS (A): t _R = 1.03min; [M+H]-: 523.32.

339.22-(3-{5-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl- azetidin-3-yl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propan-2-ol

The title compound was synthesized starting from Example 339.1 (580 mg) following the procedure described in Example 309 step 309.2. The crude was evaporated to dryness to give 510 mg of the title compound as white solid as hydrochloride salt. LC-MS (A): t _R = 0.7min; [M+H] ⁺ : 423.21.

339.32-(3-{5-[(R)-Hydroxy-( 1 -isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-yl)-propan-2-ol

The title compound was synthesized starting from Example 339.2 following the procedure described in Example 337 step 337.3. The crude material was purified by Prep LC-MS (IX) and (VI). LC-MS (A): t _R = 0.76min; [M+H]-: 465.11 . Example 340: 2-(3-{5-[(R)-(1-Ethyl-3-methyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-yl)-propan-2-ol

The title compound was synthesized starting from Example D2.2 and 2-hydroxy-2-methylpropanoic acid and following a three-step procedure composed of Example 339 step 339.1 and step 339.2 followed by Example 338. The crude material was purified by Prep LC-MS (IX) then (VI) and finally by Prep TLC (Dioxane+2%Et3N 80% / EtOH20%). LC- MS (A): t _R = 0.74min; [M+H]"·: 451.11.

Example 341 and Example 342 were synthesized starting from Example E1.1 and the appropriate hydroxyamidine of formula (E2), and following the procedure described in Example 332. The hydroxyamidine precursors of formula (E2) are indicated in the table below. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 343 to Example 364 were synthesized starting from Example D2.1 and the appropriate acid of formula (D3), and following the procedure described in Example 134. The acid precursors of formula (D3) are indicated in the table below unless commercially available. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 365 and Example 366 were synthesized starting from Example D2.1 and 1 , 3-D i methyl -5-Oxo py rro I id i n e-3- carboxylic acid, and following the procedure described in Example 134. Prep LC-MS and Chiral Prep (HPLC) conditions, Chiral HPLC and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 367 to Example 369 were synthesized starting from Example D2.1 and the appropriate commercially available acid following the two-step procedure described in Example 332 steps 332.1 to 332.2. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 370 1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}- [1 ,2,4]oxadiazol-5-yl)-piperidin-1 -yl]-butan-1 -one

To a solution of Example 367 (29.8mg) in DCM (1ml) placed at 0°C were added DIPEA (38,2 mί) and butyryl chloride (5.84 mί), resulting mixture was left warmed to rt and stirred overnight. Solvent was evaporated and residue was purified by Prep LC-MS (IX) and (VI). LC-MS (A): t _R = 0.8min; [M+H] ⁺ : 532.09. Example 371 to Example 388 were synthesized starting from Example 367 and the appropriate commercially available acid chloride, chloroformate or sulfonyl chloride following the procedure described in Example 370. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 389: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5- (1-methylamino-cyclopropyl)- [1,2,4]oxadiazol-3-yl]-pyridin-3-yl}-methanol

A solution of Example 333 (220mg) in MeCN (2ml) and HCI (1 M, 2mL) was stirred 48h at 100°C. The crude was evaporated and placed under HV. The residue was purified by Prep LC-MS (IX) and (VI). LC-MS (A): tR = 0.59min; [M+H] ⁺ : 448.25.

Example 390 and Example 391 were synthesized starting from Example 389 and the appropriate commercially available acid chloride or sulfonyl chloride following the procedure described in Example 370. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 392: (R)-(1,3-Dimethyl-azetidin-3-yl)-[6-(2,2-dimethyl-cyclopenty loxy)-pyridazin-4-yl]-(4-isopropyl-phenyl)- methanol

392.1 3-[(R)-[6-(2,2-Dimethyl-cyclopentyloxy)-pyridazin-4-yl]-hydr oxy-(4-isopropyl-phenyl)-methyl]-3-methyl-azetidine- 1-carboxy\\c acid tert-butyl ester To a solution of Example F1.6.2 (35mg) in dioxane (1mL) were added 2,2-dimethylcyclopentanol (27.8mg) and NaH (60% in mineral oil, 12.4mg), resulting mixture was stirred 22h at 65°C. The resulting crude was cooled down to rt, diluted with MeCN, filtered through a syringe filter and purified by Prep LC-MS (VIII) to afford 18.1 mg of the title compound as white powder. LC-MS (A): tR = 1.16min; [M+H] ⁺ : 510.16.

392.2 (R)-[6-(2,2-Dimethyl-cyclopentyloxy)-pyridazin-4-yl]-(4-isop ropyl-phenyl)-(3-methyl-azetidin-3-yl)-methanol A solution of Example 392.1 (18.1 mg) solved in HCI in dioxane (4M, 0.5mL) was stirred 2h at RT. The reaction mixture was cooled at 0°C, basified to pH=8 with aq. sat. NaHC0 ₃ , diluted with water and extracted with DCM. The combined org. layers were dried (MgS04), filtrated off, evaporated and dried under HV to afford 13.8mg of the title compound as beige solid. LC-MS (A): t _R = 0.84min; [M+H] ⁺ : 410.19.

392.3 (R)-(1,3-Dimethyl-azetidin-3-yl)-[6-(2,2-dimethyl-cyclopenty loxy)-pyridazin-4-yl]-(4-isopropyl-phenyl)-methanol The title compound (6.3mg, white powder) was synthesized starting from Example 392.2 (13.8mg) and following the procedure described in Example F1.1 step F1.1.2. Resulting crude was purified by Prep LC-MS (V). LC-MS (A): t _R = 0.85min; [M+H] ⁺ : 424.20.

Example 393: (R)-[6-(3,3-Difluoro-cyclopentyloxy)-pyridazin-4-yl]-(1,3-di methyl-azetidin-3-yl)-(4-isopropyl-phenyl)- methanol

The title compound (7mg, white solid) was synthesized starting from Example F1.6.2 (35mg) and 3,3- difluorocyclopentan-1-ol (30.6mg) following the three-step procedure described in Example 392. Resulting crude was purified by Prep LC-MS (VII). LC-MS (A): t _R = 0.78min; [M+H] ⁺ : 432.12.

Example 394: 2-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yloxy}- phenyl)-ethanol

394.13-[(R)-Hydroxy-{6-[2-(2-hydroxy-ethyl)-phenoxy]-pyri dazin-4-yl}-(4-isopropyl-phenyl)-methyl]-3-methyl-azetidine- 1-carboxy\\c acid tert-butyl ester

To a solution of Example F1.6.2 (200mg) in NMP (2.3mL) were added 2-hydroxyphenethyl alcohol (67 mί), molecular sieves (3A powder, 200mg) and CS2CO3 (366mg). The resulting mixture was stirred at 65°C for 2.5 days, cooled down to RT, diluted with MeCN, filtered through a syringe filter and purified by Prep LC-MS (XX) to afford 53mg of the title compound as white solid. LC-MS (A): t _R = 1.03min; [M+H] ⁺ : 534.14.

394.22-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridazin-3-yloxy}-phenyl)-ethano l

The title compound (13.8mg, white solid) was synthesized starting from Example 394.1 (47.5mg) and following the procedure described in Example 82 step 82.2 and 82.3. Resulting crude was purified by Prep LC-MS (V). LC-MS (A): t _R = 0.71 min; [M+H] ⁺ : 448.18.

Example 395 to Example 397 were synthesized starting from Example F1.6.2 and the appropriate commercially available alcohol following the procedure described in Example 394. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 398 to 407 were synthesized starting from the corresponding Example of formula (F1) and the appropriate alkyne of formula (F5), and following the procedure described in Example 15. The precursors of formula (F1) and (F5) are indicated in the table below unless commercially available. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 408: 1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl- pyrimidin-4-yl)-pentan-3-ol A solution of Example 398 (15mg) was dissolved in MeOH (0.3mL), Pd/C (10% w/w, 50% water, 3mg) was added and resulting mixture was stirred for 17h under hydrogen. The reaction mixture was filtered off and evaporated to dryness to afford 12mg of the title compound as white solid. LC-MS (A): t _R = 0.64min; [M+H]" ^· : 489.21.

Example 409 to Example 412 were synthesized starting from Example F1.2 and the appropriate alkyne of formula (F5), according to a two-step procedure described in Example 15 (Prep LC-MS conditions for the purification described in the table below) followed by Example 408 (no purification performed). The alkyne precursors of formula (F5) are indicated in the table below unless commercially available. LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A). Example 413: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[2- (1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl]-pyridin- 3-yl}-methanol

413.1 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-tri methylsilanylethynyl-pyridin-3-yl)-methanol

The title compound (21 mg, white powder) was synthesized from Example F1.2 (200mg) and trimethyl acetylene (97.3 L), and following the procedure described in Example 15. Resulting crude was purified by Prep LC-MS (VII) then (XIV). LC-MS (A): t _R = 0.88min; [M+H] ⁺ : 407.20.

413.2 (R)-(1,3-Dimethyl-azetidin-3-yl)-(5-ethynyl-pyridin-3-yl)-(4 -isopropyl-phenyl)-methanol

The title compound (18mg, yellow oil) was synthesized from Example 413.1 (20mg) following the procedure described in Example F5.1 step F5.1.2. LC-MS (A): t _R = 0.73min; [M+H] ⁺ : 335.17. 413.3 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(1H -pyrrolo[2,3-b]pyridin-2-ylethynyl)-pyridin-3-yl]- methanol

The title compound (12mg, yellow powder) was synthesized from Example 413.2 (18mg) and 2-lodo-1H-pyrrolo[2,3- B]pyridine (18mg), and following the procedure described in Example 15. Resulting crude was purified by Prep LC-MS (VII). LC-MS (A): t _R = 0.77min; [M+H] ⁺ : 451.03.

413.4 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[2- (1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl]-pyridin-3-yl}- methanol

The title compound (8mg, light yellow solid) was synthesized from Example 413.3 (11 mg) following the procedure described in Example 1119-7775. LC-MS (A): t _R = 0.57min; [M+H] ⁺ : 455.19. Example 414: 4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-ethyl)- piperidine-1 -carboxylic acid tert-butyl ester

The title compound (28mg, rose resin) was synthesized from Example 407 (52mg) following the procedure described in Example 48. Resulting crude was basified with aq. sat. NaHC0 ₃ solution and extracted with DCM over phase separator and solvent was evaporated to dryness. LC-MS (A): t _R = 0.73min; [M+H] ⁺ : 522.18. Example 415 to Example 417 were synthesized starting from Example F1.2 and the appropriate alkyne of formula (F5), according to a two-step procedure described in Example 15 followed by Example 48. The alkyne precursors of formula (F5) are indicated in the table below. Prep LC-MS conditions from both steps and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A). Example 418: 8-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridazin-3-yl}-ethyl)- 5,6,7,8-tetrahydro-quinolin-8-ol

418.1 8-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridazin-3-ylethynyl}-5,6,7,8- tetrahydro-quinolin-8-ol

The title compound (27mg, brown solid) was synthesized from Example F1.6 (50mg) and Example F5.14 (33.8mg), and following the procedure described in Example 15. Resulting crude was purified by Prep LC-MS (IX) LC-MS (A): tR = 0.63min; [M+H] ⁺ : 483.16.

418.28-(2-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridazin-3-yl}-ethyl)-5, 6, , 8- tetrahydro-quinolin-8-ol

The title compound (2mg, white solid) was synthesized from Example 418.1 (27mg) following the procedure described in Example 48. Resulting crude was purified by Prep LC-M (IX) LC-MS (A): t _R = 0.58min; [M+H]-: 487.2.

Example 419: 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridazin-3-yl}-2-(6- methoxy-pyridin-2-yl)-butan-2-ol

419.13-[Hydroxy-{6-[(R)-3-hydroxy-3-(6-methoxy-pyridin-2- yl)-but-1-ynyl]-pyridazin-4-yl}-(4-isopropyl-phenyl)-methyl] - 3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound (154mg, pale rose powder) was synthesized from Example F1.6.2 (200mg) and Example F5.9 (89mg), and following the procedure described in Example 15. Resulting crude was purified by Prep LC-MS (VII). LC- MS (A): t _R = 1.07min; [M+H]"·: 573.09.

419.2 3-[Hydroxy-{6-[(R)-3-hydroxy-3-(6-methoxy-pyridin-2-yl)-buty l]-pyridazin-4-yl}-(4-isopropyl-phenyl)-methyl]-3- methyl-azetidine-1 -carboxylic acid tert-butyl ester

The title compound (126mg, yellow solid) was synthesized from Example 419.1 (152mg) following the procedure described in Example 408. LC-MS (A): t _R = 1.04min; [M+H]-: 578.05.

419.3 4-{5-[ ( R)-Hydroxy-( 4-isopropyl-phenyl) -( 3-methyl-azetidin-3-yl) -methyl]-pyridazin-3-yl}-2-( 6-methoxy-pyridin-2- yl)-butan-2-ol

The title compound (25mg, brown solid) was synthesized from Example 419.2 (54mg) following the procedure described in Example 309 step 309.2. Resulting crude was purified by Prep LC-MS (VII). LC-MS (A): t _R = 0.72min; [M+H]-: 477.03.

419.4 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyiidazin-3-yl}-2-(6-methoxy-pyridin- 2-yl)-butan-2-ol

The title compound (9mg, white powder) was synthesized from Example 419.3 (23mg) following the procedure described in Example F1.1 step F1.1.2. Resulting crude was purified by Prep LC-MS (VI). LC-MS (A): t _R = 0.74min; [M+H]-: 491.01. Example 420: 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridazin-3-yl}-2-(6-methyl- pyridin-2-yl)-butan-2-ol

The title compound (10mg, white powder) was synthesized from Example F1.6.2 and Example F5.27, and following the four-step procedure described in Example 419. Resulting crude was purified by Prep LC-MS (VI). LC-MS (A): t _R = 0.57min; [M+H] ⁺ : 475.21.

Example 421: (1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(6-pyrroli din-1-yl-pyridin-2-yl)-methanol The title compound (0.7mg, brown solid) was synthesized starting from Example A4.2 and 2-bromo-6-(pyrrolidine-1- yl)pyridine, following the procedure described in Example D1.1 but omitting the steps D1.1.2 and D1.1.3. Resulting crude was purified by Prep LC-MS (XIV) then (XVIII). LC-MS (A): t _R = 0.85min; [M+H] ⁺ : 380.22. Example 422 and Example 423 were synthesized starting from AcCI and the appropriate amine precursor, and following the procedure described in Example 370. The amine precursors are indicated in the table below. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 424: 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yloxy}- cyclohexanone

The title compound is Example 261.2 and was synthesized as described exactly in Example 261 steps 261.1 and 261.2. LC-MS (A): t _R = 0.65min; [M+H] ⁺ : 423.23.

Example 425: 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-cyclohexanol Title compound (7mg, white powder) was synthesized from Example 327 step 327.3 (41 mg) and following the procedure described in Example 261 step 261.3. Resulting crude was purified by Prep LC-MS (VI). LC-MS (A): t _R = 0.55min; [M+H]" ^· : 409.09.

Example 426 (R)-(5-Cyclopentyloxymethyl-pyridin-3-yl)-(1,3-dimethyl-azet idin-3-yl)-(4-isopropyl-phenyl)-methanol To a solution of Example F1.2 (30mg) and potassium cyclopentoxymethyltrifluoroborate (15.9mg) in a dioxane/water mixture (10:1, 1mL) were added Cs ₂ C0 ₃ (75.4mg), Pd(OAc) ₂ (0.519mg) and RuPhos (2.27mg). The resulting mixture was stirred for 45h at 95°C, allowed to cool down to RT, diluted with MeOH and water, filtered through a syringe filter and purified by Prep LC-MS (XIV) to give 6mg of the title compound as colorless resin. LC-MS (A): tR = 0.69min; [M+H]"·: 409.16.

Example 427 (1-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-ylmethoxy}- piperidin-1 -yl)-ethanone

427.1 (4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl -phenyl)-methyl]-pyridin-3-ylmethoxy}-piperidine-1- carboxylic acid tert-butyl ester

The title compound (29mg, off-white solid) was synthesized from Example F1.2 (100mg) and potassium (1-Boc-4- piperidinyloxy)methyl trifluoroborate (82.5mg), and following the procedure described in Example 426. The resulting crude was purified by Prep LC-MS (VII). LC-MS (A): t _R = 0.79min; [M+H] ⁺ : 524.15.

427.2 (R)-(1,3-dimethylazetidin-3-yl)(4-isopropylphenyl)(5-((piper idin-4-yloxy)methyl)pyridin-3-yl)methanol, hydrochloride salt

The title compound (6mg, yellow resin) was synthesized from Example 427.1 (9mg) following the procedure described in Example 309 step 309.2. LC-MS (A): t _R = 0.47min; [M+H] ⁺ : 424.28.

427.3 (1-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-ylmethoxy}-piperidin-1- yi)-ethanone

The title compound (0.7mg, colorless resin) was synthesized from Example 427.2 (6mg) and AcOH (2.07 L), and following the procedure described in Example 140 step 140.3. The resulting crude was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.58min; [M+H] ⁺ : 465.88.

Example 428: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[6-(te trahydro-pyran-4-yl)-pyridazin-4-yl]-methanol

428.1 (R)-[6-(3, 6-Dihydro-2H-pyran-4-yl)-pyridazin-4-yl]-( 1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-methanol The title compound (27mg, yellow solid) was synthesized from Example F1.6 (50mg) and 3,6-dihydro-2H-pyran-4- boronic acid pinacol ester (62.6mg), and following the procedure described in Example 303. The resulting crude was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.69min; [M+H] ⁺ : 394.22.

428.2 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[6-(te trahydro-pyran-4-yl)-pyridazin-4-yl]-methanol

The title compound (7mg, white solid) was synthesized from Example 428.1 (27mg) following the procedure described in Example 48. Resulting crude was purified by Prep LC-M (IX). LC-MS (A): t _R = 0.68min; [M+H]-: 396.24.

Example 429: 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridazin-3-yl}-2-phenyl- butan-2-ol 429.13-[ ( R)-Hydroxy-[ 6-( 3-hydroxy-3-phenyl-but- 1 -ynyl) -pyridazin-4-yl]-( 4-isopropyl-phenyl)-methyl]-3-methyl- azetidine-1 -carboxylic acid tert-butyl ester

The title compound (52.5mg, white powder) was synthesized from Example F1.6.2 (80mg) and DL-2-phenyl-3-butyn-2- ol (41.4mg), and following the procedure described in Example 165 step 165.1. The resulting crude was purified by Prep LC-MS (XII). LC-MS (A): t _R = 1.07min; [M+H] ⁺ : 542.08.

429.2 3-chloro-4-( 5-((R) -hydroxy ( 4-isopropylphenyl) ( 3-methylazetidin-3-yl)methyl)pyridazin-3-yl) -2-phenylbut-3-en-2- ol, hydrochloride salt

The title compound (69mg, yellow solid) was synthesized from Example 429.1 (52.5mg) following the procedure described in Example 309 step 309.2. LC-MS (A): t _R = 0.77min; [M+H]-: 478.10.

429.3. 3-Chloro-4-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-i sopropyl-phenyl)-methyl]-pyridazin-3-yl}-2-phenyl- but-3-en-2-ol

The title compound (20.4mg, beige solid) was synthesized starting from Example 429.2 (69mg), and following the procedure described in Example F1.1 step F1.1.2. Resulting crude was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.79min; [M+H] ⁺ : 492.13.

429.4. 4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridazin-3-yl}-2-phenyl-butan-2-ol The title compound (5mg, white powder) was synthesized from Example 429.3 (20.4mg) following the procedure described in Example 48. Resulting crude was purified by Prep LC-MS (IX). LC-MS (A): t _R = 0.74min; [M+H]-: 460.18.

Example 430 (R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{6-[(S)-(tet rahydro-furan-3-yl)oxy]-pyridazin-4-yl}- methanol

430.1. 3-((R) -Hydroxy-(4-isopropyl-phenyl) -{ 6-[ ( S) -( tetrahydro-furan-3-yl) oxy]-pyridazin-4-yl}-methyl)-3-methyl- azetidine-1 -carboxylic acid tert-butyl ester

The title compound (25.3mg, white powder) was synthesized from Example F1.6.2 (35mg) and (S)-(+)- hydroxytetrahydrofuran (19.6 L), and following the procedure described in Example 277 but heating the mixture at 65°C for 1 h. The resulting crude was purified by Prep LC-MS (VI). LC-MS (A): t _R = 1.03min; [M+H]-: 484.15.

430.2. (R)-(4-lsopropyl-phenyl)-(3-methyl-azetidin-3-yl)-{6-[(S)-(t etrahydro-furan-3-yl)oxy]-pyridazin-4-yl}-methanol

The title compound (21.4mg, beige solid) was synthesized from Example 430.1 (25.3mg) following the procedure described in Example 309 step 309.2. LC-MS (A): t _R = 0.66min; [M+H]"·: 384.11.

430.3. (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{6-[(S )-(tetrahydro-furan-3-yl)oxy]-pyridazin-4-yl}-methanol The title compound (11.3mg, white powder) was synthesized starting from Example 430.2 (21.4mg), and following the procedure described in Example F1.1 step F1.1.2. Resulting crude was purified by Prep LC-MS (V). LC-MS (A): t _R = 0.67min; [M+H] ⁺ : 398.16. Example 431 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{6-[(R )-(tetrahydro-furan-3-yl)oxy]-pyridazin-4-yl}- methanol

The title compound (5.6mg, white powder) was synthesized from Example F1.6.2 (35mg) and (R)-(+)- hydroxytetrahydrofuran (19.6 L), and following the three-step procedure described in Example 430. The resulting crude was purified by Prep LC-MS (V). LC-MS (A): t _R = 0.67min; [M+H] ⁺ : 398.17.

Example 432 to 444 were synthesized starting from Example F1.6 and the appropriate commercially available carbamate (F4) or amide-containing reagent of Formula (F3), and following the procedure described in Example 167 step 167.1. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC- MS (A).

Example 445: 2-(3-{5-[(S)-(3-Fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4-is opropyl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-propan-2-ol

445.1 3-[(5-Cyano-pyridin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-3-fluoro-azetidine-1 -carboxylic acid tert-butyl ester

To a solution of Example A4.13 (1.50 g) and 5-bromonicotinonitrile (1.08 g) in THF (30 mL) at -78 °C, a solution of HexLi in THF (2.3 M, 1.3 mL) was added dropwise during 20min. The reaction mixture was stirred at -78 °C for 20min, before the cooling bath was removed and the reaction was quenched with aq. NH ₄ CI. The mixture was extracted with EA twice, the combined organic layers were washed with brine, dried over Na ₂ S0 ₄ , filtered and concentrated under vacuo. The residue was purified by CC (CombiFlash, RediSep 40 g, gradient n-Heptane/EA 90:10 to 60:40 over 25 min at 40 mL/min) to give the desired product as a yellow foam (1.49 g). It was further purified by prep LC-MS (XVII then XII) to give the title compound as white solid (1.04 g). LC-MS (A): t _R = 1.09 min; [M+H] ⁺ : 426.24.

445.2 3-[(S)-(5-Cyano-pyridin-3-yl)-hydroxy-(4-isopropyl-phenyl)-m ethyl]-3-fluoro-azetidine-1 -carboxylic acid tert-butyl ester Example 445.1 (1.04 g) was purified by prep chiral HPLC (XL) to give the title compound as pure enantiomer (450 mg). Chiral SFC (F): t _R = 1.86 min.

445.33-Fluoro-3-[(S)-hydroxy-[5-(N-hydroxycarbamimidoyl)- pyridin-3-yl]-(4-isopropyl-phenyl)-methyl]-azetidine-1- carboxylic acid tert-butyl ester

Example 445.2 (150 mg) together with hydroxylamine hydrochloride (74 mg) and K ₂ CO ₃ (195 mg) were suspended in EtOH (2.3 mL). The mixture was heated to 85 °C and stirred for 15 h. The reaction mixture was filtered, the residue was washed with more EtOH and the filtrate was concentrated under vacuo to give the title compound as off-white solid (149 mg), which was used in subsequent steps without further purification. LC-MS (A): t _R = 0.80 min; [M+H]-: 459.28.

445.43-Fluoro-3-[(S)-hydroxy-{5-[5-( 1 -hydroxy- 1 -methyl-ethyl)-[ 1,2, 4]oxadiazol-3-yl]-pyridin-3-yl}-(4-isopropyl- phenyl)-methyl]-azetidine-1 -carboxylic acid tert-butyl ester

Example 445.3 (120 mg), alpha-hydroxyisobutyric acid (37 mg), PyBOP (423 mg) and K ₃ PO ₄ (227 mg) were treated with DMF (2 mL) and NEt3 (0.14 mL). The mixture was heated to 85 °C and stirred for 15 h. The reaction was cooled to room temperature, diluted with EA, washed with aq. NaHC0 ₃ , aq. NH ₄ CI and brine, dried over Na ₂ S0 ₄ , filtered and concentrated under vacuo to give an orange oil. The residue was purified by CC (CombiFlash, RediSep 12 g, gradient n-Heptane/EA 90:10 to 50:50 over 20 min at 30 mL/min) to afford the title compound as a colorless amorphous solid (90 mg). LC-MS (A): t _R = 1.06 min; [M+H] ⁺ : 527.28.

445.52-(3-{5-[(S)-(3-Fluoro-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- propan-2-ol, hydrochloride salt

Example 445.4 (90 mg) was dissolved in a solution of HCI in dioxane (4 M, 0.43 mL) and stirred at RT for 1 .5 h. A thick slurry resulted and to improve stirring, dioxane (0.5 mL) and little MeOH (0.15 mL) were added. After another 1.5 h at RT full conversion was achieved and the mixture was concentrated under vacuo to give the title compound as white solid (76 mg). It was used in the next steps without further purification. LC-MS (A): t _R = 0.69 min; [M+H]-: 427.26. 445.62-(3-{5-[(S)-(3-Fluoro-1-methyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5-yl)-propan-2-ol

To a solution of Example 445.5 (35 mg) in DCM (0.5 mL) at 0 °C was added a solution of formaldehyde in H ₂ 0 (37 wt. %, 14 uL). After stirring for 5 min, NaBH(OAc) ₃ (23 mg) was added, the suspension was stirred at 0 °C for 1 h. The mixture was treated with NEt ₃ (0.01 mL) and additional aq. formaldehyde solution (37 wt %, 0.02 mL) and NaBH(OAc) ₃ (18 mg). After stirring at 4 °C for 16 h, the reaction mixture was concentrated under vacuo, filtered through a syringe filter and purified by prep LC-MS (V) to give the title compound as a white solid (21 mg). LC-MS (A): t _R = 0.70 min; [M+H]"·: 441.25.

Example 446: 2-(3-{5-[(S)-(1-Cyclopropyl-3-fluoro-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-propan-2-ol

A solution of Example 445.5 (42 mg) in DCM (0.5 mL) and NEt3 (0.01 mL) was cooled to 0 °C, before (1- ethoxycyclopropoxy)trimethylsilane (0.05 mL) and AcOH (0.02 mL) were added. After stirring for 5 min, NaBH(OAc) ₃ (28 mg) was added and the suspension was stirred at 0 °C for 1 h. Acetic acid (0.03 mL) was added and the mixture was allowed to warm to RT. After stirring for 2.5 h, the reaction mixture was heated to 40 °C and stirred for 2 h. The mixture was cooled to RT, quenched with sat. aq. NaHC03 and extracted with EA three times. The combined organic layers were dried over Na2S04, filtered and concentrated under vacuo to give a yellow oil (being mostly reaction intermediate. The residue was taken up in MeOH (0.5 mL) and thereto was added NaBHsCN (18 mg). The mixture was heated to 65 °C and stirred for 1 h. The reaction mixture was concentrated under vacuo, redissolved in MeCN, filtered through a syringe filter and subjected to prep LC-MS (VI then IX) to give the title compound as a white solid (11 mg). LC-MS (A): t _R = 0.73 min; [M+H] ⁺ : 467.29.

Example 447: 1-[4-(3-{5-[(S)-(3-Fluoro-1-methyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone

447.1 3-[(S)-{5-[5-(1-Acetyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl ]-pyridin-3-yl}-hydroxy-(4-isopropyl-phenyl)-methyl]-3- fluoro-azetidine-1 -carboxylic acid tert-butyl ester

A mixture of Example 445.3 (179 mg), 1-acetylpiperidine-4-carboxylic acid (84 mg), PyBOP (568 mg), K3PO4 (304 mg) and DIPEA (0.18 mL) in DMF (2.5 mL) was stirred at 85 °C for 15 h. The reaction mixture was cooled to RT, diluted with EA, washed with aq. NaPICOs, aq. NH4CI and brine, dried over Na2S04, filtered and concentrated under vacuo to give an orange oil, which was purified by CC (CombiFlash, RediSep 12 g, gradient DCM to DCM/MeOFI 90:10 over 20 min at 30 mL/min) to give a colorless amorphous solid (149 mg). LC-MS (A): t _R = 1.10 min; [M+Fi] ⁺ : 594.12.

447.2 1-[4-(3-{5-[(S)-(3-Fluoro-azetidin-3-yl)-hydroxy-(4-isopropy l-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-1-yl]-ethanone, hydrochloride salt

Example 447.1 (145 mg) was treated with a solution of HCI in dioxane (4 M, 0.43 mL) and stirred for 1 h. The reaction mixture was concentrated under vacuo to give the desired product as slightly yellow solid (155 mg). The compound was used in the next step without further purification. LC-MS (A): t _R = 0.70 min; [M+Fi]-: 494.28.

447.3 1 -[4-( 3-{5-[ ( S) -( 3-Fluoro- 1 -methyl-azetidin-3-yl) -hydroxy-( 4-isopropyl-phenyl) -methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin- 1 -yl]-ethanone

A suspension of Example 447.2 in DCM (1 .0 mL) was cooled to 0 °C. Thereto was added a solution of formaldehyde in water (37 wt. %, 14 uL) and NaBFI(OAc)3 (68 mg). The mixture was stirred for 5 h at 0 °C and 1 h at RT. More formaldehyde solution (37 wt. %, 0.05 mL) and NaBFI(OAc)3 (65 mg) were added. The mixture was stirred at RT for 1 h. The reaction mixture was poured into aq. NaFICOs and extracted with DCM/MeOFI (9:1) three times. The combined organic layers were passed through a phase separator and concentrated under vacuo to give a colourless oil, which was purified by prep LC-MS (V) to give a white solid (64 mg). LC-MS (A): t _R = 0.71 min; [M+Fi]-: 508.29.

Example 448: 1-[4-(3-{5-[(S)-(1-Cyclopropyl-3-fluoro-azetidin-3-yl)-hydro xy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone

448.1 5-[(S)-(3-Fluoro-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl) -methyl]-nicotinonitrHe

Treatment of Example 445.2 (450 mg) with a solution of HCI in dioxane (4 M, 2.65 mL) led to a colourless solution that quickly turned into a thick suspension. To help stirring, MeOFI (1.0 mL) was added and the mixture was stirred at RT for 1 h. The mixture was concentrated under vacuo, then purified by prep LC-MS (V) to give a white solid (160 mg). LC- MS (A): t _R = 0.67 min; [M+H] ⁺ : 326.20. 448.25-[(S)-( 1 -Cyclopropyl-3-fluoro-azetidin-3-yl)-hydroxy-(4-isopropyl-ph enyl)-methyl]-nicotinonitrile

To a solution of Example 448.1 (100 mg) in MeOH (5 mL) was added (l-ethoxycyclopropoxy)trimethylsilane (0.19 mL), acetic acid (0.04 mL) and NaBh CN (41 mg). The suspension was heated to 55 °C and stirred for 90 min, then cooled to RT and stirred for 17 h. The reaction mixture was diluted with DCM and washed with aq. NaHC03. The aqueous phase was extracted once with DCM/MeOH (9:1). The combined organic layers were passed through a phase separator and concentrated under vacuo to give a colorless oil, which was purified by prep LC-MS (VI) to give the product as a white foam (74 mg). LC-MS (A): t _R = 0.72 min; [M+H] ⁺ : 366.24.

448.35-[(S)-( 1 -Cyclopropyl-3-fluoro-azetidin-3-yl)-hydroxy-(4-isopropyl-ph enyl)-methyl]-N-hydroxy-nicotinamidine

A suspension of Example 448.2 (74 mg), hydroxylamine hydrochloride (43 mg) and K ₂ CO ₃ (112 mg) in EtOH (1.5 mL) was heated to 90 °C and stirred for 3 h. The reaction mixture was cooled to RT, filtered and concentrated under vacuo to give the desired product as a white solid (109 mg). The crude was used in the next step without further purification. LC-MS (A): t _R = 0.55 min; [M+H] ⁺ : 399.22.

448.4 1 -[4-(3-{5-[(S)-( 1 -Cyclopropyl-3-fluoro-azetidin-3-yl)-hydroxy-(4-isopropyl-ph enyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin- 1 -yl]-ethanone

A reaction vessel was charged with Example 448.3 (109 mg), PyBOP (326 mg), K3PO4 (175 mg) and 1-acetylpiperidine- 4-carboxylic acid (48 mg), followed by DMF (1.0 mL) and DIPEA (0.11 mL). The mixture was stirred for 17 h at 80 °C and for 7 h at 95 °C. More PyBOP (200 mg) was added and the reaction was stirred at 100 °C for 20 h. More 1- acetylpiperidine-4-carboxylic acid (30 mg), PyBOP (200 mg) and K3PO4 (100 mg) were added and the mixture was stirred at 100 °C for another 18 h. The reaction mixture was cooled to RT, diluted with EA, washed with aq. NaHC03 and with brine, dried over Na2S04, filtered and concentrated under vacuo to give a yellow oil, which was purified with prep LC-MS (VI then IX) and CC (CombiFlash, RediSep 4 g, gradient DCM to DCM/MeOH/NH40H 94.5:5.0:0.5 over 20 min at 18 mL/min) to give a white solid (5 mg). LC-MS (A): t _R = 0.74 min; [M+H] ⁺ : 534.31.

Example 449 : 2-(3-{5-[(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-propan-2-ol

449.15-[(R)-( 1 -Cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-ph enyl)-methyl]-nicotinonitrile

To a solution of Example D1.1.4 (541 mg) in MeOH (6 mL) was added (l-ethoxypropoxy)trimethylsilane (0.73 mL), acetic acid (0.14 mL) and NaBHsCN (158 mg). The suspension was heated to 65 °C and stirred for 16 h. The reaction mixture was filtered, diluted with DCM and washed with aq. NaHC0 ₃ . The aqueous phase was re-extracted with DCM/MeOH (9:1). The combined organic layers were passed through a phase separator and were concentrated under vacuo to give a colourless oil, which was purified by prep LC-MS (VI) to give the desired product as a white solid (174 mg). LC-MS (A): t _R = 0.71 min; [M+H] ⁺ : 362.20.

449.25-[(R)-( 1 -Cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-ph enyl)-methyl]-N-hydroxy-nicotinamidine A mixture of Example 449.1 (87 mg), hydroxylamine hydrochloride (49 mg) and K ₂ CO ₃ (127 mg) in EtOH (1.5 mL) was heated to 85 °C and stirred for 1.5 h. The reaction mixture was cooled to RT, filtered, concentrated and dried under HV to give a white solid (101 mg), which was used in the next step without further purification. LC-MS (A): t _R = 0.55 min; [M+H]-: 395.26. 449.32-(3-{5-[(R)-( 1 -Cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy-(4-isopropyl-ph enyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-yl)-propan-2-ol

A mixture of Example 449.2 (43 mg), alpha-hydroxyisobutyric acid (7 mg), PyBOP (35 mg) and NEt3 (10 mg) in DMF (0.5 mL) was heated to 80 °C and stirred for 16 h. The reaction mixture was cooled to RT, diluted with MeCN/hbO, filtered through a syringe filter and purified by prep LC-MS (2 x VI) to give the title compound as a slightly yellow solid. LC-MS (A): t _R = 0.72 min; [M+H] ⁺ : 463.31.

Example 450 to Example 453 were prepared from Example 449.2 and the corresponding carboxylic acid according to the procedure described for Example 449.3. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A). Example 454: 1-[(R)-3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-ylmethyl)-pyrrolidin-1-yl]-ethanone

454.1 (R)-3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-iso propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol- 5-ylmethyl)-pyrrolidine-1 -carboxylic acid tert-butyl ester A mixture of Example D2.1 (39 mg), (R)-(1-Boc-pyrrolidin-3-yl)-acetic acid (36 mg), PyBOP (128 mg), K3PO4 (89 mg) and DIPEA (41 mg) in DMF (2 mL) was stirred at 85 °C for 64 h. The mixture was cooled to RT, diluted with H ₂ 0/MeCN, passed through a syringe filter and purified by prep LC-MS (XIV) to give the desired product as a white solid. LC-MS (A): t _R = 0.85 min; [M+H] ⁺ : 562.21. 454.2 (R)-(1,3-dimethylazetidin-3-yl)(4-isopropylphenyl)(5-(5-(((R )-pyrroHdin-3-yl)methyl)-1,2,4-oxadiazol-3-yl)pyridin-

3-yl)methanol hydrochloride salt

Example 454.1 (76 mg) was treated with a solution of HCI in dioxane (4 M, 2 mL) and stirred at RT for 2 h. The reaction mixture was concentrated and dried under HV. The resulting white solid was used in the next step without further purification. LC-MS (A): t _R = 0.55 min; [M+H] ⁺ : 462.24. 454.3 1 -[(R)-3-(3-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-

[1,2, 4]oxadiazol-5-ylmethyl)-pyrrolidin-1-yl]-ethanone

To a solution of Example 454.2 (15 mg) in THF (1 mL) was added DIPEA (19 mg) and acetyl chloride (2.4 mg) at 0 °C. The mixture was stirred at 0 °C for 45 min, before it was concentrated and dried under HV. The crude was purified by prep HPLC (IX) to give the title compound as a white solid (3 mg). LC-MS (A): t _R = 0.71 min; [M+H] ⁺ : 504.24. Example 455 to Example 459 were synthesized according to the 3-step procedure described for Example 454, using the corresponding acids in the first step. Prep LC-MS conditions (first and third steps) and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 460: N-[1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-

[1,2,4]oxadiazol-5-ylmethyl)-cyclopropyl]-acetamide

460.1 [1-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- ylmethyl)-cyclopropyl]-carbamic acid tert-butyl ester

A mixture of Example D2.1 (30 mg), 2-[1-({tert-butoxycarbonyl}amino)cyclopropyl]acetic acid (15 mg), PyBOP (60 mg), K3PO4 (59 mg) and DIPEA (27 mg) in DMF (0.75 mL) was heated to 90 °C and stirred for 3 h. After cooling to RT, the reaction mixture was filtered and directly purified by prep LC-MS (XIV) to give the desired product as a white solid (4 mg). LC-MS (A): t _R = 0.82 min; [M+H] ⁺ : 548.18. 460.2 (R)-{5-[5-(1-Amino-cyclopropylmethyl)-[1,2,4]oxadiazol-3-yl] -pyridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4- isopropyl-phenyl)-methanol, hydrochloride salt

Example 460.1 (4 mg) was treated with a solution of HCI in dioxane (4 M, 1 mL) and stirred at RT for 1 h. The reaction mixture was concentrated under vacuo to give the desired product as a white solid (3 mg). LC-MS (A): t _R = 0.57 min; [M+H]"·: 448.17. 460.3 N-[ 1 -(3-{5-[(R)-( 1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-met hyl]-pyridin-3-yl}-[ 1 ,2,4]oxadiazol-5- ylmethyl)-cyclopropyl]-acetamide

To a suspension of Example 460.2 (2 mg) and acetic acid (0.3 mg) in DMF (1 mL) was added HATU (1.9 mg) and DIPEA (1.7 mg). The reaction mixture was stirred at RT for 20 h, filtered and then directly purified by prep LC-MS (IX) to give the title compound as a white solid (0.5 mg). LC-MS (A): t _R = 0.69 min; [M+H]-: 490.04. Examples 461 and 462 were prepared from Example 460.2, as described for Example 460, but using the corresponding acids. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 463: N-[1-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-ylmethyl)-cyclopropyl]-N-methyl-acetam ide

The title compound was prepared from Example D2.1, according to the 3-step procedure described for Example 460, but using the corresponding carboxylic acid in the first step. Prep LC-MS was used to purify the intermediate after step 1 (VII) and the final product (IX). LC-MS (A): t _R = 0.72 min; [M+H] ⁺ : 504.29.

Example 464: N-[2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-1,1-dimethyl-ethyl]-propionamide hydrochloride464. 1 [2-(3-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-1, 1-dimethyl-ethyl]-carbamic acid tert-butyl ester

A mixture of Example D2.1 (789 mg), N-Boc-3-amino-3-methylbutanoic acid (633 mg), PyBOP (3.00 g), K3PO4 (1.63 g) and DIPEA (738 mg) in DMF (12 mL) was heated to 80 °C and stirred for 16 h. The reaction mixture was cooled to RT, diluted with H ₂ 0/MeCN, filtered through a syringe filter and purified by prep LC-MS (VII) to give a lightly yellow solid (516 mg). LC-MS (A): t _R = 0.88 min; [M+H] ⁺ : 550.31.

464.2 (R)-{5-[5-(2-Amino-2-methyl-propyl)-[1,2,4]oxadiazol-3-yl]-p yridin-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl- phenylj-methanol, hydrochloride salt

Example 464.1 (516 mg) was treated with a solution of HCI in dioxane (4 M, 4.7 mL) and stirred at RT for 1.5 h. The reaction mixture was concentrated under vacuo to give the desired product as a white solid (577 mg). LC-MS (A): t _R = 0.59 min; [M+H] ⁺ : 450.08.

464.3 N-[2-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- yl)-1, 1 -dimethyl-ethyl]-propionamide

To a solution of propionic acid (5 mg) in DMF (0.15 mL) were added DBU (32 mg) and HATU (32 mg). The solution was stirred at RT for 10 min and was then added to a solution of Example 464.2 (30 mg) and DBU (25 mg) in DMF (0.15 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h, before more premixed (for 10 min) propionic acid (5 mg), DBU (32 mg) and HATU (32 mg) in DMF (0.15 mL) was added. The mixture was stirred for 1 h at 0 °C, before it was diluted with MeCN/hbO, filtered through a syringe filter and purified by prep LC-MS (IX) to give the title compound as white solid (5.5 mg). LC-MS (A): t _R = 0.78 min; [M+H] ⁺ : 506.31 .

Examples 465 to Example 468 were synthesized starting from Example 464.2 according to the procedure described for Example 464, with the difference that the corresponding preactivated acid (1 .2 equiv.) was only added once (since the conversion was sufficient). Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Examples 469 to Example 472 were synthesized from Example D2.1 and the corresponding substituted 1-Boc- piperidine-4-carboxylic acids according to the 3-step procedure described for Example 464. In the last step, correspondingly different carboxylic acids were used. Prep LC-MS conditions (first and third steps) and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 473: 1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-3,3,3-trifluoro-propa n-1-one

473.14-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- yl)-piperidine-1 -carboxylic acid tert-butyl ester

To a solution of N-Boc-piperidine-4-carboxylic acid (69 mg) in DMSO (0.25 mL) was added CDI (52 mg). The mixture was stirred at RT for 30 min. Thereto was added a solution of Example D2.1 (100 mg) in DMSO (0.25 mL). The resulting solution was stirred at 85 °C for 30 min and directly purified by prep LC-MS (IX) to give the title compound as white solid (83 mg). LC-MS (A): t _R = 0.87 min; [M+H] ⁺ : 562.43. 473.2 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5- piperidin-4-yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]- methanol

Example 473.1 (83 mg) was treated with a solution of HCI in dioxane (4 M, 1.11 mL) and stirred at RT for 2 h. The reaction mixture was concentrated and dried under HV. The residue was purified by prep LC-MS (VII) to give the desired product as white solid (31 mg). LC-MS (A): t _R = 0.57 min; [M+H] ⁺ : 462.38. 473.3 1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- yl) -piperidin- 1 -yl]-3, 3, 3-trifluoro-propan- 1 -one To a solution of 3,3,3-trifluoropropionic acid (3.4 mg) and HATU (10 mg) in DMF (0.5 mL) was added DIPEA (10 mg) and the mixture was stirred for 5 min before Example 473.2 (10 mg) in DMF (0.5 mL) was added. The reaction mixture was stirred for 2 h at RT, then it was diluted with MeCN/H ₂ 0, filtered through a syringe filter and purified by prep LC- MS (VI) to give the title compound as white solid (2.5 mg). LC-MS (A): t _R = 0.79 min; [M+H]-: 572.37.

Example 474: 1 -[4-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-oxetan-3-yl-ethanon e

474. 1 Oxetan-3-yl-acetic acid (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{5- [1-(2-oxetan-3-yl-acetyl)- pipeiidin-4-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-3-yl)-methyl ester

The compound was synthesized from Example D2.1 (100 mg) and N-Boc-piperidine-4-carboxylic acid (86 mg) according to the 3-step procedure described for Example 464. In the third step, the corresponding acid (3-oxetanacetic acid) was used. Prep LC-MS purification was used after the first step (XIV) and the third step (V). LC-MS (A): t _R = 0.73 min; [M+H] ⁺ : 658.39.

474.2 1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- yl) -piperidin- 1 -yl]-2-oxetan-3-yl-ethanone

To a solution of Example 474.1 (11 mg) in MeOH (1 mL) was added K ₂ CO ₃ (22 mg) and the mixture was stirred at 45 °C for 5 h. The reaction was cooled to RT, diluted with EA and washed with water. The aqueous phase was reextracted with EA twice, the combined organic layers were dried over Na2S04, filtered and concentrated under vacuo. The crude was purified by prep LC-MS (V) to give the title compound as a white solid (4.4 mg). LC-MS (A): t _R = 0.72 min; [M+H]"·: 560.31.

Examples 475, 476 and 477 were synthesized from Example D2.1 and the corresponding piperidine carboxylic acids, according to the 4-step procedure described for Example 474 (in the first step of Example 475, molecular sieves instead of K ₃ PO ₄ were used). In the third step the corresponding carboxylic acids were used. For Example 477, the reaction mixture in the first step was stirred at 100 °C for 41 h to reach full conversion. Prep LC-MS conditions (steps 1, 3 and 4) and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 478: 1-[cis-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-3-methyl-piperidin-1-yl]-ethanone

478.1 cis-4-({{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[(E)-hydroxyimino]- methyl}-carbamoyl)-3-methyl-piperidine-1-carboxylic acid tert-butyl ester

A mixture of Example D2.1 (65 mg), cis-N-Boc-3-methylpiperidine-4-carboxylic acid (56 mg), PyBOP, molecular sieves (3A, 50 mg) and DIPEA (67 mg) in DMF (3 mL) was stirred at RT for 16 h. The reaction mixture was filtered, diluted with MeCN/hhO, passed through a syringe filter and directly purified by prep LC-MS (IX) to give the desired compound as yellow oil (143 mg). LC-MS (A): t _R = 0.78 min; [M+H] ⁺ : 594.44. 478.24-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-is opropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl) - cis-3-methyl-piperidine-1 -carboxylic acid tert-butyl ester

A mixture of Example 478.1 (143 mg), molecular sieves (3A, 150 mg) and DIPEA (32 mg) in DMF (1 mL) was heated to 100 °C and stirred for 16 h. The reaction mixture was cooled to RT, diluted with MeCN/hhO, passed through a syringe filter and purified by prep LC-MS (Method XIV) to give the desired product as brown powder (40 mg). LC-MS (A): t _R = 0.90 min; [M+H] ⁺ : 576.43.

478.3 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[5- (cis-3-methyl-piperidin-4-yl)-[1,2,4]oxadiazol-3-yl]- pyridin-3-yl}-methanol, hydrochloride salt

Example 478.2 (40 mg) was treated with HCI in dioxane (4 M, 0.5 mL) and the mixture was stirred at RT for 30 min. The reaction was concentrated and dried under HV to give the desired product as a sticky solid (31 mg). LC-MS (A): t _R = 0.59 min; [M+H] ⁺ : 476.37.

478.4 Acetic acid (R)-{5-[5-(cis-1-acetyl-3-methyl-piperidin-4-yl)-[1, 2, 4]oxadiazol-3-yl]-pyridin-3-yl}-(1, 3-dimethyl- azetidin-3-yl)-(4-isopropyl-phenyl)-methyl ester To a solution of Example 478.3 (31 mg) in DMF (0.5 mL) was added DBU (27 mg), before it was cooled to 0 °C. Thereto was added a premixed (10 min) solution of acetic acid (5.1 mg), DBU (11 mg) and HATU (38 mg) in DMF (0.5 mL). The mixture was stirred at 0 °C for 1 h and 1 h at RT. The reaction was diluted with MeCN/H ₂ 0, passed through a syringe filter and purified by prep LC-MS (IX) to give the bis-acylated product as a white solid (11 mg). LC-MS (A): tR = 0.79 min; [M+H] ⁺ : 560.43.

478.5 1-[cis-4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-3-methyl-piperidin- 1 -yl]-ethanone

To a solution of Example 478.4 (11 mg) in MeOH (0.5 mL) was added K ₂ CO ₃ (26 mg) and the mixture was stirred at RT for 16 h. The reaction was diluted with MeCN/hbO passed through a syringe filter and purified by prep LC-MS (Method VI) to give the title compound as white solid (6 mg). LC-MS (A): t _R = 0.77 min; [M+H]"·: 518.24.

Example 479: 5-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-1 -methyl-piperidin-2-one

A mixture of Example D2.1 (25 mg), 1-methyl-6-oxo-piperidine-3-carboxylic acid (16 mg), PyBOP (83 mg), K ₃ PO ₄ (58 mg) and DIPEA (26 mg) in DMF (1 mL) was heated to 85 °C and stirred for 16 h. The reaction mixture was diluted with MeCN/hbO, passed through a syringe filter and purified by prep LC-MS (IX then V) to give the title compound as white solid (7.6 mg). LC-MS (A): t _R = 0.69 min; [M+H] ⁺ : 490.11.

Example 480 to Example 497 were synthesized from Example D2.1 and the corresponding carboxylic acids according to the procedure described for Example 479. If necessary, to achieve full conversion the reaction mixture can be stirred up to 20 h, at slightly higher temperature (90 °C). Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 498: 1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-4-hydroxy-piperidin-1-yl]-ethanone

The title compound was synthesized from Example D2.1 and Example D3.13 according to the procedure described for Example 479. The product was purified by prep LC-MS (IX then V) and prep chiral SFC (XXXII) to give the title compound as a yellow, sticky solid. LC-MS (A): t _R = 0.66 min; [M+H] ⁺ : 520.36.

Example 499: 3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-propionitrile

To a solution of 3-cyanopropionic acid (33 mg) in DMSO (0.25 mL) was added CDI (55 mg) and the mixture was stirred at RT for 30 min. Thereto was added a solution of Example D2.1 (65 mg) in DMSO (0.25 mL). The mixture was stirred at 85 °C for 1 h. The reaction was cooled to RT, diluted with MeCN/hhO, passed through a syringe filter and purified by prep LC-MS (XIV) to give the title compound as a white solid (25 mg). LC-MS (A): t _R = 0.73 min; [M+H] ⁺ : 432.35. Example 500: 1 -[4-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-3-methoxy-piperidin-1-yl]-ethanone The title compound was synthesized from Example D2.1 and Example D3.14, according to the procedure described for Example 499. The product was purified by prep LC-MS (V+IX) to yield to title compound as a white solid. LC-MS (A): t _R = 0.73 min; [M+H] ⁺ : 534.41.

Example 501: 1-[(R)-3-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4- isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone 501.13-[(R)-{5-[5-((R)-1-Acetyl-piperidin-3-yl)-[1,2,4]oxadi azol-3-yl]-pyridin-3-yl}-hydroxy-(4-isopropyl-phenyl)-methyl ]-

3-methyl-azetidine-1 -carboxylic acid tert-butyl ester A mixture of Example D2.2 (125 mg), (3R)-1-acetylpiperidine-3-carboxylic acid (74 mg), PyBOP (244 mg), K ₃ PO ₄ (238 mg) and DIPEA (109 mg) in DMF (3 mL) was heated to 90 °C and stirred for 20 h. Due to incomplete conversion the same amounts of carboxylic acid and PyBOP were added again and the mixture was stirred for another 6 h at 90 °C. The reaction mixture was cooled to RT, diluted with MeCN/hhO, passed through a syringe filter and purified by prep LC-MS (XII) to give the desired product as an off-white solid (120 mg). LC-MS (A): tR = 1.08 min; [M+H]-: 590.24. 501.2 1-[(R)-3-(3-{5-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-a zetidin-3-yl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- yl)-piperidin-1-yl]-ethanone hydrochloride salt

Example 501.1 (113 mg) was treated with a solution of HCI in dioxane (4 M, 1.5 mL) and stirred at RT for 1 h. The reaction mixture was concentrated under vacuo to give the desired product as an off-white solid (106 mg). LC-MS (A): t _R = 0.72 min; [M+H] ⁺ : 490.16.

501.3 1 -[(R)-3-(3-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}- [1,2, 4]oxadiazol-5-yl)-piperidin- 1 -yl]-ethanone

To a solution of Example 501.2 (89 mg) in dioxane (4.7 mL) was added NEt3 (55 mg), a solution of formaldehyde in H2O (37 wt. %, 52 mg) and NaBH(OAc)3 (60 mg). The mixture was stirred at RT for 3 h, before it was diluted with MeCN/hbO, filtered and purified by prep LC-MS (IX) to give the desired product as an off-white solid (49 mg). LC-MS (A): t _R = 0.73 min; [M+H] ⁺ : 504.14.

Examples 502 to Example 508 were prepared from D2.2 and the corresponding carboxylic acids, according to the 3- step procedure described for Example 501. In case of incomplete conversion in the first step, more carboxylic and PyBOP was added, or the reaction mixture was stirred at slightly higher temperatures (up to 100 °C). For Examples 507 and 508, K ₃ PO ₄ was replaced by molecular sieves (3A). Example 504 was additionally purified by CC (CombiFlash, RediSep 4 g, gradient DCM to DCM/MeOH/NEUOH 90:10:1 over 20 min at 18 mL/min) after the prep LC-MS. Prep LC- MS conditions (steps 1, 3) and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Examples 509 to Example 514 were prepared according to the 3-step procedure described for Example 501, using Example D2.2 and the corresponding carboxylic acids indicated in the table below. Examples 510 and 511 were derived from the same carboxylic acid (Example D3.16), the corresponding epimeric mixture after step 1 was separated by prep chiral SFC (XXXIII). Prep LC-MS conditions (steps 1, 3) and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 515 and Example 516 were synthesized according to the 3-step procedure described for Example 501, using Example D2.2 and 2-oxopiperidine-4-carboxylic acid. The epimeric mixture after step 1 was separated by prep chiral HPLC (XLIII). Prep LC-MS conditions (steps 1, 3) and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 517: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5- methyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]- methanol 517.1 3-{(R)-Hydroxy-(4-isopropyl-phenyl)-[5-(5-methyl-[1,2,4]oxad iazol-3-yl)-pyridin-3-yl]-methyl}-3-methyl-azetidine- 1-carboxy\\c acid tert-butyl ester

To a solution of acetic acid (9.5 mg) in DMSO (0.25 mL) was added CDI (28 mg). The mixture was stirred at RT before a solution of Example D2.2 (60 mg) in DMSO (0.25 mL) was added. The reaction was stirred at 85 °C for 16 h. It was then purified by prep LC-MS (VII) to give the desired product as a white solid (43 mg). LC-MS (A): tR = 1.08 min; [M+H] ⁺ : 479.38.

517.2 (R)-(4-lsopropyl-phenyl)-(3-methyl-azetidin-3-yl)-[5-(5-meth yl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol, hydrochloride salt

Example 517.1 (43 mg) was treated with a solution of HCI in dioxane (4 M, 0.6 mL) and stirred at RT for 0.5 h. The reaction mixture was concentrated under vacuo to give the desired product as yellow amorphous solid (46 mg). LC-MS (A): t _R = 0.71 min; [M+H] ⁺ : 379.27.

517.3 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(5- methyl-[1,2,4]oxadiazol-3-yl)-pyridin-3-yl]-methanol

To a solution of Example 517.2 (46 mg) in dioxane (1 mL) was added NEt3 (55 mg), a solution of formaldehyde in H2O (37 wt. %, 17 mg) and NaBH(OAc)3 (35 mg). The mixture was stirred at RT for 1 h, before it was diluted with MeCN/hbO, filtered and purified by prep LC-MS (VI) to give the desired product as a white solid (20 mg). LC-MS (A): t _R = 0.73 min; [M+H]-: 393.31.

Example 518: (R)-{5-[5-(1,1-Difluoro-ethyl)-[1,2,4]oxadiazol-3-yl]-pyridi n-3-yl}-(1,3-dimethyl-azetidin-3-yl)-(4- isopropyl-phenyl)-methanol

The title compound was synthesized from Example D2.2 and 2,2-difluoropropionic acid, according to the 3-step procedure described for Example 517. The crude material was purified by Prep LC-MS (VII) (step 1) and (VI) (step 3). LC-MS (A): t _R = 0.81 min; [M+H] ⁺ : 443.33.

Example 519: 4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-3-yl)-tetrahydro-pyran-4-ol

519.1 3-[(R)-Hydroxy-{5-[3-(4-hydroxy-tetrahydro-pyran-4-yl)-[ 1, 2, 4]oxadiazol-5-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)- methyl]-3-methyl-azetidine-1 -carboxylic acid tert-butyl ester

To a solution of Example E1.1 (50 mg) in DMF (1 mL) was added CDI (23 mg). The mixture was stirred for 30 min before DIPEA (30 mg) was added. Then it was stirred at RT for 16 h. Example E2.16 (27 mg) was added and the reaction was heated to 90 °C for 3 h, after which molecular sieves (3A, 60 mg) were added and the mixture was heated again at 90 °C for 14 h. The reaction was cooled to RT, diluted with MeCN/hbO, passed through a syringe filter and purified by prep LC-MS (VI) to give the desired compound as a white solid (12 mg). LC-MS (A): t _R = 1.01 min; [M+H] ⁺ : 565.40. 519.24-(5-{5-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-aze tidin-3-yl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3-yl)- tetrahydro-pyran-4-ol hydrochloride salt

Example 519.1 (12 mg) was treated with a solution of HCI in dioxane (4 M, 1 mL), stirred at RT for 90 min, then concentrated under vacuo to give the desired product as a white solid (14 mg). LC-MS (A): tR = 0.67 min; [M+H] ⁺ : 465.13.

519.34-(5-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-[ 1,2, 4]oxadiazol-3- yl)-tetrahydro-pyran-4-ol

To a suspension of Example 519.2 (14 mg) in dioxane (0.2 mL) was added NEt3 (9 mg), a solution of formaldehyde in H2O (37 wt. %, 9 mg) and NaBH(OAc)3 (10 mg). The mixture was stirred at RT for 90 min. The reaction was diluted with MeCN/H20, passed through a syringe filter and purified by prep LC-MS (IX then V) to give the title compound as a white solid (3 mg). LC-MS (A): t _R = 0.67 min; [M+H] ⁺ : 479.38.

Examples 520 to Example 523 were prepared from Example E1.1 and the corresponding hydroxyamidines (Examples indicated in the table below) according to the 3-step procedure described for Example 501, but using one equivalent of acid (Example E1.1) and 1.5-2.0 equivalents of hydroxyamidine. The applied hydroxyamidine of formula E2, the LC- MS retention times and observed masses, as well as the purification methods used after step 1 and 3 are shown in the table below. Examples 520 and 521 were generated from the same reaction sequence. Example 523 was prepared from Example E1.1 and the corresponding hydroxyamidine (indicated in the table) according to the procedure described for Example 519. The LC-MS conditions used were LC-MS (A).

Example 524: 4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}- [ 1 , 2 , 4] oxadi azol -3-y I methy I )-tetr ahy d ro-py r an-4-o I

The title compound was synthesized from Example E1.1 and the corresponding hydroxyamidine (Example E2.20) according to the 3-step procedure described for 517, but using 1 equivalent of acid and 1.5 equivalents of hydroxyamidine. Prep LC-MS was used to purify the intermediate after step 1 (Method VI) and the final product after step 3 (Method V). LC-MS (A): t _R = 0.68 min; [M+H] ⁺ : 493.39.

Example 525: [4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopro pyl-phenyl)-methyl]-pyridin-3-yl}- [1 ,2,4]oxadiazol-3-yl)-piperidin-1-yl]-[1 ,4]dioxan-2-yl-methanone

525.15-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-azetid in-3-yl)-methyl]-nicotinic acid, hydrochloride salt Example E1.1 (1.20 g) was treated with a solution of HCI in dioxane (4 M, 14 mL). The mixture was stirred at RT for 1 h. The suspension was filtered, the residue was washed with dioxane, then dried under HV to give the desired compound as a white solid (1.13 g). LC-MS (A): t _R = 0.67 min; [M+H]"·: 341.22.

525.25-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopr opyl-phenyl)-methyl]-nicotinic acid, formic acid salt

To a suspension of Example 525.1 (1.13 g) in dioxane (27 mL) were added NEt ₃ (1.14 mL), a solution of formaldehyde in H2O (37 wt. %, 0.32 mL) and NaBH(OAc)3 (895 mg). The mixture was stirred at RT for 90 min, filtered and directly purified by prep LC-MS (IX) to give the title compound as a white solid (142 mg). LC-MS (A): t _R = 0.59 min; [M+H]-: 355.25.

525.34-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4 -isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3- yl)-piperidine-1 -carboxylic acid tert-butyl ester

To a solution of Example 525.2 (140 mg) in DMF (3.2 mL) were added DIPEA (0.17 mL) and PyBOP (236 mg). After stirring at RT for 15 min, a solution of E2.19 (170 mg) in DMF (0.9 mL) and K3PO4 (282 mg) were added. The mixture was stirred at 85 °C for 16 h. After cooling to RT, more PyBOP (259 mg), K3PO4 (282 mg) and DIPEA (0.17 mL) were added and the reaction was stirred at 85 °C for another 4 h. The mixture was cooled to RT, diluted with MeCN/H ₂ 0, passed through a syringe filter and purified by prep LC-MS (Method VIII) to give the desired product as a white solid (88 mg). LC-MS (A): t _R = 0.88 min; [M+H] ⁺ : 562.35. 525.4 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-[5-(3- piperidin-4-yl-[1,2,4]oxadiazol-5-yl)-pyridin-3-yl]- methanol

Example 525.3 (88 mg) was treated with a solution of HCI in dioxane (4 M, 1.2 mL) and stirred for 1 h. The reaction mixture was concentrated under vacuo to give the title compound as a pale yellow solid (102 mg). LC-MS (A): tR = 0.56 min; m/z [M+2H+MeCN] ²⁺ : 252.35.

525.5 [4-(5-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-[ 1, 2, 4]oxadiazol-3- yl)-piperidin-1-yl]-[1,4]dioxan-2-yl-methanone

To a solution of Example 525.4 (50 mg) in DMF (0.36 mL) was added DBU (51 mg) and a premixed (10 min) solution of 1,4-dioxane-2-carboxylic acid (23 mg), HATU (72 mg) and DBU (20 mg) in DMF (0.36 mL) at 0 °C. The mixture was stirred at 0 °C for 1 h. The reaction was then diluted with MeCN/H ₂ 0, passed through a syringe filter and purified by prep LC-MS (V then IX) to give the title compound as a white solid (25 mg). LC-MS (A): tR = 0.73 min; [M+H] ⁺ : 576.41 . Example 526: 1-[4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-3-yl)-piperidin-1-yl]-2-methoxy-ethanone

526.1 Methoxy-acetic acid (R)-(1,3-dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{3- [1-(2-methoxy-acetyl)-piperidin-4- yl]-[1 ,2,4]oxadiazol-5-yl}-pyridin-3-yl)-methyl ester

The title compound was synthesized from Example 525.4 and methoxy acetic acid, according to the procedure described for Example 525 (step 5). LC-MS (A): t _R = 0.74 min; [M+H] ⁺ : 606.44.

526.2 1-[4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3- yl)-piperidin-1-yl]-2-methoxy-ethanone, formic acid salt

To a solution of Example 526.1 (59 mg) in MeOH was added K ₂ C0 ₃ (128 mg) and the mixture was stirred at 45 °C for 2 h. The reaction was cooled to RT, filtered, diluted with MeCN/H ₂ 0, passed through a syringe filter and purified by prep LC-MS (V then IX) to give the title compound as a white solid (30 mg). LC-MS (A): t _R = 0.72 min; [M+H]"·: 534.45.

Example 527: (R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1 -methanesulfonyl-piperidin-4-yl)-

[1.2.4]oxadiazol-5-yl]-pyridin-3-yl}-methanol

To a solution of Example 525.4 (51 mg) and DIPEA (46 mg) in DCM (1.5 mL) at 0 °C was added methanesulfonyl chloride (10 mg). The mixture was stirred at 0 °C for 90 min. The solvent was then removed under vacuo, the residue was purified by prep LC-MS (IX) to give the desired product as a white solid (22 mg). LC-MS (A): t _R = 0.75 min; [M+H]-: 540.36.

Example 528: (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-{3- [1-(2-methoxy-ethanesulfonyl)-piperidin-4- yl]-[1,2,4]oxadiazol-5-yl}-pyridin-3-yl)-methanol

Example 528 was synthesized from Example 525.4 and 2-methoxyethane-1-sulfonyl chloride according to the procedure described for Example 527. LC-MS (A): t _R = 0.78 min; [M+H]-: 584.38. Example 529: 1-[4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}- [1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-hydroxy-ethanone

529.12-(tert-Butyl-diphenyl-silanyloxy)-1-[4-(5-{5-[(R)-( 1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)- methyl]-pyridin-3-yl}-[1 ,2, 4]oxadiazol-3-yl) -piperidin- 1 -yl]-ethanone

To a solution of Example 525.2 (45 mg) in DMF (0.56 mL) were added DIPEA (44 mg) and PyBOP (182 mg). After stirring at RT for 15 min, a solution of E2.21 (74 mg) in DMF (0.5 mL) and K3PO4 (97 mg) were added and the reaction was stirred at 85 °C for 16 h. More PyBOP (91 mg), K3PO4 (50 mg) and DIPEA (44 mg) were added and the mixture was stirred at 100 °C for 5 h. The reaction was cooled to RT, diluted with MeCN/hbO, passed through a syringe filter and purified by prep LC-MS (2x Method XX) to give the desired product as a white solid (10 mg). LC-MS (A): tR = 1.02 min; [M+H] ⁺ : 758.52.

529.2 1-[4-(5-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-3- yl)-piperidin-1-yl]-2-hydroxy-ethanone

To a solution of Example 529.1 (10 mg) in THF (0.2 mL) was added a solution of TBAF in THF (1.0 M, 0.02 mL). The reaction mixture was stirred at RT for 90 min, then diluted with MeCN/hbO, passed through a syringe filter and purified by prep LC-MS (V then IX) to give the title compound as a white solid (1.5 mg). LC-MS (A): tR = 0.69 min; [M+H] ⁺ : 520.39.

Example 530: (R)-(1 ,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-[1 ,2,4]oxadiazol-3-yl-pyridin-3-yl)-methanol

530.13-[(R)-Hydroxy-(4-isopropyl-phenyl)-(5-[1,2,4]oxadia zol-3-yl-pyridin-3-yl)-methyl]-3-methyl-azetidine-1- carboxylic acid tert-butyl ester

To a solution of Example D2.2 (50 mg) in DMA (0.5 mL) was added trimethyl orthoformate (0.11 mL) and boron trifluoride diethyl etherate (4.6 mg). The reaction mixture was stirred at 50 °C for 2.5 h. MeCN was added and the mixture was passed through a syringe filter and purified by prep LC-MS (VII) to give the desired product as a white solid (32 mg). LC-MS (A): t _R = 1.06 min; [M+H] ⁺ : 465.34.

530.2 (R)-(4-lsopropyl-phenyl)-(3-methyl-azetidin-3-yl)-(5-[1,2,4] oxadiazol-3-yl-pyridin-3-yl)-methanol

Example 530.1 (32 mg) was treated with a solution of HCI in dioxane (4 M, 0.3 mL) and stirred at RT for 30 min. The solvent was evaporated and the residue dried under HV to give the desired product as a white solid (39 mg). LC-MS (A): t _R = 0.69 min; [M+H] ⁺ : 365.18.

530.3 (R)-(1,3-Dimethyl-azetidin-3-yl)-(4-isopropyl-phenyl)-(5-[1, 2,4]oxadiazol-3-yl-pyridin-3-yl)-methanol

To a solution of Example 530.2 (39 mg) in dioxane (1 mL) was added NEΪ3 (10 mg), a solution of formaldehyde in H2O (37 wt. %, 16 mg) and NaBH(OAc)3 (32 mg). The reaction was stirred at RT for 1.5 h. The mixture was filtered and concentrated under vacuo, the crude was purified by prep LC-MS (VI) to give the title compound as a white solid (29 mg). LC-MS (A): t _R = 0.71 min; [M+H] ⁺ : 379.26. Example 531 : 1 -[4-(3-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}- [1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone

531.13-[(R)-{5-[5-(1-Acetyl-piperidin-4-yl)-[1,2,4]oxadia zol-3-yl]-pyridin-3-yl}-hydroxy-(4-isopropyl-phenyl)-methyl] -3- methyl-azetidine-1 -carboxylic acid tert-butyl ester To a solution of Example D2.2 (1.7 g) in DMF (34mL) were added 1 -acetylpiperidine-4-carboxylic acid (967 mg), followed by PyBOP (4.57 g), DIPEA (1.96 mL) and K3PO4 (3.23 g). The resulting solution was stirred at 85°C overnight. Additional 0.5 equivalent of reagents were added and the resulting mixture was stirred at 85°C overnight. The reaction mixture was allowed to cool down to RT, filtered off, and evaporated in vacuo. The crude material was purified by Prep LC-MS (XXXV) to give the title compound as a white solid (1.76 g). LC-MS (A) tR = 1.08 min; [M+H] ⁺ : 590.13. 531.2 1-[4-(3-{5-[(R)-Hydroxy-(4-isopropyl-phenyl)-(3-methyl-azeti din-3-yl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)- piperidin-1-yl]-ethanone

A solution of Example 531.1 (1.76 g) in HCI 4M in dioxane (35 mL) was stirred at RT for 1 h. The reaction mixture was evaporated in vacuo and dried in HV to afford 1.57 g as yellow solid. LC-MS (A) tR = 0.72min; [M+H] ⁺ : 490.2.

531.3 1-[4-(3-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5- yl)-piperidin-1-yl]-ethanone

The title compound was prepared starting from Example 531.2 (1.57 g), and following the procedure described in Example D1.1 step D1.1.5. The crude material was purified by Prep LC-MS (XXXVI) followed by Prep LC-MS (XXXVII) to give the title compound as a white solid (900 mg). LC-MS (A): tR = 0.72 min; [M+H] ⁺ : 504.12.

Example 532 to Example 566 were synthesized starting from the appropriate precursor of Formula (A7) or (D5) and following the procedure described in Example 1, except that TEA was used to neutralize the hydrochloride salt and DCM was replaced by dioxane. Prep LC-MS conditions and LC-MS data of Example 532 to Example 566 are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 567 to Example 577 were synthesized starting from the appropriate precursor of Formula (J1), (J3) or (J5) and the appropriate precursor of Formula (J2), (J4) or (J6), respectively, following the method as indicated in the table below. Prep LC-MS conditions and LC-MS data of Example 567 to Example 577 are listed in the table below. The LC- MS conditions used were LC-MS (A).

Method A

A mixture of compound (J1) (1 eq), boron species (J2) (1.3 to 1.6 eq), cataCXium ^® A Pd G3 (0.05 to 0.1 eq) and CS2CO3 (3 eq) in a mixture of toluene (5 mL/mmol) and water (0.5 mL/mmol) was flushed with argon, heated at 100°C in a sealed vial and stirred for 18h. It was filtered over Celite, the cake was washed with EA and the filtrate was concentrated in vacuo. The crude was purified by Prep LC-MS (see method in the Table below) and/or CC using SNAP KP-NH™ prepacked cartridges from Biotage and eluting with EA/MeOFI or DCM/MeOFI. Method B

A mixture of boronic ester (J3) (1 eq), copper(l) reagent (J4) (1.2 eq) and KF (1 eq) in DMF (10 mL/mmol) was heated at 50°C in a sealed vial and stirred for 18h. It was filtered over Celite, the cake was washed with EA and the filtrate was concentrated in vacuo. The crude was purified by Prep LC-MS (see method in the Table below) and/or CC using SNAP KP-NH™ prepacked cartridges from Biotage and eluting with EA/MeOFI or DCM/MeOFI.

Method C

To a solution of phenol (J5) (1 eq) in DMF (20 mL/mmol) was added at RT, halide (J6) (5 eq) and K ₂ CO ₃ (2.4 eq). The mixture was heated at 100°C and stirred for 40h. It was partitioned between EA and half sat. NaPIC0 ₃ . The aq. phase was extracted with EA/MeOFI 95/5 and the combined org. phases were dried over MgSC>4 and concentrated in vacuo. The crude was purified by Prep LC-MS (see method in the Table below) and/or CC using SNAP KP-NH™ prepacked cartridges from Biotage and eluting with EA/MeOFI or DCM/MeOFI. Example 578 1 -[4-(3-{5-[(R)-Hydroxy-(1 -isopropyl-3-methyl-azetidin-3-yl)-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone

Example 531.2 (40mg) was dissolved in dioxane (881 pL), then acetone (23.5pL) and sodium triacetoxyborohydride (35.7mg) were added and the mixture was stirred at RT for 15min. The reaction mixture was taken up in DCM, quenched with aq. sat. NaHC03. The phases were separated with a phase separator, evaporated and purified by prep LC-MS (VI), then by CC (Biotage, 11g KP-NH, solvent A: Hept, solvent B: EA, gradient (in %B): 25 for 1CV, 15 to 100 over 4CV, 100 for 9CV) to give 5mg colorless glassy oil. LC-MS (A) tR = 0.78min; [M+H] ⁺ : 532.22.

Example 579 1-[4-(3-{5-[(R)-[1-(2,2-Difluoro-ethyl)-3-methyl-azetidin-3- yl]-hydroxy-(4-isopropyl-phenyl)-methyl]- pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanon e

Example 531.2 (32mg) was dissolved in MeOH (0.256pL), then TEA (44.6pL) and 2-lodo-1 , 1 -difluoroethane (11.5pL) were added. The mixture was shaken at 60°C for 6 days, while 2x 2-iodo-1 , 1 -difluoroethane (11.5pL, 23pL) were added after 4h and 22h. The mixture was filtrated through a syringe filter, diluted with MeOH and purified by prep LC- MS (VI) to give 20mg off-white foam. LC-MS (A) tR = 0.76min; [M+H] ⁺ : 554.10

Example 580 1-[4-(3-{5-[(R)-Hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azetid in-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin- 3-yl}-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone

580.1 1-[4-(3-{5-[(R)-{1-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl ]-3-methyl-azetidin-3-yl}-hydroxy-(4-isopropyl-phenyl)- methyl]-pyridin-3-yl}-[1 ,2, 4]oxadiazol-5-yl) -piperidin- 1 -yl]-ethanone

Example 531.2 (50mg) and CS2CO3 (65.2g) were taken up in DMF (500pL), then (2-bromoethoxy)-tert- butyldimethylsilane (33.1 pL) was added. The mixture was shaken at 70°C for 1h40, filtrated through a syringe filter, diluted with DMF and purified by prep LC-MS (VIII) to give 29mg off-white foam. LC-MS (A) t _R = 0.97min; [M+H] ⁺ : 648.34.

580.2 1-[4-(3-{5-[(R)-Hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azetid in-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-

[1.2.4]oxadiazol-5-yl)-piperidin- 1 -yl]-ethanone

Example 580.1 (29mg) was dissolved in THF (500pL), cooled to 0°C and then TBAF 1 M in THF (102pL) was added, the mixture was stirred for 1h at RT. The mixture was taken up in EA, washed with aq. sat. NaHCOs and water. The org. layer was washed with brine, dried over MgS04, filtrated, concentrated and purified by prep LC-MS (V) to give 11mg beige glassy oil. LC-MS (A) t _R = 0.72min; [M+H] ⁺ : 534.13.

Example 581 to Example 585 were synthesized following the procedure described in Example F1.1 step F1.1.2 starting from Example 531.2 and using the appropriate commercially available aldehyde and purified by prep LC-MS and CC (Biotage, 11g SPHERE Amino, solvent A: Hept, solvent B: EA), if necessary. The purification conditions and the LC- MS (A) data are listed in the table below.

Example 586 to Example 635 were synthesized starting from the corresponding Example F1.2 and the appropriate alkyne, and following the procedure described in Example 15. The precursor alkyne is indicated in the table below unless commercially available. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 408. LC-MS and prep LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 648 to Example 653 were synthesized starting from the corresponding Example F1.2 and the appropriate alkyne, and following the procedure described in Example 15, where the amount of Pd(PPh3)4 was adjusted to 0.1 eq and the base was changed to pyrrolidine (3.5eq). The precursor alkyne is indicated in the table below unless commercially available. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example F5.27, and following the procedure described in Example 15, where the amount of Pd(PPh3)4 was adjusted to 0.1 eq and the base was changed to pyrrolidine (3.5eq). The precursor bromopyridine is indicated in the table below. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A). procedure described in Example 15. The precursor alkyne is indicated in the table below unless commercially available. Prep LC-MS conditions and LC-MS data are listed in the table below. The LC-MS conditions used were LC-MS (A).

Example 665 and Example 666 were synthesized following the procedure described in Example D1.1 step D1.1.5 using the corresponding free azetidine A7.34 and the appropriate carbonyl reagent, purified (if necessary) by prep LC-MS. The LC-MS (A) data are listed in the table below.

Example 667 and Example 668 To a solution of A7.34 (30mg) in MeOH (1 mL) were added at RT TEA (20.2 L) followec by commercial available 2-iodoethanol (57.3mg) for Example 667 and 1 , 1 -difluoro-2-iodoethane (57mg) for Example 668, respectively. The resulting mixture was shaken at reflux over weekend. The mixture was purified by prep LC-MS. Prep LC-MS data and LC-MS (A) data are listed in the table below.

Example 669 1 -(4-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridin-3-yloxymethyl}- piperidin-1 -yl)-ethanone

669.14-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-is opropyl-phenyl)-methyl]-pyridin-3-yloxymethyl}-piperidine-1- carboxylic acid tert-butyl ester A flask was charged with G1.2 (11 mg), N-Boc-4-piperidinemethanol (22.4mg), toluene abs. (300mI_) and cyanomethylenetributylphosphane (19.6mί) at RT. The resulting suspension was stirred at 110°C under argon overnight, then evaporated and purified by prep LC-MS (VIII) to give 25mg off-white powder. LC-MS (A) t _R = 0.77min; [M+H]"·: 524.15.

669.2 (R)-(1,3-dimethylazetidin-3-yl)(4-isopropylphenyl)(5-(piperi din-4-ylmethoxy)pyridin-3-yl)methanol, hydrochloride salt

The title compound was synthesized from Example 669.1 and following the procedure described in Example 309 step 309.2. LC-MS (A) t _R = 0.49; [M+H] ⁺ : 424.22.

669.3 1-(4-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yloxymethyl}-piperidin-1- yi)-ethanone To a suspension of Example 669.2 (28mg) in DCM (1mL) were added DIPEA (48.3 L), AcOH (9.7 L), EDC.HCI (13mg) and HOBt (9mg) at RT. The resulting solution was stirred at RT for 1 h, then the mixture was evaporated and purified by prep LC-MS (IX) to give 1mg white powder. LC-MS (A) t _R = 0.63min; [M+H]- 465.98.

Example 6704-{5-[(R)-(1-Cyclopropyl-3-methyl-azetidin-3-yl)-hydroxy- (4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6- methyl-pyridin-2-yl)-but-3-yn-2-ol The title compound was synthesized following the procedure described in Example B2.1, step 2 using (1- ethoxycyclopropoxy)trimethylsilane instead of formaldehyde and using sodium cyanoborohydride instead of NaBH(OAc) ₃ . The crude was purified by prep LC-MS (V). LC-MS (A) t _R = 0.66min; [M+H]+: 496.21. Example 671 to Example 679 were synthesized starting from the appropriate Example F3.2 to F3.10, and following procedure described in Example 167.1. LC-MS (A) data, prep LC-MS methods and the precursors are listed in the table below. pyridazin-3-yl}-pyrrolidin-2-one

680.1. 4-(1-Acetyl-piperidin-4-yl)-pyrrolidin-2-one

To a suspension of 4-(piperidin-4-yl)pyrrolidin-2-one (100mg) in THF (2mL) was added DIPEA (0.12mL) followed by acetic anhydride (0.053mL) at RT and the resulting suspension was stirred at RT for 3h. The reaction mixture was diluted with water and extracted with DCM (3x). The combined org. layers were dried over MgSC>4 and concentrated to dryness to give the desired product (98mg) as white solid. LC-MS (A): tR = 0.47min; [M+H] ⁺ : 211.2.

680.1. 4-(1-Acetyl-piperidin-4-yl)-1-{5-[(R)-(1,3-dimethyl-azetidin -3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridazin-

3-yl}-pyrrolidin-2-one

The title compound was synthesized starting from the Example F1.6 and Example 680.1, and following the procedure described in Example 167.1. The crude product was purified by described Prep LC-MS (IX)). LC-MS (A): tR = 0.68min; [M+Fi]-: 520.13.

Example 681 : 5-{5-[(R)-(1 ,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-meth yl]-pyridazin-3-yl}-hexahydro- furo[2,3-c]pyrrol-4-one

The title compound was synthesized starting from the Example F1 .6 and rac-(3aR,6aS)-hexahydro-2FI-furo[2,3-c]pyrrol-

4-one, and following the procedure described in Example 167, step 1. The crude product was purified by described Prep LC-MS (IX). LC-MS (A): t _R = 0.66min; [M+H] ⁺ : 437.1.

Example 682: 1-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridazin-3-yl}-4-(6- isopropyl-pyridin-2-yl)-pyrrolidin-2-one

The title compound was synthesized starting from the Example F1.6 and Example F3.2, and following the procedure described in Example 167, step 1. The crude product was purified by described Prep LC-MS (V). LC-MS (A): tR = 0.63min; [M+H] ⁺ : 513.88.

Example 683: 1-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-7, 8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl)-ethanone

683.1 1-(2-Chloro-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-etha none

The title compound was synthesized from 2-chloro-5H,6H,7H,8H-pyrido[4,3-d] pyrimidine hydrochloride following the procedure in Example F5.54. LC-MS (A) t _R = 0.53; [M+Fi]-: 212.03

683.2 (R)-(5-((1,3-dimethylazetidin-3-yl)(hydroxy)(4-isopropylphen yl)methyl)pyridin-3-yl)boronic acid A heated-out vial was charged with F1.2 (200mg), Bis(pinacolato)diboron (200mg), [1,1 - Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) complex with dichloromethane (21 mg), potassium acetate (153mg) and DMF (4m L) at RT, sealed, 3x evacuated and backfilled with argon and shaken at 80°C overnight. The reaction mixture was diluted with water and MeOFI, filtrated off and purified by prep LC-MS, method (VIII) to give 107mg pale purple powder. LC-MS (A) tR = 0.49min; [M+H] ⁺ : 355.07

683.3 1 -(2-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-7, 8-dihydro-5H- pyrido[4, 3-d]pyrimidin-6-yl) -ethanone

A vial was charged with the Example 683.1 (22mg), Example 683.2 (44.4mg), Pd(PPh ₃ )4 (18.3mg), K2CO3 1 M (1mL) and dioxane (1mL) at RT, sealed degassed with argon in ultrasonic bath for 5min and shaken at 100°C for 1h30 The resulting light brown susp was shaken at 100°C. The reaction mixture was allowed to cool down, diluted with water and MeOFI, filtrated off and purified by prep LC-MS (IX) to give 22mg white powder after lyophilization. LC-MS (A) t _R = 0.65min; [M+H] ^÷ : 486.12.

Example 684: 1-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isoprop yl-phenyl)-methyl]-pyridin-3-yl}-7, 8-dihydro- 5H-[1,6]naphthyridin-6-yl)-ethanone

684.1 -(2-Chloro-7,8-dihydro-5H-[1 , 6]naphthyridin-6-yl)-ethanone

The title compound was synthesized from 2-ch I oro-5, 6, 7 , 8-tetr ahy d ro- 1,6-naphthyridine hydrochloride following the procedure in Example F5.54. LC-MS (A) t _R = 0.63min; [M+H] ⁺ : 211.09

684.2 1 -(2-{5-[(R)-( 1, 3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methy l]-pyridin-3-yl}-7, 8-dihydro-5H- [1, 6]naphthyridin-6-yl)-ethanone

The title compound was synthesized following the procedure in Example 683, step 3, Example 684.1 replacing Example 683.1. The crude product was purified by Prep LC-MS (XIV). LC-MS (A) t _R = 0.64min; [M+Fi] ⁺ : 485.13 Example 685: 1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin- 5-yl)-piperidin-1-yl]-ethanone

685.14-(2-Chloro-pyrimidin-5-yl)-3, 6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester

The title compound was synthesized following the procedure described in Example 280, step 1 using 5-bromo-2- chloropyrimidne and 3,6-dihydro-1 FH-pyridine-1 -N-Boc-4-boronic acid, pinacol ester. Instead of direct purification via prep LC-MS the reaction mixture was extracted with 3x DCM. The combined org. layers were dried over MgS04, filtrated off, evaporated and purified by CC (Biotage, 10g SNAP, solvent A: Hept, solvent B: EA, gradient (in %B): 10 for 2CV, 10 to 30 over 5CV, 30 for 2CV) and by a second CC Biotage, 10g SNAP, solvent A: Hept, solvent B: EA, gradient (in %B): 10 for 3CV, 10 to 30 over 3CV, 30 for 2CV. LC-MS (A): t _R = 0.94min; [M+H] ⁺ : 296.03

685.22-chloro-5-(1,2,3,6-tetrahydropyridin-4-yl)pyrimidin e, hydrochloride salt The title compound was synthesized following the procedure described in Example F5.56.2 using Example 658.1. LC- MS (A) t _R = 0.36min ; [M+H] ⁺ :196.12

685.3 1 -[4-(2-Chloro-pyrimidin-5-yl)-3, 6-dihydro-2H-pyridin-1-yl]-ethanone

The title compound was synthesized following the procedure described in Example F5.54 using Example 685.2. LC- MS (A) t _R = 0.63; [M+H] ⁺ 138.04

685.4 1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-5-yl)-3,6- dihydro-2H-pyridin- 1 -yl]-ethanone

The title compound was synthesized like described in Example 683.3 using Example 685.3 and purified by prep LC- MS (VI) then (XX). LC-MS (A) t _R = 70min; [M+H] ⁺ 512.11

685.5 1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-5-yl)- piperidin-1-yl]-ethanone

To a flask already containing Example 685.4 (8mg) were added Pd/C (1.66mg) and MeOH (300mI_) at RT under argon. The flask was 3x evacuated and backfilled with argon, then 3x evacuated and backfilled with Eh. The resulting mixture was stirred at RT under hb overnight. The flask was 3x evacuated and backfilled with argon. The reaction mixture was filtrated through a syringe filter, the filter was washed with MeOH and the filtrate was evaporated and dried at HV to 6mg white solid. LC-MS (A) t _R = 0.69min; [M+H] ⁺ : 513.72

Example 686: 1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin- 4-yl)-piperidin-1-yl]-ethanone

686.14-(2-Chloro-pyrimidin-4-yl)-3, 6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester

The title compound was synthesized following the procedure described in 280, step 1 using 4-bromo-2- chloropyrimidine and 3,6-dihydro-1 H-pyridine-1 -N-Boc-4-boronic acid, pinacol ester and purified with the adapted gradient (in %B): 30 for 3CV, 30 to 50 over 3CV, 50 for 2CV, 50 to 70 over 2CV, 70 for 1CV. LC-MS (A) t _R = 0.98min; [M+H] ⁺ : 296.06

686.22-chloro-4-(1,2,3,6-tetrahydropyridin-4-yl)pyrimidin e hydrochloride salt

The title compound was synthesized following the procedure described in F5.56.2 using Example 686.1. LC-MS (A) t _R = 0.38min; [M+H] ⁺ : 193.14

686.3 1 -[4-(2-Chloro-pyrimidin-4-yl)-3, 6-dihydro-2H-pyridin-1-yl]-ethanone

The title compound was synthesized following the procedure described in Example F5.54 using Example 686.2. LC- MS (A) t _R = 0.67min; [M+H] ⁺ : 238.08

686.4 1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-4-yl)-3,6- dihydro-2H-pyridin- 1 -yl]-ethanone The title compound was synthesized like described in Example 683.3 using Example 686.3 and purified by prep LC- MS method (VI). LC-MS (A) t _R = 0.72min; [M+H] ⁺ : 512.05

686.5 1-[4-(2-{5-[(R)-(1,3-Dimethyl-azetidin-3-yl)-hydroxy-(4-isop ropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-4-yl)- piperidin-1-yl]-ethanone

The title compound was synthesized following the procedure described in Example 685.5 using 686.4. LC-MS (A) t _R = 0.71min; [M+H] ⁺ : 513.77.

Depending on the purification conditions, the title compounds/intermediates in Example 332 to 686 may be isolated as free bases or as salts such as formate salts, or hydrochloride salts. Whenever isolating a title compound/intermediate as a salt, formate salt or hydrochloride salt is indicated at the end of the chemical name and can refer to a mono-, di- or tri-formate salt, or mono-, di-, or tri-hydrochloride salt.

II. BIOLOGICAL ASSAYS

FLIPR assay: The bioactivity of compounds is tested in a fluorometric imaging plate reader (FLIPR: Molecular Devices) using engineered HEK-293 cells expressing the human CCR6 (GenBank: AY242126). Frozen cells are plated on Poly- L-Lysine precoated 384-well plates 2 days prior to bioassay in DMEM medium supplemented with 10% FCS and 1% Penicillin-Streptomycin. At the day of bioassay, cell supernatant is discarded and cells are dye loaded for 30 minutes at room temperature in the dark with Fluo-8-AM (Focus Biomolecules) in Flanks Balanced Salt Solution (Gibco), buffered with 20 mM Flepes at pH 6.75 and supplemented with 0.05 % BSA. This buffer, but lacking the dye, is also used for washing and compound dilution steps (assay buffer). Cells are washed free of excess dye with a wash-station (Biotek), leaving 40 microliter of assay buffer at the end. Cells were incubated for 15 minutes at room temperature in the dark, before adding compounds. Stock solutions of test compounds are made up at a concentration of 10 mM in DMSO, and serially diluted first in DMSO and then transferred in assay buffer to concentrations required for inhibition dose response curves. After a 45-minute incubation period in assay buffer at room temperature, 10 microliters of each compound dilution are transferred from a compound plate to the plate containing the recombinant cells in the FLIPR instrument according to the manufacturer's instructions. After cells and compounds were preincubated for 30 minutes at room temperature in the dark, 10 microliter agonist CCL20 (Peprotech) at a final concentration of 10 nM is added, again using the FLIPR instrument. Changes in fluorescence are monitored before and after addition of the test compounds and agonist. Emission peak values above base level after CCL20 addition are exported after base line subtraction.

The calculated IC50 values may fluctuate depending on the daily assay performance. Fluctuations of this kind are known to those skilled in the art. In the case where IC50 values have been determined several times for the same compound, mean values are given. Data are shown in Table 1.